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Abstract  
 
Parkinson’s disease (PD) is classically defined as a motor disorder of 
neurological aetiology. However, there has been a recent movement towards a 
reconceptualisation of PD in recognition of the multitude of cognitive and psychiatric 
disturbances that also feature in the disease (Stern, Lang, & Poewe, 2012). 
Depression and anxiety are the two most clinically significant psychological 
disturbances in PD and affect up to half of all individuals with PD (Negre-Pages et 
al., 2010). Research has shown that both depression and anxiety are among the 
greatest predictors of poor quality of life in PD and consistently rated as more 
detrimental to well-being than motor symptoms (Carod-Artal et al., 2008), even in 
the most advanced stages of disease where motor symptoms have fully progressed 
(Hely et al., 2005). Despite this, the majority of cases of depression and anxiety are 
not optimally managed or treated to remission in PD, largely due to a lack of 
empirical research to inform best practice guidelines. This research aimed to make a 
significant contribution to current knowledge in relation to the treatment of 
depressive and anxiety disorders in PD.  Four studies were conducted. 
 
Study 1 was the first broad meta-analysis of randomised placebo-controlled 
treatment trials (RCT) for depression and/or anxiety in PD and provided a systematic 
comparison of the efficacy of existing treatments for depression and/or anxiety in PD 
to better inform clinical care and future research. A comprehensive literature search 
highlighted the dearth of controlled treatment trials for depression and anxiety in PD 
with only nine well-designed placebo-controlled RCTs available for analysis. 
Random-effects modelling supported previous claims that there is a lack of evidence 
for the efficacy of antidepressants in PD at present (Klaassen et al., 1995).  The 
pooled effect for antidepressants in general (d = .71, 95% CI = -1.33 to 3.08) and 
first-line selective serotonin reuptake inhibitor treatments for depression in PD (d = 
.57, 95% CI = -1.33 to 2.47) were both non-significant. Most significantly, Study 1 
highlighted the potential of non-pharmacological interventions, particularly, 
Cognitive Behavioural Therapy (CBT), in treating depression and anxiety in PD. A 
recent RCT of CBT in PD (Dobkin et al., 2011) resulted in the largest effect on 
depression in PD over all other interventions (d = 1.57, 95% CI = 1.06 to 2.07) and 
strongly warranted further investigation of CBT interventions in PD. 
xii 
 
Study 2 evaluated the validity and reliability of the Depression, Anxiety and 
Stress Scale-21 (DASS-21; Lovibond & Lovibond, 1995) as an assessment tool for 
depression and anxiety in PD. The DASS-21 was the primary outcome measure used 
in Studies 3 and 4 of this thesis however it has not been previously validated in a PD 
sample. Selection of appropriate psychological measurement scales has been strongly 
emphasised in PD given the high degree of symptom overlap between depression, 
anxiety and PD, with use of inappropriate scales potentially invalidating research 
findings (Schrag et al., 2007). Confirmatory factor analysis using structural equation 
modelling was conducted based on responses of a sample of 327 Australian adults 
with PD and provided strong support for the factorial validity of the DASS-21 in PD, 
with replication of the scale’s a priori structure within the present sample. Moreover, 
the DASS-21 also displayed strong evidence of internal consistency, criterion 
validity, and discriminant validity. Overall, Study 2 provided strong support for the 
use of the DASS-21 as a primary outcome measure in this research and for clinical 
use in PD populations. 
 
Study 3 provided a direct contribution to the empirical literature on CBT in 
PD and was the first RCT of a group CBT intervention for depression and anxiety in 
PD. A waitlist-controlled RCT evaluating the efficacy of an 8-week group CBT 
intervention was conducted with 18 Australian adults with PD and depression and/or 
anxiety. At posttreatment, multilevel linear mixed-effects modelling showed that 
participants who received CBT experienced significant large improvements in 
depression (d = 1.12) and anxiety (d = .89) relative to waitlist control as assessed by 
the DASS-21. Acute treatment gains were all maintained over the follow-up period, 
with the largest gains observed at six-month follow-up (ds = .94 to 2.26), and 
strongly support the utility of group CBT as an alternative to antidepressant 
regimens. Despite these positive results, significant recruitment difficulties (and 
associated small sample size) reduced the overall validity and generalisability of 
study findings. In spite of recruitment efforts over a 28-month period, the response 
rate for the trial was less than 1%. Examination of the literature revealed similar 
recruitment difficulties in previous treatment trials for depression in PD, leading to 
the hypothesis that there may be significant barriers to seeking psychological 
treatment among individuals with PD and the conceptualisation of Study 4. 
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 Study 4 was an exploration of mental health service utilisation and barriers to 
psychological treatment in a PD population. Responses for this study were based on 
the same sample as Study 2. Participants were 327 Australian adults with PD. The 
results of this study confirmed the underutilisation of mental health services among 
individuals with PD. Despite clinically relevant symptoms of depression and/or 
anxiety in 59% of the sample, only 8% of participants were currently engaged in 
professional treatment. The key finding of this study was that the underutilisation of 
mental health services in PD may stem from a lack of awareness regarding 
psychological complications among individuals with PD. Second to prior treatment 
experience, a logistic regression analysis showed that having had a PD physician-
initiated discussion regarding psychological symptoms in PD was the next most 
substantial predictor of willingness to seek mental health treatment. Ultimately, this 
study highlighted the importance of promoting awareness of PD as “more than just a 
motor disorder" as a means of facilitating help-seeking for psychological 
complications in PD. 
 
Overall, this research found that depression and anxiety remain largely 
overlooked and unaddressed in PD. It would appear that increasing scientific 
recognition of the importance and impact of depression, anxiety and other 
psychological complications in PD over the past 25 years has not necessarily 
translated into increased clinical care. The final contribution of the present work was 
a set of clinical recommendations for the treatment of depression and anxiety in PD 
based on the findings of this research. Recommendations encompassed areas from 
facilitating awareness and understanding of psychological symptoms in PD, 
assessment and diagnosis, and treatment and evaluation. 
 
1 
 
Thesis Overview 
 
 “It [is] striking that… in an illness defined by its motor manifestations, 
affective and cognitive symptoms may have more significance..”  
 
(Weintraub, Moberg, Duda, Katz, & Stern, 2004, p. 788). 
 
 
In 1817, English physician James Parkinson introduced the shaking palsy to 
the world. In his pioneering paper, ‘An Essay on the Shaking Palsy’, Parkinson 
painted a vivid picture of a ‘most distressing malady’ characterised by the unusual 
combination of progressive loss of intentional movement with involuntary movement 
gains. Today, almost 200 years after Parkinson’s seminal publication, the shaking 
palsy, or Parkinson’s disease (PD) as it was renamed, is well recognised as a chronic 
and progressive neurodegenerative disease affecting an estimated 6.3 million 
individuals worldwide (Baker & Graham, 2004). 
 
Classic definitions of PD conceptualise the disease as a motor disorder 
characterised by four cardinal features; resting tremor, muscle rigidity, postural 
instability and slowness of physical movement. However, more recent work suggests 
that PD may be more accurately conceptualised as a ‘neuropsychiatric disorder’ in 
recognition of the multitude of psychiatric and cognitive symptoms that also feature 
in the disease, including but not limited to; depression, anxiety, dementia, psychosis, 
and impulse control disorders (Weintraub & Burn, 2011) 
 
This research focuses on the two most clinically significant non-motor 
complications in PD; depression and anxiety. Approximately 40 to 50% of 
individuals with PD will experience clinical depression (Burn, 2002) while 
approximately 30 to 40% will meet clinical criteria for an anxiety disorder (Leentjens 
et al., 2008). Research has consistently shown that both depression and anxiety are 
among the greatest predictors of poor quality of life in PD and consistently rated as 
more detrimental to well-being and health status than motor symptoms (Hinnell et 
al., 2011), even in the most advanced stage of illness where motor symptoms have 
fully progressed (Hely, Morris, Reid, & Trafficante, 2005). 
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The original aim of this project was to make a significant contribution to the 
psychological treatment literature in PD by conducting the first randomised 
controlled trial of a group Cognitive Behavioural Therapy (CBT) intervention for 
depression and anxiety in PD. This aim was accomplished and reported findings 
provide strong preliminary support for the efficacy of group CBT for depression and 
anxiety in PD. However, significant and unforeseen difficulties with participant 
recruitment were encountered and led to expansion of the scope of the present work. 
Specifically, recruitment difficulties resulted in the identification of a novel area of 
research that has yet to be comprehensively explored in PD – barriers to seeking 
mental health treatment. This thesis now comprises four studies each offering a 
unique scientific contribution to the existing knowledge regarding depression and 
anxiety in PD. 
 
 
Outline of Chapters 
 
Chapter 1 provides a broad overview of depressive and anxiety disorders in 
PD, beginning with a brief overview of PD as background knowledge for this 
research. The remainder of Chapter 1 examines depression and anxiety in PD 
including an overview of aetiology, significance, diagnostic challenges and a review 
of the negative outcomes associated with untreated depression and anxiety in PD, 
ultimately highlighting the importance of appropriate clinical attention and treatment. 
 
 Chapter 2 explores current treatment options for depression and anxiety in 
PD. Specifically, Chapter 2 presents the results of Study 1 which is the first broad 
meta-analysis of both pharmacological and non-pharmacological treatment trials for 
depression and/or anxiety in PD. The aim of Study 1 was to provide a systematic 
comparison of the efficacy of current treatments for depression and/or anxiety in PD 
to better inform clinical care and future research. 
 
Chapter 3 introduces and examines the feasibility of CBT as a treatment for 
depression and anxiety in PD. The first part of the chapter provides a brief overview 
of CBT for depression and anxiety. The remainder of the chapter establishes a 
rationale for the use of CBT in PD by reviewing the relevant theoretical and 
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empirical literature.  The chapter concludes with a review of existing studies 
evaluating the use of CBT in PD populations and highlights promising preliminary 
results but the pressing need for more controlled empirical research, particularly for 
group CBT interventions. 
 
Chapter 4 presents the findings of Study 2 which is an investigation of the 
validity and reliability of the Depression, Anxiety, and Stress Scale-21 (DASS-21) in 
a PD sample. The DASS-21 was the primary outcome measure used in Studies 3 and 
4 of this thesis however it has not been previously validated in PD. Selection of 
appropriate measurement scales has been strongly emphasised in PD, with use of 
inappropriate scales potentially invalidating research findings. The aim of this study 
was to therefore provide support for the use of the DASS-21 as a primary outcome 
measure in this thesis. 
 
 Chapter 5 presents the findings of Study 3 which is the first randomised 
waitlist-controlled trial of a group CBT intervention for depression and anxiety in 
PD. This study aimed to make a direct contribution to the empirical treatment 
literature on depression and anxiety in PD by evaluating the efficacy of an 8-week 
PD-specific group CBT intervention. Participants were 18 adults with PD and a 
comorbid DSM-IV diagnosis of at least one depressive and/or anxiety disorder. 
 
 Chapter 6 presents the results of Study 4, which is an exploration of barriers 
to seeking mental health treatment among a sample of 327 Australian adults with PD. 
This study was conceptualised post hoc as a direct result of recruitment difficulties 
encountered in Study 3. The aim of Study 4 was to examine patterns of mental health 
service utilisation among individuals with PD and to identify any pertinent barriers to 
seeking mental health treatment that may help to understand the recruitment 
difficulties during the clinical trial. 
 
Finally, this thesis closes with Chapter 7 which presents a general discussion 
of the current state of knowledge in relation to depression and anxiety in PD and 
outlines the unique contributions of the present work to this field of knowledge, 
along with an outline of clinical and future research recommendations.
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CHAPTER 1  |         Depression and Anxiety in  
                Parkinson’s Disease 
 
 
 
 
1.1 Introduction 
 
James Parkinson’s initial account of the shaking palsy described a disease 
predominantly affecting physical functioning with ‘the senses and intellects being 
uninjured’. It was not until almost six decades later that cognitive and psychological 
disturbances in Parkinson’s disease (PD) were acknowledged, when in 1875, French 
neurologist Jean-Martin Charcot noted that ‘psychic faculties are definitely impaired 
… the mind becomes clouded and the memory is lost’ (Charcot, 1875, p. 179). 
 
Today, the range of psychological complications in PD is widely recognised. 
More than 60% of individuals with PD experience at least one neuropsychiatric 
symptom at any given time, with 45% experiencing two or more (Schrag, 2004). 
Depression and anxiety are the two most common psychological problems in PD 
and, depending on study methodology, affect between 30 to 75% of individuals with 
Parkinson’s at some point during their illness (Veazey et al., 2005). 
 
This chapter comprises two parts. The first provides a brief overview of PD 
as background knowledge for this research including a review of the definition of 
PD, clinical presentation, epidemiology, neuropathology, and treatment options. The 
second half of the chapter focuses on the occurrence of depression and anxiety in PD, 
beginning with an overview of the prevalence, clinical presentation, aetiological 
models and challenges with diagnosis of depression and anxiety in PD. The chapter 
closes with a review the negative outcomes associated with untreated depression and 
anxiety, highlighting the importance of clinical attention and treatment. 
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1.2 Definition of Parkinson’s Disease 
 
Parkinson’s disease is part of the parkinsonism family of disorders which are 
a group of movement conditions characterised by four cardinal features; resting 
tremor, muscle rigidity, postural instability and slowness of physical movement or 
bradykinesia (Alves et al., 2008). PD is the most common form of parkinsonism, 
accounting for 95% of cases (Ben-Shlomo & Sieradzan, 1995), and is also known as 
idiopathic or primary parkinsonism in that there is no known cause for symptoms 
(Ellenberg, Koller, & Langston, 1995). Other primary parkinsonism conditions 
include progressive supranuclear palsy, multiple system atrophy, and dementia with 
Lewy bodies. Secondary or symptomatic parkinsonism is used to describe cases in 
which a known aetiology is available and includes conditions such as drug-induced 
parkinsonism, malignant neuroleptic syndrome, and post-encephalitic parkinsonism 
(Ellenberg et al.).  
 
 
1.3 Epidemiology 
 
PD is the second most common neurodegenerative disorder after Alzheimer’s 
disease (Phillips, 2007). In Australia, there are an estimated 100 000 individuals 
living with PD which is equivalent to a prevalence of approximately 0.5% in the 
general population (Barlow-Stewart, 2007) or between 3.4 to 4.9% for adults aged 55 
years and over (Chan et al., 2005). Global estimates of the incidence of PD suggest 
approximately 20 new cases per 100 000 individuals per annum (Barlow-Stewart). In 
2011, it was estimated that that 10 500 new cases of PD were diagnosed in Australia 
which is equivalent to almost 30 new diagnoses per day (Deloitte Access Economics, 
2011). This figure is likely to be an underestimate of the true incidence of PD, 
however, as it pertains to diagnosed cases only. A review of five European 
epidemiological studies by De Rijik and colleagues (1997) suggested that there is an 
average of 3.2 undiagnosed cases of PD for every ten that are diagnosed. Thus, a 
substantial number of people are affected by PD and researchers suggest that the 
prevalence of PD in Australia will increase by an estimated 15% in the next five 
years as a result of demographic ageing (Aarsland, 2002). 
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1.4 Clinical Presentation 
 
1.4.1 Cardinal Symptoms  
 Resting tremor is the most visible symptom of PD and is experienced by 70 
to 90% of individuals (Weintraub et al., 2008). It is generally the first symptom to 
manifest and is typically first seen in the thumb or wrist (Rao, Hofmann, & Shakil, 
2006). With disease progression, tremor is also often evidenced in the hands, jaw, 
tongue and/or legs (Frank, Pari, & Rossiter, 2006). Resting tremor is not a major 
cause of functional impairment in PD despite being the most overtly noticeable 
symptom (Simuni, 2007). 
 
 Muscle rigidity is the most commonly occurring cardinal symptom and is 
experienced by more than 90% of individuals with PD (Rao et al., 2006).  Two types 
of muscle rigidity are commonly described in PD. The ‘lead pipe’ pattern of rigidity 
refers to the experience of a consistent intensity of resistance with passive 
movement, while the ‘cogwheel’ pattern refers to a fluctuating intensity of resistance 
with movement, often resulting in jerky movements (Frank et al., 2006). 
 
 Bradykinesia affects approximately 80 to 90% of people with PD (Weintraub 
et al., 2008). It is generally the most disabling of the cardinal symptoms as it is 
unpredictable in occurrence and limits personal independence by making completion 
of simple everyday activities difficult such as rising from a chair, getting in and out 
of a car or turning over in bed (Rao et al., 2006). In some cases, individuals with PD 
can experience an extreme form of bradykinesia termed akinesia, which is the 
complete inability to initiate intentional movement (Frank et al., 2006). 
 
Postural instability is generally the last of the cardinal symptoms to appear 
and its manifestation indicates advancing disease (Weintraub et al., 2008). The most 
common postural changes observed in PD are forward flexed and stooped posture as 
well as difficulties with maintaining and/or correcting posture and balance (Pallone, 
2007). Postural instability can be severely debilitating as it places individuals with 
PD at a high susceptibility to falls and fall-related injuries (Simuni & Sethi, 2007). 
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1.4.2 Onset 
PD predominantly affects older adults with an average onset age of 62 years 
(de Lau & Breteler, 2006). However, PD can also affect younger adults as well as 
teenagers and children (see Table 1). Early-onset PD is generally accepted as a 
manifestation of idiopathic PD only occurring at a younger age, with post-mortem 
findings showing a matching neuropathology between people with early-onset and 
later-onset PD (Yokochi, 1993).  Juvenile PD is suggested to be a separate disease 
process from idiopathic and early-onset PD however, with research suggesting a 
strong genetic component in cases of juvenile PD (Muthane et al.). 
 
Table 1  
Classification of Parkinson’s Disease Based on Age of Onset 
 Age of Onset Percentage of Cases 
PD > 40 years 85 – 90% 
Young/Early Onset  21 – 40 years 10 – 15% 
Juvenile PD Before 21 years Rare 
 
 
1.4.3 Progression 
The Hoehn and Yahr Staging Scale (Hoehn & Yahr, 1967) remains the most 
widely accepted classification system for the progression of PD. The scale divides 
the progression of PD into five stages (see Table 2). However, disease progression 
does not always occur in a linear manner. It is common for individuals to experience 
a reduction in symptoms during treatment and subsequently drop back a stage, or 
undergo accelerated progression and advance through several stages (Scheife, 2000).  
 
Moreover, while the Hoehn and Yahr scale provides a reliable overview of 
the typical stages and symptoms of PD, there has been widening recognition of the 
heterogeneity of the disease (Burn et al., 2011; Selikhova et al., 2000). Clinical 
observations have shown great diversity in the symptom presentation of PD with 
many researchers suggesting the existence of a number of distinct subtypes (e.g., 
Brooks & Doder, 2000; Francis & Perry, 2007; Lewis & Barker, 2009; Paulus & 
Jellinger, 1991; Spiegel et al., 2007). Currently, the only universally accepted PD  
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Table 2  
The Hoehn and Yahr Parkinson’s Disease Staging Scale (Hoehn & Yahr, 1967) 
Stage Clinical Presentation 
1 Unilateral involvement only, usually minimal or no functional impairment. 
Symptoms: tremor of one limb, changes in posture and facial expression. 
2 Bilateral involvement without balance impairment. Posture and gait affected. 
3 First signs of postural instability; significant slowing of body movements, some 
restriction of activities but is capable of leading an independent life; disability is 
mild to moderate. 
4 Severe symptoms: walking limited, rigidity and bradykinesia. Severely disabling 
disease; individual is markedly incapacitated and is unable to live alone. 
5 Cachectic stage. Individual is restricted to bed or a wheelchair unless aided. 
 
 
sub-classification is based on age at disease onset however, it has been suggested that 
distinct subtypes may exist based on: (i) predominant motor symptoms (e.g., tremor-
dominant vs. akinetic-rigid, postural instability and gait disturbance (PIGD) vs. non-
PIGD), (ii) clinical course and progression (e.g., benign vs. malignant), (iii) cognitive 
impairment, and (iv) depressive symptomatology (Burn et al., 2011). 
 
 
1.5 Neuropathology 
 
1.5.1 Dopaminergic Cell Death 
The pathological hallmark of PD is the degeneration of the substantia nigra 
and associated dopaminergic cell death. The substantia nigra is a midbrain structure 
which forms part of the basal ganglia, a large group of subcortical nuclei comprising 
the substantia nigra along with the striatum, globus pallidus and subthalamic nuclei 
(Brown & Marsden, 1998). The compact zone of the substantia nigra (SNPC) contains 
pigmented cells which produce the neurotransmitter dopamine. Dopamine is then 
released by the SNPC via the nigrostriatal pathway for storage in the striatum 
(Phillips, 2007). In PD, the dopaminergic cells of the SNPC progressively degenerate 
resulting in a severe loss of dopamine (Hornykiewicz, 1998). 
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 Dopamine is involved in a number of complex functions in the brain 
including the regulation of neuronal ‘circuits’ between the basal ganglia, thalamus 
and frontal cortices (Mandir & Vaughan, 2000). Researchers suggest there are at 
least five such basal ganglia-thalamocoritical circuits operating in parallel and 
connecting with different frontal cortical areas to execute various bodily functions 
(Alexander & Crutcher, 1990). Table 3 provides a summary of these circuits.  
 
Table 3  
Summary of Basal Ganglia-Thalamocortical Circuits 
Circuit Cortical Input Areas Primary Function 
Motor Primary motor cortex 
Somatosensory cortex 
Arcuate premotor area 
Supplementary motor area 
Regulation and control of body 
movement 
Oculomotor Frontal eye fields 
Dorsolateral prefrontal cortex 
Posterior parietal cortex 
Oculomotor control 
Cognitive Dorsolateral prefrontal cortex 
Posterior parietal cortex 
Arcuate premotor area 
Working memory, planning, 
attention, problem solving, 
processing speed, spatial memory 
‘Lateral 
Orbitofrontal’ 
Lateral orbitofrontal cortex 
Superior temporal gyrus 
Inferior temporal gyrus 
Anterior cingulate area 
Not completely functionally 
characterised but thought to play a 
role in behaviour 
Limbic Anterior cingulate area 
Primary motor cortex 
Entorhinal cortex 
Superior temporal gyrus 
Inferior temporal gyrus 
Regulation and control of 
behaviours underlying motivation, 
decision-making and goal-
directed reward 
 
 
In PD, the motor circuit is proposed to be compromised (Lewis & Barker, 
2009). The motor circuit is primarily responsible for the execution and regulation of 
body movement and receives and transmits neuronal activity between the basal 
ganglia and the primary motor cortex, somatosensory cortex and premotor areas 
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(Alexander & Crutcher, 1990). Neuronal activity is transmitted from the frontal 
cortices, processed and passed through the basal ganglia to the thalamus and 
transmitted back to the originating cortex via one of two contrasting parallel 
pathways: (i) the ‘direct pathway’ which has a net excitatory effect and thus 
increases body movement, or (ii) the ‘indirect pathway’ which has a net inhibitory 
effect and thus decreases body movement (Mandir & Vaughan, 2000).  
 
Dopamine is suggested to stimulate as well as regulate neuronal activity in 
the motor circuit to facilitate execution of motor responses initiated by the higher 
order cortical areas. The loss of dopamine in PD disrupts normal functioning of the 
motor circuit and is proposed to lead to hyperactivity of the indirect pathway (Bonnet 
& Houeto, 1991; Lewis & Barker, 2009), resulting in an overall inhibition of the 
circuit and ultimately, body movement. When approximately 70 to 80% of 
dopaminergic cells have degenerated, the clinical symptoms of PD begin to manifest 
(Doudet al., 1985; Mandir & Vaughan, 2000; Watts & Mandir, 1992). 
 
While the pathological hallmark of PD is the loss of dopaminergic cells in the 
substantia nigra pars compacta, degeneration of dopaminergic cells is also evidenced 
in mesolimbic and mesocortical structures, in particular, the ventral tegmental area 
(VTA; Leentjens, 2004). Dopaminergic neurons in the VTA project to limbic and 
cortical areas involved in cognition, motivation, emotion, and reward-seeking 
behaviour (Jones, Kornblum, &Kauer, 2000). It has been hypothesised that loss of 
dopamine in the VTA may disrupt these processes and thus increase the risk of 
depression (Fibiger, 1984). In support, neuropathology studies have revealed more 
severe degeneration of dopaminergic neurons in the VTA of people with PD with 
affective disorders and dementia compared to those with PD without such 
disturbances (Torack & Morris, 1988). Lowered levels of dopamine in PD may also 
play a role in the development of anxiety. Dopaminergic disturbance has been 
implicated in the development of social anxiety disorder (Potts & Davidson, 1992), 
panic disorder (Argyl, 1990; Pitchot et al., 1992), and obsessive compulsive disorder 
(McDougle, Goodman, & Price, 1994; Marazziti et al., 1992). 
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1.5.2 Non-Dopaminergic Cell Death 
In addition to the loss of dopaminergic neurons, selective degeneration of 
non-dopaminergic cells is also commonly evidenced in PD and has been suggested to 
play a major role in the development of non-motor and psychological symptoms 
(Ahlskog, 2005; Benarroch, 1999; Chaudhuri, Healy, & Schapira, 2006).  
 
1.5.2.1 Noradrenergic cell loss. The most prominent non-dopaminergic cell 
loss in PD occurs in the rostral and caudal locus coeruleus where noradrenergic cell 
loss has been evidenced (Brooks & Doder, 2000; Burn; 2002; Cummings, 1992). 
Noradrenergic cells in the locus coeruleus project to limbic and cortical regions 
including the cerebral cortex, ventral striatum, amygdala, hippocampus and anterior 
cingulate gyrus (Wiener & Lang, 1989), and have been found to be involved in the 
processes of cognition, arousal, learning, sleep regulation and stress response 
mediation (Brunello et al., 2003; Frazer, 2000). Disruption to these processes through 
reduced noradrenergic activity has been proposed to place people with PD at greater 
susceptibility to depressive disorders (Cummings, 1992) and particularly panic 
disorder (Nutt & Lawson, 1992; Richard et al., 1996). 
 
1.5.2.2 Serotonergic cell loss. Loss of the neurotransmitter serotonin has also 
been documented in PD. Studies have demonstrated a large reduction of serotonergic 
neurons in the raphe nuclei, and milder losses in the putamen, caudate, globus 
pallidus, hypothalamus, and frontal cortex of individuals with PD (Richard et al., 
1996). Levels of the serotonin metabolite 5-hydroxyindole acetic acid (5-HIAA) in 
the cerebrospinal fluid of people with PD have also been found to be approximately 
50% lower than those without PD (Mayeux et al., 1986). Changed serotonergic 
activity in PD has been suggested to place people with PD at increased susceptibility 
to developing OCD (Insel et al., 1990), social anxiety disorder (Miner & Davidson, 
1995), GAD and panic disorder (Charney, Woods, Krstyal, & Heninger, 1990), and 
especially, depression (Leentjens, Scholtissen, Vreeling, & Verhey, 2006). While the 
exact role of serotonin in the development of depressive disorders is not known, 
studies have revealed lower cerebrospinal 5-HIAA levels in persons with depression 
compared to those without an affective disorder (Burn, 2002). Greater serotonin loss 
is also proposed to be associated with more severe depression, with 5-HIAA levels in 
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persons with major depression found to be generally lower than those with milder 
depressive symptoms (Burn). This is consistent with Mayeux and colleagues’ (1984) 
finding that cerebrospinal 5-HIAA levels in depressed PD patients were 20% lower 
than those with PD not experiencing depression, although not all studies have been 
able to detect this difference (Kuhn et al., 1996).  
 
1.5.3 Lewy Body Formation 
 The second pathological marker of PD is the formation of distinct neuronal 
inclusions termed Lewy bodies in the brain. These inclusions predominantly form in 
the substantia nigra but have also been identified in neurons of the hypothalamus, 
brain stem, sympathetic and parasympathetic nervous systems (Wakabayashi & 
Takahashi, 1997). The purpose of Lewy bodies or the mechanism underlying their 
formation is unclear, however, they have also been found in the brains of individuals 
with other neurodegenerative diseases such as Alzheimer’s disease and dementia 
with Lewy bodies (Loatharius & Brundin, 2002). 
 
 
1.6 Treatment and Management 
 
1.6.1 Primary Treatment 
 Pharmacotherapy is currently the first-line, most widespread and effective 
treatment for PD. A selection of drug treatments is available to help manage motor 
symptoms (symptomatic therapy) and/or attempt to slow the progression of the 
disease (neuroprotective therapy). There are six main classes of PD medications 
which operate using different mechanisms (see Table 4). 
 
1.6.1.1 Symptomatic treatment. Symptomatic treatment of PD commences 
when an individual begins to experience functional impairment. Levodopa is the 
primary and most effective drug class used to manage symptoms in PD (NICE, 
2006). Levodopa is a neutral amino acid and the precursor of dopamine. As 
dopamine cannot cross the blood-brain barrier, levodopa is ingested and converted to 
dopamine once past the blood-brain barrier (NICE). Although effective, a number of 
aversive side effects are associated with levodopa treatment and thus the delay of 
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Table 4  
Pharmacological Treatments for Parkinson’s Disease (Starkstein &Merello, 2002) 
Drug Group Medications Function Side Effects 
Levodopa 
(Dopaminergic Agents) 
Sinemet, Kinson, 
Madopar 
Symptomatic Nausea, increased dreams, hallucinations, 
dyskinesias 
Dopaminergic Agonists Sifrol, Cabaser, 
Permax, Parlodel, 
Kripton, Apomine 
Symptomatic / Potentially 
neuroprotective 
Nausea, dizziness, confusion, increased sleepiness 
Catechol-O-
Methyltransferase (COMT) 
Inhibitors 
Stalevo, Comtan, 
Tazmar 
Symptomatic 
Adjunct to levodopa to extend 
levodopa response 
Increased dyskinesia, discolouration of urine 
Anti-viral agents Symmetrel Symptomatic 
Used to treat levodopa-induced 
dyskinesias 
Rare but may include insomnia, confusion and 
rashes on the legs 
Anticholinergics Artane, Cogentin, 
Akineton 
Symptomatic 
 
Dry mouth, constipation, urinary retention, memory 
loss, hallucinations, blurred vision, confusion 
Monoamine Oxidase-B 
Inhibitors 
Eldepryl, Azilect Neuroprotective Sleep disturbance 
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levodopa administration is recommended until the later stages of the disease (NICE, 
2006). Most notably, early research suggested that long-term use of levodopa 
accelerates the neurodegenerative process of PD and results in treatment-related 
motor dysfunction, specifically, the development of dyskinesias (Swanson, 1994). 
More recent work has shown that long-term use of levodopa does not enhance 
progression of PD pathology (e.g., Parkkinen et al., 2011), however dyskinesias 
remain a common side-effect of levodopa use in PD.  Early research also suggested 
that the effectiveness of levodopa wears off with disease progression and can result 
in rapid and unpredictable swings between periods of fluid motor control to a state of 
complete incapacity to conduct voluntary movement (Olanow et al., 2001), a 
phenomenon commonly referred to as the on-off effect of levodopa treatment. Again, 
however, more recent research suggests that this effect largely reflects the inability of 
the degenerating brain to effectively absorb levodopa with disease progression rather 
than non-efficacy of the levodopa itself (Parkkinen et al.). 
 
To delay the onset of levodopa-related treatment complications, dopamine 
agonists, a class of medications which mimic the effect of dopamine, are generally 
the first-line choice for initial symptomatic treatment of PD (NICE, 2006). These 
drugs are less effective than levodopa and thus are most suitable for the treatment of 
early symptoms. Dopamine agonists also have a lower side effect profile when 
compared to levodopa and are therefore employed initially to delay the onset of 
treatment-related motor complications (Swanson, 1994), although the development 
of impulse control disorders has been linked with dopamine agonist use. 
 
1.6.1.2 Additional drugs used in PD. A number of additional medications 
are also prescribed alongside symptomatic and neuroprotective drugs in PD to 
enhance the effect of these drugs and/or to act as neuroprotective agents. There are 
currently no proven neuroprotective agents for PD, however, several potential 
neuroprotective substances have been identified including monoamine oxidase-B 
(MAO-B) inhibitors, vitamin E, caffeine, and co-enzyme Q10 (National Institute of 
Health and Clinical Excellence; NICE, 2006). Catechol-o-methyltransferase (COMT) 
inhibitors are often prescribed with levodopa to extend the levodopa response (NICE, 
2006). Anti-viral agents are a second drug class that are also commonly prescribed 
concomitantly with levodopa, particularly after the onset of treatment-related motor 
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complications (Starkstein & Merello, 2002). In particular, Amantadine is an anti-
viral agent with antiparkinsonian effects and has been found to be useful in treating 
levodopa-induced dyskinesias (Olanow et al., 2001).  
 
1.6.2 Challenges in Pharmacological Treatment of PD 
 Perhaps the most important challenge in the pharmacological treatment of PD 
is how to best handle polypharmacy (Preskorn & Lacey, 2007). Concomitant 
symptomatic and neuroprotective treatments along with adjuvant treatment for any 
levodopa-induced motor complications ultimately mean that a person with PD will 
be taking several antiparkinsonian drugs at any given time. In fact, it is common 
practice for a person with PD to take up to five different medications simultaneously 
for their motor symptoms (Swanson, 1994). Several authors have highlighted the 
potential dangers of polypharmacy in PD, most notably the risk of aversive drug 
interactions. As posed by Swanson, “is it possible that enthusiasm for new drugs has 
blinded us to the point that we are doing patients harm?” (p. 401).  
 
Despite these concerns, polypharmacy in PD is considered to be safe and 
rational at large. The PD treatment model has even been used to develop similar 
rational polypharmaceutical treatments for other health conditions (i.e., Preskorn & 
Lacey, 2007). However, care must be taken in consideration of potential adverse 
interactions with any additional medications. Given the age of the majority of 
individuals with PD, concurrent pharmacological treatment for comorbid health 
conditions is very common (Olanow et al., 2001).  Combinations of different 
antiparkinsonian drugs are tested to ensure safety and minimal side effects, however, 
it is not possible to know the outcome of every non-PD drug combination with 
antiparkinsonian medications. Thus, it is best to minimise the use of any additional 
medications where possible, only reserving such treatment for cases that are 
absolutely essential (Marsh, 2000; Swanson).  
 
Overall, pharmacological treatment in PD is complex and challenging but 
highly effective when correctly implemented. Continual monitoring, review and 
adjustment of dosage, timing, drug type and combinations is ultimately required to 
ensure maximal functioning and safety with symptom progression (Starkstein & 
Merello, 2002). 
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1.7 Non-Motor Symptoms 
 
 Although classically defined as a motor disorder, a growing number of 
researchers have suggested that PD may be better conceptualised as a multisystem 
disease, in recognition of the wide range of non-motor disturbances which also 
feature in PD including autonomic dysfunction, sleep-related problems, 
communication difficulties and cognitive and psychological disturbances (Braak, 
Ghebremedhin, Rub, Bratzke, & Tredici, 2004).  
 
1.7.1 Autonomic and Gastrointestinal Symptoms 
Dysfunction of the autonomic nervous system (or dysautonomia) has long 
been recognised in PD (Micieli et al., 2003). Such symptoms have been documented 
in people with PD across every stage of the disease, on and off medication, including 
those with a very short duration of illness (Awerbuch & Sandyk, 1994). Common 
symptoms of dysautonomia in PD include bladder disturbances, excessive sweating, 
orthostatic hypotension and sexual dysfunction while common gastrointestinal 
complications include drooling, reflux and vomiting, nausea, constipation and 
incontinence (Borek, Amick & Friedman, 2006). Dysautonomia occurs in PD more 
frequently and with greater severity in comparison to age-matched controls 
(Siddiqui, Rast, Lynn, Auchus, & Pfeiffer, 2002), but is suggested to be milder than 
dysautonomia in patients with pure autonomic failure or multiple system atrophy 
(Montastruc, Senrad, Rascol, & Rascol, 1996).  
 
1.7.2 Sleep Disturbances 
Almost all people with PD experience sleep disturbances, usually 
commencing in the early stages of the disease (Chaudhuri, 2003). Common sleep 
disturbances include restless leg syndrome, insomnia, sleep apnea, enuresis (bed 
wetting) and rapid eye movement (REM) sleep disorders (Garcia-Borreguero, 
Larosa, & Bravo, 2003). Sleep problems in PD have been linked with dysfunction in 
central sleep regulation centres but can also be secondary to PD symptoms (Rye & 
Jakovic, 2002). For example, insomnia is common in cases when motor symptoms 
and restless legs continually arouse an individual and thus make it difficult to fall 
into and maintain sleep (Chaudhuri et al., 2006). Up to 50% of people with PD are 
also affected by daytime hypersomnia, most notably excessive sleepiness and 
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involuntary dozing (Abbot et al., 2005). In addition, a number of sleep disorders also 
commonly occur in PD including but not limited to; arousal disorder (vivid dreams, 
sleep terror disorder), REM sleep disorder, REM behaviour disorder), and sleep-
wake transition disorder (e.g., sleep-talking and jerking; Ferreri et al., 2006). 
 
1.7.3 Communication Symptoms 
 People with PD experience a number of communication challenges that are 
predominantly secondary to motor symptoms. Non-verbal communication can be 
challenging due to a masked expression and decreased body language caused by 
rigidity of facial and bodily muscles, respectively (Ferreri et al., 2006). Thus, people 
with PD can often appear disengaged, distant or disinterested. Verbal communication 
can also be difficult with 50 to 90% of individuals with PD likely to develop speech 
and voice disorders (Ramig, Fox, & Sapir, 2004). Common speech disturbances 
include reduced speaking volume (hypophonia), monotone speech (hypoprosdia), 
hoarse voice, increasingly rapid and less distinct speech (festination), and imprecise 
articulation (Hartelius & Svensson, 1994). Collectively, these symptoms can make 
interpersonal communication very challenging for both people with PD and their 
family members (Ramig et al.). 
 
1.7.4 Cognitive and Psychological Symptoms 
 There is a particularly high rate of cognitive and psychological disturbances 
in PD to the degree that several authors have recently suggested that PD may be 
more accurately conceptualised as a neuropsychiatric disease (Weintraub & Burn, 
2011). Cognitive difficulties in PD and can range from mild impairment to overt 
dementia. Dementia affects an estimated 30% of people with PD, usually in the latter 
stages of the disease, while approximately 50% are likely to experience mild 
cognitive impairment (Ferreri et al., 2006). Symptoms of cognitive impairment are 
idiosyncratic, however, impairments in executive functioning (i.e., planning and 
working memory), visuospatial ability, attentional and language functioning are 
commonly reported (Camicioli & Fisher, 2004).  
 
A range of psychological disorders have also been observed in PD with the 
most common being anxiety, depression, psychosis and addiction (Ferreri et al., 
2006). Up to 75% individuals with PD can report depressive symptoms (Veazey et 
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al., 2005) while approximately 40 to 50% meet diagnostic criteria for clinical 
depression at some stage of their illness (Burn, 2002). Similarly, between 30 to 40% 
of people with PD will experience an anxiety disorder at some stage including but 
not limited to; generalised anxiety disorder, panic disorder and social anxiety 
disorder (Richards et al., 1996). The prevalence of psychosis in PD has been 
estimated at between 20 and 40% (Papapetropoulos & Mash, 2005). Common 
psychotic symptoms that have been reported in people with PD include sensing 
presences, visual, auditory and/or tactile illusions or hallucinations, and paranoid 
delusions (Fenelon et al., 2000). It is proposed that the neurochemical changes 
inherent in PD may place individuals at greater susceptibility to developing these 
psychological disorders (Frisina et al., 2008).  
 
1.7.5 The Importance of Non-Motor Symptoms in PD 
Although historically perceived as secondary aspects of PD, non-motor 
symptoms contribute substantially to both the clinical picture and burden of disease 
in PD (Chaudhuri et al., 2013). Studies investigating quality of life in PD have 
consistently shown that symptoms such as anxiety, depression and cognitive 
impairment are the greatest predictors of poor quality of life in PD and are 
consistently rated as more detrimental to subjective well-being and health status than 
motor symptoms (i.e., Behair, Srivastava, & Pandey, 2005; Carod-Artal, 2008; Den 
Oudsten et al., 2007; Hinnell, Hurt, Landau, Brown, & Samuel, 2011; Rahman, 
Grifin, Quinn, & Jahanshai, 2008; Soh et al., 2011). Studies investigating perceived 
functional disability in PD have also reported that non-motor symptoms such as 
dribbling, sleep disturbance, memory failure and depression are consistently rated by 
patients as the most disabling features of PD (Gulati et al., 2004). This has been 
shown to be the case even in the most advanced stages of disease. For example, in a 
longitudinal study following a group of individuals with PD for between 15 and 18 
years, Hely, Morris, Reid and Trafficante (2005) reported  that participants described 
cognitive failure, hallucinations and depression to be the ‘most troubling’ symptoms 
at final follow-up. Thus, even in the final stages of PD whereby motor symptoms 
were fully progressed, non-motor symptoms were still perceived to be more 
functionally disabling. Moreover, non-motor symptoms, particularly dementia, 
psychiatric disturbance and autonomic failure, are the predominant cause of 
hospitalisation and institutionalisation of individuals with PD as well as the major 
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cause of morbidity and eventual death in PD (Chaudhuri & Martinez-Martinez, 2008; 
Findley et al., 2003; Hagell, Nordling, Reimer, Grabowski, & Persson, 2002; Schrag, 
Jahanshahi, & Quinn, 2000). In recognition of the significance of non-motor 
symptoms in PD, a number of researchers have recently proposed a 
reconceptualisation of both the definition and clinical classification of PD to 
incorporate non-motor symptoms as core elements of the disease (Chaudhuri et al., 
2013; Stern, Lang, & Poewe, 2012; Weintraub & Burn, 2011).   
 
1.7.6 Non-Motor Treatment 
Despite their adverse effect on quality of life and mortality, non-motor 
symptoms are largely underreported by individuals with PD, underrecognised by 
phsyicians, and ultimately, undertreated. In contrast to the established framework for 
the treatment of motor symptoms in PD, the management of non-motor disturbances 
is largely inadequate at present (Frisina et al., 2008). Primary treatment strategies in 
PD (i.e., dopaminergic replenishment) have been found to have minimal effect on the 
majority of non-motor symptoms (Muller, 2002). For example, in a Movement 
Disorder Society task force review of surgical and pharmacological treatments for 
PD, Goetz and colleagues (2005) concluded that dopaminergic therapies could not be 
recommended for non-motor symptoms in PD due to a lack of evidence of their 
efficacy in treating such symptoms. Chaudhuri, Healy and Schapira (2006) suggest 
this is because the majority of non-motor symptoms in PD have a purported 
noradrenergic or serotonergic basis while primary treatment in PD is focused on 
restoration of the dopaminergic system. In addition to dopaminergic therapy having a 
lack of effect for non-motor symptoms, dopaminergic drugs have also been reported 
to cause and/or exacerbate certain non-motor symptoms (Muller, 2002). For 
example, it is well known that significant sleep disturbances can emerge as a direct 
result of dopaminergic and other antiparkinsonian medications (Garcia-Borregueor, 
Larrosa, & Bravo, 2003). Addiction and impulse control disorders (ICDs) have also 
been linked with dopaminergic therapies in PD, with ICDs linked particularly with 
the use of dopamine agonists (Ferreri et al., 2006). Addiction and dependence to 
levodopa has been well documented among individuals with PD (Stocchi, 2005). 
Pathological gambling has also been described in PD, particularly among those 
taking the dopamine agonist pramipexole (Morgan, Iyer, & Sethi, 2006). 
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Hypersexuality and lack of sexual impulse control have also been described in PD 
and linked with dopaminergic treatment (Klos et al., 2005; Riley, 2002).  
 
Thus, while dopaminergic therapies are the most common treatment for PD, 
there is evidence that these therapies complicate non-motor symptoms. In recognition 
of this, The National Institute for Health and Clinical Excellence (2006) have 
recently acknowledged the bias towards treatment of motor symptoms in PD and 
highlighted a pressing need for research into the appropriate management of non-
motor symptoms. Lang and Obeso (2004) suggest that current dopaminergic 
replenishment strategies are inadequate for the treatment of PD on the whole and that 
alleviation of motor symptoms should not be the ultimate goal of PD treatment. The 
authors further stated that the development of a primary treatment which addresses 
both motor and non-motor symptoms will be the next “truly major advance” (p. 
315) in the management of PD. The remainder of this chapter focuses on the two 
most prevalent non-motor symptoms in PD; depression and anxiety. 
 
 
1.8 Depression in PD 
 
1.8.1 Definition 
Depression is characterised by the experience of low mood and/or the 
absence of positive affect. The Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV-TR; American Psychiatric Association; APA, 2000) specifies 
three depressive disorders; major depressive disorder, dysthymic disorder and 
depressive disorder not otherwise specified. Major depressive disorder (MDD) is 
characterised by the presence of depressed mood and/or a marked loss of interest 
and/or pleasure in nearly all activities for a period lasting at least two weeks (APA). 
Dysthymic disorder, also known as dysthymia, is a milder and chronic form of major 
depressive disorder and is characterised by the presence of a chronically low or 
depressed mood, occurring for the most of the day, more days than not, over a 
minimum two year period (APA). The DSM-IV-TR category of DDNOS refers to a 
group of conditions with depressive features that do not meet the clinical criteria for 
major depressive disorder, dysthymia, adjustment disorder with depressed mood, or 
adjustment disorder with mixed anxiety and depressed mood (APA). Aside from low 
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mood, other symptoms that occur in depression include disturbances to; sleep, 
appetite, weight, psychomotor functioning, concentration and energy, and feelings of 
worthlessness and guilt as well as recurrent thoughts of death and/or suicide. At least 
five symptoms occurring over a two-week period are required for a diagnosis of 
MDD, while a minimum of three symptoms present over a two-year period are 
required a diagnosis of dysthymia (APA). 
 
1.8.2 Prevalence 
Depression is the most common non-motor complication in PD, with up to 
75% of people with PD likely to experience depressive symptoms at some stage 
throughout their illness (Brooks & Doder, 2000; Veazey et al., 2005). While the 
exact rate of depression in PD is not known, an average prevalence rate of 40 to 50% 
is commonly cited in the literature (Lemke, 2008; Stella, Banzato, Quagliato, & 
Viana, 2008). There is wide variability in prevalence estimates, however, with 
reported rates ranging from 2.7% to more than 90% depending on the definition of 
depression, assessment method and study sample used (Reijnders et al., 2008). 
 
Three systematic reviews of studies examining the prevalence of depression 
in PD have been published. In the first systematic review of the prevalence of 
depression in PD, Slaughter and colleagues (2001) reported clinically significant 
depression in 42% of people with PD across 11 studies using DSM-III or DSM-III-R 
criteria. Minor depression was the most common affective disturbance, affecting 
37% of participants, while 22.5% met diagnostic criteria for dysthymia and 25%, 
major depressive disorder. Similarly, in a systematic review of 8 studies by Veazey 
and colleagues (2005), major depression was found to affect between 7 and 32% of 
persons with PD while 10 to 31% met clinical criteria for dysthymia. In the most 
recent systematic review and meta-analysis of 104 studies assessing the prevalence 
of depression in PD, Reijnders and colleagues (2008) reported slightly lower rates 
than the two earlier reviews, finding major depressive disorder in 17% of people with 
PD, subclinical depression in 22%, and dysthymia in 13% of individuals. 
 
 In addition to clinical depression, a significant proportion of individuals with 
PD have been found to display depressive symptoms, although not at a clinical level 
(Brooks & Doder, 2000). Across eight studies examining self-reported depressive 
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symptomology in PD, Veazey and colleagues (2005) found between 27 to 76% of 
people with PD, with an average of 54%, experienced depressive symptoms at some 
stage of their illness. A similar review by Reijnders and colleagues (2008) returned a 
lower although still marked average rate of 35%. 
 
1.8.2.1 Prevalence comparisons. Despite the variability in prevalence 
estimates, it is clear that there is a marked occurrence of depression in PD 
populations. Approximately 15% of Australian adults between the ages of 16 and 85 
will experience a lifetime depressive disorder (Australian Bureau of Statistics; ABS, 
2007). Major depression is the most common lifetime depressive disorder affecting 
an estimated 11.6% of Australians, while approximately 2% will experience 
dysthymia (ABS). When compared with even the most conservative prevalence 
estimates of depression in PD (i.e., Reijnders et al., 2008), it can be seen that 
depression is substantially more prevalent in PD, with major depression and 
dysthymia occurring 1.5 and 6.5 times more frequently in PD, respectively. In 
addition, comparison against the rate of depression in older adults also reveals a 
higher prevalence of depression in PD. Depression affects an estimated 10% to 25% 
of older adults (Blazer, 2002; Hunkeler et al., 2006; Reynolds & Kupfer, 1999). 
Thus, depression is two to four times more common in people with PD. 
 
Perhaps it is not surprising to find that depression is more common among 
people with PD compared to the general population and healthy older adults given 
the additional physical and mental stressors associated with living with PD. 
However, studies comparing the rate of depression in PD against other motor 
disorders with a comparable level of functional disability have revealed a higher rate 
of depressive disorders in PD. Miller and colleagues (2007) compared the rate of 
depression in people with PD, people with dystonia and people with essential tremor. 
Prevalence rates of 48%, 37% and 34% were reported respectively, indicating a 
higher rate of depression in PD. Similar findings have been made with respect to 
other neurological diseases. Starkstein and colleagues (1996) examined the rate of 
depression in people with Alzheimer’s disease and people with PD with dementia. 
Groups were matched for age, sex and cognitive impairment. Major depression was 
significantly higher in the PD group (30%) compared to Alzheimer’s (6%). However, 
the same rate of dysthymia (27%) was found for both groups. In addition, the 
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severity of depression in PD has also been found to be significantly higher when 
compared to similarly disabled groups. Ehmann, Beninger, Gawel and Riopelle 
(1990) examined depressive symptoms in individuals with PD and people with 
various chronic disabling conditions matched for functional disability (e.g., 
amyotrophic lateral sclerosis and peroneal muscular dystrophy). People with PD 
were found to score significantly higher across all factors on the Beck Depression 
Inventory-II (Beck, Steer & Brown, 1996) than the control group.  
 
 
1.9 Anxiety in PD 
 
1.9.1 Definition 
 Anxiety is a broad overarching term used to describe a number of anxiety 
disorders characterised by the presence of distressing fear, worry and apprehension 
(Richard, Schiffer, & Kurlan, 1996). Other psychological and autonomic symptoms 
central to anxiety disorders include irritability, poor concentration, sleep disturbance, 
sweating, dry mouth, heart palpitations, restlessness, muscle tension and avoidance 
behaviour (NICE, 2000). There are a range of anxiety disorders listed in the DSM-
IV-TR defined by their symptom presentation, response to medications, and 
presumed aetiologic mechanisms. Some common anxiety disorders that present in 
PD include generalised anxiety disorder, panic disorder, and social anxiety disorder. 
 
1.9.2 Prevalence 
 Studies examining the occurrence of anxiety in PD are somewhat limited in 
comparison to those investigating depression however, the available results suggest 
that anxiety disorders are also common in PD populations. Between 30 to 40% of 
individuals with PD will meet DSM criteria for an anxiety disorder at some point of 
their illness and a recent large-scale study by Negre-Pages and colleagues (2010) 
showed that up to 51% of individuals with PD can experience clinically significant 
anxiety based on scores equal or greater to 8 on the Hospital Anxiety and Depression 
Scale (HADS; Snaith & Zigmond, 2000). Panic disorder has been suggested as the 
most frequently occurring anxiety disorder in PD, affecting between 13 to 30% of 
individuals (Leentjens et al., 2008). Up to 11% of people with PD experience 
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generalised anxiety disorder, and one study reported social anxiety disorder in 15% 
of participants with PD (Stein, Heuser, Juncos, & Uhde, 1990). 
 
1.9.2.1 Prevalence comparisons. Similar to depression, comparison of the 
rate of anxiety disorders in PD against other populations suggests an elevated rate of 
anxiety in PD. The ABS estimate that 26% of Australian adults will be affected by a 
lifetime anxiety disorder, with approximately 5.2% likely to experience panic 
disorder and 5.9%, generalised anxiety disorder (ABS, 2007). Comparisons against 
prevalence estimates of anxiety in PD indicate that the rate of anxiety disorders is 1.5 
times greater among individuals with PD, with panic disorder up to 6 times greater 
and generalised anxiety almost two times higher. In particular, the high occurrence of 
anxiety in PD is considered atypical given that the onset of anxiety disorders in later 
life is not common in primary psychiatric populations (Henderson et al., 1992). An 
American study estimated the prevalence of anxiety to be 3.5% for adults over 65 
years living independently and 5.5% for those in institutionalised care (Walsh & 
Bennett, 2001). Other epidemiological studies have reported rates ranging from 0.7 
to 9% for community-dwelling older adults (Flint, 1994).  
 
Rates of anxiety disorders in PD are also considerably higher when compared 
with other equally debilitating diseases. In their comparison of anxiety disorders in 
PD and multiple sclerosis, Schiffer and colleagues (1988) reported 75% of the PD 
group met diagnostic criteria for past or present generalised anxiety disorder, 
compared to only 10% of individuals with multiple sclerosis. Similarly, Menza, 
Robertson-Hoffman and Banapace (1993) compared anxiety in people with PD and 
controls with chronic ortheoarthritis matched for age and illness duration. Twenty-
nine percent of PD participants were found to meet diagnostic criteria for an anxiety 
disorder compared to 5% of controls. Stein and colleagues (1990) reported 
significantly higher rates of anxiety in PD patients (38%) compared to patients with 
various chronic illnesses (11%). A higher prevalence of anxiety has also been 
reported in PD compared to Type I diabetes as well as rheumatoid arthritis (Mondolo 
et al., 2007). 
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1.9.3 Comorbidity of Depression and Anxiety in PD 
 In addition, there is a high rate of comorbid depression and anxiety in 
individuals with PD. In general, depressive and anxiety disorders commonly co-
occur in primary psychiatric populations with several studies reporting comorbid 
major depression and anxiety disorders in up to 66% of primary psychiatric patients 
(DiNardo et al., 1990; Ormel et al., 1991; Sherbourne et al., 1996; Zung et al., 1990). 
However, this rate is generally lower in older adult populations. Alexopoulos (1990) 
reported a 38% rate of comorbid anxiety disorders in elderly outpatients with major 
depression. Similarly, Lenze and colleagues (2000) found 35% of older adults over 
60 with depressive disorders had at least one lifetime anxiety disorder with 23% 
having a current diagnosis. Comorbidity rates of depression and anxiety in PD have 
been found to be significantly higher than those in general older adult populations. In 
a study by Menza and colleagues (1993), 67% of PD patients with depression were 
found to have an anxiety disorder while 92% with an anxiety disorder had comorbid 
depression. 
 
Overall, both depression and anxiety have been found to be more prevalent in 
PD compared to within the general population, older adult populations, with patients 
with chronic illness, as well as patients with various motor and neurological diseases. 
In addition, the comorbidity rate of the two conditions is also considerably higher. 
Collectively, the statistics presented in this section suggest a significant relationship 
between anxiety, depression and PD, where these psychiatric disorders are more 
common compared to other chronic, motor or neurological diseases. Most 
importantly, these findings highlight the clinical significance of depressive and 
anxiety disorders in PD and suggest the pressing need for appropriate treatment. 
 
 
1.10 Assessment, Diagnosis and Symptom Presentation of  
Depression and Anxiety in PD 
 
Although commonly occurring, detecting depression and anxiety in PD can 
often be challenging as there is considerable overlap between the clinical features of 
the psychological disorders and PD. Symptoms such as psychomotor retardation, 
facial masking and appetite disturbance are common in both PD and depression 
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(Cummings, 1992; Guze & Barrio, 1991), while tremor, tension and muscle aches 
feature in both anxiety and PD (Leentjens et al., 2008). In addition, sleep 
disturbance, fatigue and cognitive difficulties are common in all three (Brooks & 
Doder, 2000). A thorough assessment procedure is therefore crucial in recognising 
depressive and anxiety disorders in PD. 
 
Assessment for depression, anxiety and other psychological conditions in PD 
is most frequently performed by the individual’s general medical practitioner 
(Parkinson’s Western Australia, 2003). Currently, there are no best practice 
guidelines or procedures in place to aid physicians in this process despite the known 
prevalence of depression and anxiety in PD. However, McDonald and colleagues 
(2003) recommend a two-step assessment process. First, it is advised that physicians 
screen all PD patients for psychological disturbance, especially depression. Okun and 
Watts (2002) suggest this can be easily accomplished by asking patients to complete 
self-rating scales in the waiting room before an appointment. Scores on these scales 
can then be used to determine whether patients require a more comprehensive 
clinical assessment. This assessment may be conducted by the general practitioner, or 
via referral to a mental health professional (i.e., a psychologist or psychiatrist). 
 
1.10.1 Screening 
Screening using rating scales is quick, convenient and can be highly effective 
in detecting signs of psychological disturbance in PD (Okun & Watts, 2002). 
However, selection of appropriate scales for use with persons with PD is essential. 
Due to the symptom overlap between anxiety, depression and PD, scales developed 
for the general population may not always be a valid measure of depression and/or 
anxiety in PD. Generally, these scales have a propensity to overestimate the presence 
and/or severity of depression and anxiety in PD as they do not differentiate between 
PD symptoms and symptoms of anxiety or depression (McDonald et al., 2003). 
Scales featuring a large number of physical and somatic symptoms, in particular, are 
likely to overestimate depression and/or anxiety in persons with PD due to the high 
overlap between physical and somatic symptoms in depression, anxiety and PD. 
 
1.10.1.1 Depression scales. There are currently no scales which specifically 
measure depression in PD. However, a number of general population scales have 
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been found to be suitable for use in PD populations. A Movement Disorder Society 
task force review (i.e., Schrag et al., 2007) evaluated the suitability of several 
popular depression scales as assessment tools for depression in PD. Scales that were 
investigated included the Beck Depression Inventory (BDI-I; Beck et al., 1961), 
Montgomery-Asberg Depression Scale (MADRS; Montgomery & Asberg, 1979), 
Geriatric Depression Scale (GDS; Yesavage et al., 1982), Hospital Depression and 
Anxiety Scale (HADS; Snaith & Zigmond, 2000) and Hamilton Depression Rating 
Scale (Ham-D; Hamilton, 1960). All scales were found to have some utility as 
screening tools of depression in PD. In particular, the Ham-D and BDI were 
recommended as they are the only scales to have been validated in PD populations. 
 
The Ham-D is a 17-item clinician-rated scale considered to be the ‘gold 
standard’ for assessing depressive symptoms (Bagby, Ryder, Schuller, & Marshall, 
2004). With regards to PD, the task force review recommended the Ham-D as being 
most suitable for assessing depression severity in treatment trials, correlation studies 
with PD symptoms or pathological markers, and for examining the phenomenology 
of depression in PD (Schrag et al., 2007). The clinician administered nature of the 
scale limits its use as a screening tool for PD in clinical situations however. The 
BDI-I was proposed to be a potentially more appropriate clinical screening tool due 
to its self-report nature. The BDI-I is a 21-item self-report scale of depression that is 
widely used in both clinical and research settings (Steer, Cavalieri, Leonard, & Beck, 
1999). Schrag and colleagues recommended the use of the BDI-I in PD patients for 
clinical screening, assessing severity of depressive symptoms and for monitoring 
change during treatment. More recent research has since confirmed the validity and 
utility of the Ham-D for assessing depressive symptoms in PD (e.g., Dissanayaka, 
O’Sullivan, Silburn, & Mellick, 2011). 
 
Since the 2007 Movement Disorders taskforce review, several other 
psychometric scales measuring depression have also been validated in PD samples.  
Specifically, Dissanayaka and colleagues (2011) showed that the Geriatric 
Depression Scale and self-reported Hamilton Depression Rating Scale (HDI) are also 
valid measurement tools of depression with individuals with PD. Particularly; the 
authors recommended the use of the GDS over the HDI due to its brevity and slightly 
higher sensitivity in detecting depression in PD.  
 28
 
1.10.1.2 Anxiety scales. As with depression, no scales specifically measuring 
anxiety in PD have been developed. However, a similar Movement Disorder Society 
taskforce review (i.e., Leentjens et al., 2008) was commissioned to assess the utility 
of popular anxiety rating scales as assessment tools in PD. Scales included in the 
review were the Beck Anxiety Inventory (BAI; Beck, Epstein, Brown, & Steer, 
1988), the Hospital Depression and Anxiety Scale (HADS; Zigmond & Snaith, 
1983), Zung Self-Rating Anxiety Scale (SAS) and Anxiety Status Inventory (ASI; 
Zung, 1971), Speilberger State Trait Anxiety Inventory (STAI; Spielberger, Gorsuch, 
& Lushene, 1970), and the Hamilton Anxiety Rating Scale (Ham-A; Hamilton, 
1959). The review committee found that as validation studies of these scales in PD 
were limited, none could be recommended for use in PD populations. However, all 
scales were classed as ‘tentatively suitable’ for use in PD, pending further research.  
 
Since this review, the Ham-A, BAI and HADS have all been validated in PD 
samples. Leentjens and colleagues (2012) compared the three scales as assessment 
tools for anxiety in PD and reported good acceptability, score distribution, inter-rater 
reliability and test-retest reliability for all three measures. The authors recommended 
use of the Ham-A, BAI and HADS in screening for anxiety in clinical practice or for 
assessing symptom severity in research studies however stated that further 
investigation of each scale as a measure of treatment response was required. 
Additionally, Matheson and colleagues (2010) conducted a validation study of the 
Geriatric Anxiety Inventory (GAI; Pachana et al., 2007) in PD. The GAI is a 
relatively new self-report anxiety scale developed specifically for the measurement 
of anxiety in older adults. The GAI contains 20 items and focuses on cognitive 
symptoms of anxiety. Matheson and colleagues reported that the GAI showed good 
internal consistency and test-retest reliability, displayed good concurrent validity 
against the STAI and DSM-IV and was overall an appropriate measure of anxiety 
with individuals with PD. 
 
1.10.2 Clinical Assessment and Diagnostic Approach 
A well-structured clinical assessment is the most crucial factor in detecting 
depression and anxiety in PD, and should ideally involve three elements; (i) an 
examination of personal, social, medical and psychiatric history, (ii) a cognitive 
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status assessment, and (iii) a structured assessment of current psychological 
symptoms, in which the DSM-IV-TR and associated diagnostic interviews (e.g., the 
Structured Clinical Interview for DSM (SCID; First, Spitzer, Gibbon, & Williams, 
2002) are considered the gold standard (Okun & Watts, 2002). 
 
Diagnosis of depression and/or anxiety in PD is challenging even when strict 
clinical criteria are employed, however. Due to the symptom overlap between 
anxiety, depression and PD, people with PD can often display symptoms resembling 
the former conditions without actually having a depressive or anxiety disorder. The 
primary challenge to clinicians in diagnosis is therefore how to best deal with this 
symptom overlap. Two major diagnostic strategies have been proposed. The 
inclusive approach suggests that all presenting symptoms in support of a depressive 
and/or anxiety disorder should be counted towards a diagnosis. Conversely, the 
exclusive strategy advises that symptoms which may be accounted for by PD, most 
commonly physical and somatic symptoms, should not be counted towards a 
psychological diagnosis (Leentjens et al., 2003). The DSM-IV-TR is premised on an 
exclusive diagnostic approach, although with some leeway, advising that symptoms 
should only be discounted when they are clearly and fully accounted for by a general 
medical condition (APA, 2000). 
 
Differentiating between the aetiological roots of presenting symptoms is 
essentially impossible to accomplish in clinical practice, however, with any such 
attribution an informed presumption at best (Starkstein et al., 2011). The ultimate 
difficulty with employing an exclusive strategy is that valid symptoms may 
potentially be ignored and can consequently result in failure to detect a presenting 
depressive and/or anxiety disorder. For example, there is current evidence indicating 
that specific somatic symptoms featuring in both PD and depression are central to the 
diagnosis of depression in PD (Leentjens et al., 2003). Automatic exclusion of these 
symptoms would therefore potentially result in failure to detect a considerable 
number of cases of depression in PD. Several expert PD taskforces have thus 
recommended that an inclusive diagnostic approach may represent the best strategy 
for diagnosing depression and anxiety in PD (Leentjens et al., 2008; Marsh, 
McDonald, Cummings, & Ravina, 2006; Schrag et al., 2007). Although the potential 
for false positives and consequently overdiagnosis is acknowledged, this would 
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appear preferable to failing to recognise and ultimately failing to provide treatment to 
those affected by depression and/or anxiety in PD. 
 
1.10.3 Clinical Presentation 
 In addition to difficulties with diagnostic approach, recognition of depression 
and/or anxiety in PD can be challenging in itself, with a number of researchers 
suggesting a differing symptom profile of depression and anxiety in PD compared to 
that in primary psychiatric patients (Brook & Doder, 2000). 
 
1.10.3.1 Depression. The clinical manifestation of depression in PD is generally 
similar to that of primary depressive disorders with common symptoms being 
negative emotional reactions, low energy, lack of interest, difficulty with 
concentration or decision-making, sadness, hopelessness, social isolation, and sleep 
difficulities (Burn, 2002; Farabaugh et al., 2009), although some slight differences in 
symptom presentation have been reported. For example, higher rates of pessimism, 
irrational thinking, sadness, and dysphoria have been observed (Cummings, 1992; 
McDonald et al., 2003), while there also appears to be a lesser frequency of guilt, 
self-blame, feelings of failure, and completed suicides (Brown et al., 1988; Richard 
et al., 1996; Slaughter et al., 2001). In particular, illness-related concerns and 
cognitions feature prominently in depression in PD (Brook & Doder, 2000). For 
example, higher rates of sadness, pessimism, and dysphoria in PD have been linked 
with thoughts of hopelessness and helplessness in regards to having PD and one’s 
inability to cope (Hurt, Weinman, Lee, & Brown, 2012; McDonald et al., 2003). A 
bimodal frequency of depression in PD has also been commonly reported. An initial 
peak of cases usually occurs in the period shortly following diagnosis of PD, with a 
second peak observed in the latter, more advanced stages of illness (Brown & 
Jahanshai, 1995; Celesia & Wanamaker, 1972; Cummings, 1999; Schrag, Jahanashi, 
& Quinn, 2001; Starkstein et al., 1992). Thus, these are the most crucial times for 
physicians to monitor and assess any potential depressive symptoms in people with 
PD. In addition, cases of depression predating the onset of PD have also been 
reported in an estimated 12 to 37% of individuals with PD with depressive 
syndromes (Burn, 2002; Taylor et al., 1986). It remains unclear as to why this occurs, 
however, some researchers have suggested that in some cases depression may act as 
a predisposing factor for PD (Brooks & Doder, 2002). 
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1.10.3.2 Anxiety. The pattern of anxiety disorders in PD generally differs to 
that observed in the general population. According to the ABS (2007), the three most 
common lifetime anxiety disorders in Australia, in order from most to least, are post-
traumatic stress disorder, social phobia, and agoraphobia. In PD however the three 
most commonly occurring anxiety disorders from most to least are panic disorder, 
generalised anxiety disorder and social phobia (Dissanayaka et al., 2010; Prediger et 
al., 2012). Thus an atypical presentation of anxiety is observed in PD.  
 
There has been little research investigating differences in the symptom profile 
of the various anxiety syndromes in primary populations and PD. However, an 
especially high rate of panic symptoms has been noted in PD, even in those without 
panic disorder (Richard et al., 1996). It has also been suggested that anxiety in PD 
can manifest as a ‘fear of falling’, a concern which is frequently observed among 
patients (Bloem, Grimbergen, Cramer, Willemsen, & Zwinderman, 2001). Further, 
similar to depression, predominant concerns in anxiety in PD have been found to 
focus on PD itself, particularly, anxiety regarding the unpredictability of motor 
symptoms, the uncertainty of prognosis and the perceptions of others towards PD 
(Backer, 2000). Thus, clinicians examining PD patients for potential anxiety are 
advised to pay particular focus to these symptoms and cognitions. Studies examining 
the onset and course of anxiety disorders in PD suggest that anxiety disorders in PD, 
namely phobias, often precede the diagnosis of PD (Henderson et al., 1992; Stein et 
al., 1990; Vazquez et al., 1993). Sporadic cases of anxiety preceding the onset of 
familial PD have been reported, however (i.e., Lauterbach & Duvoisin, 1991). A 
recent study of 513 individuals with PD in the UK also reported a significant 
association between anxiety and younger age-of-onset of PD (Burn et al., 2012). The 
prevalence and severity of anxiety was significantly higher among study participants 
who were diagnosed with PD before 55 years of age. 
 
 
1.11 Aetiology of Depression and Anxiety in PD 
 
Early explanations for the occurrence of depression and anxiety in PD heavily 
favoured a biomedical aetiology (Leentjens et al., 2004). A number of similar 
neurochemical changes have been observed in people with anxiety, depression and 
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PD, leading to the hypothesis that depression and anxiety develop as a direct result of 
the neurochemical changes inherent within PD (Frisina et al., 2008).  
Specifically, changes to the dopaminergic, serotonergic and noradrenergic 
neurotransmitter systems have been demonstrated in all three conditions (Richard et 
al., 1996). For example, dopaminergic cell loss in the ventral tegmental area (VTA) 
has been well-documented in PD (Leentjens et al., 2004), and implicated in the 
development of depression (Fibiger, 1984) as well as social anxiety disorder (Potts & 
Davidson, 1992), panic disorder (Pitchot et al., 1992), and obsessive compulsive 
disorder (OCD; McDougle, Goodman, & Price, 1994). Similarly, significant loss of 
serotonergic neurons in the raphe nuclei and a 50% reduction in the levels of the 
serotonin metabolite 5-HIAA in the cerebrospinal fluid has been well demonstrated 
in PD (Mayeux et al., 1986) and implicated in the development of OCD (Insel, 
1992), social anxiety disorder (Miner et al., 1995), GAD, panic disorder (Charney, 
Woods, Krstyal, & Heninger, 1990), and especially depression (Leentjens et al., 
2006). Finally, loss of noradrenergic cells in the locus coeruleus is well described in 
PD. Noradrenergic cells in the locus coeruleus project to limbic and cortical regions 
involved in the processes of cognition, arousal, sleep regulation and stress response 
mediation (Brunello et al., 2003). Disruption to these processes has been proposed to 
place people with PD at greater susceptibility to depressive disorders (Burn; 2002) 
and especially panic disorder (Richard et al., 1996). Adrenergic receptors have been 
found to produce panic symptoms (e.g., increased heart rate, pupil dilation, diversion 
of blood flow to muscles) when binded with an agonist, and a significant decrease in 
α2-adrenergic receptor sensitivity has been observed in PD (Charney et al.). 
 
A general consensus has been established asserting that a pure biomedical 
aetiology of depression and anxiety in PD is not likely (Frisina et al., 2008). This 
consensus was drawn based on observations that while dopaminergic, serotonergic 
and noradrenergic changes are evident in all individuals with PD, not all people with 
PD develop depression and anxiety (Poewe & Seppi, 2001). It is thus generally 
acknowledged that rather than constituting a direct cause of depression and anxiety 
in PD, underlying neurochemical changes inherent within PD are likely to place 
people with PD at a greater vulnerability to developing depression and anxiety 
(Taylor & Saint-Cyr, 1990), with the onset of psychological disturbance ultimately 
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precipitated by the many life stresses, changes and challenges associated with living 
and coping with PD (Serra-Mestres & Ring, 2002).  
1.11.1 Stressful Life Events and the Development of Depression and Anxiety 
Major life events, changes and stresses are well recognised as risk factors for 
psychological illness (Goldberg, 2006). With respect to depression, an association 
between stressful life events and the onset of depressive illness has been well 
documented. Retrospective studies examining life events preceding the onset of 
depression have consistently reported a significantly higher occurrence of antedating 
negative life events in people with depression when compared to the same time 
period in non-depressed controls (e.g., Kendler, Karkowski, & Prescott, 1999; 
Kessler, 1997; Paykel, 2007; Wilhem et al., 2006). In particular, certain types of life 
events have been reported significantly more often and include undesirable events, 
exits from the social field, traumatic events, events related to employment and 
marriage, and events concerning illness and disability (Evans & Katona, 1993) all of 
which are associated with PD. No significant differences in preceding desirable 
events have been reported, however.  
 
Similar findings have been made in regards to anxiety disorders. In a study of 
people with panic disorder by Faravelli and Pallanti (1989), comparison of life events 
during the year preceding the onset of panic disorder against the same time period in 
healthy controls revealed a significantly greater number of negative life events, loss-
themed events, threat-themed events as well as adjustment-themed events for the 
panic group. In particular, loss and danger-themed life events were found to be most 
frequently associated with panic disorder (Faravelli & Pallanti; Finlay-Jones & 
Brown, 1981). Most interestingly, and also consistent with earlier findings by 
Faravelli (1985) and Roy-Byrne, Geraci and Uhde (1986), it was found that the 
highest concentration of negative life events was reported in the month immediately 
preceding the onset of panic disorder.  The experience of unexpected, negative and 
very important life events has also been found to result in a threefold increase in the 
risk of generalised anxiety disorder (Blazer, Hughes, & George, 1987). Thus, there is 
a strong relationship between stressful life experiences and the development of both 
depression and anxiety. 
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Living with a chronic illness is considered to be one of the most stressful 
circumstances in life (Clarke & Currie, 2009). PD presents many challenges to both 
the affected individual and their family, with considerable disruptions to normal 
functioning. Multiple losses, whether actual or perceived, are commonly 
experienced. The most obvious loss is that of health and physical functioning, with 
the predominant challenge in PD being adaptation to motor symptoms and 
deteriorating health. However, several other stressors and challenges are common in 
PD and include; employment and financial issues most frequently associated with 
inability to work due to physical symptoms, marital problems and social problems, 
self-consciousness and negative self-awareness in regards to physical symptoms, as 
well as fear and uncertainty about the future, especially in regards to the awareness 
that available treatments are only palliative (McDonald et al., 2003).  
 
It has been proposed that the daily stresses and challenges associated with 
living with PD combined with a biological vulnerability due to underlying 
neurochemical changes is likely responsible for the manifestation of depressive and 
anxiety disorders in PD (Serra-Mestres & Ring, 2002). Thus, a diathesis-stress 
model for the aetiology of depression and anxiety in PD is proposed.  
 
 
1.12 Correlates of Depression and Anxiety in PD 
 
Research examining the correlates of depression and anxiety in PD have 
consistently shown that both conditions are significantly associated with a number of 
negative outcomes in PD including; poorer quality of life, greater cognitive 
impairment, more severe motor impairment, and greater functional impairment. In 
this section, the main findings in this area will be reviewed. 
 
1.12.1 Motor Symptoms 
 Investigations into the relationship between anxiety, depression and motor 
functioning in PD have resulted in mixed findings. With respect to depression, early 
studies reported no relationship between depression and symptom severity and/or 
progression in PD (e.g., Huber, Paulson, & Shuttleworth, 1988; Mayeux et al., 1981; 
Mayeux, 1984). However, several more recent studies have reported more severe 
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motor symptoms in people with PD with depressive disorders compared to those 
without (e.g., Dissanayaka et al., 2011; Dissanayaka et al., 2011b; Prado & Barbosa, 
2005; Rojo et al., 2003; Stella et al., 2008; Weintraub et al., 2004). It is not clear 
whether this indicates that depression results in faster symptom progression or 
whether individuals with more severe motor symptoms are more likely to develop 
depression due to the cross-sectional nature of existing investigations. Thus at 
present, the impact of depressive symptoms on motor functioning in PD remains 
unclear. A longitudinal study following individuals with PD with and without 
depression throughout their illness and comparing rates of motor progression 
between the two groups is required.   
 
However, there does appear to be a relationship between motor symptoms 
and anxiety, and potentially of a reciprocal nature. Marsh (2000) suggests that 
anxiety can worsen motor impairment, with more pronounced and/or frequent 
bradykinesia, freezing (motor blocks) and dyskinesias being common. Greater motor 
impairment can in turn lead to greater anxiety about one’s ability to cope with 
worsening symptoms. In support, Lauterbach and colleagues (2003) found that 
people with PD with panic disorder (current or past) experienced more freezing per 
day when compared to those with PD without anxiety. A recent cross-sectional study 
by Dissanayaka and colleagues (2010) also showed a significant association between 
presence of anxiety and severity of PD symptoms among 114 Australian adults with 
PD. Similarly, in the largest cross-sectional study of anxiety symptoms in PD to date, 
Leentjens and colleagues (2012) showed that among 342 individuals with PD, 
generalised anxiety disorder, agoraphobia, and social phobia were more prevalent 
among individuals with PD with motor fluctuations. 
 
1.12.2 General Functioning and Health Status 
 Anxiety, and in particular, depression, have also been associated with greater 
functional impairment and lower health status in PD (e.g. Ehman et al., 1990; 
Holroyd, Currie, & Wooten, 2005; Menza & Mark, 1994). For example, Stella and 
colleagues (2008) reported significantly greater functional impairment in people with 
PD with depression compared to those with PD and no depressive illness. Similarly, 
Dissanayaka et al. (2010) showed a significant association between anxiety and 
greater impairment of daily functioning as assessed by the Activities of Daily Living 
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subscale of the Unified Parkinson’s Disease Rating Scale (Fahn et al., 1987). It is not 
clear whether this indicates that individuals whose daily activities are significantly 
impaired by PD are more likely to develop depression and/or anxiety out of 
frustration and sadness for loss of physical functioning, or whether inactivity and 
avoidance associated with depression and anxiety results in decay in activities of 
daily living. A study by Weintraub, Moberg, Duda, Katz and Stern (2004) suggests 
that it may be the latter that is true, however. In a study of 114 community-dwelling 
individuals with PD, the authors showed that depression contributed significantly and 
most strongly to the decay of daily functional capacity over all other study variables 
including motor symptoms.  
 
1.12.3 Quality of Life 
 There have been several studies investigating health-related quality of life in 
people with PD. Health-related quality of life is a subjective rating of the degree to 
which one’s health is affecting the quality of one’s life situation (Schrag, 2006). 
Depression has consistently been found to be the main determinant of poor quality of 
life in people with PD, as well as consistently rated by persons with PD as more 
detrimental to subjective well-being than motor symptoms and disability factors 
(e.g., Behair, Srivastava, & Pandey, 2005; Carod-Artal, 2008; Rahman, Grifin, 
Quinn, & Jahanshai, 2008). In a recent cross-sectional study of 462 individuals with 
PD in the UK, Hinnel and colleagues (2012) showed that depression explained the 
largest proportion of variance in low quality of life measured using the Parkinson’s 
Disease Questionnaire-8 (PDQ-8; Peto et al., 1995), over all other study variables 
including age, PD duration, comorbid health conditions, and motor symptoms. 
Similarly, depression has been found to negatively correlate with an extensive range 
of specific life domains. Using the Medical Outcomes Study 36-Item Short Form 
Health Survey (SF-36; Ware & Sherbourne, 1992), Kupio, Marttila, Helenius, 
Toivonen and Rinne (2000) reported high negative correlations between depressive 
symptoms and every SF-36 dimension including vitality, social functioning, role 
limitations and bodily pain. Depression was also found to be more strongly 
associated with all dimensions than physical symptoms. In a similar study using the 
Parkinson’s Disease Questionnaire-39 (PDQ-39; Peto et al., 1995), Schrag and 
colleagues (2000) also reported significant correlations between depression and all 
PDQ-39 dimensions including activities of daily living, mobility, communication and 
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social support. Comparison of PDQ-39 scores for depressed and non-depressed PD 
patients also revealed significantly poorer quality of life across each dimension of the 
PDQ-39 for PD participants with depression. 
 In addition, anxiety has also been found to adversely affect quality of life in 
PD. A recent study by Hinnell et al. (2011) found that second to depression, anxiety 
symptoms were the second strongest unique predictor of poor quality of life among a 
sample of 462 individuals with PD in the UK. Moreover, using stepwise linear 
regression, an earlier study by Rahman and colleagues (2008), demonstrated that 
anxiety symptoms significantly accounted for a further 17% of variance in quality of 
life in addition to the variance already explained by depressive symptoms. This was 
the first study to recognise the additional contribution of anxiety to health-related 
quality of life in PD and highlights the need for further research into the unique 
impact of anxiety disorders on well-being in PD.  
 
1.12.4 Cognition 
 Cognitive difficulties are commonly evidenced in PD and can range from 
mild impairment to severe dementia.  A considerable body of research has found that 
individuals with PD experiencing depression generally exhibit more severe cognitive 
decline when compared to those with PD without affective disturbance (Emre, 2003; 
Kupio et al. 2000; Morrison et al., 2004; Rojo et al., 2003; Uekermann et al., 2003; 
Zgaljardic, Borod, Foldi, & Mattis, 2003). Stefanova and colleagues (2006) found 
that impairment in planning, organisation, and problem solving ability was common 
in all people with PD. Those with dysthymia also evidenced visuospatial and 
executive dysfunction, while those with major depression exhibited even broader 
impairment, affecting episodic visuospatial memory and spatial working memory, on 
top of visuospatial, executive, planning, organisation and problem solving 
impairment (Stefanova et al.).  
 
Similarly, in an earlier study by Starkstein and colleagues (1992), it was 
found that people with PD with major depression evidenced significantly greater 
declines in cognitive functioning over a 12-month period compared to those with PD 
and minor depression, who in turn showed significantly greater decline than 
individuals with PD with no depressive illness. Further, it was demonstrated that this 
marked decline in the major depression group was evident irrespective of whether 
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individuals still had a diagnosis of major depression at the time of follow-up. This 
finding suggests that depression may have an early and lasting effect on cognitive 
functioning in PD. However, a second follow-up study of longer duration by Kremer 
and Starkstein (2000), found that individuals who received treatment for depression 
evidenced less cognitive decline over a 3 to 4 year period compared to those who did 
not receive help. Thus depression may have a particular influence on early cognitive 
impairment in PD, but further declines can be avoided with the treatment of 
depressive symptoms. This finding highlights the importance of treating depressive 
syndromes in PD, especially given evidence of a significantly greater risk for 
developing dementia in individuals with PD with depression predominantly due to 
associated cognitive impairment (Lombardi, Woolston, Roberts, & Gross, 2001).  
 
The effect of anxiety on cognitive functioning in PD is less clear. Research 
on cognition and anxiety in PD is limited and much of the early research suggests no 
significant difference in cognitive performance between people with PD with anxiety 
disorders and those without (i.e., Fleminger, 1991; Lauterbach, 1993). However, a 
limited number of more recent studies suggest that anxiety may be associated with 
greater cognitive impairment in PD (i.e., Klepac, Hajnsek, & Trulja, 2010; Ryder et 
al., 2002). 
1.13 Chapter Summary 
 
There is a particular relationship between depression, anxiety and Parkinson’s 
disease where rates of these disorders are greater than those observed in any other 
medical or non-medical population. Neurochemical changes and unique psychosocial 
stressors encountered in PD place individuals with PD at between 1.5 to 6 times 
greater risk for developing depression and anxiety compared with the general 
population. 
 
Recognition and diagnosis of depression and anxiety in PD is complicated by 
a three-way symptom overlap and can be challenging for clinicians however it is 
imperative that both conditions are detected and appropriately treated. Studies 
examining the correlates of depression and anxiety in PD highlight a range of 
negative outcomes associated with untreated depression and anxiety in PD. Anxiety 
has been linked with more frequent and/or profound motor symptoms, while a strong 
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body of evidence associates depression with greater cognitive decline and a 
significant risk for developing dementia. Moreover, both conditions have been linked 
with greater functional impairment as well as significantly poorer quality of life.  
 
Research to date has shown that the range of adverse outcomes associated 
with depression and anxiety in PD can be attenuated with effective treatment. The 
next chapter reviews and provides a systematic evaluation of current treatment 
options for depression and anxiety in PD. 
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CHAPTER 2  |      Study I.  A Meta-Analysis of  
                                 Randomised Placebo-Controlled   
                                 Treatment Trials for Depression and                        
                                 Anxiety in Parkinson’s Disease  
 
 
 
2.1 Introduction 
  
Despite the negative outcomes associated with untreated depression and 
anxiety in Parkinson’s disease (PD), only an estimated 20% of people with PD 
experiencing depressive and/or anxiety complications receive some form of 
professional treatment (Frisina et al., 2008). A substantial knowledge deficit has been 
identified as an underlying factor, with researchers and clinicians alike calling out for 
more evidence-based information to guide clinical efforts (Weintraub & Burn, 2011). 
 
In this chapter the current treatment options for depression and anxiety in PD 
are reviewed by reporting on a meta-analysis of randomised placebo-controlled 
treatment trials of depression and/or anxiety in PD. Meta-analysis is a statistical 
technique in which the results from multiple treatment trials are pooled to derive a 
single standardised treatment effect (Borenstein et al., 2010). Meta-analytic findings 
hold more validity than single-trial effect estimates and offer the additional 
advantage of allowing comparisons of efficacy to be made across different treatment 
modalities through use of a common standardised metric (Borenstein et al.). 
 
This was the first broad meta-analysis of both pharmacological and non-
pharmacological treatments for depression and anxiety in PD and aimed to contribute 
to the current knowledge base of treatments for depression and anxiety in PD by 
systematically integrating the existing empirical research and identifying the most 
viable treatment option at present. The first half of the chapter provides an overview 
of the different treatment modalities for depression and anxiety in PD. The remaining 
half outlines the study methodology and presents the findings of the first broad meta-
analysis of placebo-controlled RCTs for depression and/or anxiety in PD. 
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2.2 Overview of Treatments for Depression and Anxiety in PD 
 
2.2.1 Pharmacotherapy for Depression and Anxiety 
Pharmacological management currently represents the first-line treatment 
approach for depressive and anxiety disorders in PD. In a recent survey of 33 United 
States PD specialist neurologists responsible for the care of over 16,000 individuals 
with PD regarding preferred treatments for anxiety in PD, Palanci, Marsh and 
Pontone (2011) reported that all surveyed physicians indicated that they preferred to 
prescribe various classes of psychiatric medication as the treatment of choice. Non-
pharmacological therapies were not mentioned. Traditionally, the two most 
commonly administered psychiatric medications in PD have been selective serotonin 
reuptake inhibitors and tricyclic antidepressants (Veazey et al., 2005). 
 
2.2.1.1 Serotonin reuptake inhibitors (SSRIs). SSRIs are currently the most 
commonly administered antidepressants for the treatment of depression in PD. An 
early survey of practicing neurologists by the Parkinson Study Group (Richard & 
Kurlan, 1997) revealed that 51% of physicians used SSRIs as a preferred first-line 
treatment for depression in PD. More recent studies (i.e., Chen et al., 2007; 
Weintraub et al., 2003) report increased use of SSRIs in contemporary treatment, 
with approximately two-thirds of physicians now choosing SSRIs as a first-line 
therapy. SSRIs are a class of medications which increase serotonin levels by 
inhibiting its reuptake and are widely used for the treatment of depression as well as 
anxiety in primary psychiatric populations (Veazey et al., 2005). SSRIs have a 
stimulating effect and have been reported to be well tolerated in older adults 
(Corrigan, Denahan, Wright, Ragual, & Evans, 2000). There are a range of 
medications in the SSRI drug class (see Table 5), and all have been anecdotally 
reported to be of comparable efficacy in treating depression in PD (Masterton, 2003).  
 
There have been several uncontrolled trials (Hauser  & Zesiewicz, 2004; 
Kulisevsky et al., 2008; Marino et al., 2008; Meara, Bhowmick, & Hobson, 1997; 
Menza, Marin, Kaufman, Mark, & Lauritano, 2004; Tesei et al., 2001; Verma et al., 
2012; Weintraub et al., 2006) and randomised controlled trials (RCT) for SSRIs in 
PD to date (Alca et al., 2011; Andersen et al., 1980; Antonini et al., 2006; Avila et 
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Table 5  
Range of Selective Serotonin Reuptake Inhibitors 
Medication Trade Name(s) 
Fluoxetine Prozac, Sarafem, Fontex 
Paroxetine Aropax, Paxil, Seroxat 
Sertraline Zoloft, Lustral 
Fluvoxamine Luvox 
Citalopram Celexa, Cipramil 
 
 
al., 2003; Devos et al., 2008; Leentjens et al., 2003; Menza et al., 2009; Richard et 
al., 2012; Serrano-Duenas, 2002; Wermuth et al., 1988; Xia et al., 2012). However, 
the efficacy of SSRIs for depression and anxiety in PD remains unclear at present. In 
the most recent meta-analysis of antidepressant treatments for depression in PD, 
Rocha et al. (2013) reported a slightly better response rate associated with SSRIs 
relative to placebos (risk ratio = 1.20) across five placebo-controlled RCTs, however 
this result was not statistically significant (95% CI = .57 to 2.52). An earlier meta-
analysis of SSRIs for the treatment of depression in PD by Skapinakis et al. (2010) 
also failed to find a significant benefit of SSRIs over placebo in PD (RR = 1.08, 95% 
CI = .75 to 1.55) across 6 trials. Thus, despite their first-line status, there is a lack of 
empirical support for the efficacy of SSRI treatments for depression in PD at the 
present time. There have been no studies specifically examining the effect of SSRIs 
on anxiety as a primary outcome in PD. 
 
2.2.1.2 Tricyclic antidepressants (TCAs). TCAs are the second most 
commonly administered medications for depression and/or anxiety in PD.  TCAs 
were initially the preferred first-line treatment for depression in PD however a recent 
investigation indicated a sharp decrease in the contemporary use of TCAs in PD 
populations, with only 7% of people with PD reported currently taking a TCA (Chen 
et al., 2007). This decline has been linked to the high side-effect profile associated 
with TCA treatment (Veazey et al., 2005). TCAs are sedatives and the majority are 
serotonin-norepinephrine reuptake inhibitors blocking the reuptake of both serotonin 
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and noradrenaline (Vajda & Solinas, 2005). There are a wide range of TCAs. Table 6 
displays some of the more commonly used medications in the TCA drug class.  
 
Table 6  
Common Tricyclic Antidepressants Used in PD 
Medication Trade Name(s) 
Amitriptyline Elavil, Endep 
Desipramine Norpramin, Pertofrane 
Doxepin Adapin, Sinequan 
Imipramine Tofranil 
Nortriptyline Pamelor, Aventyl 
Trimipramine Surmontil 
 
 
At present, there is insufficient data to recommend the use of a specific TCA 
in PD (Veazey et al., 2005). However, nortriptyline is generally favoured as there is 
more information available about its use in PD (Vajda & Solinas, 2005). An early 
clinical trial by Andersen, Aabro, Gulmann, Hjelmsted and Pedersen (1980) found 
significantly greater improvement in depression in patients on nortriptyline relative 
to placebo. Similarly, in a recent placebo-controlled trial, Menza and colleagues 
(2009) reported a significant reduction in depressive symptoms in participants taking 
nortriptyline with a large effect size observed at posttreatment relative to control  
(d = 1.20). A general consensus asserts that TCAs are more effective than SSRIs in 
treating depression in PD, especially with those with more severe symptoms (Devos 
et al., 2008; Masterton, 2003) however there are few controlled studies of TCAs in 
PD. Rocha et al. (2013) recently reported a superior response rate for TCAs relative 
to SSRIs in PD (RR = 1.78, 95% CI = 1.06 to 2.99) however this comparison was 
only based on two trials (Devos et al., 2008; Menza et al., 2009). Again, there have 
been no studies examining the use of TCAs for anxiety disorders in PD although it 
has been suggested that TCAs may also be more superior than SSRIs for anxiety in 
PD as many of the antidepressants in this drug class are serotonin-norepinephrine 
uptake inhibitors, and there is evidence for noradrenergic dysfunction in the 
development of anxiety disorders in PD, particularly, panic disorder (Marsh, 2000). 
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Anecdotal evidence from various physicians suggests that nortriptyline, venlafaxine 
and mirtzapine may be beneficial for anxiety symptoms in PD (Marsh). 
 
2.2.1.3 Criticisms of Psychopharmacotherapy for Depression and 
Anxiety in PD.  Although widely utilised, the use of antidepressants in PD has 
garnered considerable criticism in recent times. Four main criticisms have emerged, 
namely; (1) a lack of empirical support for the efficacy of such treatments, (2) 
substantial side effects, (3) the potential for adverse drug interactions, and (4) a high 
risk of relapse. 
 
2.2.1.3.1 Efficacy. Despite comprising the first-line treatment for depression 
and anxiety in PD, there is little empirical evidence to support the efficacy of 
antidepressant therapies in PD at present. There have been four meta-analyses of 
antidepressant treatments for depression in PD to date (Klaassen et al., 1995; Rocha 
et al., 2013; Skapinakis et al., 2010; Weintraub et al., 2005), and all three have not 
been able to demonstrate a significant advantage of antidepressants for depression in 
PD over placebo. In the first published meta-analysis, Klassen and colleagues aimed 
to review placebo-controlled antidepressant trials in PD but could not identify any 
studies which met their inclusion criteria. The authors thus concluded that there was 
no empirical evidence to support the widespread use of antidepressants in PD. 
Weintraub and colleagues conducted a meta-analysis based on 11 antidepressant 
trials (RCTs and non-RCTs) in PD and reported a significant and large pooled effect 
for antidepressants in PD (d = .95, 95% CI = .76 to 1.14), however, this effect was 
less than that of participants who were treated by placebo (d = 1.18, 95% CI = .55 to 
1.81). Skapinakis and colleagues (2010) reported a slightly better response rate 
associated with SSRIs relative to placebos, however this result was not statistically 
significant (RR = 1.08, 95% CI = .75 to 1.55). Most recently, Rocha et al. (2013) 
reported an improved response rate associated with SSRI treatments relative to 
placebo following the publication of the largest RCT of antidepressants in PD to date 
(i.e., Richard et al., 2012) however again this result was not significant (RR = 1.20, 
95% CI = .57 to 2.52). Thus, there is a lack of a consistent evidence base to support 
the widespread use of pharmacological treatment for depression and anxiety in PD at 
the present time.   
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2.2.1.3.2 Side effects. Frequent reports of adverse side effects have also been 
noted with antidepressant use in PD. TCAs can often leave individuals with blurred 
vision, sedation, urinary retention, memory impairment, in confused states and 
possibly delirium at higher doses, as well as increase the risks of falls (Veazey et al., 
2005). In addition, TCAs have been linked with the development of cognitive 
disorders, orthostatic hypotension, cardiac arrhythmias and seizures (Allain, 2000; 
Klaassen et al., 1995). Although generally regarded as more effective, the use of 
TCAs is generally limited in PD populations primarily due to its high side effect 
profile. SSRIs can lead to gastrointestinal complications, sexual dysfunction, 
sweating, insomnia, weight changes, agitation and nightmares (Vajda & Solinas, 
2005). In particular, SSRIs have been found to exacerbate PD motor symptoms in 
some cases (Gerber & Lynd, 1998; Klassen et al.; Linazasoro, 2000; Veazey et al.), 
although improvements to bradykinesia with citalopram use has been reported (i.e., 
Rampello, Chiechio, Raffaele, Vecchio, & Nicholetti, 2002). However, more recent 
research suggests that while side-effects are commonly associated with 
antidepressant treatment in PD, such effects are generally only mild and transient 
(Richard et al., 2012). 
 
2.2.1.3.3 Drug interactions. In addition, concerns regarding polypharmacy 
and the potential for adverse interactions between antidepressants and PD 
medications are particularly important. As noted in Chapter 1, it is common for 
people with PD to take up to five different antiparkinsonian drugs to manage motor 
symptoms, along with other medication for comorbid health problems (Swanson, 
1994). Adding an antidepressant and potentially an anti-anxiety medication (e.g., 
benzodiazepines) into the mix has the potential to be very dangerous. In particular, 
caution is advised when considering combining TCAs or SSRIs with the MAO-B 
inhibitor selegiline, commonly used for neuroprotection in PD, due to reports of 
increased tremor, agitation, restlessness and decreased consciousness (Richard et al., 
1996; Veazey et al., 2005). A fatal ‘serotonin syndrome’, although of rare incidence, 
has also been identified resulting from adverse interactions between selegiline and 
SSRIs fluoxetine and fluvoxamine (Vajda & Solinas, 2005). Thus, to reduce the risk 
of aversive interactions, Marsh (2000) recommends that all non-essential 
pharmacotherapy in PD be eliminated. Muller (2002) also advises against 
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pharmacotherapy of non-motor symptoms in PD, where possible, in order to avoid 
complications with antiparkinsonian medication. 
 
2.2.1.3.4 Long-term utility. Finally, there are concerns in relation to relapse 
and the long-term utility of pharmacological treatments. There have not been any 
studies investigating symptom relapse specifically in regards to depression and 
anxiety in PD, however, it is widely acknowledged that relapse rates for both 
depression and anxiety are very high (Kuyken et al., 2008).  
 
There are two main stages to pharmacological treatment for depression and 
anxiety; (1) acute treatment and (2) continuation therapy. An ‘adequate period of 
treatment’ during the acute phase is considered to be prescriptions covering at least 
120 days (Dunn et al., 1999). This is followed by continuation therapy to prevent 
relapse. For major depression in older adults, the National Institute of Health and 
Clinical Excellence (2010) currently recommend a minimum 12-month duration of 
continuation therapy and between 2 to 4 years for those with recurrent major 
depression in order to prevent relapse. Thus, significant ongoing treatment is 
required in order to maintain any acute treatment gains. Cessation of psychiatric 
medication following acute treatment has been found to be associated with a 77% 
increase in the risk of relapse in major depression (Melfi et al., 1998), and a 54 to 
70% relapse rate for panic disorder (Otto et al., 2001).  
 
In practice, however, the majority of patients are not considered at high risk 
for relapse and therefore not offered continuation therapy (Melfi et al., 1998). Of 
those who do receive ongoing treatment, adherence rates have been found to be low, 
with many patients discontinuing with their medication because it is too effortful or 
due to unpleasant side effects (Cooper et al., 2007; Olfson, Marcus, Tedeschi, & 
Wan, 2006; van Schaik et al., 2004). Thus, the majority of patients do not receive the 
recommended length of continuation treatment and it can be derived that the rate of 
relapse in these individuals is high.  
 
Overall, the findings presented in this section strongly suggest that the 
widespread use of pharmacological treatments for depression and anxiety in PD is a 
concern based on issues regarding efficacy and safety.   
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2.2.3 Other Pharmacotherapy 
2.2.3.1 Selective norepinephrine reuptake inhibitors (SNRIs). Due to the 
observed efficacy of TCAs over SSRIs in PD, several researchers have proposed that 
medications with a primary noradrenergic mechanism may be effective for 
depression and anxiety in PD (Carpenter, Milosavljevic, Schecter, Tyrka, & Price, 
2005). Several SNRIs have been trialled for depression in PD in recent years. Lemke 
(2002) conducted a small open-label trial of reboxetine for depression with 16 
individuals with PD and reported a significant decrease in Ham-D scores following 
acute 4-week treatment, Z = -3.31, p <.008. Reboxetine is a medication currently 
approved in Europe for the treatment of attention-deficit/hyperactivity disorder 
(ADHD), clinical depression and panic disorder (Lemke). Weintraub and colleagues 
(2010) conducted an 8-week double-blind randomised placebo-controlled trial of 
atomoxetine with 55 participants with PD and major depressive disorder. 
Atomoxetine is also currently approved for ADHD treatment with reported 
antidepressant effects (Carpenter et al.). No significant differences in response rates 
for depression were observed between the treatment and placebo groups at 
posttreatment based on Inventory of Depressive Symptoms scores although a 
significant reduction in State Anxiety Inventory scores was observed for participants 
treated with atomoxetine relative to placebo (mean group difference = -4.69, p = .08). 
In a recent RCT, Richard et al. (2012) examined the comparative efficacy of the 
SNRI venlafaxine, SSRI paroxetine, and placebo for the treatment of depression in 
115 individuals with PD. The trial showed that venlafaxine was of equal efficacy to 
paroxetine in reducing Ham-D scores following 12-weeks of treatment, and that both 
drugs were significantly superior to placebo. 
 
 2.2.3.2 Dopamine agonists. In recent times, there has also been increasing 
interest in the effect of certain antiparkinsonian medications in reducing depression 
in PD. Specifically, trials of the dopamine agonist pramipexole in treating PD motor 
symptoms have shown significant secondary improvements in depressive symptoms 
(Leentjens et al., 2009), leading to interest in pramipexole as a possible primary 
antidepressant agent in PD. The particular interest in dopamine agonists for 
depression in PD stems from the potential dual benefit in treating both motor and 
depressive symptoms simultaneously, thereby eliminating the need for introducing 
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additional drug treatments and reducing the risk of any aversive side effects 
associated with polypharmacy. Pramipexole is a non-ergoline dopamine receptor 
agonist and exerts its antiparkinsonian effects by acting directly on dopamine 
receptors and mimicking the effect of dopamine, thereby alleviating motor 
symptoms. The mechanisms underlying the antidepressant effects of pramipexole are 
not clear at present however it has been suggested that dopamine dysfunction may 
contribute to the development of depression in some individuals. Thus, dopamine 
agonists which increase central dopamine levels may have an inadvertent effect on 
depressive symptoms.  
 
Several experimental studies of pramipexole as a treatment for depression in 
PD have emerged over the past ten years (Kano et al., 2008; Lemke, Brecht, Koester, 
& Reichmann, 2006; Rektorova et al., 2003).  In a recent large-scale randomised 
controlled trial examining the effects of pramipexole against placebo on depressive 
symptoms among 296 individuals with PD, Barone and colleagues (2010) reported a 
significant difference in the mean change in BDI-I scores favouring pramipexole at 
posttreatment. At 12-weeks, a statistically significant but small treatment effect was 
observed favouring pramipexole, with participants randomised to pramipexole 
treatment experienced a mean reduction of 5.9 points on the BDI compared with 4.0 
for the placebo group (p = .01). An earlier RCT comparing pramipexole against the 
SSRI sertraline among 67 individuals with PD and comorbid major depressive 
disorder (Barone et al., 2006) demonstrated a broad equivalence between the two 
drugs at posttreatment in terms of mean point reduction on the Hamilton Depression 
Inventory. However, a higher rate of recovery was observed for participants in the 
pramipexole condition (60.6%) compared with the sertraline group (27.3%), leading 
the authors to conclude to that dopamine agonists may be a viable alternative to 
antidepressants in PD. However, there have been a number of smaller trials of 
dopamine agonists for depression in PD that have not been able to find any 
significant improvement in depression following pramipexole treatment (e.g., Kano 
et al., 2008; Leentjens et al., 2011). 
 
2.2.4 Omega-3 Fatty Acid Supplements 
 In recent times there has also been interest in the effect of fish oil 
supplementation on depressive symptoms in PD. Epidemiological studies showing a 
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lower prevalence of depression within nations with high dietary fish consumption 
(i.e., Freeman, 2000; Morris, Evans, Tangney, Bienias, & Wilson, 2005) have led to 
investigations into the potential antidepressant properties of fish oil and/or its 
constituents, particularly, Docosahexaenoic acid (DHA) and Eicosapentaenoic acid 
(EPA). Polyunsaturated fatty acids have been shown to be effective in reducing 
depressive symptoms in trials with primary psychiatric populations (i.e., De Vriese, 
Christophe, & Maes, 2003; Lin & Su, 2007; Nemets, Stahl, & Belmaker, 2002; Su, 
Huang, Chiu, & Shen, 2003), although other studies have not shown any benefits of 
fish oil for depression (i.e., Marangell et al., 2003; Silvers, Woolley, Hamilton, 
Watts, & Watson, 2005). The emerging interest in fish oil supplements for 
depression in PD is also related to research findings showing a reduced risk of 
developing PD among older adults with a high dietary intake of polyunsaturated fatty 
acids (De Lau et al., 2005) as well as the finding that DHA is able to reduce and/or 
delay the development of levodopa-induced dyskinesias in parkinsonian-treated 
monkeys (Samadi et al., 2006). Thus, similar to dopamine agonists, the appeal of 
Omega-3 fatty acid supplements for the treatment of depression in PD is largely 
related to a potential dual benefit. In a double-blind placebo-controlled RCT of 
omega-3 fatty acid supplementation in 31 individuals with PD and major depression, 
Moralez Da Silva and colleagues (2008) reported a significant reduction in MADRS 
scores for the fish oil group. 
 
2.2.5 Brain Stimulation Procedures 
In addition to pharmacological and supplementation therapies, brain 
stimulation procedures have also been of key interest to researchers and clinicians for 
depression and/or anxiety in PD. 
 
 2.2.5.1 Electroconvulsive therapy. Electroconvulsive therapy (ECT) is a 
procedure involving the electrical induction of seizures and its potential in treating 
depression in PD has long been recognised. There have been several case reports of 
ECT for depression in PD (Bailine et al., 2008; Burke, Peterson, & Rubin, 1988; 
Chou et al., 2005) however there have been no larger trials. An early case study of 
ECT for depression in PD was published by Asnis (1977) who examined the use of 
ECT with a 61 year old man with PD and chronic depression. ECT was administered 
three times a week over a 6-week period. The participant’s pretreatment severity of 
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depression was severe as rated by the Zung Self-Rating Depression Scale). 
Following the fifth week of ECT, the participant no longer scored within the clinical 
range for depression severity. However, subsequent follow-ups one week and one-
month following treatment cessation showed that depression levels had returned to a 
severe level. The most recent case report of ECT in PD was presented by Marino and 
Friedman (2013) who reported successful treatment of anxiety following ECT in two 
individuals with PD with longstanding histories of depression and severe anxiety. 
 
2.2.5.2 Repetitive transcranial magnetic stimulation. Repetitive 
transcranial magnetic stimulation (rTMS) is a second brain stimulation technique that 
has received attention in PD. RTMS is a non-invasive procedure that involves 
placing metal coils on an individual’s head to induce strong magnetic fields which in 
turn produce localised electrical changes to targeted brain sites (Kozel & George, 
2002; Siebner et al., 2000). High frequency rTMS of the left dorsolateral prefrontal 
cortex is an approved treatment for resistant-depression in the US and Canada and 
several other countries (Chen, 2010), and is currently entering into mainstream 
clinical practice in Australia (Fitzgerald, 2012). Increasing interest in rTMS for 
depression in PD has recently emerged, with several researchers suggesting that the 
localised nature of rTMS may make it a safer as well as more effective treatment 
alternative to psychiatric pharmacotherapy in PD (Epstein et al., 2007). Particularly, 
rTMS is able to accurately target specific brain areas and thus avoid any exacerbation 
of motor complications by prohibiting inadvertent stimulation of the primary motor 
cortex (Epstein et al.). Moreover, the acute phase of treatment for rTMS is 
considerably shorter than pharmacological or psychological regimens, with a course 
of rTMS generally completed in between 10 and 30 days, and consisting of a 30 to 
45 minute daily session over the acute period (Fitzgerald). 
 
There have been several open trials (Dragasevic et al., 2002; Epstein et al., 
2007; Kormos, 2007) and RCTs (Fregni et al., 2004; Pal et al., 2010) of rTMS for the 
treatment of depression and/or anxiety in PD in recent times. In the largest of these, 
Fregni and colleagues compared the efficacy of rTMS against the SSRI fluoxetine in 
treating depression in 42 individuals with PD and a comorbid DSM-IV diagnosis of 
major or minor depression. Participants were randomised to a combination of either 
active rTMS and placebo drug treatment or sham rTMS and fluoxetine. Following 
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two weeks of treatment, an equivalent reduction in Ham-D scores was observed for 
both groups (rTMS: -9.5, fluoxetine: -10.5, p = .278), leading the authors to conclude 
that rTMS is as effective as SSRI treatment in the treatment of depression in PD 
 
2.2.6 Psychotherapy 
Finally, an emerging interest in psychological interventions for depression 
and anxiety in PD has surfaced in recent years. In recognition of the aversive side 
effects often associated with mainstay pharmacological treatments, researchers have 
turned their interest to arguably the safest treatment modality for psychological 
disturbances – psychotherapy.  
 
In particular, a growing interest in Cognitive Behavioural Therapy (CBT) for 
depression and anxiety in PD has surfaced over the past decade. CBT is an 
overarching term used to refer to a family of therapies guided by Beck’s (1965) 
‘cognitive theory’. Broadly, the central premise of cognitive theory is that 
psychological disorders are manifestations of underlying cognitive distortions (Clark, 
Beck, & Alford, 1999). Cognitive biases are posited to stem from dysfunctional core 
beliefs about oneself and the environment (Beck, 2008). CBT is a time-limited and 
structured form of therapy, employing a combination of cognitive and behavioural 
techniques, which aims to help individuals identify the maladaptive thoughts and 
beliefs underlying emotional and psychological discomfort and to ultimately replace 
such thoughts with more functional alternatives (Westbrook et al., 2011). Thus, 
cognitive change is the proposed key to achieving symptomatic relief as well as the 
primary aim of any CBT treatment (Brewin, 1996).  
 
In a review of CBT for PD, Laidlaw (2008) highlighted several treatment 
characteristics that make CBT a ‘potentially very effective’ treatment option for 
psychological disturbances in PD including; a here-and-now focus, enhancement of 
problem-solving skills and ability to deal with increasingly difficult challenges with 
disease progression, enhancement of social engagement and particularly, its ability to 
directly address illness-related concerns.Previous research has shown that illness-
related concerns feature prominently in both depression and anxiety in PD (Brook & 
Doder, 2000). Higher rates of sadness, pessimism, and dysphoria have been observed 
in depression in PD and linked with hopelessness and helplessness in regards to 
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having PD (McDonald et al., 2003). Similarly, predominant concerns in anxiety in 
PD have been found to focus on the unpredictability of motor symptoms, the 
uncertainty of prognosis and the perceptions of others towards PD (Backer, 2000). 
While illness-related concerns are common and expected among those with medical 
illnesses, it has been suggested that individuals with depression and anxiety and 
comorbid medical illness tend to have distorted beliefs regarding their illness and 
their ability to cope. Although pharmacotherapy is able to bring about symptomatic 
relief (e.g., raise mood, reduce tension, improve sleep etc.), illness-related concerns 
are largely unaddressed. The primary benefit of CBT over pharmacotherapy is 
therefore its ability to directly address illness-related concerns such as those outlined 
in the example above. Cognitive therapy can be used to identify and correct any 
distortions in thinking while behavioural experiments may be particularly useful to 
build confidence and show clients what they are capable of achieving in spite of 
physical limitations (Cole & Vaughan, 2005). CBT is able to help clients develop a 
realistic yet hopeful perspective of life with PD which acknowledges loss and 
limitations but at the same time encourages the highest possible level of functioning 
(Evans, 2007).  
 
Moreover, CBT is an established treatment for depression and anxiety that 
has demonstrated equal efficacy as pharmacotherapy in primary populations over the 
acute phase of treatment and superior performance to pharmacotherapy over the 
long-term in regards to maintenance of acute treatment gains and relapse prevention 
(NICE, 2010). There is also increasing evidence of the efficacy of CBT in treating 
depression and anxiety in older adults (Pinquart, Duberstein, & Lyness, 2007), and 
individuals with various chronic illnesses (Hackett, Anderson, & House, 2004), and a 
growing body of research now also supports the efficacy of CBT in treating 
depression and/or anxiety in PD populations (e.g., Dobkin et al., 2011; Farabaugh et 
al., 2010; Feeney, Egan, & Gasson, 2005; Gupta, 2000;; Mohlman et al., 2010). In a 
recent RCT of individual CBT for the treatment of depression in PD, Dobkin and 
colleagues (2011) reported statistically significant and large effects on both 
depression (Ham-D; d = 1.59, BDI; d = 1.1) and anxiety (Ham-A; d = .98) following 
a 10-week CBT programme. At 1-month follow-up, improvements in clinician and 
self-rated depression as well as anxiety were maintained. 
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2.3 A Meta-Analysis of Randomised Placebo-Controlled Trials  
for Depression and/or Anxiety in PD 
 
The preceding review provides a brief overview of the main treatment 
approaches for depression and anxiety in PD at the present time. Overall, 
psychopharmacotherapy currently represents the first-line and most widespread 
treatment approach for depression and anxiety in PD. However, antidepressant 
treatment regimens in PD are complicated by concerns regarding safety and the 
efficacy of such treatments is unclear. Several other treatments have been put 
forward as potentially safer and more effective alternatives for depression and 
anxiety in PD including dopamine agonists, Omega-3 supplementation, CBT and 
rTMS. The aim of this meta-analysis is to systematically examine the efficacy of the 
different treatment approaches for depression and anxiety in PD and to identify the 
most viable treatment option at the present time. 
 
There have been four published meta-analyses for depression in PD to date 
(Klaassen et al., 1995; Rocha et al.; 2013; Skapinakis et al., 2010; Weintraub et al., 
2005), while there have been no meta-analyses for anxiety in PD. A fifth meta-
analysis of antidepressant therapies in PD was identified (Frisina, Tenebaum, & 
Borod, 2008) however this study did not specifically examine the treatment of 
clinical depression in PD (i.e., a DSM or ICD diagnosis of depression was not a 
required inclusion criteria). Of the four existing meta-analyses specifically for 
depressive disorders in PD, all have focused solely on the efficacy of antidepressant 
interventions. The present study is therefore the first meta-analysis of both 
pharmacological and non-pharmacological treatments for depression in PD as well as 
the first meta-analysis of any kind for anxiety in PD, and begins with a brief 
overview of the different treatments for depression and anxiety in PD. 
 
 
2.4 Search Strategy 
 
 A comprehensive literature search was conducted for treatment studies of 
depression and/or anxiety in PD. Several online databases including Medline, 
PubMed, PsycInfo, Proquest, EMBASE, ScienceDirect and Google Scholar were 
 54
systematically searched from the first available year of publication to April 2013 for 
the keywords; Parkinson’s disease, depression, anxiety, treatment, therapy, RCT, 
trial, CBT, antidepressants. Reference lists of previous meta-analyses of treatments 
for depression in PD were also searched. 
 
 
2.5 Study Selection 
 
To be eligible for inclusion in the meta-analysis, studies had to: 
1. Feature participants with idiopathic PD 
2. With a concurrent diagnosis of depression and/or anxiety according to DSM 
or ICD-10 criteria  
3. Evaluated an intervention targeting depression and/or anxiety in PD as the 
primary focus  
4. Used a randomised controlled design with a non-active control (no treatment, 
treatment as usual, clinical monitoring, waitlist, placebo) 
5. Employed a standardised primary outcome measure for depression and/or 
anxiety to assess participant change 
6. Included sufficient quantitative data from which an effect size could be 
computed (means, SDs, t or F values and probability values) 
7. Be written in English 
 
 
2.6 Statistical Analysis 
 
All aspects of this meta-analysis were conducted in line with 
recommendations by the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement (PRISMA, 2009). Statistical analyses were 
guided by recommendations by Borenstein, Hedges, Higgins and Rothstein (2010), 
DerSimonian and Kacker (2007) and Marin-Martinez and Sanchez-Meca (2009). 
 
2.6.1 Effect Size Calculation 
 Effect sizes for each study were represented by the standardised mean 
difference (Cohen’s d) between the treatment and control groups at posttreatment. 
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Three methods were used to calculate effect sizes. Where there was sufficient data 
reported (pretreatment and posttreatment means and standard deviations for both 
treatment and control groups), effect sizes were calculated using change scores, 
according to the following formula: 
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where: MT∆ =  mean change in treatment group  
                       from pretreatment to posttreatment 
            MC∆ =  mean change in control group from  
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 nT = number of participants (treatment group) 
nC = number of participants (control group) 
σT  = standard deviation (treatment group) 
σC  = standard deviation (control group) 
 
 
 The change score method enhances the precision of the effect size estimate 
by comparing the absolute magnitude of change over the treatment period between 
the treatment and control groups. Thus, change scores are able to account for any 
differences in pretreatment levels of an outcome that are not otherwise reflected in 
traditional effect size estimates based only on the difference between posttreatment 
scores. The change score method has been used in several previous meta-analyses 
(e.g., Kobak et al., 1998; Watson & Rees, 2008).  
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 Where all the required means and standard deviation statistics were not 
available, effect sizes were computed using t-values or F statistics reported for 
between-group comparisons on posttreatment scores. Effect sizes based on t-values 
were calculated using the following formula: 
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 Effect sizes based on F-values were calculated using: 
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 Where a study did not report all the required means, standard deviations or 
any t or F-values, but reported probability levels for a one-way two-group test (e.g., a 
t-test, two-group ANOVA or ANCOVA) based on posttreatment scores, probability 
levels were used to calculate effect size. The corresponding t-value for the reported 
probability was attained through a t distribution table and then substituted into the 
effect size formula based on the t statistic to estimate effect size as per Ray and 
Shadish (1996). 
 
 
 2.6.1.1 Hedge’s small sample correction. As Cohen’s d is known to 
overestimate the effect size in small samples, Hedge’s small sample correction 
(Hedge, 1981) was applied to effect size estimates where the number of participants 
was less than 20. Corrected effect sizes were computed using the formula: 
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 2.6.1.2 Multiple treatment conditions. Finally, where a study included two 
active treatment conditions against a single control condition, participants in the 
control condition were split evenly into two subgroups to serve as controls for each 
treatment condition. In doing so, each individual’s data was included only once in the 
analysis as required for a meta-analysis (Borenstein et al., 2010). Hedge’s small 
sample correction was then applied where the sum of the treatment and split control 
group was less than 20. 
 
2.6.2 Pooled Effect Size Calculation 
 The pooled effect size represents the overall or combined effect of all 
included studies in a meta-analysis and is computed by calculating the weighted 
mean of the effect sizes of each individual study (Borenstein, Hedges, & Rothstein, 
2007). There are two models for computing a pooled effect size; the fixed-effects 
model and the random effects model. The fixed-effects model assumes that all 
studies within a meta-analysis are functionally identical in terms of sample 
characteristics, study design and method, and the nature of the treatment intervention 
employed (Borenstein et al., 2010). In contrast, the random-effects model assumes a 
degree of heterogeneity in participant characteristics, design, method and treatment 
interventions across each study included in a meta-analysis (Hunter & Schmidt, 
2002). In recent times, a wide consensus has been established supporting the 
increased precision of random-effects models for meta-analyses (e.g., Brockwell & 
Gordon, 2001; Erez, Bloom, & Wells, 1996; Hedges & Vevea, 1998; Kisamore & 
Brannick, 2008; Sanchez-Meca & Marin-Martinez, 2008). 
 
A random effects model was thus employed to estimate the pooled effect size 
in this study to control for differences in participant characteristics across each study, 
as well as differences relating to the nature of each treatment intervention. Individual 
effect sizes from each study were weighted to account for both within-study variance 
and between-study variance using the Hedges and Vevea (1998) ‘weighting by 
inverse variance’ method. 
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2.6.2.1 Within-study variance. Within study variance (vi) was calculated 
using the formula: 
)n  2(n
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   where:  nT = number of participants (treatment group) 
     nC = number of participants (control group) 
     d = effect size 
 
 
 
2.6.2.2 Between-study variance. Between-study variance (T
2
) was calculated 
using the DerSimonian and Laird (1986) general method-of-moments estimate: 
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Where  d = effect size, d = mean effect size, n = number of studies and  vi = 
within-study variance. Where the value of T
2
 was negative, T
2
 was set to 0 as a 
variance cannot be negative (Borenstein et al., 2010). 
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 2.6.2.3 Weighted effect size. Individual weights for each study were then 
computed using the formula, then multiplied by the effect size estimate in each study 
to produce a weighted effect size for each study. 
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 2.6.2.4 Pooled effect size. The weighted mean effect size for all studies was 
then computed to determine the pooled effect size (MW). A separate pooled effect 
size was computed for each different treatment modality (pharmacological, 
psychotherapy, rTMS etc.) using the following formula: 
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 2.6.2.5 Statistical significance. Finally, to test the statistical significance of 
pooled effect sizes, 95% confidence intervals were calculated as a function of the 
pooled effect size and standard error of the pooled effect size (SEM) using the 
following formulas: 
∑
=
i
W
W
1
1.96 -  M Limit  Lower             
∑
+=
i
W
W
1
1.96   M Limit  Upper  
(Borenstein et al., 2010) 
 
 The null hypothesis was rejected at the .05 significance level if the calculated 
confidence interval did not include zero, and indicated that there was an overall 
significant effect of treatment for depression and/or anxiety in PD across the studies 
included in the meta-analysis. 
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2.6.3 Publication Bias 
 Publication bias refers to the tendency for researchers and scientific journals 
to publish only positive results from clinical trials (i.e., significant and large effect 
sizes) while neglecting to report any small or non-significant findings (Thornton & 
Lee, 2000). Consequently, pooled effect sizes in meta-analyses based only on 
published studies may overstate the true effect of a given treatment intervention.  
 
To assess publication bias in this study, funnel plots and Egger’s regression 
asymmetry test were employed. Funnel plots are scatterplots of effect sizes from 
individual studies (X-axis) against an index of each study’s precision (often the 
standard error of the effect size) on the Y-axis (Sterne, Egger, & Smith, 2001). When 
there is no publication bias in a meta-analysis, the distribution of effect sizes 
resembles a symmetrical inverted funnel, while an asymmetrical distribution 
indicates the presence of bias (Sterne et al.). Egger’s (1997) test is a statistical test for 
funnel plot asymmetry and involves a simple linear regression between weighted 
effect size estimates against their standard errors. Statistically significant regressions 
indicate that the results of a meta-analysis are affected by publication bias. The Fail-
Safe N method (Rosenthal, 1979) was also used to examine any publication bias 
present in the meta-analysis. The fail-safe N refers to the number of unpublished null 
studies required to negate the significance of the pooled effect size in a meta-analysis 
and was calculated according to the following formula: 
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     where:  k = number of studies 
       ZC = critical Z value 
       kΖ = mean Z for k studies 
 
Rosenthal (1979) asserts that a fail-safe N value greater than 5k + 10 indicates 
a low likelihood of publication bias within a meta-analysis. 
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2.6.4 Heterogeneity Analysis 
 A second essential component of a meta-analysis is to demonstrate the 
consistency of treatment effects across studies to show support for the validity and 
generalisability of the pooled effect estimate. Heterogeneity within a meta-analysis is 
undesirable as it indicates that a treatment has differential effects across separate 
studies (Higgins, Thompson, Deeks, & Altman, 2003). The degree of heterogeneity 
in a meta-analysis can be computed according to the I
2
 statistic (Higgins & 
Thompson, 2002), which is an index of the proportion of total variance in the pooled 
effect size that is due to heterogeneity between studies. Values for the I
2
 statistic are 
expressed as a percentage with 0% indicating no observed heterogeneity (Higgins et 
al.). The I
2
 statistic was calculated using the following formula: 
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2.7 Results 
 
2.7.1 Search Results 
A total of 86 treatment trials for depression and/or anxiety in PD were 
identified. Fifty-six papers were excluded as they were case studies or case series 
(26), uncontrolled trials (28), or non-randomised controlled trials (3). This resulted in 
a total of 29 randomised controlled trials (see Table 7). There were 28 RCTs for the 
treatment of depression in PD, while one RCT was targeted at the treatment of 
comorbid depression and anxiety.  There were no RCTs of any intervention solely 
for anxiety in PD.  Publication dates ranged from 1980 to 2011, with the majority of 
studies (72%) published over the past 10 years. There were 16 RCTs of 
antidepressant interventions, 4 RCTs of antiparkinsonian medications, 5 RCTs for 
rTMS, 2 RCTs for CBT, and one RCT each of atomoxetine and Omega-3 
supplementation. There were no RCTs for ECT for depression in PD.
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Of the 29 RCTs, 16 were excluded as these were active-comparator trials, 
leaving 13 placebo-controlled RCTs. A further four placebo-controlled trials were 
excluded. The Andersen et al. (1980) trial of the TCA nortriptyline was omitted for 
not using a standardised outcome measure. The Barone et al. (2010) trial of the 
dopamine agonist pramipexole and Werneck et al. (2009) trial of trazodone 
(serotonin antagonist and reuptake inhibitor) were excluded as participants in both 
studies were not required to have a clinical diagnosis of depression according to 
DSM or ICD criteria. Finally, The Djokic et al. (2010) trial comparing six 
antidepressants with placebo was also excluded as there was insufficient quantitative 
data in the published conference abstract to calculate effect sizes.  
 
Two active-comparator RCTs have been previously included in an earlier 
meta-analysis of placebo-controlled RCTs of SSRIs in PD (i.e., Skapinakis et al., 
2010). The authors argued that the low dosage of the comparator amitriptyline drug 
in the Antonini et al. (2006) study, as well as the unestablished nature of the rTMS 
treatment in the Fregni et al. (2004) trial were equivalent to placebo-controlled 
conditions. These two trials were not included in the main analysis for this study as 
they were not explicit placebo-controlled trials, however they were included as part 
of the subsequent sensitivity analysis to examine whether their inclusion would 
significantly alter the results of the main analyses. 
 
2.7.2 Study Characteristics  
Table 8 summarises the characteristics of the nine trials included in the meta-
analysis. There were five placebo-controlled RCTs of antidepressants for depression 
in PD (Devos et al., 2008; Leentjens et al., 2003; Richard et al., 2012 Menza et al., 
2009; Wermuth et al., 1998) and one RCT each of Omega-3 fatty-acid 
supplementation (Da Silva et al., 2008), atomoxetine (Weintraub et al., 2010), rTMS 
(Pal et al., 2010) and CBT (Dobkin et al., 2011a). There were no eligible RCTs of 
dopamine agonists or ECT for depression in PD and no new placebo-controlled 
RCTs of antidepressants for depression in PD since the publication of the Rocha et 
al. (2013) meta-analysis. 
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Table 7  
List of Randomised Controlled Trials for Depression and/or Anxiety in PD 
Intervention Type First Author (Year) Treatment Comparison N 
Antidepressant Alca (2011) 
Andersen (1980) 
Sertraline (SSRI) 
Nortriptyline (TCA) 
Venlafaxine (SNRI) 
Placebo 
32 
22 
 Antonini (2006) Sertraline (SSRI) Amitriptyline (TCA) 31 
 Avila (2003) Nefazodone (SARI) Fluoxetine (SSRI) 16 
 Dell’Agnello (2001) 
 
 
Devos (2008) 
Fluoxetine (SSRI) 
 
 
Citalopram (SSRI) 
Desipramine (TCA) 
Fluvoxamine (SSRI) 
Citalopram (SSRI) 
Sertraline (SSRI) 
Placebo 
62 
 
 
48 
 Djokic (2010) 
 
 
 
 
 
Leentjens (2003) 
Clomipramine (TCA) 
Fluoxetine (SSRI) 
Sertraline (SSRI) 
Escitalopram (SSRI) 
Mirtazapine (NaSSa) 
Tianeptine (SSRE) 
Sertraline (SSRI) 
Placebo 
 
 
 
 
 
Placebo 
339 
 
 
 
 
 
12 
 Menza (2009) Nortriptyline (TCA) 
Paroxetine (SSRI) 
Placebo 52 
 Rabey (1996) 
Richard (2012) 
 
Serrano-Duenas 
(2002) 
Trivedi (2003) 
Fluvoxamine (SSRI) 
Paroxetine (SSRI) 
Venlafaxine (SNRI) 
Fluoxetine (SSRI) 
 
Sertraline (SSRI) 
Amitriptyline (TCA) 
Placebo 
 
Amitriptyline (TCA) 
 
Bupropion 
47 
115 
 
77 
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 Wermuth (1998) 
Werneck (2009) 
Xia (2012) 
Citalopram (SSRI) 
Trazodone (SARI) 
Fluoxetine (SSRI) 
Placebo 
Placebo 
Fluoxetine (SSRI) + 
Eelectroacupuncture 
18 
20 
60 
Pharmacological 
(other) 
Barone (2006) Pramipexole (DA) Sertraline (SSRI) 67 
Barone (2010) Pramipexole (DA) Placebo 287 
 Rektorova (2003) 
Steur (1997) 
Pramipexole (DA) 
Moclobemide (MAO-I) 
Pergolide (DA) 
Moclobemide + 
SSelegiline 
41 
10 
 
 Weintraub (2010) Atomoxetine (SNRI) Placebo 55 
Supplements Moralez Da Silva 
(2008) 
Omega-3 fatty-acid Placebo 29 
rTMS Boggio (2005) 
Cardoso (2008) 
Fregni (2004) 
Fregni (2006) 
Left prefrontal rTMS 
Left prefrontal rTMS 
Left prefrontal rTMS 
Left prefrontal rTMS 
Fluoxetine (SSRI) 
Fluoxetine (SSRI) 
Fluoxetine (SSRI) 
Fluoxetine (SSRI) 
25 
21 
42 
26 
 Pal (2010) Left prefrontal rTMS Placebo (sham rTMS) 22 
Psychotherapy Dobkin (2011) Individual CBT Clinical monitoring 80 
 Veazey (2009) Telephone CBT Telephone counselling 10 
TCA = tricyclic antidepressant, SSRI = selective serotonin reuptake inhibitor, SARI = serotonin 2 
antagonist/reuptake inhibitor, DA = dopamine agonist, SNRI = selective norepinephrine reuptake 
inhibitor, rTMS = repetitive transcranial magnetic stimualation, CBT = cognitive behavioural therapy 
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2.7.3 Primary Effect on Depression 
A forest plot of effect sizes and 95% confidence limits for all interventions 
appears in Figure 1.  Overall, all interventions favoured the treatment condition at 
posttreatment with effect sizes ranging from .08 to 1.64. However, only 58% of the 
treatment effects were statistically significant. These were; citalopram and 
desipramine (Devos et al., 2008), nortriptyline (Menza et al., 2009), paroxetine and 
venlafaxine (Richard et al., 2012), Omega-3 supplementation (Moralez Da Silva et 
al., 2008), and CBT (Dobkin et al., 2011). 
 
2.7.3.1 Pooled effect sizes. A pooled effect size was computed only for 
antidepressant interventions as this was the only treatment modality with more than 
one published placebo-controlled RCT. The pooled effect for antidepressants (N = 8) 
was moderate (d = .71) in favour of antidepressants, although this was not 
statistically significant (95% CI = -1.33 to 3.08). There was also substantial 
heterogeneity observed between the antidepressant studies, I
2
 = 68.53%, p < .05.  
 
2.7.3.2 Publication bias. Due to the small number of studies, visual 
verification of the presence or absence of asymmetry using funnel plots was difficult 
to accomplish. However, Egger’s regression test showed no evidence of publication 
bias among the antidepressant studies, p = .652. A fail-safe N statistic was not 
computed given that the pooled effect of antidepressants was non-significant. 
 
2.7.3.3 Sensitivity and subgroup analyses. Given the significant 
heterogeneity observed across antidepressant studies, subgroup analyses were 
conducted for SSRIs and TCAs separately. The pooled effect for SSRIs was 
moderate and non-significant (d = .57, 95% CI = -1.33 to 2.47). The pooled effect for 
TCAs was significant and large (d = 1.35, 95% CI = .19 to 2.52). There was no 
longer any significant heterogeneity across studies for both SSRIs (I
2
 = 0.00%, p > 
.05) and TCAs (I
2
 = 21.13%, p > .05), suggesting that the initial heterogeneity was 
attributable to the different drug classes and mechanisms of action. 
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Table 8  
Characteristics of Placebo-Controlled Randomised Controlled Trials for Depression 
in PD used in the Present Meta-Analysis  
First 
author 
Year Location Condition Design 
Time 
(weeks) 
Diagnostic 
system 
N 
Primary 
Outcome 
Devos 2008 France 1. Citalopram 
2. Desipramine 
3. Placebo 
Double-
blind 
parallel 
4 DSM-IV 48 MADRS 
Dobkin 2011 USA 1. CBT 
2. Clinical 
monitoring 
Parallel 10 DSM-IV 80 HAM-D 
Leentjens 2003 Netherlands 1. Sertraline 
2. Placebo  
Double-
blind 
parallel 
10 DSM-IV 12 MADRS 
Menza 2009 USA 1. Paroxetine 
2. Nortriptyline 
3. Placebo  
Double-
blind 
parallel 
8 DSM-IV 52 HAM-D 
Moralez 
Da Silva 
2008 Brazil 1. Omega-3  
2. Placebo  
Double-
blind 
parallel 
12 DSM-IV 29 MADRS 
Pal 2010 UK 1. rTMS 
2.Placebo  
Double-
blind 
parallel 
10  
days 
DSM-IV 22 MADRS 
Richard 
 
2012 USA 1. Sertraline 
2. Venlafaxine 
3. Placebo 
Double-
blind 
parallel 
12 DSM-IV 115 HAM-D 
Weintraub 2010 USA 1. Atomoxetine 
2. Placebo  
Double-
blind 
parallel 
8 DSM-IV 55 IDS-C 
Wermuth 1998 Denmark 1. Citalopram 
2. Placebo  
Double-
blind 
parallel 
8 DSM-III-R 37 HAM-D 
DSM-IV = Diagnostic and Statistical Manual of Mental Disorders (fourth edition), DSM-III-R = 
Diagnostic and Statistical Manual of Mental Disorders (third edition, revised), MADRS = 
Montgomery-Asberg Depression Scale, HAM-D = Hamilton Depression Inventory, IDS-C = 
Inventory of Depressive Symptomatology-Clinician
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Figure 1. Forest Plot of Effect Sizes for Depression 
 
 
A further sensitivity analysis was conducted including data from two 
additional active-comparator antidepressant trials
 
(Antonini et al., 2006; Fregni et al., 
2004) that were included in the Skapinakis et al. (2010) meta-analysis of placebo-
controlled RCTs of SSRIs for depression in PD. Inclusion of these two trials did not 
significantly alter findings. The pooled effect for antidepressants remained moderate 
and non-significant (d = .62, 95% CI = -2.13 to 3.37), as did the pooled effect for 
SSRIs (d = .48, 95% CI = -1.88 to 2.84), although there was a slight reduction in the 
magnitude of both pooled effects. 
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2.7.4 Anxiety 
 There were no RCTs of any treatment for anxiety in PD, however, four of the 
depression trials reported the effect of treatment on anxiety as a secondary outcome 
(Devos et al., 2008; Dobkin et al., 2011; Menza et al., 2009; Weintraub et al., 2010). 
There were two trials of antidepressants, one trial of CBT and one trial of 
atomoxetine. Table 9 provides a summary of the characteristics of these studies and 
the outcome data reported for anxiety used to estimate effect sizes. 
 
Table 9  
Study Characteristics of Randomised Placebo-Controlled Trials for Depression in 
PD Reporting the Secondary Effect on Anxiety 
Study Condition N Time 
(weeks) 
Outcome 
measure 
T1  
M 
T1 
SD 
T2 
M 
T2 
SD 
∆M t p 
Devos 
(2008) 
1. Citalopram 
2. Desipramine 
3. Placebo 
48 4 HAM-A 
18.00 
20.00 
18.00 
N.R. 
N.R. 
N.R. 
6.00 
8.00 
10.00 
N.R. 
N.R. 
N.R. 
-12.00 
-12.00 
-8.00 
N.R
. 
N.R 
.05 
.05 
- 
Dobkin 
(2011) 
1.CBT 
2. Monitoring 
80 10 HAM-A 
19.32 
18.49 
4.41 
4.35 
14.73 
18.21 
4.54 
4.35 
-4.59 
-0.28 
- - 
Menza 
(2009) 
1. Paroxetine 
2. Nortriptyline 
3. Placebo 
52 8 HAM-A 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
N.R
. 
N.R 
.074 
.0001 
- 
Weintraub 
(2010) 
1. Atomoxetine 
2. Placebo 
55 8 SAI 
55.9 
56.5 
10.5 
10.4 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
N.R. 
4.69 .08 
HAM-A = Hamilton Anxiety Rating Scale, SAI = State Anxiety Inventory 
 
 
A forest plot of effect sizes and 95% confidence intervals for all interventions 
reporting the secondary effect of treatment on anxiety, as well as the pooled effect 
for antidepressants, SSRIs and TCAs appears in Figure 3. Apart from paroxetine 
which showed no significant effect on anxiety, all interventions resulted in large and 
statistically significant reductions in anxiety with effect sizes ranging from .93 to 
1.98. A pooled effect size for antidepressants was computed by pooling data from the 
Devos et al.
 
(2008) and Menza et al. (2009) trials. The pooled effect size for 
antidepressants on anxiety in PD was large (d = 1.13) but non-significant (95% CI = 
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-.67 to 2.94). Again, there was substantial inconsistency in the effect of 
antidepressants on anxiety across studies, I
2
 = 75.35%, p <.05 
 
Subgroup analyses were conducted to estimate the pooled effect of SSRIs and 
TCAs on anxiety in PD separately in light of the observed heterogeneity across 
antidepresant studies. Similar to depression, the pooled effect for TCAs was large 
and significant (d = 1.40, 95% CI = .09 to 2.70) while the pooled effect for SSRIs 
was non-significant (d = .85, 95% CI = -.40 to 2.09). A forest plot of effect sizes and 
95% confidence intervals for all interventions reporting the secondary effect of 
treatment on anxiety, as well as the pooled effect for antidepressants, SSRIs and 
TCAs appears in Figure 2. Overall, TCAs, atomoxetine and CBT all demonstrated a 
significant and large secondary effect on anxiety outcomes. 
 
 
Figure 2. Forest Plot of Effect Sizes for Subgroup Analyses for Anxiety 
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2.8 Discussion 
 
 In the first published meta-analysis of treatments for depression in PD, 
Klaassen and colleagues (1995) concluded that there was no available empirical 
evidence with which to base a treatment plan for depression in PD. Despite 
increasing awareness of the significance of psychiatric and non-motor disturbances 
in PD over the past decade and a half, it would appear that the empirical literature for 
treatments for depression and anxiety in PD remains in an elementary stage. An 
extensive literature search revealed only nine trials meeting the inclusion criteria of 
being randomised placebo-controlled trials for depression and/or anxiety in PD, and 
employing formal diagnostic procedures and standardised outcome measures. Thus, 
despite the high prevalence of depression and anxiety in PD there is still a 
considerable lack of controlled research in the treatment of these disorders. 
 
2.8.1 Main Findings  
This meta-analysis was the first to provide a controlled pooled effect size 
estimate for antidepressant therapies in PD. While there have been four prior meta-
analyses assessing the efficacy of antidepressant therapies for depression in PD to 
date, none of these reviews calculated a pooled effect size of antidepressant therapies 
in PD. There was insufficient empirical data to do so at the time of the Klaassen et al. 
(1995) review, while Weintraub and colleagues (2005) pooled results from both 
RCTs and non-RCTs and reported an uncontrolled pooled effect size for 
antidepressant therapies in PD. In the two most recent meta-analyses, Skapinakis et 
al. (2010) and Rocha et al. (2013) both calculated and reported risk ratios for 
antidepressant response in PD rather than standardised treatment effects. The present 
analysis showed that the pooled effect of antidepressants for depression in PD was 
moderate but non-significant (d = .71, 95% CI = -1.33 to 3.08), as was the pooled 
effect for the current first-line SSRI treatments (d = .57, 95% CI = -1.33 to 2.47). 
Antidepressants appeared to have a greater effect on anxiety in PD, with large pooled 
effect sizes observed for both antidepressant therapies in general (d = 1.13, 95% CI = 
-.67 to 2.94) and SSRI treatments (d = .85, 95% CI = -.40 to 2.09), although again, 
both results were non-significant. 
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The finding that both antidepressants in general and SSRI therapies have a 
non-significant pooled effect on depression in PD relative to placebo is consistent 
with prior results. Weintraub et al. (2005) reported a large and statistically significant 
effect of antidepressants on depression in PD (d = .95, 95% CI = .76 to 1.14). 
However, this effect was less than that for placebo for depression in PD (d = 1.18, 
95% CI = .55 to 1.81) suggesting that there appears to be no benefit of antidepressant 
therapies relative to placebo, consistent with the present findings. Skapinakis and 
colleagues (2010) reported a slightly better response rate associated with SSRIs 
relative to placebos, however this result was not statistically significant (RR = 1.08, 
95% CI = .75 to 1.55). Most recently, Rocha et al. (2013) reported an improved 
response rate associated with SSRI treatments relative to placebo following the 
publication of the largest RCT of antidepressants in PD to date (i.e., Richard et al., 
2012) however again this result was not significant (RR = 1.20, 95% CI = .57 to 
2.52). 
 
While it has been suggested that this result indicates that the widespread use 
of antidepressants in PD is largely unjustified (i.e., Chen et al., 2007), the magnitude 
of the pooled effect obtained in this study suggests that antidepressant therapies show 
promise in the treatment of the depression in PD. A pooled effect size of .71 
represents a moderate to large effect and indicates that individuals with PD treated 
with antidepressants do experience a reduction in depressive symptoms compared 
with placebo, even if this effect is statistically non-significant. Similar to the 
conclusions of Rocha et al. [24] and Skapinakis et al. [56], at this stage, it is likely 
that the non-significance of the pooled effect for antidepressants in PD reflects a 
Type II error due to the very limited number of available placebo-controlled RCTs in 
the literature at present (n = 5). Ultimately, there is a need for more controlled 
research to resolve the ambiguity surrounding the efficacy of antidepressant therapies 
in PD. 
 
In regards to the comparative efficacy of SSRIs and TCAs, the results of this 
meta-analysis support the general consensus that TCAs are more effective than 
SSRIs for the treatment of depression in PD. The pooled effect for TCAs was large 
and significant for both depression and anxiety, while the pooled effects for SSRIs 
were moderate but non-significant. Rocha et al. (2013) also reported a superior 
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response rate for depression associated with TCAs than SSRIs (RR = 1.78, 95% CI = 
1.06 to 2.99). Despite the efficacy of TCAs in PD, the high side-effect profile 
associated with this class of medications has seen a sharp decline in its use in PD. 
Thus, SSRIs remain the most widely used treatment for depression in PD at present. 
It is therefore imperative to resolve the ambiguity surrounding the efficacy of SSRIs 
for depression in PD, to ensure that individuals with PD are being offered the most 
optimal first-line treatment. 
 
However, although the current results suggest that antidepressant therapies do 
show promise in reducing symptoms of depression and anxiety in PD, there still 
remains concerns regarding polypharmacy, adverse drug interactions, and harmful 
side effects. These concerns regarding safety have ultimately resulted in an emerging 
interest in the utility of non-pharmacological treatment approaches for depression 
and anxiety in PD in recent times. The present analysis was the first to systematically 
examine the efficacy of non-pharmacological therapies for depression and anxiety in 
PD, and highlighted the potential of several non-pharmacological treatments as 
viable alternatives to antidepressant therapies for depression and anxiety in PD.  
 
Although these findings must be interpreted with caution as they are based on 
the results of single RCTs, at this stage it would appear that there are several 
treatment options that warrant further research as alternatives and/or adjuncts to 
antidepressant therapies. The trial of Omega-3 supplementation (Moralez Da Silva et 
al., 2008) resulted in a significant large effect on depressive symptoms (d = .92, 95% 
CI = .15 to 1.69), while the trial of atomoxetine
 
(Weintraub et al., 2010) resulted in a 
significant large effect on anxiety symptoms (d = 1.29, 95% CI = .71 to 1.87). In 
addition, the CBT trial (Dobkin et al., 2011a) resulted in the largest effect on 
depression in PD (d = 1.57, 95% CI = 1.06 to 2.07) over all other interventions 
including TCAs, as well as a large secondary effect on anxiety symptoms (d = 1.03, 
95% CI = .57 to 1.50). While these results are promising, neither Omega-3 
supplementation nor atomoxetine are established treatments for depression and/or 
anxiety in primary psychiatric populations at present. CBT, however, has extensive 
evidence for efficacy in the treatment of depression and anxiety in general 
psychiatric populations and general older adult populations. In a meta-analysis of 26 
RCTs of CBT interventions for depression in older adult populations, Pinquart, 
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Duberstein and Lyness (2007) reported a pooled effect size of 1.12 at posttreatment 
against non-active controls. Moreover, CBT has been shown to be of equal efficacy 
to pharmacotherapy for the acute treatment of depression and anxiety in primary 
populations, and superior to pharmacological treatments over the long-term, with 
pharmacological treatments associated with an 82% increase in the relative risk of 
relapse of depression (NICE, 2010a; 2010b). 
 
In recognition of the potential of CBT for depression in PD, Black (2011) 
recently urged researchers and clinicians alike to truly consider the utility of this 
‘new (old)’ treatment modality as an alternate to current pharmacological regimens 
for depression in PD. CBT is a safe, effective and established treatment approach for 
depression and anxiety in primary populations that has demonstrated long-term 
benefits and preliminary evidence of its efficacy in PD is now emerging. When 
considering that the major criticisms of current first-line SSRI treatments are related 
to a lack of efficacy, aversive side effects and high relapse rates, it would appear that 
CBT offers a promising alternative approach. 
 
2.8.2 Limitations and Direction for Future Research 
There are several limitations to this meta-analysis. First, the restriction of 
studies to only those in English language excludes trials conducted and reported in 
non-English speaking countries. Direct comparison of treatment effects across 
studies employing different control groups (primarily placebo-controlled vs. waitlist-
controlled) is a second limitation of the study. The primary limitation of this meta-
analysis concerns the limited number of studies available for inclusion for analysis 
which has important implications for the interpretation of findings. As previously 
noted, while current results indicate that the pooled effect of antidepressant therapies 
for the treatment of depression in PD is non-significant, this result may likely 
represent a Type-II error given that moderate to large effect sizes were observed. 
Ultimately, there is a pressing need for more well-designed placebo-controlled trials 
of SSRIs in PD to provide a more accurate estimate of treatment effect. This is 
especially important given that such treatments currently constitute the first-line 
approach for depression and anxiety in PD. It is therefore imperative to resolve the 
ambiguity surrounding the efficacy of SSRIs for depression in PD to better inform 
clinical care. If SSRIs are to continue to be the first-line treatment for depression in 
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PD, there needs to be a solid empirical base to support the efficacy of such 
interventions in PD.  
 
There are two other important directions for future research in the depression 
and anxiety treatment area. First, is an urgent need for research and treatment trials 
specifically for anxiety in PD. While the empirical literature for depression 
treatments in PD is steadily increasing, there remains no RCTs of pharmacological or 
psychological treatments for anxiety in PD. Anxiety and depression share an overlap 
of symptoms however there are core components of anxiety disorders that are 
distinct from depression and that require specific clinical attention. Previous research 
has shown that anxiety accounts for a significant proportion of unique variance in 
poor quality of life in PD, beyond any variance explained by depressive symptoms 
(Rahman et al., 2008). Thus, anxiety disorders on their own comprise a significant 
component of the burden of disease in PD and research and development of 
appropriate treatments for anxiety in PD is duly needed.  
 
Finally, researchers developing treatments for depression and/or anxiety in 
PD need to also consider the use of CBT as an alternative to current pharmacological 
regimes. While pharmacological treatments have been heavily favoured for the 
treatment of depression in PD, CBT offers a safer alternative. Preliminary data 
indicates that CBT may be a more efficacious treatment approach than current first-
line SSRI interventions however there is a pressing need for more empirical studies 
of CBT in PD in order to establish the true magnitude of treatment effect. Overall, 
this meta-analysis highlights the promise of CBT as a treatment for both depression 
and anxiety in PD and strongly warrants further exploration of this currently 
understudied treatment modality in PD.  
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2.9 Chapter Summary 
  
This study was the first known meta-analysis of both pharmacological and 
non-pharmacological randomised placebo-controlled treatment trials for depression 
and/or anxiety in PD. Despite growing awareness of psychiatric and non-motor 
disturbances in PD, there remains a considerable dearth of empirical research in this 
area at the present time. An extensive literature search uncovered only nine well-
designed placebo-controlled RCTs for depression in PD, and no trials specifically for 
anxiety. Based on the available results, it would appear that both pharmacological 
and non-pharmacological interventions show potential in the treatment of depression 
and anxiety in PD. While the pooled effects of antidepressant therapies in PD were 
non-significant, the moderate to large magnitude of the pooled effect for both 
depression and anxiety is promising. More controlled trials are required to establish a 
more valid and reliable estimate of the treatment effect of antidepressants in PD. 
CBT appears to be a particularly promising non-pharmacological approach, and the 
results of this meta-analysis strongly suggest that future research needs to also be 
directed at the development and evaluation of CBT interventions in PD. Overall, 
however, it is difficult to draw definitive conclusions regarding the efficacy or non-
efficacy of treatments for depression in PD given the very limited amount of 
empirical research in this area. There is a pressing need for more well-designed 
placebo-controlled trials of both pharmacological and non-pharmacological 
treatments for depression and/or anxiety in PD, especially given the range of 
negative outcomes associated with both conditions in PD.  
 
In the next chapter, the feasibility of CBT as a potentially more viable, safer 
and effective alternative to pharmacological treatment for both depression and 
anxiety in PD is more closely explored. 
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CHAPTER 3  |        Cognitive Behavioural Therapy       
                                    as a Treatment for Depression and  
                                    Anxiety in Parkinson’s Disease 
 
 
 
 
3.1 Introduction 
 
In recent times, increasing interest in psychotherapy as an alternate to 
pharmacological treatments for depression and anxiety in Parkinson’s disease (PD) 
has emerged.  In primary psychiatric populations, psychotherapy is an established 
treatment used to manage a wide range of psychological disturbances and the 
preferred method of treatment by patients (Prins et al., 2008).  
 
 Recent meta-analyses have concluded that psychotherapy used alone is 
equally effective as pharmacological interventions for the acute treatment of 
depression, panic disorder, social anxiety and generalised anxiety disorder (NICE, 
2010). Moreover, the side-effect profile associated with psychotherapy is minimal to 
none (Dobkin et al., 2011), and long-term sustained benefits have been widely 
demonstrated (NICE). 
 
Cognitive Behavioural Therapy (CBT) has been identified as a potential 
therapy of choice for use in PD. This chapter examines the feasibility of CBT for 
depression and anxiety in PD. The first part of the chapter provides a brief overview 
of CBT for depression and anxiety, including a review of the underpinning 
theoretical framework, therapy components and course of treatment. The remainder 
of the chapter establishes a rationale for the use of CBT in PD by reviewing the 
relevant theoretical and empirical literature.  The chapter concludes with an 
empirical review of existing studies evaluating the use of CBT in PD populations and 
highlights promising preliminary results but. ultimately, a need for more well-
designed clinical research, particularly for group CBT interventions. 
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3.2 Cognitive Theory 
 
Cognitive Behavioural Therapy is an overarching term used to refer to a 
family of therapies guided by Aaron Beck’s ‘cognitive theory’. Cognitive theory was 
first formulated in the mid-1960s to account for the aetiology of depression and has 
since been applied to a wide range of psychological conditions including anxiety, 
personality, eating and substance disorders (Beck, 2008).  
 
3.2.1 Psychological Disturbances in PD: A Cognitive Explanation 
There is a general consensus among researchers that depressive and anxiety 
disorders likely manifest in PD as a result of a complex interaction between 
neurochemical changes inherent within the PD degenerative process and 
environmental stressors associated with living and coping with a chronic and 
progressively disabling illness (Poewe & Seppi, 2001; Serra-Mestres & Ring, 2002). 
However, no model accounting for this process has been proposed. The following is 
a proposed cognitive explanation for the occurrence of depression and anxiety in PD. 
 
Broadly, cognitive theory proposes that at the core of psychological 
disturbance lies a set of dysfunctional and maladaptive attitudes or core beliefs 
termed ‘schemas’ (Clark, Beck, & Alford, 1999). These schemas form following the 
experience of adverse developmental events (or a single negative event) and become 
integrated within an individual’s cognitive facilities (Beck, 2008). Schemas vary in 
terms of stability and salience depending on the intensity of the adverse 
experience(s) and are latent until activated by a major stressful event in later life or a 
series of smaller stressful events (Beck). Cognitive theory thus proposes a diathesis-
stress model of psychopathology. Once activated, dysfunctional cognitive schemas 
‘hijack’ normal cognitive processes to produce automatic memory, attentional and 
perceptual biases that are in line with dysfunctional beliefs (Beck). Ultimately, what 
results is a distorted and dysfunctional perception of reality which triggers as well as 
maintains psychological disturbance (Garrat & Ingram, 2007). 
 
Contemporary forms of the cognitive model also acknowledge other diatheses 
for depression, such as the role of genetic and biological predispositions (Beck, 
2008), which is particularly relevant to PD. Specifically, a number of studies have 
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identified a higher rate of depression among individuals carrying the short variant of 
the serotonin transporter gene, 5-HTTLPR (i.e., Uher, 2008). It is also widely 
acknowledged that underlying neurochemical changes in PD constitute a biological 
predisposition for developing depression and anxiety (Poewe & Seppi, 2001). The 
mechanisms underlying the influence of genetic and/or biological predispositions in 
the development of depression and anxiety are not fully understood (Beck, 2008). It 
is possible that a genetic and/or biological predisposition may predispose certain 
individuals to developing dysfunctional schemas in response to adverse 
developmental experiences which then act as a diathesis for depression and anxiety 
in later life (Path A; see Figure 3). It may also be possible that, rather than play a role 
in the formation of schemas, genetic and/or biological predispositions make it easier 
for latent schemas to become activated in response to stressful events in later life 
(Path B). 
 
In terms of genetic predisposition, Beck (2008) states that an accumulating 
body of evidence suggests that negative cognitive biases are linked with possession 
of the 5-HTTLPR gene. Thus, it may be the case that genetics predispose certain 
individuals to developing dysfunctional self-schemas in response to adverse 
experiences (i.e., Path A). In terms of PD, however, it is likely that Path B represents 
a more likely aetiological pathway given the temporal ordering of the model. As 
dysfunctional schemas are proposed to develop in response to adverse developmental 
experiences, it is unlikely that PD (typically occurring in late-life) would have an 
impact on the formation of schemas. Rather, it is more likely that neurochemical 
changes inherent within PD lower the activation thresholds of preformed schemas, 
thus making it easier for individuals with PD to develop depression and/or anxiety in 
response to the many stresses, changes and challenges associated with living and 
coping with the illness. 
 
The cognitive model appears to be a promising explanation that is able to 
account for both the elevated levels of depression and anxiety in PD relative to other 
medical populations (i.e., lowered schema-activation threshold due to neurochemical 
changes), as well as why not all individuals with PD develop depression and/or 
anxiety (i.e., dependent on core beliefs shaped by early developmental experiences). 
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Figure 3. Cognitive Model of Psychopathology in Parkinson’s Disease adapted from 
Beck (2008, p. 972). 
 
 
Disorder-specific cognitive explanations follow the general cognitive model, 
however, each differ in terms of the underlying schemas postulated to be responsible 
for causing psychological distress. 
 
3.2.1.1 Depressive schemas. In his pioneering work, Beck analysed the 
thoughts and dreams of his patients and noted a pervasive theme of negativity across 
their self-evaluations, evaluations of life and others, memories and expectations 
(Beck, 2008). Beck asserted that this negativity appeared to be the result of a 
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systematic cognitive bias in the way his patients processed and subsequently 
interpreted the world around them, and proposed that an underlying negative self-
schema was ultimately responsible.  
 
Developmental events that have been linked with adulthood depression most 
commonly involve the experience of some form of loss (Beck, 2008). In particular, 
parental loss in childhood has been commonly reported among those with severe 
depression (Beck). These early experiences of loss are proposed to lead to the 
development of negative core beliefs about oneself and the world, particularly 
around themes of helplessness (Abramsom, Seligman, & Teasdale, 1978) and 
hopelessness (Abramson, Metalsky, & Alloy, 1989). Common core beliefs observed 
in depression include ‘I am useless’, ‘Nothing works out’, ‘Nobody cares about me’ 
and “Things will never get better’ (Westbrook et al., 2011). When activated in later-
life following the experience of stressful events, these negative beliefs dominate 
cognitive processes and produce a systematic negative bias including; attentional 
bias to negative aspects of experiences, selective recall for negative aspects of 
experiences, blocking of positive events and memories, interpretation of everyday 
events in a negative light, and internalisation of negative occurrences (Garratt & 
Ingram, 2007; Westbrook et al.). Ultimately, what results is a pervasive and distorted 
negative perception of oneself, the world and the future which then triggers as well 
as maintains depression (Beck, 2008). 
 
 3.2.1.2 Anxiety schemas.  Following successful establishment of CBT for 
depression, Beck, Emery and Greenberg proposed the first cognitive model of 
anxiety in 1985 (Beck, 2008). In this seminal formulation, Beck and colleagues 
posited that underlying all anxiety disorders are a set of distorted beliefs regarding 
personal vulnerability to some form of threat or danger (Clark, 1999). Each anxiety 
disorder is associated with a specific perceived threat. Salkoviskis (1985) suggested 
that at the centre of OCD is a set of distorted beliefs regarding responsibility for 
harming oneself or others. Clark (1986) proposed there is an underlying set of 
catastrophic misinterpretations regarding the dangers of bodily sensations in panic 
disorder. Underlying social anxiety disorder is suggested to be danger-oriented 
schemas regarding social interaction and negative evaluations from, and rejection by, 
others (Clark & Wells, 1995). For generalised anxiety disorder, it has been suggested 
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that beliefs about the threatening nature of ambiguity and uncertainty (Dugas, 
Gagnon, Ladoucer, & Freeston, 1998) or of worry itself (Wells & Carter, 1999) may 
underlie persistent worrying. When activated, these danger-oriented schemas 
produce perceptual, attentional and memory biases towards threat cues and lead to an 
overestimation of threat and danger (Beck, 2005). This pervasive perception of 
danger ultimately results in the feelings of fear, worry and apprehension that are seen 
in anxiety disorders, accompanied by a range of dysfunctional safety behaviours to 
minimise such fears accordingly (Salkovskis, 1991). 
 
 
3.3 Cognitive Behavioural Therapy for Depression and Anxiety 
 
Depression and anxiety commonly co-occur and there a number of 
similarities in the cognitive distortions and coping behaviours present in both 
conditions. Individuals with anxiety believe that some sort of undesirable event is 
about to occur and react to this belief with fear, worry and apprehension, while 
individuals with depression typically believe that an undesirable event has already 
occurred and that they are helpless and their lives hopeless (Beck, 2008). In both 
situations, the primary dysfunctional coping behaviour is withdrawal and/or 
avoidance (Westbrook et al., 2011). Thus, it is often helpful to address the two 
conditions together in treatment. 
 
3.3.1 CBT Overview 
CBT is a broad term referring to a family of therapies directly derived from 
the cognitive framework of psychopathology and employing a combination of 
cognitive and behavioural techniques (Martin, 2007). The central premise of 
cognitive theory is that psychological disorders are manifestations of underlying 
cognitive distortions. Thus, cognitive change is the proposed key to achieving 
symptomatic relief as well as the primary aim of any CBT treatment (Brewin, 1996).  
 
CBT treatments are highly structured, time-limited and problem-oriented 
(Lipchik, Smitherman, Penzien, & Holyroyd, 2006). Sessions generally last between 
one to two hours and follow a strict agenda beginning with agenda setting, 
homework review, session content, goal setting, setting of homework assignments 
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and ending with a session summary. The structure of CBT serves to increase the 
efficiency of the treatment process, facilitates learning for the client, combats inertia, 
and allows each session to focus on specific problems and potential solutions 
(Wright, 2006). CBT is also centred on a highly collaborative therapeutic 
relationship. Both client and clinician are seen as equal contributors to therapy and 
the client is actively involved in all aspects of treatment from case formulation to 
selection of treatment strategies and goals (Westbrook et al., 2011). This 
collaborative method ultimately encourages clients to take an active role in the 
process of change (Wright).  
 
The key treatment components of CBT are psychoeducation, cognitive 
therapy, behavioural interventions and between-session tasks (or homework). The 
collective aim of these strategies is to identify and challenge dysfunctional thinking 
and core beliefs. Psychoeducation is used to explain the cognitive model and 
associated concepts to the client. Cognitive therapy is used to directly target 
dysfunctional automatic thoughts and core beliefs. Behavioural experiments are used 
to test the validity of automatic thoughts and dysfunctional core beliefs (e.g., through 
behavioural experiments) as well as to target dysfunctional behaviours and shape 
healthy behaviours. Homework is used to consolidate learning of in-session content 
and skills and encourages clients to be active in the process of change. Research 
suggests that clients who consistently complete homework tasks are more likely to 
benefit from CBT (Burns & Nolen-Hoeksema, 1992). 
 
3.3.1 Course of Treatment 
CBT for depression and anxiety typically adheres to the following course of 
treatment; (1) identification of specific problems and goals for therapy, (2) case 
formulation, (3) simple cognitive and behavioural strategies, (4) identifying and 
challenging automatic thoughts, and (5) identification and modification of 
dysfunctional core beliefs (Westbrook et al., 2011). 
 
3.3.1.1 Initial stages of therapy. The initial therapy sessions are concerned 
with conceptualising the client’s problems, establishing specific treatment goals and 
providing some immediate symptomatic relief. Simple cognitive strategies such as 
distraction and counting thoughts, are introduced to temporarily reduce unwanted 
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cognitions and provide some relief from depression and anxiety (Westbrook et al., 
2011). These strategies are also useful for helping clients begin to increase 
objectivity and distance themselves from their thoughts (Westbrook et al.). 
Behavioural techniques such as relaxation training are also frequently used in the 
early stages of therapy to provide relief from stress and tension and improve sleep 
quality. Behavioural activation is a third strategy that is often employed in the early 
stages of CBT for depression and anxiety to target inactivity and avoidance 
behaviours. Various activities are systematically planned across the client’s day. 
Scheduling activities counteracts inertia and loss of motivation, prevents excessive 
rumination, as well as promotes feelings of pleasure, enjoyment and a sense of 
accomplishment on a daily basis (Rupke, Blecke, & Renfrow, 2006). 
 
3.3.1.2 Cognitive therapy. The central therapeutic work in CBT for 
depression and anxiety is aimed at identifying and challenging automatic thoughts 
and dysfunctional core beliefs. Cognitive therapy is the primary strategy used to help 
clients modify dysfunctional thinking patterns (Lipchik et al., 2006). There are five 
steps involved; (1) monitoring and becoming aware of automatic thoughts, (2) 
identification of cognitive biases, (3) appraisal of cognitive biases, (4) developing 
more balanced perspectives, and (5) modifying core beliefs (Beck et al., 1979).  
 
In the first stage, the cognitive paradigm is introduced through 
psychoeducation and the clinician helps the client to become aware of their 
automatic thoughts and the connections between cognitions, affect and behaviour. In 
the second stage, the client and clinician work together to identify cognitive biases or 
errors present in the clients’ thinking. Cognitive biases include extreme thinking 
(e.g., all-or-nothing thinking, having unrealistic expectations), selective attention 
(e.g., picking out and dwelling on a single negative, dismissing positives and 
exaggerating negatives), relying on intuition and self-reproaching thinking (e.g., self-
blame; Westbrook et al., 2011). The next stage is appraisal. In this step the client and 
clinician work together to challenge the validity of maladaptive thoughts by testing 
them and gathering evidence for and against the clients’ thoughts. The aim of this 
stage is for clients to realise that their thoughts are subjective opinions that have been 
distorted because of the beliefs they hold rather than objective statements of truth 
(Westbrook et al.). In the next stage, a more balanced way of thinking is developed. 
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Using the evidence generated in the appraisal stage, the client is asked to generate an 
alternate, more objective, perspective of the situation. In the final stage, the client 
and clinician work together to identify the clients’ core beliefs that are responsible 
for eliciting automatic thoughts. Once identified, core beliefs can be tested and 
challenged in much the same way as automatic thoughts (Wright, 2006).  
 
3.3.1.3 Behavioural interventions. Behavioural tasks are an important 
component of CBT. Increasing evidence has shown that behavioural change is often 
directly related to a corresponding change in cognition (Chambless & Gracely, 1988; 
DeRubels et al., 1990). Thus, behavioural techniques employed in CBT focus on 
altering dysfunctional behaviour as a means of altering underlying maladaptive 
thought processes (Garrat & Ingram, 2007). In addition to tasks that target 
dysfunctional behaviours and shape more healthy behaviours (e.g., activity 
scheduling) behavioural techniques can also be used to test the validity of automatic 
thoughts and core beliefs in depression and anxiety (Westbrook et al., 2011). Specific 
techniques include behavioural experiments and exposure and response prevention 
(ERP). Behavioural experiments are learning experiences designed to test specific 
thoughts or assumptions and need to be controlled to ensure positive outcomes in 
order to prevent further reinforcement of the client’s dysfunctional beliefs 
(Westbrook et al.). ERP is a common technique used for OCD (Westbrook et al.). 
ERP involves exposing the client to their feared situation and preventing the usual 
accompanying safety behaviour. In CBT, the aim of ERP is to test and challenge the 
validity of the client’s thoughts and assumptions rather than to habituate the fear 
response as in more classic behavioural interventions (Westbrook et al.). As with 
behavioural experiments, ERP needs to be conducted in controlled settings to ensure 
a positive outcome so as to not reinforce dysfunctional beliefs.  
 
3.3.1.4 Relapse prevention. In addition to targeting dysfunctional thoughts 
and beliefs, CBT focuses on enhancing the client’s problem-solving skills as a means 
of preventing relapse. Individuals with depression (and to a lesser extent anxiety) 
have been shown to display deficits in problem-solving (Mynors-Wallis et al., 2000). 
Structured problem-solving techniques encourage clients to take an active role in the 
management of their depression and promote feelings of accomplishment and 
satisfaction. Structured problem-solving involves the identification of a problem that 
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the client is currently experiencing, generating a list of possible solutions and then 
narrowing it down to the most plausible option (Westbrook et al., 2011). Practicing 
structured problem-solving throughout therapy ultimately equips clients with the 
tools to be able to resolve problems on their own once therapy has ended and 
therefore protects against relapse (Lipchik et al., 2006). 
 
3.3.2 Treatment Format 
 CBT can be delivered in a number of different formats and at varying levels 
of intensity. The NICE (2010) classify individual and group CBT as high intensity 
psychological interventions, while low intensity CBT interventions include guided 
self-administered CBT and computerised CBT (CCBT). Individual CBT is often the 
preferred format of therapy as it allows tailoring of treatment to meet individual 
needs. Clients work closely with a clinician and therefore have more privacy as well 
as the opportunity to build a stronger therapeutic relationship. Group CBT treatments 
consist of between 4 to 10 clients per group, are highly structured and facilitated by 
two therapists. Group CBT has a strong psychoeducational element and aims to 
equip clients with techniques and strategies to self-manage symptoms. Group CBT is 
particularly advantageous for improving social skills and increasing social support as 
it provides an opportunity for people experiencing similar struggles to share and 
work through their problems together. Low intensity CBT interventions are most 
suitable for people with milder psychological difficulties (NICE). Self-help and 
guided self-help forms of CBT involve providing the client with written materials to 
teach them to self-manage their condition(s). CCBT interventions are delivered using 
computer- or internet-based programmes and differ from self-help programmes in 
that they are interactive and require input from the client. CCBT can be used as a 
standalone treatment or as an adjunct to individual or group treatment (NICE).  
 
 
3.4 Theoretical Rationale for CBT for Depression and Anxiety in PD 
 
There are sound theoretical and clinical reasons for considering the 
application of CBT in PD populations. In a review of CBT for PD, Laidlaw (2008) 
highlighted several treatment characteristics that make CBT a ‘potentially very 
effective’ treatment option for psychological disturbances in PD. These include; (1) a 
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here-and-now focus on current concerns and difficulties, (2) ability to target illness-
related concerns, (3) enhancement of problem-solving skills and ability to deal with 
increasingly difficult challenges with disease progression, and (4) enhancement of 
social engagement and support. 
 
3.4.1 Present-Focused and Problem-Oriented Therapy 
Older adults are significantly more ‘set in their ways’ and have stronger and 
more established personalities than younger adults (Steuer et al., 1984). Thus, the 
problem-oriented approach in CBT may be more appealing, relevant and engaging 
for older adults as it focuses on skill-building rather than personality change (Steuer 
& Hammen, 1983). In addition, older adults can present with histories of 
psychological difficulties spanning several decades, and Laidlaw (2006) states that 
there is often less therapeutic gain to be made by focussing on historical issues. Thus, 
the present-focused approach in CBT which targets current problems and 
maintenance factors may be more beneficial in providing symptomatic relief for 
older adults when compared with other forms of psychotherapy that place a larger 
emphasis on background issues (Laidlaw & McAlpine, 2008). 
 
3.4.2 Illness-Related Concerns 
Previous studies have found that illness-related concerns feature prominently 
in both depression and anxiety in PD (Brook & Doder, 2000). Higher rates of 
sadness, pessimism, and dysphoria have been observed in depression in PD and 
linked with hopelessness and helplessness in regards to having PD (McDonald et al., 
2003). Similarly, predominant concerns in anxiety in PD have been found to focus on 
the unpredictability of motor symptoms, the uncertainty of prognosis, and the 
perceptions of others towards PD (Backer, 2000). While illness-related concerns are 
common and expected among those with medical illnesses, it has been suggested that 
individuals with depression and anxiety and comorbid medical illness tend to have 
distorted and/or exaggerated beliefs regarding their illness and/or their ability to 
cope. For example, Evans (2007) states that older people with depression and anxiety 
and comorbid physical illness tend to ruminate about physical limitations and 
develop exaggerated beliefs about their level of functional impairment which 
consequently affects their confidence. As a result, these individuals tend to become 
more passive and isolated which further contributes to depression and anxiety as well 
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as increases functional impairment. Similarly, rumination about the future and the 
prognosis of PD can be a significant source of depression and anxiety for many 
individuals with PD (Cole & Vaughan, 2005). However, it is often not the future in 
itself that is threatening or distressing but rather what the individual believes will 
occur. Individuals with depression and anxiety have been shown to have a grossly 
distorted image of future events as well as to underestimate their capacity to cope 
accordingly which is what ultimately contributes to emotional distress (Cole & 
Vaughan). Anxiety and panic over motor symptoms is another common feature in 
anxiety in PD. It has been suggested that an underestimation of one’s capacity to 
cope with motor symptoms and bodily changes may underlie this panic (Evans). 
 
While pharmacotherapy is able to bring about symptomatic relief (e.g., 
improve sleep and mood and reduce tension), illness-related concerns are largely 
unaddressed. The primary benefit of CBT over pharmacotherapy is its ability to 
directly address illness-related concerns and any cognitive distortions. Cognitive 
therapy can be used to identify and correct any distortions and/or exaggerations in 
thinking while behavioural experiments may be particularly useful to build 
confidence and show clients what they are capable of achieving in spite of physical 
limitations (Cole & Vaughan, 2005). CBT is able to help clients develop a realistic 
yet hopeful perspective of life with PD which acknowledges loss and limitations but 
at the same time encourages the highest possible level of functioning (Evans, 2007).  
 
3.4.3 Problem Solving and Active Coping 
Thompson (1996) states that transition points and loss are the two most 
common events which trigger depression for older adults. The progressive nature of 
PD means that individuals with PD will inevitably be faced with several transition 
points throughout their illness, have to encounter increasingly difficult challenges, 
and be confronted with the progressive loss of health and well-being. Thus, self-
management skills are vital to prevent relapse. The problem-solving and active 
coping components of CBT have been suggested to be particularly helpful in this 
regard, by providing individuals with PD with the necessary skill set to be able to 
deal with inevitable future problems as they arise (Laidlaw & McAlpine, 2008). 
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3.4.4 Social Engagement and Support 
Finally, social isolation and inadequate social support have been identified as 
significant risk as well as maintenance factors for depression among older adults 
(Dean, Kolody, & Wood, 1990; Glass, Mendes de Leon, Bassuk, & Berkman, 2006; 
Oxman & Hull, 1997). CBT may therefore be particularly useful for use in PD as it 
encourages social engagement through strategies such as behavioural activation and 
activity scheduling (Westbrook et al., 2011). The aim of these strategies is to 
increase positive reinforcement and foster a sense of pleasure, accomplishment and 
mastery. Engagement with others also creates the potential to build meaningful 
relationships and ultimately enhance social support.  In particular, Thompson and 
colleagues (2000) state that group CBT interventions are highly suited for older 
adults who tend to experience less social contact than younger adults. Group CBT 
not only increases social contact for older adults but also reduces any stigma 
associated with depression and anxiety and psychological treatment as clients are 
able to meet others who are experiencing similar difficulties. 
 
 
3.5 Empirical Rationale for CBT for Depression and Anxiety in PD 
The empirical rationale for the use of CBT for depression and anxiety in PD 
populations is strong. In an examination of the feasibility of CBT for the treatment of 
depression in PD, Cole and Vaughan (2005) highlighted three main findings 
supporting the use of CBT as an alternate to pharmacological treatments for 
depression and anxiety in PD. First, CBT is equally effective as pharmacotherapy for 
depression and anxiety in primary populations. Second, there is considerable 
evidence supporting the safety and efficacy of CBT in older adult populations and 
third, an increasing body of research also suggests that CBT is effective with 
individuals with various chronic, motor and neurological diseases. 
 
3.5.1 CBT versus Pharmacotherapy in Primary Populations 
As discussed in Chapter 2.8, CBT is an established treatment for depression 
and anxiety that has demonstrated efficacy in primary populations. The National 
Institute of Health and Clinical Excellence (NICE; 2010a) currently reports a large 
effect (d = .89) for CBT for depression in primary populations against waitlist 
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controls. Similarly, CBT is currently recommended by the NICE (2010b) as the most 
effective psychological treatment for anxiety disorders, particularly GAD and panic 
disorder. A mean large effect (d = 1.09) on anxiety has been reported for CBT for 
GAD and panic disorder against waitlist controls at post-treatment (NICE). 
 
In regards to the comparative efficacy of CBT and pharmacotherapy, the 
NICE (2010a, 2010b) reports a broad equivalence between the two treatment modes 
for the acute treatment of depression and anxiety in primary psychiatric populations. 
However, CBT is generally more effective over the long-term and in regards to 
relapse prevention. Treatment by antidepressants was found to be associated with an 
82% increase in the risk of relapse of depression compared with CBT treatment 
(NICE). CBT has also been shown to be superior to TCAs and SSRIs in maintaining 
acute treatment gains for anxiety, with Heimberg and colleagues (1994) reporting 
that all participants who received CBT in their study were found to maintain 
treatment gains at 6-month follow-up compared to only half of the group treated with 
the antidepressant phenelzine.  
 
Moreover, studies examining the efficacy of combined CBT and 
antidepressant treatment highlight a benefit for adding CBT to pharmacological 
regimens. Across nine studies, it was found that combined CBT and 
pharmacotherapy had a significant medium effect over pharmacological treatment 
alone (NICE, 2010). Combined treatment was also associated with a lower risk of 
treatment discontinuation. In contrast, six studies comparing combined 
antidepressant and CBT treatment with sole CBT interventions reported no 
significant between-group differences on BDI and Ham-D scores at post-treatment 
and one-month follow-up (NICE). Thus, while additional clinical benefits can be 
derived from adding CBT to pharmacological regimes, there appears to be no such 
benefit for adding antidepressants to CBT regimens.  
 
Collectively, these findings indicate that while there is a broad equivalence 
between the efficacy of CBT and various pharmacological treatments for depression 
and anxiety in the acute phase of treatment, lower discontinuation rates associated 
with CBT along with demonstrated sustained long-term benefits suggest that CBT is 
a more beneficial treatment overall. 
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3.5.2 CBT for Depression and Anxiety in Older Adult Populations 
An increasing empirical body of research also supports the use of CBT as a 
treatment for depression and anxiety in older adult populations. In the most recently 
published meta-analysis comparing various pharmacological and psychological 
treatments for depression in older adults aged over 60 years, Pinquart, Duberstein 
and Lyness (2007a) found that CBT was the most effective treatment for clinician-
rated depression. A mean effect size of 1.12 at post-treatment was reported for CBT 
versus control across 26 studies, compared to a mean effect size of .69 for 
pharmacological treatments against a control across 77 studies. In addition, CBT was 
also found to be more effective for older adult depression than other forms of 
psychotherapy including psychodynamic therapy (d = .76), interpersonal therapy  
(d = .14) and supportive psychotherapy (d = .57; Pinquart, Duberstein, & Lyness, 
2007b). CBT was also found to have a large long-term effect (i.e., 6-month follow-up 
or longer) on depression in older adults across four studies (d = .93). A higher drop-
out rate was reported for CBT among older adults compared to general adult primary 
populations, however, with Pinquart and colleagues reporting average probability of 
discontinuation in CBT with older adults to be 29% across 25 studies.  
 
Two further randomised controlled trials of CBT for older adult depression 
have since been published. Laidlaw and colleagues (2008) compared CBT against 
treatment as usual (TAU) for depression in a sample of 44 older adults aged 60 years 
and over with mild to moderate MDD. TAU was defined as standard clinical care. 
Significant reductions on all primary outcome variables were reported for both CBT 
and TAU at post-treatment, 3-month and 6-month follow-ups however, no significant 
differences were found between CBT and TAU across any of the measured time-
points. Thus, contrary to the findings of Pinquart and colleagues’ earlier meta-
analysis, there was a broad equivalence between CBT and TAU. Examination of the 
percentage of participants meeting diagnostic criteria for MDD across each study 
time-point highlighted a benefit for CBT over TAU, however. At 6-month follow-up, 
27% of CBT participants still met diagnostic criteria for MDD compared to 53% of 
TAU participants. Wilkinson and colleagues (2009) compared a brief group CBT 
intervention against TAU specifically for relapse prevention of depression in older 
adults aged 60 years and over. Overall, CBT was found to be associated with a 30% 
reduction in the risk of relapse of depression among older adults.  
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CBT has also been shown to be an effective treatment for older adult anxiety. 
In the most recent meta-analysis of CBT for anxiety (GAD, panic disorder, social 
anxiety disorder and anxiety DNOS) in older adults aged over 60 years, Hendriks, 
Voshaar, Keijsers, Hoogduin, and van Balkom (2008) reported a pooled standardised 
mean effect size of .44 for CBT compared to waitlist controls and .51 for CBT 
compared to active controls. Thus, on average, CBT demonstrated a significant 
moderate effect in reducing anxiety symptom severity in older adult populations. 
However, this reported effect does not appear to be as strong as has been 
demonstrated in general adult populations (i.e., d = 1.09; NICE, 2010b). While CBT 
has been shown to be of equal or higher efficacy than benzodiazepine, SSRI and 
TCA treatment for anxiety in primary populations, Pinquart and Duberstein (2007) 
found that SSRIs (d = 1.68) and benzodiazepines (d = 1.76) were both significantly 
more effective than CBT for the acute treatment of anxiety in older adults. At six-
month follow-up, this difference was no longer statistically significant however and 
treatment gains were maintained for all pharmacotherapy and CBT groups. In respect 
to treatment discontinuation, Pinquart and Duberstein (2007) found no significant 
differences between drop-out rates for CBT (27%) and pharmacotherapy (22%), 
although a slightly higher attrition rate was associated with CBT.  
 
Overall, these findings suggest that CBT is effective in alleviating anxiety in 
older adults. However, a number of researchers have suggested that the observed 
reduced efficacy of CBT in older adult populations highlights the need for specific 
adaptations of standard CBT for anxiety protocols to enhance learning for older 
adults (i.e., Ayers, Sorrell, Thorp, & Wetherell, 2007; Mohlman, 2004; Wolitzky-
Taylor, Castriotta, Lenze, Stanley, & Craske, 2010). 
 
3.5.3 CBT for Depression and Anxiety with Individuals with Chronic Illnesses 
Finally, there is also evidence to suggest that CBT is an effective treatment 
for anxiety and, particularly, depression in individuals with various chronic illnesses 
including; chronic pain (e.g., Morley, Eccleston, & Williams, 1999), multiple 
sclerosis (e.g., Mohr, Boudewynn, Goodkin, Bostrom, & Epstein, 2001) stroke (e.g., 
Hackett, Anderson, & House, 2004), Type II diabetes (e.g., Gonzalez et al., 2010), 
HIV (e.g., Safren et al., 2009) and rheumatoid arthritis (e.g., Sharpe, Sensky, 
Timberlake, Ryan, & Allard, 2003).  
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Currently, the NICE (2010) recommends low-intensity CBT interventions 
(e.g., self-guided CBT and CCBT) for sub-clinical and mild depression, and both 
individual and group CBT for moderate, severe and complex depression in 
individuals with chronic physical illness. In a review of five RCTs of individual CBT 
versus standard care for depression in coeliac disease, multiple sclerosis and cancer 
(i.e., Addolorato et al., 2004; Manne et al., 2008; Mohr et al., 2000; Savard et al., 
2006), the NICE reports a statistically significant moderate to large effect favouring 
CBT at post-treatment (d = .84). Further, individual CBT was associated with 37% 
reduction in the risk of non-remission at post-treatment relative to standard care. At 
6-month follow-up, however, the effect of CBT over standard care was reduced to a 
small size (d = .07). In addition, group CBT has been found to have a significant 
moderate effect on depression (d = .54) over standard care at post-treatment across 
10 studies in chronic illness populations including HIV, epilepsy, cancer, diabetes, 
multiple sclerosis and renal disease (i.e., Antoni et al., 2006; Chesney et al., 2003; 
Davis et al., 1984; Evans et al., 1995; Heckman & Carlson, 2007; Larcombe & 
Wilson, 1984; Lii, Tsay, & Wang, 2007). Group CBT was also associated with a 
59% reduction in the risk of non-remission at post-treatment relative to standard care. 
However, there appears to be no significant difference between group CBT and other 
psychosocial interventions (e.g., health education and peer support) for depression in 
chronic illness populations including HIV, cancer and cardiovascular disease across 
five studies (i.e., Chesney et al.; Evans et al., Heckman et al., Kunik et al., 2008). 
 
 There have been fewer studies evaluating the use of CBT for the treatment of 
anxiety in chronic illness populations in comparison to depression. However, the 
available results are promising. For example, Kunik and colleagues (2001) compared 
a single 2-hour group CBT session with an educational intervention for the treatment 
of anxiety in older adults with chronic obstructive pulmonary disease (COPD). At 6-
week follow-up, it was found that participants in the CBT group showed significantly 
greater reductions in anxiety as rated by the BAI compared to the control group. 
Similarly, a more recent study also evaluating CBT for anxiety in COPD (i.e., Kunik 
et al., 2008) found that an 8-week group CBT intervention was effective in reducing 
BAI scores at post-treatment. However, there was no significant difference between 
the CBT and control group (educational intervention). Shemesh and colleagues 
(2006) evaluated the use of individual CBT for the treatment of posttraumatic stress 
 92
symptoms in individuals with ischemic heart disease who have had a myocardial 
infarction. At 6-month follow-up, participants in the CBT intervention experienced a 
57% improvement in anxiety symptoms on average, while those in the control 
condition showed no significant difference from pre-treatment to follow-up. Finally, 
Kostis, Rosen, Cosgrove, Shindler and Wilson (1994) examined the effect of 
combined exercise training, CBT and dietary control on depression and anxiety in 
individuals with congestive heart failure compared to a pharmacological intervention 
and placebo. At 12-week follow-up, statistically significant reductions in Ham-A 
scores and BDI depression scores were observed for the intervention group while in 
contrast, participants who received pharmacotherapy or placebo evidenced 
deterioration in anxiety and depression. Due to the multidisciplinary nature of the 
study intervention, however, it is not possible to conclude whether CBT was 
exclusively responsible for reducing anxiety and depression. Nevertheless, these 
results provide promising preliminary support for the efficacy of CBT in the 
treatment of anxiety across various chronic illnesses. 
 
 
3.6 Potential Limitations and Modifications of CBT in PD 
As it can be seen, there is a strong theoretical and empirical rationale for the 
use of CBT for the treatment of depressive and anxiety disorders in PD. However, 
there are several potential limitations of CBT that need to be addressed in order to 
optimise CBT for people with PD.  
 
First, and arguably most importantly, cognitive changes and impairment 
inherent in PD need to be addressed. Cognitive modification is the core therapeutic 
strategy in CBT and requires clients to be able to directly assess and manipulate their 
cognitions. Therefore, CBT will not be suitable for all individuals with PD given the 
high occurrence of cognitive impairment in PD. Up to 30% of people with PD 
experience overt dementia while up to 50% are likely to experience mild cognitive 
impairment (Ferreri et al., 2006). Symptoms of cognitive impairment in PD can 
include impairments in executive functioning, visuospatial ability, attentional and 
language functioning (Camicioli & Fisher, 2004). In addition, small but significant 
declines in cognitive capacity are observed as part of the normal human ageing 
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process. Screening for cognitive impairment is therefore imperative to determine an 
individual’s suitability for CBT, with individuals experiencing moderate or severe 
cognitive impairment not likely to fully benefit from CBT. Individuals with mild 
cognitive impairment may still benefit from CBT, but it may be necessary to 
implement various procedural modifications to enhance learning for clients including 
frequent repetition of key concepts, frequent summaries and reviews of content 
covered, and multimodal delivery of information (e.g., audio and visual; Evans). 
Psychoeducation material and homework tasks may similarly need to be summarised 
and reduced down to enhance learning for clients. 
 
Other procedural modifications to accommodate PD symptoms also need to 
be considered. For example, individuals with PD often experience difficulties with 
fine motor skills due to tremor of the limbs and therefore tasks such as handwriting 
can be effortful. A reduction of in-session writing may be a useful modification. 
Verbal and non-verbal communication is also often affected in PD therefore the pace 
of therapy may need to be slowed. The structure of the therapy sessions may also 
need to be modified to allow for regular breaks to enable clients to attend to PD-
related needs such as taking medications or relieving restless legs.  
 
Finally, content modifications also need to be implemented in order to 
increase the relevance of the CBT programme to clients’ problems and concerns. 
Given that the symptom profile of depression and anxiety in PD has been found to 
differ from that observed in general populations with a greater emphasis on illness-
related concerns (McDonald et al., 2003), CBT in this population needs to also 
involve conceptual modifications to address health beliefs and beliefs about 
disability and living with PD. For example, it would be useful to modify any 
examples used in the standard CBT protocol to be PD-relevant. In addition, the 
inclusion of PD-specific activities and discussions which address common concerns 
in PD such as the fear of falling, anxiety regarding motor symptoms, eating in public, 
uncertainty regarding prognosis and the future may enhance the effectiveness of CBT 
in PD populations. 
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3.7 Cognitive Behavioural Therapy in Parkinson’s Disease:  
An Empirical Review 
 
In recognition of the potential of CBT in treating depression and anxiety in 
PD populations, several clinical studies of CBT in PD have emerged in recent times. 
Overall, the collective results of these studies suggest that CBT is a relevant and 
efficacious treatment for depression and anxiety as well as other psychological 
problems in PD. In the following section, a review of existing studies evaluating the 
use of CBT in PD populations is presented. 
 
3.7.1 Overview of Studies of CBT in PD 
 There have been 21 published experimental studies of CBT for depression 
and/or anxiety in PD to date (see Table 10). Sixteen studies evaluated specific CBT 
interventions in PD while the remaining four incorporated CBT elements into 
educational programmes. Of the 16 specific interventions, 10 targeted individuals 
with PD with a clinical diagnosis of depression and/or anxiety. The remaining six 
studies evaluated the use of CBT for the treatment of depressive and/or anxiety 
symptoms in people with PD in general (i.e., participants did not necessarily have a 
clinical diagnosis of depression and/or anxiety). CBT interventions that have been 
tested in PD populations for depression and/or anxiety include individual CBT, 
group CBT, home-based self-help CBT and telephone-administered CBT. The 
majority have been preliminary studies employing case study (n = 4; 20%), case 
series (n = 4; 20%) or uncontrolled trial designs (n = 8; 40%). There has been one 
controlled trial of CBT in PD (5%), and two randomised controlled trials (RCT; 
15%), although only one of these was designed specifically for clinical depression 
and/or anxiety in PD (i.e., Dobkin et al., 2011). 
 
3.7.2 CBT for Clinical Depression and/or Anxiety in PD 
 There have been 11 studies evaluating the use of CBT for individuals with 
PD and a comorbid clinical diagnosis of depression and/or anxiety (i.e., Dobkin, 
Allen, & Menza, 2006; Dobkin, Allen, & Menza, 2007; Dobkin et al., 2011a; Dobkin 
et al, 2011b; Farabaugh et al., 2010; Feeney, Egan, & Gasson, 2005; Gupta, 2000; 
Heinrichs, Hoffman, & Hofmann, 2001; Laidlaw, Thompson, Dick-Siskin, & 
Gallagher- Thompson, 2003; Leroi & King, 2008; Mohlman et al., 2010).  
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Table 10  
Experimental Studies of CBT in PD 
First Author Year Design Intervention PD Specific? Participants Primary Outcomes 
A’Campo 2010 RCT (Treatment 
vs. usual care) 
Group education with 
CBT (8 sessions) 
 64 PD (35 Intervention; 
29 Control) 
Depression (SDS); Quality of life 
(PDQ-39);  
Cole  2005 Case series Self-help CBT  
(7 sessions) 
Yes 5 PD with elevated GDS 
depression scores 
Depression (BDI, GDS); Quality of 
life (PDQoL-Q) 
Dobkin 2006 Case series Individual CBT Yes 3 PD with MDD Depression (Ham-D, BDI); Negative 
cognitions (IQ); Anxiety (STAI); 
Social support (AIFQ) 
Dobkin 2007 Uncontrolled trial Individual CBT (10-14 
sessions) 
Yes 15 PD with MDD Depression (Ham-D, BDI); Anxiety 
(STAI); Negative cognitions (IQ); 
Social support (AIFQ) 
Dobkin 2011a RCT (CBT vs. 
clinical 
monitoring) 
Individual CBT  
(10 sessions) 
Yes 80 PD with MDD, 
dysthymia or DDNOS 
(41 CBT; 39 Control) 
Depression (Ham-D, BDI), Anxiety 
(Ham-A); Negative cognitions (IQ); 
Quality of life (SF-36); PD symptoms 
(UPDRS) 
Dobkin 2011b Uncontrolled trial Telephone CBT  
(10 sessions) 
Yes 21 PD with MDD, 
dysthymisa or DDNOS 
Depression (Ham-D, BDI), Anxiety 
(Ham-A), Quality of life (SF-36), 
Negative cognitions (IQ) 
Dreisig 1999 Controlled trial 
(CBT vs.TAU) 
Individual CT  
(6 sessions) 
No 79 PD (9 CT; 70 Control) Depression (SDS, MDI), 
psychological symptoms (PPQ) 
Ellgring 1993 Uncontrolled trial Group CBT 
(5 to 8 sessions) 
Yes 34 PD Interviewer assessment 
Farabaugh 2010 Uncontrolled trial Individual CBT  
(12 sessions) 
No 8 PD with MDD Depression (Ham-D); Quality of life 
(SF-36); Negative cognitions (DAS, 
ATQ-R; Stress (PSS) 
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First Author Year Design Intervention PD Specific? Participants Primary Outcomes 
Feeney 2005 Case series Group CBT  
(8 sessions) 
No 4 PD with depression 
and/or anxiety 
Depression (BDI-II), anxiety (STAI) 
Fitzpatrick 2010 Uncontrolled trial Group MBCT 
(8 sessions) 
No 12 PD Qualitative analysis 
Gupta 2000 Case study Individual CBT N/A 1 PD with MDD Clinician’s assessment 
Heinrichs 2001 Case study Group CBT No 1 PD with social anxiety 
disorder 
Anxiety (STAI; FAQ; LSAS) 
Laidlaw 2003 Case study Individual CBT Yes 1 PD with MDD Clinician’s assessment 
Leroi 2008 Uncontrolled trial Individual CBT 
(6 to 10 sessions) 
Yes 8 PD with depression 
and/or anxiety 
Global Assessment Scale (GAS) 
Macht 2007a Case series Individual CBT Yes 3 PD Clinician’s assessment 
Macht 2007b Uncontrolled trial Group education  with 
CBT elements 
 151 PD Depression (SDS); Quality of life 
(PDQ-39), 
Mohlman 2010 Case study Individual CBT/APT  No 1 PD with GAD Anxiety (Ham-A, PSWQ; PSWQ, 
STAI); Depression (Ham-D, BDI) 
Simons 2006 Uncontrolled trial Group education with 
CBT (8 sessions) 
 22 PD PD symptoms (UPDRS), Quality of 
life (PDQ-39); Depression (SDS);  
Trend 2002 Uncontrolled trial Individual 
rehabilitation with 
CBT (6 sessions) 
 118 PD Depression and anxiety (HADS); 
Quality of life (Euroqol-5D) 
Veazey 2009 Case series 
(CBT vs. Support) 
Telephone CBT  
8 phone sessions) 
No 10 PD (5 CBT; 5 Control) Anxiety (BAI); Depression (PHQ-9); 
Quality of life (PDQ-39) 
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Six studies focused specifically on the treatment of depression in PD, one study 
examined CBT as a treatment for social anxiety in PD (i.e., Heinrichs et al.), one 
evaluated the use of CBT in treating GAD in PD (i.e., Mohlman et al.), and three 
studies examined CBT in the treatment of comorbid depression and anxiety in PD 
(i.e., Feeney et al.; Laidlaw et al.; Leroi & King). 
 
3.7.2.1 Case studies and case series. Four case studies and two case series of 
CBT for depression and/or anxiety in PD have been published. Gupta (2000) was the 
first to examine the effect of CBT for clinical depression in PD. He provided a brief 
anecdotal account of his experience in delivering individual home-based CBT to a 90 
year old man with PD and MDD. Significant improvements in depression symptom 
severity and activity levels were reported following several CBT sessions, although 
how this improvement was measured was not reported. Similarly, Laidlaw and 
colleagues (2003) explored the effect of a PD-specific individual CBT intervention 
on depression in an individual with PD and MDD who was unresponsive to initial 
antidepressant medication. CBT was reported to reduce depression, anxiety and 
insomnia and significantly increase activity levels according to the clinician’s 
judgement.  
 
Two case studies of CBT for the treatment of anxiety disorders in PD have 
also been presented. Heinrichs and colleagues (2001) examined the use of a group 
CBT intervention in treating social anxiety in a 60 year old man with PD whose 
predominant social fears centred on others noticing his PD tremor and looking 
foolish in public. The intervention was a standard group CBT for social anxiety 
programme and the client with PD was entered into a group with four other 
individuals without PD. Main treatment components included repeated in vivo 
exposure in session, video feedback, didactic training and mirror exposure. At 
posttreatment, significant improvements on several measures of social anxiety were 
noted (e.g., LSAS, SPAI, FQ) as well as for the BDI and STAI, and these gains were 
all maintained at 6-month follow-up. Further, independent assessments using the 
ADIS-IV revealed that the client had subclinical social phobia at posttreatment and 
no clinical diagnosis of social phobia at 6-month follow-up. Mohlman and colleagues 
(2010) examined the effect of a combined individual CBT and Attention Process 
Training (CBT/APT) intervention in treating a 74 year old man with PD with GAD 
 98
and memory and attentional deficits. Main CBT components included standard 
cognitive restructuring, progressive muscle relaxation, and exposure. APT techniques 
were aimed at improving cognitive skills rather than anxiety. At posttreatment, the 
client no longer met clinical criteria for GAD and showed marked reductions on all 
anxiety measures (Ham-A, PSWQ, STAI, BAI) as well as reductions in depressive 
symptoms (Ham-D, BDI).  
 
There have been two case series of CBT for depression and/or anxiety in PD. 
Feeney and colleagues (2005) examined the effect of a group CBT intervention for 
four individuals with PD and comorbid depression and anxiety. Minor procedural 
adaptations were implemented to accommodate motor symptoms but there were no 
conceptual modifications. At 1-month follow-up, three participants demonstrated 
clinically significant improvement in depression (BDI-II), although they did not 
recover. The remaining participant showed deterioration in depression at both post-
treatment and follow-up. In regards to anxiety, two participants showed clinically 
significant improvement in anxiety (STAI) at 1-month follow-up, while the 
remaining two participants’ anxiety symptom severity remained unchanged. Dobkin 
and colleagues (2006) evaluated the use of individual CBT for treating depression in 
three adults with PD and comorbid recurrent MDD. The intervention was adapted to 
address PD-specific issues and included training in stress management, behavioural 
activation, sleep hygiene, relaxation techniques and cognitive restructuring. At 
posttreatment, clinically significant reductions in depression (Ham-D and BDI) were 
observed for all three participants and these gains were maintained at 1-month 
follow-up. A notable improvement in negative and suicidal thoughts (IQ) was also 
observed. There was minimal change in anxiety symptoms (STAI) however the 
intervention primarily targeted depression. 
 
Overall, the findings from these case studies and series support the efficacy of 
CBT in treating depression and anxiety in PD populations. It must be noted that 
reported effects may be overstated, however, due to limited sample sizes. Further, the 
generalisability of case studies and series is ultimately limited as the effect of an 
intervention on a single (or small number of) individual(s) may not be representative 
of all individuals with PD.  
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 3.7.2.2 Uncontrolled trials. There have been four uncontrolled trials of CBT 
for depression in PD. Both Dobkin and colleagues (2007) and Farabaugh and 
colleagues (2010) evaluated the use of individual CBT for depression in individuals 
with PD and comorbid MDD, with the latter authors specifically targeting 
individuals with PD and MDD who had not responded to initial pharmacotherapy. 
Dobkin and colleagues’ intervention was adapted to address PD-specific needs and 
concerns while Farabaugh and colleagues used a standard CBT protocol. At post-
treatment, Dobkin and colleagues reported an 80% remission rate of depression 
based on Ham-D scores. A significant large effect on depression was observed  
(d = 2.53) and maintained at 1-month follow-up (d = 2.39). A significant decrease in 
negative thoughts (IQ) was also observed at both post-treatment and  
1-month follow-up. A reduction in anxiety (STAI) was observed at post-treatment 
and 1-month follow-up; however this difference was not statistically significant. 
Similarly, Farabaugh and colleagues reported a significant linear decrease in mean 
Ham-D scores from pretreatment to posttreatment, although a slightly slower 
remission rate of depression (57%) was observed. Linear declines in negative 
cognitions (ATQ-R) and stress (PSS) were also reported although these differences 
were not statistically significant. Ham-D scores were also found to significantly and 
positively correlate with ATQ-R and PSS scores, suggesting that observed 
improvements in depression were in part related with reductions in stress and 
negative automatic thoughts.  
 
Leroi and King (2008) evaluated a PD-specific individual CBT intervention 
for eight individuals with PD and a comorbid anxiety and/or depressive DSM-IV 
diagnosis. At posttreatment, improvements in both depression and anxiety as rated by 
the Global Attainment Scale were recorded for all participants. In addition, all 
participants no longer met full clinical criteria for depression and/or anxiety, with 
symptoms falling within the subclinical range following treatment.  
 
The results of these uncontrolled trials provide support for the efficacy of 
CBT in treating depression in PD and have increased generalisability over the case 
studies and series described earlier. However, these findings must still be interpreted 
with caution as the sample sizes in these trials are still relatively limited (mean N = 
10; range 8 to 15). Further, the use of uncontrolled research designs prevents an 
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examination of the effect of non-specific treatment factors (i.e., time, therapeutic 
alliance, placebo effect) on symptom improvement. However, both Dobkin and 
colleagues (2007) and Farabaugh and colleagues (2010) argued that simultaneous 
reductions in and significant correlations between depression and negative thoughts 
in their respective studies preliminarily indicates that symptomatic improvement may 
be directly related to the active cognitive modification component of CBT.  
 
3.7.2.3 Randomised controlled trials. Dobkin and colleagues (2011) 
recently published the first RCT of individual CBT for clinical depression in PD. The 
authors compared an individual CBT programme for depression (MDD, dysthymia 
or DDNOS) against a control group who received clinical monitoring. The CBT 
programme was tailored to address PD-specific needs and included a stronger 
emphasis on behavioural and anxiety management than standard CBT for depression 
protocols. Participants in the CBT condition received 10 weekly sessions using a 
manualised protocol while those in the control condition were monitored closely and 
continued with existing treatment regimens over the corresponding period. No new 
treatments for depression were initiated for participants in the control condition. At 
post-treatment, a significant large effect on depression favouring CBT was reported 
(Ham-D; d = 1.59, BDI; d = 1.1) as well as a significant large effect on clinician-
rated anxiety (Ham-A; d = .98). At 1-month follow-up, improvements in clinician 
and self-rated depression as well as anxiety were all maintained. Thus, the results of 
this seminal RCT provide strong support for the efficacy of CBT in treating 
depression as well as anxiety in PD populations. 
 
Overall, there is good preliminary evidence for the efficacy of CBT in 
treating depressive and/or anxiety disorders in PD, given the lack of controlled 
research at present. All ten empirical studies of CBT for depressive disorders in PD 
reported statistically and/or clinically significant improvement in depression 
following treatment. All four studies targeting anxiety or comorbid depression and 
anxiety in PD reported clinically significant improvement in anxiety following CBT. 
In addition, significant improvement in anxiety was also observed in two CBT trials 
that primarily targeted depression. Finally, the vast majority of reported acute 
treatment gains were maintained at follow-up. While there are several inherent 
methodological limitations in each described study particularly around issues of 
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generalisability (i.e., restricted sample sizes) and internal validity (i.e., lack of 
controlled studies), together, these studies form a strong preliminary evidence base 
for the efficacy of CBT in treating depression and anxiety disorders in PD 
populations. 
 
3.7.3 CBT for Depressive and/or Anxiety Symptoms in PD 
 In addition to CBT for depressive and/or anxiety disorders in PD, there is also 
preliminary evidence to suggest that CBT is effective for reducing depressive and/or  
anxiety symptoms in individuals with PD in general (i.e., people with PD who do not 
necessarily have a clinical diagnosis of depression and/or anxiety). Six empirical 
studies have been published; two case series (Cole & Vaughan, 2005; Macht, 
Pasqualini, & Taba, 2007), two uncontrolled trials (Ellgring et al., 1993; Fitzpatrick, 
Simpson, & Smith, 2010), one controlled trial (Dreisig, Beckmann, Wermuth, 
Skovlund, & Bech, 1999), and one small pilot RCT (Veazey, Cook, Stanley, Lai, & 
Kunik, 2009). 
 
 3.7.3.1 Case series. Cole and Vaughan (2005) examined the efficacy of a 
brief self-help CBT intervention for depression in 5 individuals with PD 
experiencing elevated depressive symptoms (as rated by the GDS).  Participants were 
provided with a CBT self-help booklet written specifically for depression in PD and 
instructed to complete the seven modules in the booklet over seven weeks (spending 
60-minutes on each session). At posttreatment, clinically significant improvement in 
depression (GDS) was reported for 4 of the 5 participants. Macht and colleagues 
(2007) provided individually-tailored CBT to 3 individuals with PD experiencing 
depressive and anxiety symptoms in regards to various aspects of PD including; 
uncertainty  of prognosis, negative perception by others due to motor symptoms, 
sexual problems secondary to motor symptoms, and  inability to handle 
unpredictable symptoms. Different CBT techniques were selected for each client 
based on the primary presenting problem. Macht and colleagues reported that CBT 
was successful in reducing depressive and anxiety symptoms in all three participants 
based on clinician judgement. In particular, CBT decreased social anxiety and 
increased acceptance of PD in one client, reduced the second client’s anxiety about 
his sexual performance, and increased the third client’s ability to cope with episodes 
of freezing of gait. 
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3.7.3.2 Uncontrolled trials. There have been two uncontrolled trials 
examining the efficacy of CBT for depressive and/or anxiety symptoms in 
individuals with PD. Ellgring and colleagues (1993) were the first to apply any form 
of CBT in a PD population. The authors conducted a series of PD-specific group 
seminars based on CBT techniques including stress management, cognitive 
restructuring, social skills training and relaxation training for 34 individuals with PD. 
An independent assessment a month following the seminars revealed significant 
reductions in overall depression and stress, improved social functioning and 
increased acceptance of PD among participants. Fitzpatrick and colleagues (2010) 
conducted a group mindfulness-based cognitive therapy (MBCT) intervention for 12 
individuals with PD who had elevated scores on the Depression, Anxiety and Stress 
Scales (DASS; Lovibond & Lovibond, 1995). The MBCT course was based on a 
standard protocol. The aim of this study was not to assess the efficacy of MCBT but 
to provide a qualitative account of the experience of therapy for participants 
therefore the effect of MBCT on DASS scores was not reported. Overall, Fitzpatrick 
and colleagues concluded that MBCT was accepted by participants as a mode of 
treatment for psychological difficulties in PD and was particularly useful for 
enhancing social support and consolidating existing coping skills. 
 
 3.7.3.3 Controlled trials. There has been one published controlled trial of 
CBT for psychological functioning (including depressive symptoms) in PD. Dreisig 
and colleagues (1999) compared the effect of combined self-help and individual 
cognitive therapy (CT) against TAU on psychological functioning in 79 individuals 
with PD. Nine individuals with PD were selected to receive the intervention while 
the remaining 79 continued with TAU and served as a control. CT was individually 
tailored according to each participant’s psychological profile as assessed by The 
Psychodiagnostic Profile (unknown author), however, no PD-specific modifications 
were included in the treatment protocol. At posttreatment, it was found that 
participants in the CT group experienced significant improvements in anxiety and 
hopelessness as rated by the Psychological Profile Questionnaire (PPQ; unknown 
author) when compared with controls. Considerable improvements in the PPQ 
alienation, recognition, contact, ability and self-centredness factors were also noted 
in comparison with the control group. Further, average improvement on the total 
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PPQ was significantly higher for the CT group. However, there are several 
limitations with this trial, most notably; small sample size for the intervention group, 
significantly unequal group sizes, lack of randomisation and unclear participant 
selection strategy, and use of non-validated diagnostic and outcome scales for 
depression. Thus, the findings of this study must be interpreted with caution. 
 
3.7.3.4 RCTs. There has been one small RCT of CBT for depressive and/or 
anxiety symptoms in PD. Veazey and colleagues (2009) examined the efficacy of an 
individual telephone-based CBT intervention versus supportive telephone-based 
counselling for 10 individuals with PD who had elevated symptoms of depression or 
anxiety as assessed by the Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, 
& Williams, 2001) and BAI, respectively. The CBT intervention involved an initial 
face-to-face individual CBT session followed by eight weekly telephone sessions. 
The protocol for the telephone intervention was based on CBT techniques for older 
adults but was not PD-specific. Treatment components included psychoeducation, 
relaxation training, cognitive therapy, problem solving, activity scheduling, exposure 
and sleep-management. Participants in the comparison group received eight weekly 
telephone calls that were supportive rather than therapeutic in nature. At 
posttreatment, a medium effect on depression (PHQ-9) favouring CBT was observed 
(ɳ
2
 = .09) and this was maintained at 1-month follow-up (ɳ
2
 = .11). Similarly, a 
medium effect on anxiety (BAI) favouring CBT was observed at posttreatment (ɳ
2
 = 
.08), with a large effect observed at 1-month follow-up (ɳ
2
 = .50). Although an RCT 
design was used, the relatively small sample size in this study ultimately limits the 
validity and generalisability of reported results. Veazey and colleagues stated that 
unexpected difficulties in recruiting and retaining participants were experienced and 
contributed to the low sample size. This may indicate that telephone-based treatment 
is less preferable than more standard interventions, with Charidmou, Seamons, Seali 
and Schrag (2011) suggesting that face-to-face CBT interventions should be 
evaluated first before modified approaches. Nevertheless, the results of this study 
provide further support for the efficacy of CBT in PD. 
 
 Collectively, the findings presented suggest that CBT is effective not only for 
clinical populations, but also for the broader PD population. There is a high rate of 
psychological problems in PD and studies have shown that up to 76% of individuals 
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with PD report experiencing depressive symptoms at any given time (Veazey et al., 
2005). Thus, CBT may be useful not only for treating depressive and/or anxiety 
disorders, but also for addressing broader psychological symptoms as a means of 
preventing the development of more severe psychological problems. However, as 
with the discussion of studies of CBT for clinical depression and anxiety in PD, it 
must be noted that small sample sizes (mean N = 23) and the predominance of case 
series and uncontrolled research designs in this area ultimately limits the 
generalisability and validity of reported findings. 
 
3.7.4 Group Educational Programmes with CBT Elements in PD 
 In addition, there have been four  studies evaluating the use of group 
educational programmes with CBT elements for broad psychological functioning in 
PD; one RCT (i.e., A’Campo et al., 2010) and three uncontrolled trials (i.e., Macht et 
al., 2007; Simons et al., 2006; Trend et al., 2002). Group educational programmes 
are distinct from group CBT interventions in that they are didactic in basis rather 
than based on the CBT model and use of Socratic questioning, include a range of 
other activities aside from CBT techniques, and aim to enhance general psychosocial 
well-being and quality of life rather than specifically target symptoms of depression 
and anxiety. 
 
Trend and colleagues (2002) developed and evaluated the first group 
education programme for individuals with PD. Their intervention was an intensive 
multidisciplinary rehabilitation programme which included individual attention from 
various health professionals including a physiotherapist, occupational therapist, 
specialist PD nurse and speech therapist, as well as group activities including 
psychoeducation, talks by various PD experts and training in CBT relaxation 
techniques. At posttreatment, significant improvements in quality of life (EQ-5d) and 
depression (HADs) were observed. There was no significant change in HADs 
anxiety scores, however. Simons and colleagues (2006), Macht and colleagues 
(2007) and A’Campo and colleagues (2010) all evaluated the efficacy of a 
standardised psychosocial intervention for improving quality life, psychosocial 
functioning and depressive interventions in individuals with PD. The intervention 
was designed to specifically address psychosocial problems in PD and employed 
several CBT techniques (e.g., self-monitoring, activity scheduling and cognitive 
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restructuring) along with stress management, social skills training and a social 
competence intervention. A’Campo and colleagues compared their intervention with 
TAU while Macht and colleagues and Simons and colleagues had no control 
condition. At posttreatment, Macht and colleagues and Simons and colleagues 
reported no significant improvement in quality of life (PDQ-39) or depression (SDS). 
Macht and colleagues reported significant improvement in general psychological 
functioning (BELA-P) while Simon and colleagues did not. A’Campo and colleagues 
reported that participants in their intervention group showed improvement in quality 
of life (PDQ-39) and depression (SDS), however, there was no significant difference 
between intervention and control groups. The intervention group also showed greater 
improvement in general psychosocial functioning (BELA-P) than controls although, 
again, this difference was not statistically significant.  
 
There are currently mixed findings in regards to the efficacy of group 
educational programs featuring CBT techniques in PD.  Trend and colleagues (2002) 
reported significant improvement in depression and quality of life following 
intervention. However, the remaining three studies did not. Simon and colleagues 
(2006) reported significant improvement in psychological functioning following 
intervention although, again, Macht et al. (2007) and A’Campo et al. (2010) did not. 
However, it must be highlighted that these group programmes were not explicitly 
designed as clinical interventions. Baseline levels of depression were within the 
normal range for three of the four studies and within the mild range for the remaining 
study (i.e., Macht et al.). Similarly, baseline quality of life ratings all fell within the 
normal to mild range. Therefore, non-significant changes in depression and quality of 
life following intervention may likely represent a floor effect (i.e., significant 
improvement cannot be observed as baseline levels were already within normal 
range), rather than the non-efficacy of CBT. It may also be argued that as outcome 
levels remained within the normal range following treatment, CBT may have been 
effective in maintaining healthy levels of psychological functioning. 
 
 The findings presented suggest that CBT may be (1) efficacious for treating 
depressive and anxiety disorders in PD populations, (2) able to prevent the 
development of clinical depression and anxiety by reducing depressive and anxiety 
symptoms in individuals with subclinical symptoms, and (3) maintain normal mood 
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levels and healthy psychological functioning. However, it must be noted that the 
outcome literature for CBT for depression and anxiety in PD is still in relative 
infancy with the vast majority of existing empirical studies employing uncontrolled 
research designs with relatively small sample sizes. Thus, an assessment of the true 
magnitude of the treatment effect and clinical significance of changes is ultimately 
limited, as well as is the validity and generalisability of reported results. 
Nevertheless, these studies form a preliminary evidence base for the efficacy of CBT 
for depression and anxiety disorders in PD populations. 
 
 
3.8 Direction for Future Research:  
Group CBT for Depression and Anxiety in Parkinson’s Disease 
 
 There is growing support for the efficacy of CBT for the treatment of 
depressive and anxiety disorders in PD. In particular, there is strong support for the 
efficacy of individual CBT for depression and anxiety in PD, with eight of the ten 
CBT trials for clinical depression and/or anxiety in PD focusing on individual 
interventions. Group CBT remains understudied however despite being identified as 
a highly suitable treatment format for older adults experiencing psychological 
difficulties (i.e., Thompson et al., 2000). There are several practical and therapeutic 
advantages for group CBT in PD which warrant further investigation of this 
treatment modality in PD populations including; cost and time-effectiveness, 
normalisation and destigmatisation, and social and interpersonal learning. 
 
3.8.1 Existing Studies of Group CBT for Depression and/or Anxiety in PD 
While there have been a number of large group-based didactic programmes 
featuring CBT elements in PD, there have only been two studies of group CBT 
interventions specifically designed to treat individuals with PD with a clinical 
diagnosis of depression and/or anxiety; one case study (i.e., Heinrichs et al., 2001) 
and one case series (i.e., Feeney et al., 2005), for a total sample of five participants. 
The findings from these studies have been previously described and both preliminary 
indicate that group CBT may be efficacious in treating clinical depression and 
anxiety in PD. However, the very limited collective sample size and use of case 
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study designs ultimately restrict the meaningful conclusions that can be drawn from 
these studies.  
3.8.2 Practical and Therapeutic Advantages of Group CBT 
 Despite the limited empirical evidence for the efficacy of group CBT in 
treating depressive and anxiety disorders in PD, there are two main reasons to 
consider the use of group treatment for individuals with PD with depression and 
anxiety; (1) group CBT is equally effective as individual CBT for the treatment of 
depression and anxiety in primary populations (NICE, 2010a; NICE, 2010b), and (2) 
group CBT offers several additional unique therapeutic benefits that are particularly 
suited to chronic illness and older adult populations (Thompson et al., 2000).  
 
3.8.2.1 Therapeutic benefits. It is well documented that older adults and 
individuals with chronic illnesses experience increased stigma, withdrawal, social 
isolation and reduced social support primarily due to increased functional 
impairment (Husaini et al., 2004). Group therapy may therefore be particularly 
beneficial for such individuals, as it provides a context which promotes social 
interaction, mutual support, and reciprocal validation and facilitates enhancement of 
social skills (Morrison, 2001). Exposure to others who are experiencing similar 
difficulties can also help to reduce PD-related as well as mental illness-related stigma 
by providing an opportunity for group members to recognise common shared 
experiences among members and the universality of their concerns (Lewinsohn & 
Clarke, 1999). Paparella (2004) asserts that knowing that others share the same 
experiences of illness can be a powerful unifying force. Group CBT also offers the 
chance for social and interpersonal learning to occur which can enhance participants’ 
grasp of cognitive concepts. For example, Tucker and Oei (2007) state that it is 
easier to recognise cognitive distortions in others thinking due to increased 
objectivity. This then facilitates re-examination of one’s own cognitions and makes 
recognition of one’s cognitive distortions easier. In such a way, group members can 
essentially become co-therapists for each other (Vinogradov & Yalom, 1994). 
Helping others can also promote positive feelings of mastery, competence and 
achievement (Himle, Van Etten et al., 2003). Further, the presence of others during 
therapy can enhance treatment compliance due to peer reinforcement (Fischer et al., 
1998). These non-specific factors associated with group therapy have been found to 
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consistently produce significant improvements in treatment outcomes (e.g., Corey & 
Corey, 2002; Horvath & Bedi, 2002).  
 
It must be noted that there are also several disadvantages associated with 
group compared to individual treatment, however. For example, there is a risk of low 
group cohesiveness, confrontation between group members, dominance by members 
with stronger personalities and development of subgroups (Morrison, 2001). Group 
CBT treatments are also frequently highly structured and there is minimal room for 
tailoring of treatment to accommodate specific client problems (Husaini et al., 2004). 
There is also lessened privacy which may prevent clients from disclosing more 
private, distressing or disturbing problems. Further, individuals receive less 
individual attention from clinicians which can result in less in-depth exploration of 
problems compared to individual treatment (Tucker & Oei, 2007). Group treatment 
may therefore not be suited for all individuals.  
  
3.8.2.2 Practical benefits. In addition to the unique therapeutic benefits of 
group CBT, there are also several practical benefits, particularly for healthcare 
providers. Group CBT is more cost and time-effective than individual CBT and a 
greater number of clients can receive treatment at a time (Fals-Stewart, Marks, & 
Schafer, 1993; Himle et al., 2003). However, potential difficulties with scheduling of 
a common convenient appointment time for all group members may ultimately lead 
to higher attrition rates (Morrison, 2001). 
 
Overall, there is a strong practical and therapeutic rationale for the delivery of 
CBT in a group format in PD. Several authors have suggested that group 
psychotherapy should be offered as a first-line treatment for depression in older 
adults, particularly for those who present with complaints related to social isolation 
and difficulty adjusting to loss (Husaini et al., 2004; Peterson & Halstead, 1998; 
Tucker & Oei, 2007). However, it is acknowledged that group treatment may not be 
suited for all individuals in light of the disadvantages raised. Morrison (2001) thus 
suggests that group CBT be offered as frontline treatment in a stepped-care system, 
whereby individual therapy can be offered to those who decline initial group therapy. 
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3.8.3 Direction for Future Research 
 There are clear therapeutic and practical advantages for group CBT for in PD, 
and there is some preliminary support for the efficacy of the group treatment 
modality for depression and anxiety in PD at present. However, the existing outcome 
literature for group CBT specifically for the treatment of depressive and/or anxiety 
disorders in PD is rudimentary at best. There have only been two published case 
studies and/or series for a total sample of 5 participants. While both studies reported 
clinically significant improvement in depression and anxiety following group CBT, 
the conclusions that can be drawn about the efficacy of group CBT is substantially 
restricted. Thus, there is a pressing need for controlled trials to provide a more 
reliable assessment of the magnitude of the treatment effect and clinical significance 
of group CBT for depression and anxiety in PD. 
 
There are several phases involved in the experimental investigation of a 
psychological treatment. Briefly, these are; Phase I: Manual writing and pilot trial, 
Phase II: Preliminary trials (single site), Phase III: Large efficacy trials (multiple 
sites), and Phase IV: Effectiveness trials (application of intervention with 
demonstrated efficacy into real-world settings; Mohr et al., 2009). At present, 
existing evaluations of group CBT for depression and anxiety in PD are best 
classified as Phase I evidence. Therefore, the next step in establishing the efficacy of 
group CBT in PD would be to conduct preliminary trials. Preliminary trials assess 
the feasibility of treatment delivery, provide early efficacy evidence for an 
intervention as well as provide an estimate of the treatment effect to guide future 
larger efficacy trials (Rounsaville & Carroll, 2001).  
 
There are several methodological considerations for conducting preliminary 
efficacy trials. Mohr and colleagues (2009) assert that, ideally, preliminary trials 
should be smaller-scale randomised controlled trials. The RCT is deemed the most 
powerful research design for treatment evaluation purposes and features two core 
elements; randomisation of participants to conditions and inclusion of control and/or 
comparison groups (Rounsaville & Carroll, 2000). Randomisation serves to minimise 
the effect of individual bias on treatment outcome (Chia, 2000). Control and/or 
comparison groups allow for an examination of the effect of non-specific factors on 
treatment outcome. In early efficacy studies, Mohr and colleagues suggest 
 110
comparison against a non-active control (e.g., no treatment, TAU or waitlist control) 
as it is an important first step to show that an intervention is more effective than 
doing nothing. Further, non-active control conditions control for traditional threats to 
internal validity (e.g., time, spontaneous remission, maturation, regression to the 
mean) while not affecting statistical power as harshly as active control conditions 
(Rounsaville & Carroll). This is particularly important in preliminary trials where 
sample sizes are generally small and maintaining adequate statistical power is 
essential for detecting treatment effects. It must be noted that non-active controls do 
not allow for an evaluation of the effects of non-specific treatment factors on 
outcome (e.g., attention, rapport, group cohesiveness); therefore conclusions 
regarding the efficacy of specific treatment components cannot be drawn. However, 
Mohr and colleagues state that non-specific control conditions are not necessary for 
Phase I or II research as the primary aim of these studies is to demonstrate a 
significant treatment effect to justify larger trials. Strict controls can therefore be 
counterintuitive to this aim as they significantly reduce statistical power and increase 
the risk of a Type II error (Mohr et al). 
 
 In addition to these methodological considerations, there is also a need for the 
development and evaluation of PD-specific group CBT protocols for depression and 
anxiety in PD, in order to optimise treatment for participants and maximise any 
treatment effects. The importance of modifying standard CBT protocols to 
accommodate the unique symptom profile of depression and anxiety in PD was 
discussed earlier in this chapter. Specifically, it was recommended that both 
procedural and conceptual modifications should be implemented. Procedural 
modifications are important to accommodate PD symptoms and to enhance the 
learning process for participants. Content modifications are important to address 
specific disease-related concerns which feature prominently in depression and 
anxiety in PD (e.g., fear of falling, anxiety regarding motor symptoms, uncertainty of 
prognosis etc.). The two existing studies of group CBT for depression and/or anxiety 
in PD both used standard CBT protocols in their respective studies and thus reported 
treatment effects of group CBT may have been attenuated. Thus, the next step in the 
evaluation process of group CBT for depression and anxiety in PD is a small-scale 
RCT of a PD-specific intervention against a non-active control condition. 
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3.9 Chapter Summary 
 
There are compelling grounds to consider the use of CBT as an alternative to 
pharmacotherapy for depression and anxiety in PD populations. First, CBT is an 
established treatment that is equally effective as pharmacotherapy for the acute 
treatment of depression and anxiety in primary populations. Second, CBT is superior 
to pharmacotherapy in terms of long-term efficacy and side-effect reduction. Third, 
CBT has demonstrated efficacy in the treatment of depression and anxiety in older 
adult populations and there is also strong support for the efficacy of CBT with 
individuals with various chronic, motor and neurological diseases. 
 
A growing body of research now also supports the efficacy of CBT for the 
treatment of depression and anxiety disorders in PD populations. There is 
particularly strong evidence for the efficacy of individual CBT interventions in PD, 
while group CBT interventions remain understudied despite clear therapeutic and 
practical advantages for older adult populations.  
 
At present, the efficacy evidence for group CBT in PD is rudimentary at best, 
with only two published case studies/series for a total sample of five participants. 
The next step in establishing efficacy for group CBT for depression and anxiety in 
PD is a well-designed preliminary trial to guide future, larger efficacy trials. A small-
scale randomised controlled trial comparing a PD-specific intervention against a non-
active control will offer the best balance between experimental control and statistical 
power, and provide the most valid estimate of the magnitude of the treatment effect 
of group CBT for depression and anxiety in PD.  
 
Chapter 5 presents the findings of the first randomised controlled trial of 
group CBT for depression and anxiety in PD. Before this, Chapter 4 presents an 
examination of the validity and reliability of the Depression Anxiety and Stress 
Scale-21 (DASS-21; Lovibond & Lovibond, 1995) in a PD sample. The DASS-21 is 
the primary outcome measure used in both Studies 3 and 4 however it has not been 
previously validated with individuals with PD. Thus, Chapter 4 examines the 
psychometric properties of the scale to support its use as a primary outcome measure 
in the subsequent studies of this thesis.
 112
CHAPTER 4  |          
 
Study II.          An Examination of the  
                         Validity and Reliability of the  
                         Depression Anxiety and Stress Scale-21  
                         in Parkinson’s Disease 
 
 
 
4.1 Introduction 
 
The importance of selecting appropriate psychological measurement scales 
for both research and clinical use in Parkinson’s populations was discussed in 
Chapter 1. Specifically, a differing symptom presentation of depression and anxiety 
in PD along with the high symptom overlap between the three conditions can often 
mean that scales developed for the general population may not be valid measures of 
depression and anxiety in PD (Schrag et al., 2007). Ultimately, use of inappropriate 
scales can invalidate research findings (Rea & Parker, 1997). 
 
The Depression Anxiety and Stress Scales-21 (DASS-21; Lovibond & 
Lovibond, 1995) is the primary outcome measure for depression and anxiety used in 
both Studies 3 and 4 of this thesis. While the validity and reliability of the DASS-21 
has been well established in both general clinical and non-clinical samples, there has 
been no prior investigation of the scales’ psychometric and clinimetric properties in a 
Parkinson’s sample.  
 
The primary aim of this study was to provide a preliminary examination of 
the scale structure and reliability of the DASS-21 in a PD sample to support the use 
of the scale as a primary outcome measure in this research. The broader aim of this 
study was to provide information about the psychometric and clinimetric properties 
of the DASS-21 in PD to guide future researchers and clinicians considering use of 
the scale with individuals with PD. 
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4.2 Psychometric Scales for Depression and Anxiety in PD 
 
Research into the evaluation and validation of screening and/or measurement 
instruments for depression and anxiety in PD is important for enhancing both clinical 
management and the quality of scientific research (Weintraub & Burn, 2011).  There 
are currently no scales developed specifically to measure depression and anxiety in 
PD, thus clinical screening and research in PD largely relies on the use of 
psychometric scales developed for the general population (Schrag et al., 2007). There 
are two main considerations when using a general population psychometric in PD 
populations. First, given that a differing symptom presentation of depression and 
anxiety has been described in PD, scales developed for the general population may 
not always be a valid assessment of depression and anxiety among individuals with 
PD. Second, due to the symptom overlap between PD, depression, and anxiety, 
general population scales featuring a large number of items assessing the physical 
and somatic aspects of depression and anxiety can generally overestimate the 
presence and/or severity of depression and anxiety in PD as they do not differentiate 
between PD symptoms and symptoms of anxiety or depression (McDonald et al., 
2003). Thus, it is important to examine the validity and reliability of general 
population scales in PD samples prior to research and/or clinical use. 
 
Over the past five years, there has been significant advances in the number of 
general population scales measuring depression and anxiety that have been validated 
in PD. Scales that have now been validated in PD populations include the Hamilton 
Depression Rating Scale (Ham-D; Hamilton, 1960), Beck Depression Inventory 
(BDI-I; Beck et al., 1961), Geriatric Depression Scale (GDS; Yesavage et al., 1982) 
and Hospital Depression and Anxiety Scale (HADS; Snaith & Zigmond, 2000)  for 
depression, and the Hamilton Anxiety Rating Scale (Ham-A; Hamilton, 1959), Beck 
Anxiety Inventory (BAI; Beck, Epstein, Brown, & Steer, 1988), HADS, and 
Geriatric Anxiety Inventory (GAI; Pachana et al., 2007) for anxiety (see Chapter 
1.10.1 for a review of the different scales). Currently, PD taskforce reviews 
(Leentjens et al., 2012; Schrag et al., 2007) recommend the use of the BDI and BAI 
as clinical and research screening tools for depression and anxiety in PD due to their 
self-report nature and thus ability to enhance time-effectiveness over clinician-rated 
scales such as the Ham-D. 
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This study investigates the validity and reliability of the Depression Anxiety 
and Stress Scale-21 (Lovibond & Lovibond, 1995) as a measurement tool for 
depression and anxiety in a PD sample. Similar to the BDI and BAI, the DASS-21 is 
a self-report scale and thus has the benefit of being more time-effective than 
clinician-rated scales such as the Ham-D and Ham-A. Moreover, the DASS-21 
assesses both depression and anxiety within the same measure and is available in the 
public domain while the BDI and BAI are not, and thus may be useful in enhancing 
both time- and cost-effectiveness for both research and clinical purposes. 
 
The primary aim of this study was to provide evidence of the validity and 
reliability of the DASS-21 to support its use as a primary outcome measure 
throughout this thesis. As a secondary objective, this study also aimed to provide 
information about psychometric properties of the DASS-21 as a measurement tool 
for depression and anxiety in PD to guide future researchers and clinicians 
considering use of the scale within a PD sample. 
 
 
4.3 The Depression Anxiety and Stress Scale-21 
 
The DASS-21 is a 21-item short form of the 42-item DASS (Lovibond & 
Lovibond, 1995), and measures three negative affective states: Depression, Anxiety 
and Stress. The scale comprises 21 items assessing the experience of 21 negative 
psychological and/or physiological symptoms over the past week. Items are rated on 
a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me 
very much). Examples of items for each dimension include “I felt downhearted and 
blue” (Depression), “I was worried about situations in which I might panic and make 
a fool of myself” (Anxiety) and “I tended to over-react to situations” (Stress). 
Possible scores for each dimension range from 0 to 21 with higher scores reflecting 
greater experience of symptoms on the respective scale.  
 
 The DASS-21 has displayed strong psychometric properties in both clinical 
and community samples. Excellent internal consistency for each of the three factors 
has been reported with alpha values ranging from .81 to .97 across numerous studies 
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(Henry & Crawford, 2005). The test-retest reliability of the DASS-21 over a two-
week period was also reported by Brown et al. (1997) and found to be strong for all 
three factors with Depression (r = .71), Anxiety (r = .79) and Stress (r = .81). All 
correlations were significant at the .01 level. 
 
Convergent validity of the DASS-21 was assessed by Henry and Crawford 
(2005) via comparisons with the Hospital Anxiety and Depression Scale (HADS; 
Zigmond & Snait, 1983), the Personal Disturbance Scale (PDS; Bedford & Foulds, 
1978) and the Positive and Negative Affect Schedule (PANAS; Watson, Clark, & 
Tellegen, 1988). The Depression factor correlated most strongly with PDS-
Depression (r = .78) followed by the HADS-Depression factor (r = .66), providing 
evidence for convergent validity. Similarly, the Anxiety subscale was most strongly 
associated with PDS-Anxiety (r = .72) followed by HADS-Anxiety (r = .62). Stress 
was most strongly correlated with the PANAS Negative Affect factor (r = .67), 
which has been likened to a measure of stress by Brown et al., 2003. All correlations 
were significant at the .01 level. 
 
Strong discriminant validity has also been observed with people with mood 
disorders and anxiety disorders scoring significantly higher on the DASS Depression 
and Anxiety factors, respectively, relative to other diagnostic groups (Antony, 
Bieling, Cox, Murrary, & Swinson, 1988). Moreover, the DASS-21 has been found 
to be a valid and reliable measure of anxiety, depression and stress in older primary 
care patients (i.e., Gloster et al., 2008) and with elderly patients with persistent pain 
(i.e., Wood et al., 2010).  
 
There have been no studies validating the use of the DASS-21 in PD 
populations, and the scale has not been reviewed or recommended by previous 
Movement Disorder Society taskforce reviews for use in PD populations. However, 
the DASS-21 has been used by several authors to assess depression, anxiety and 
stress symptoms in people with Parkinson’s in recent times (e.g., Bucks et al., 2010; 
Butler, McNamara, & Durso, 2010; McNamara, Stavitsky, Durso, & Harris, 2010). 
As noted earlier, careful selection of scales must be undertaken in order to accurately 
assess depression and anxiety symptoms in people with PD due to the considerable 
symptom overlap between the three conditions. In particular, scales featuring a large 
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number of physical or somatic symptoms tend to result in an overestimate of the 
severity of depression and anxiety in persons with PD. According to this criterion, it 
would appear that the DASS-21 is a suitable scale for use with PD patients. The scale 
contains only four somatic items: Item 2 (dry mouth), Item 4 (difficulty breathing), 
Item 7 (trembling) and Item 19 (increase/decrease in heart rate), with the remainder 
of items assessing cognitive, affective and behavioural symptoms. Moreover, of 
these somatic symptoms, only trembling is a characteristic feature of PD (dryness of 
the mouth may be experienced as a side-effect of anticholinergic medication in some 
patients, however, excessive saliva and drooling (sialorrhea) is more common). Thus, 
the DASS-21 appears to be a suitable scale for use in PD samples on face value. This 
study provides a preliminary investigation of the validity and reliability of the 
DASS-21 in PD.  
 
4.4 Methodology and Data Analysis 
 
4.4.1 Design and Procedure 
 Analyses for this study were based on the same data and sample as that for 
Study 4. Data were primarily collected for the purposes of Study 4 which was to 
examine mental health service utilisation in PD. A cross-sectional survey 
methodology was employed. A questionnaire package comprising the DASS-21 and 
six other scales was assembled and mailed out to all members of Parkinson’s 
Western Australia (PWA) following ethical approval from both the Curtin University 
HREC and PWA research committee. A link to a web-based version of the 
questionnaire was provided for participants who preferred to submit their responses 
online. A gourmet teabag was included with each package to thank participants for 
their time. In addition, Parkinson’s Associations across Australia were contacted and 
asked to post a link to the online questionnaire on their websites. The questionnaire 
was anonymous and no personally identifying details were collected. The 
information sheet clearly outlined that (i) submission of responses was deemed 
consent to use the individual’s data in the study, and (ii) due to the anonymous nature 
of the survey, participants will not be able to request their responses be excluded 
from the research at a later date. Questionnaire packages were disseminated to PWA 
members in October 2012. Participants were given three months to return 
questionnaires. Data collection was completed in December 2012. In total, 950 
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questionnaire packages were sent out. Participants were given three months to return 
questionnaires. Data collection was completed in December 2012. Participant 
reponses on the DASS-21 were used in this study to examine scale structure and 
internal consistency. 
 
4.4.2 Participants 
 4.4.2.1 Response rate. A total of 327 questionnaire responses were received 
between October and December 2012. The majority of responses were received from 
the PWA questionnaire mail-out (N = 302, response rate = 32%). An additional 25 
responses were received through the online questionnaire however it is not possible 
to determine the source or response rate of online responses (i.e., PWA members 
submitting their responses online or members from other Parkinson’s associations 
around Australia). 
 
4.4.2.2 Participant characteristics. The sample comprised 327 Australian 
adults with Parkinson’s disease. There were 205 males (63%) and 122 females (37%) 
with a mean age of 69.9 years. The majority of participants were of an Australian 
background (87.5%), currently married (70.6%) and no longer engaging in paid 
employment (84.1%). Average age of PD diagnosis was 62 years, average duration 
of PD was 8.14 years, and the vast majority of participants were currently on 
antiparkinsonian medications (93.3%). Other demographic characteristics of the 
sample appear in Table 11. 
 
4.4.2 Statistical Power 
The minimum recommended sample size for factor analysis is 300 
(Tabachnick & Fidell, 2011). Thus, this study had sufficient power. 
 
4.4.3 Psychometric and Clinimetric Properties 
 As the data used for this study was not collected specifically for the purpose 
of scale evaluation, a comprehensive investigation into the psychometric properties 
(e.g., sensitivity, specificity, convergent validity, discriminant validity, test-retest 
reliability) of the DASS-21 in PD was not possible. Three psychometric properties 
were tested in this study; internal consistency, criterion validity and discriminant 
validity. Internal consistency was assessed using Cronbach’s alpha, with α ≥ .70 
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Table 11 
Demographic Characteristics of the Sample (N = 327) 
 M (SD) Range 
Age 69.6 (8.76) 47 to 93 
PD Duration 8.14 (7.11) <1 year to 46 years 
Age of PD diagnosis 61.85 (10.94) 26 to 87  
Number of children 2.66 (1.31) 0 to 8 
 N % 
Gender   
 Male 205 62.7 
 Female 122 37.3 
Background   
 Australian 286 87.5 
 British 29 8.9 
 New Zealander 4 1.2 
 European 4 1.2 
 USA 2 .60 
 Asian 2 .60 
Relationship Status   
 Married 231 70.6 
 In a relationship 18 5.5 
 Widowed 34 10.4 
 Not in a relationship (single, 
de-facto, divorced, separated) 
44 13.5 
Currently employed 54 16.5 
Relatives with PD 108 33.0 
On PD medication 305 93.3 
 
 
considered acceptable. Criterion validity was assessed via comparison of DASS-21 
scores between participants who reported an existing psychological diagnosis and 
those who had not, with the hypothesis that individuals with an existing 
psychological diagnosis would score significantly higher on all three DASS factors 
than those without. Discriminant validity was assessed via receiver operating 
characteristic (ROC) curves analysis to examine the accuracy of the DASS-21 in 
differentiating between individuals with and without an existing psychological 
diagnosis.  
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The clinimetric properties evaluated were in the study were acceptability, 
score distribution, and floor and ceiling effects, using the same methods as described 
by Leentjens et al. (2012) in their evaluation of the Ham-A, BAI and HADS in PD. 
Acceptability was assessed via examination of the proportion of missing responses, 
with less than 5% missing data considered acceptable (Smith et al., 2005). Score 
distribution was examined by comparing observed mean versus median scores, with 
a difference of <10% of the maximum possible score considered adequate (Leentjens 
et al.). Floor and ceiling effects were examined by the proportion of partcipants 
scoring the minimum and maximum scores, respectively, with <15% considered 
satisfactory (Leentjens et al.). 
 
4.4.4 Scale Structure 
Confirmatory factor analysis (CFA) using structural equation modelling 
(SEM) was used to verify the factor structure of the DASS-21 in the PD sample. The 
structure of the scale was compared against the proposed three-factor correlated 
structure specified by Lovibond and Lovibond (1995). CFA was conducted using 
EQS 6.1 for Windows (Build 85) (Bentler, 2005). Path diagrams of factor loadings 
were produced using IBM SPSS AMOS 16.0.  
 
4.4.4.1 Assumption testing. There are four statistical assumptions underlying 
SEM; multivariate normality, linearity, absence of univariate and multivariate 
outliers and absence of multicollinearity.  
Multivariate normality is the assumption that a set of variables have a 
combined multivariate normal distribution (Looney, 1995). Multivariate normality is 
of particular importance in SEM as the standard Maximum Likelihood estimation 
method in SEM assumes a multivariate normal distribution (Tabachnick & Fidell, 
2011). Simulation studies have shown that Maximum Likelihood estimation 
procedures are not as accurate when a set of variables are multivariate non-normally 
distributed, particularly when sample sizes are less than 2,500 (Hu et al., 1992). In a 
set of variables with a multivariate normal distribution, each individual variable must 
also have a univariate normal distribution (Looney, 1995). Thus, each item was 
initially screened for univariate normality as a first step in establishing multivariate 
normality. If any individual item was not normally distributed, multivariate 
normality was assumed to be violated (Tabachnick & Fidell). Where all items 
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showed a univariate normal distribution, skewness and kurtosis values were then 
assessed. Kline (2010) asserts that multivariate normality can be assumed when 
skewness values are less than 3, and kurtosis values are less than 10.  
 
Linearity refers to the assumption that pairs of items within a scale are 
linearly related. Linearity was tested by examining five pairwise scatterplots between 
randomly selected items as recommended by Tabachnick and Fidell (2011) who 
suggest that it is not feasible to examine all scatterplots between every possible 
pairwise combination of items within a scale to test for linearity. Univariate outliers 
were examined via inspection of standardised residuals for cases greater than 3.29 
standard deviations above or below the mean. Multivariate outliers were assessed via 
inspection of the Mahalanobis Distance statistic and Cook’s distance value for each 
case. Multicollinearity was assessed via examination of the zero-order correlation 
matrix among scale items for any correlations > .90 (Tabachnick & Fidell). 
 
 4.4.4.2 Estimation method. Maximum Likelihood was the estimation 
method employed. Where the assumption of multivariate normality was not met, the 
Yuan-Bentler correction (Yuan & Bentler, 1999) was applied to Maximum 
Likelihood estimates as part of the ‘Robust methods’ option in EQS 6.1. The Yuan-
Bentler correction adjusts both the Maximum Likelihood χ² statistic as well as the 
standard errors associated with parameter estimates based on the extent of non-
normality within a data set (Tabachnick & Fidell, 2011). Simulation studies have 
found that the Yuan-Bentler correction is the most accurate estimation method when 
data are not multivariate normally distributed and sample sizes are less than 2,500 
(Hu et al., 1992). 
 
4.4.4.3 Model fit. Model fit was assessed via three indices; the χ² statistic, the 
comparative fit index (CFI), and the root mean square error of approximation 
(RMSEA). The χ² statistic provides an index of the fit between the sample covariance 
matrix and the estimated covariance matrix (Tabachnick & Fidell, 2011). A non-
significant χ² statistic indicates a good fitting model (i.e., there is no significant 
discrepancy between the sample and estimated covariance matrices). However, the χ² 
statistic has been found to be particularly sensitive to sample size and violations of 
multivariate normality and can often result in a Type II error. In particular, when 
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sample sizes are greater than 200, trivial differences between the estimated and 
sample covariance matrices can lead to a false rejection of the null hypothesis 
(Tabachnick & Fidell). A relative χ² (or normed χ²) statistic has been proposed to 
explicitly take into account sample size and is computed by dividing the χ² statistic 
by the degrees of freedom (df). A χ² to df ratio of less than 5 is suggested to indicate 
a good-fitting model (Schumacker & Lomax, 2004). 
 
The CFI (Bentler, 1990) is an index of the discrepancy between the specified 
model and a null or independence model (i.e., a model in which all correlations are 
equal to zero). CFI values can range from 0 to 1 with values closer to 0 indicating a 
perfect fit between the specified model and an independence model. Thus, CFI 
values closer to 1 are desirable with Hu and Bentler (1999) suggesting that CFI 
values greater than .90 are indicative of an acceptable fit while CFI values greater 
than .95 indicate a good-fitting model. 
 
The RMSEA statistic (Browne & Cudeck, 1993) is an estimate of the 
discrepancy between the specified model and a perfect (saturated) model. A RMSEA 
value of 0 indicates a perfect fit (i.e., the specified model is exactly the same as a 
saturated model). Conventional guidelines state that a RMSEA value between 0 and 
.05 indicates a ‘close fit’, .05 to .08 indicates an acceptable fit, while RMSEA values 
greater than .10 indicate a poor-fitting model.  
 
 
4.5 Results  
 
4.5.1 Missing Data and Acceptability 
 Of the 327 responses received, SPSS Missing Values Analysis revealed 
minimal missing data with no items or cases missing more than 0.6% of data. Thus, 
the DASS-21 demonstrated strong acceptability.  
 
Little’s MCAR test indicated that the data were missing completely at 
random, χ² (72) = 61.06, p = .818. Expectation Maximisation (EM) was employed to 
estimate missing data. While previous authors have suggested that EM-imputed data 
may be inappropriate for inferential statistics due to biased standard errors (Brown et 
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al., 2003), Tabachnick and Fidell (2011) assert that in cases where missing data is 
minimal (< 5%) and randomly distributed, as with the present study, analysis of EM-
imputed data is permissible and preferable to the more conventionally employed 
method of mean substitution which underestimates correlation coefficients. 
 
4.5.2 Score Distribution  
Mean scores for each DASS-21 factor were higher than those reported by 
Lovibond and Lovibond (1995) in their sample of undergraduate psychology 
students. Based on normative data for the DASS-21 published by Henry and 
Crawford (2005), mean levels of depression (M = 5.26, SD = 5.08) corresponded to a 
‘Mild’ clinical severity (81
st
 percentile) while mean levels of anxiety (M = 5.28, SD 
= 3.99) corresponded to a ‘Moderate’ clinical severity (89
th
 percentile). Average 
levels of stress (M = 5.65, SD = 4.69) were within the normal range (69
th
 percentile). 
The distribution of scores for each factor was acceptable with the difference between 
observed mean and median for each subscale within 10% of the maximum possible 
scale score. There were no significant floor or ceiling effects with <15% of 
participants scoring the minimum and maximum possible score on each factor.  
 
4.5.3 Scale Structure  
4.5.3.1 Assumption testing. Tests for univariate normality via inspection of 
Kolmogorov-Smirnov statistics for each item within the DASS-21 indicated a 
violation of normality for all items (p < .05). Thus, the assumption of multivariate 
normality was not met for the data. All items were positively skewed although this is 
common when assessing psychopathological symptoms in a non-clinical sample 
(Lovibond & Lovibond, 1995). Logarithmic transformations were undertaken on all 
items as however transformation failed to produce normality and thus all original 
items were retained for analysis and the Yuan-Bentler corrected Maximum 
Likelihood estimation method was implemented in the subsequent SEM analyses to 
account for the multivariate non-normality of the data. 
 
Linearity was assessed via examination of pairwise scatterplots between four 
randomly selected items (Items 3, 9, 18, 20). Scatterplots showed a positive linear 
relationship between all pairs of items and thus the assumption of linearity was met 
for the data. Ten univariate outliers were identified (0.14%) where cases exceeded 
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±3.29 standard deviations of the mean. To reduce the influence of extreme scores 
while maintaining an adequate sample size, extreme scores were changed to one 
value above the next highest score in the distribution for that variable as per Schinka 
and Velicer (2003). Seventeen multivariate outliers (0.24%) were identified where 
cases exceeded the Mahalonbis distance Chi Square critical value of χ
2
(21) = 46.797, 
p = .001, however Cook’s distance values for all these cases were less than 1 
indicating that all cases were not influential within the dataset. Thus, all cases were 
retained for analysis. The zero-order correlation matrix between all items showed 
that all correlations between items were less than .90, indicating no multicollinearity 
among the data. 
 
4.5.5.3 Scale structure. Table 12 displays the CFA results testing the scale 
structure of the DASS-21 against Lovibond and Lovibond’s (1995) three-factor 
correlated structure. Both Maximum Likelihood and Yuan-Bentler corrected 
Maximum Likelihood estimates are reported. As the assumption of multivariate 
normality was not met, CFA results are based on the Yuan-Bentler corrected 
estimates. The χ² statistic indicated that a three-factor correlated structure was a poor 
fit for the data, χ² (186) = 226.65, p = .02. However, given the problems with the χ² 
statistic discussed in Section 4.4.4.3.1, other indices of model fit were examined. The 
relative χ² (2.67), corrected-CFI (.94) and RMSEA (.051) values all indicated a close 
fit between the three-factor model and the data and thus Lovibond and Lovibond’s 
factor structure was validated within the sample.  
 
Table 12  
Results of Confirmatory Factor Analyses for DASS-21 (n = 327) 
Maximum Likelihood 
Maximum Likelihood with 
Yuan-Bentler correction 
χ² p Relative χ² CFI RMSEA  χ² p CFI RMSEA 
497.47 .000 2.67 .92 .072 
 
 
226.65 .02 .94 .051 
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Factor loadings between items and factors appear in Figure 4.  All items 
loaded strongly onto the hypothesised factor and exceeded the minimum cut-off 
criterion of .30 as per Tabachnick and Fidell (2011). The mean inter-correlation 
between factors was .78 which is consistent with the inter-correlations originally 
reported by Lovibond and Lovibond (1995) as well as in subsequent studies by 
Antony and colleagues (1998) and Henry and Crawford (2005), who each reported 
inter-correlations of about .75 across both clinical and non-clinical samples. 
 
4.5.4 Reliability 
The DASS-21 demonstrated strong reliability in the PD sample. Cronbach’s 
alpha values of internal consistency for each factor were good to excellent, with  
α = .92 (Depression), α = .77 (Anxiety) and α = .88 (Stress) and α = .94 for the total 
scale. 
 
4.5.5 Criterion Validity 
 The DASS-21 showed good evidence of criterion validity with participants 
reporting an existing psychological diagnosis scoring significantly higher on all three 
DASS-21 subscales compared with those without a diagnosis (p < .05). Sixty eight 
(21%) participants reported a current or past psychological diagnosis and the mean 
DASS-21 scores for this group were; DASS-D (M = 8.37), DASS-A (M = 7.56), 
DASS-S (M = 8.04) compared with DASS-D (M = 4.37), DASS-A (M = 4.64) and 
DASS-S (M = 4.97) for the group without an existing diagnosis. 
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Figure 4. Factor Loadings for the DASS-21 Items and Factors 
 
 
 
4.5.6 Discriminant Validity 
 ROC curves showed that the area under the curve was .70 for both depression 
and anxiety and .69 for stress, representing fair accuracy in discriminating between 
participants with and without an existing psychological diagnosis (see Figure 5). 
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Figure 5. ROC Curve for DASS-21 
 
 
4.7 Discussion 
 
 This study was the first to examine the scale structure, reliability and 
clinimetric properties of the DASS-21 in a Parkinson’s sample and showed that 
overall, there is preliminary evidence for the reliability and validity of the DASS-21 
as a measurement tool for depression and anxiety among individuals with PD. 
 
 Factorial validity was demonstrated through replication of Lovibond and 
Lovibond’s (1995) three-factor correlated structure within the present sample. All 
three subscales demonstrated excellent internal consistency, and all items loaded 
onto the hypothesised construct. The two items with the lowest factor loadings (.39) 
were Items 2 (dry mouth) and 7 (trembling in the hands), both within the Anxiety 
factor. This finding suggests that these two symptoms may not be as strong 
indicators of anxiety in this population than within the general population and is 
likely related to PD. As noted in the introduction, dry mouth is typically not common 
in PD as rigidity of facial muscles often results in sialorrhea, or excessive saliva and 
drooling. Trembling is very common in PD and comprises one of the four cardinal 
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motor symptoms however because of this trembling may not be the most accurate 
indicator of anxiety among individuals with PD. Deletion of these two items slighty 
improved the reliability of the Anxiety scale from .77 to .80 however not to the 
extent to warrant serious consideration of item removal from the scale. Overall, all 
items of the DASS-21 appeared to be valid indicators of depression and anxiety 
within individuals with PD. 
 
The distribution of scores was good for all three DASS-21 factors with no 
significant floor or ceiling effects observed. The latter finding is particularly 
important. Given the overlap between symptoms of PD, depression, and anxiety, 
there is a a concern that individuals with PD may score highly on measures of 
depression and anxiety developed for the general population, regardless of actual 
psychological status. This study showed that there were no problems with symptom 
overlap with the DASS-21. The score distribution in the present sample was 
consistent with that described by both Lovibond and Lovibond (1995) and Henry and 
Crawford (2005) in undergraduate and community samples, respectively. Moreover, 
no participant scored the maximum possible score (28) across all three subscales, 
suggesting that the DASS-21 is able to adequately discriminate between symptoms 
of depression, anxiety, and PD, and that PD symptoms do not confound or inflate the 
assessment of depression and anxiety among individuals with PD.  
 
 There was evidence of both criterion and discriminant validity within the 
present study. Participants who reported an existing psychiatric diagnosis had 
significantly higher scores on all three DASS-21 subscales compared to those 
without. ROC curves analysis provided preliminary support for the diagnostic 
accuracy of the DASS-21. ROC curves showed that the area under of the curve 
(AUC) for all three DASS-21 subscales was around .70, which corresponds to a ‘fair’ 
degree of diagnostic accuracy (Zweig & Campbell, 1993). Previous validation 
studies of other depression and/or anxiety instruments in PD have returned higher 
AUC values including .88 for the BDI against the SCID (Visser et al., 2006), and 
76.6 for the BAI and 74.9 for the Ham-A against the MINI (Leentjens et al., 2012), 
suggesting that these scales may be more accurate screening tools than the DASS-21 
for depression and/or anxiety in PD. However, it must be noted that because the data 
used for this study was not collected specifically for the purposes of scale evaluation, 
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accuracy was based on the ability of the DASS-21 to differentiate between 
participants with and without a self-reported existing psychological diagnosis (past 
or current), rather than comparison against a structured diagnostic interview. 
Participants with historic psychological diagnoses (e.g., 10 to 50 years prior) but no 
longer showing elevated symptoms would have been included in the ‘postive  
psychological diagnosis’ group and this may have acted as a possible confound in the 
ROC curve analysis.  Moreover, DASS-21 scores were not directly compared with 
their relevant diagnostic categories (e.g., directly comparing DASS-D scores in 
participants with and without depression diagnoses) as information about specific 
psychological diagnoses was not collected and this is likely to have reduced the 
accuracy rate of the scale in this study. Future research is required to more accurately 
assess the accuracy of the DASS-21 against a gold-standard DSM-IV-TR diagnosis. 
This will also allow for an examination of the sensitivity and specificity of the 
DASS-21 and the determination of cut-off scores for research and clinical use. 
Nevertheless, it is encouraging to note that while DASS-21 scores were compared 
against a broad existing psychological diagnosis, AUC values for the DASS-21 
scales (.70) were only slightly lower than that reported for the BAI (76.6) and Ham-
A (74.9) which were directly compared with the MINI by Leentjens et al. (2012). 
 
Current expert taskforce reviews have recommended the use of the BDI and 
BAI as measurement tools for depression and anxiety in PD due to their sound 
psychometric properties and self-report nature, which enhances time-effectiveness in 
both research and clinical settings relative to clinican-rated scales (Leentjens et al., 
2012; Schrag et al., 2007). This study provides strong support for the use of the 
DASS-21 as an outcome measure for depression and anxiety in PD and as a potential 
alternative to the BDI and BAI. The DASS-21 demonstrated good validity and 
reliability within the present sample comparable to the psychometric properties 
reported for the BDI and BAI in PD. A particular strength of the DASS-21 relative to 
the BAI, however, appears to be its ability to provide an assessment of anxiety and 
depressive symptoms in PD that is not confounded or inflated by an overlap with PD 
symptoms.  Only one item (Item 6: ‘trembling in the hands’) on the DASS-21 
represented a symptom overlap between the three conditions, with the remainder of 
items comprising cognitive, behavioural or affective indicators of anxiety. This is in 
direct contrast with the BAI which contains nine items (43%) that may present a 
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potential confound in the assessment of anxiety among individuals with PD as items 
overlap with PD symptoms (i.e., numbness or tingling, feeling hot, wobbliness in 
legs, dizzy, unsteady, hands trembling, shaky, indigestion, hot/cold sweats). 
Moreover, the DASS-21 assesses both depression and anxiety within the same scale 
and is available in the public domain whereas the BDI and BAI are not, and thus may 
be more time- and cost-effective than the BDI and BAI.  
 
4.7.1 Limitations and Direction for Future Research 
While this study provides preliminary support for the validity and reliability 
of the DASS-21 in PD, a more comprehensive assessment of the psychometric and 
clinimetric properties of the scale in PD samples is required. As the data used in this 
study was not collected specifically for the purpose of psychometric evaluation, 
assessment of the critical properties such as sensitivity, specificity, convergent 
validity, and test-retest reliability of the scale, was not possible.  
 
Future researchers should aim to replicate the results of the current study in a 
larger and more representative sample of individuals with PD to confirm the 
reliability and validity of the DASS-21 in PD. In particular, a study directly 
comparing the DASS-21, BDI and BAI among a single sample would provide useful 
insight into the comparative utility of the DASS-21 against the currently 
recommended scales for use in PD. Future research is also required to more 
accurately assess the accuracy of the DASS-21 against a DSM-IV-TR diagnosis. 
 
 
4.7 Chapter Summary 
 
An emphasis has been placed on selecting appropriate psychological 
measurement scales for use in PD populations. Scales developed for the general 
population may not always constitute valid measures in PD and selection of 
inappropriate scales can ultimately invalidate research findings. Overall, this study 
showed that the DASS-21 appears to be a valid and reliable instrument for use in PD. 
There was evidence of the factorial validity, criterion validity, discriminant validity 
and internal reliability of the scale, supporting the use of the DASS-21 as a primary 
outcome measure throughout the remainder of this thesis. 
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CHAPTER 5  |                            
 
Study III.    A Randomised Controlled Trial of Group   
                     Cognitive Behavioural Therapy for   
                     Depression & Anxiety in Parkinson’s          
                     Disease 
 
 
 
 
5.1 Introduction 
  
A growing body of research now supports the efficacy of individual 
Cognitive Behavioural Therapy (CBT) interventions for depression and anxiety in 
Parkinson’s disease (PD). However, Group CBT remains understudied despite strong 
therapeutic and practical advantages that are particularly suited for older adult and 
chronic illness populations.  
 
This chapter presents the findings of the first randomised controlled trial of a 
group CBT intervention for the treatment of depression and anxiety in a PD sample. 
The first half of the chapter provides an outline of the design and methodology of the 
study while the latter half presents the results of the clinical trial and a discussion of 
the findings and clinical implications. 
 
Overall, both statistically and clinically significant reductions in depression, 
anxiety, stress and negative cognitions were observed over both the acute and follow-
up study period and provide strong preliminary support for the efficacy of group 
CBT in the treatment of depression and anxiety in PD. Significant recruitment 
difficulties were experienced, however, which limits the validity of results as well as 
suggesting that significant barriers to seeking psychological treatment may be in 
place in this population. 
 
 
 131
 
5.2 Methodology 
 
5.2.1 Research Design and Study Setting 
This study was a randomised controlled trial (RCT) comparing a group CBT 
intervention targeting comorbid depression and anxiety to a waitlist control. The 
study took place at the Curtin University Psychology Clinic in Bentley, Western 
Australia. Two waves of treatment were conducted. Wave I took place between July 
and December 2010 and Wave II took place between August and October 2011. 
Measurements were taken at pre-treatment, post-waitlist (for participants in the 
Waitlist condition), post-treatment, 1-month and 6-month follow-ups (see Figure 6). 
All aspects of the study conformed to CONSORT requirements (Moher, Schulz, & 
Altman, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Research Design of the Randomised Controlled Trial 
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5.2.2 Participants 
 5.2.2.1 Inclusion and exclusion criteria. Participants were Australian adults 
aged 18 years or over with Parkinson’s disease and a current diagnosis of depression 
and/or anxiety. Inclusion criteria included; (1) a minimum 6-month period post-
diagnosis of PD, (2) a DSM-IV-TR diagnosis of at least one depressive and/or 
anxiety disorder, (3) stabilised use of antiparkinsonian medications (if on any) for at 
least three months, and (4) stabilised use of antidepressant medications (if on any) 
for at least three months. Exclusion criteria included cognitive impairment, 
concurrent psychological treatment, current diagnosis of a DSM-IV-TR psychotic 
disorder and a high suicide risk. 
 
5.2.2.2 Participant flow.  Figure 7 outlines the participant flow in the study.  
A total of 45 individuals expressed interest in the study. Sixteen decided not to 
continue after receiving further information about the treatment. Reasons for 
discontinuation included; residence outside of the Perth metropolitan area (N = 3), 
holiday plans coinciding with treatment dates (N = 2), inability to leave the house 
due to advanced disease (N = 1) or no reason given (N = 10). Twenty-nine 
participants were screened for eligibility. Eleven participants were found to be 
ineligible due to; cognitive impairment (4 participants; 36%) and no clinically 
significant (i.e., a DSM-IV-TR diagnosis of) depression and/or anxiety (7 
participants; 64%). Eighteen adults met eligibility criteria for the study and 
comprised the intention-to-treat sample. These participants were randomly allocated 
to either Intervention or Waitlist conditions. During Wave I of treatment, one 
Intervention (N = 7) and one Waitlist group (N = 7) were conducted. Significant 
recruitment difficulties were experienced during Wave II. There were insufficient 
participants to run an Intervention and Waitlist group and so all eligible participants 
were assigned to the Intervention group (N = 4). Sixteen participants completed 
treatment (89%) while two (11%) withdrew due to scheduling difficulties  
(1 participant, 50%) and cognitive difficulties (1 participant, 50%). 
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Figure 7. Flow Diagram of Participant Recruitment and Allocation 
 
 
5.2.2.3 Demographic Characteristics of the intent-to-treat (ITT) sample.  
Of the total ITT sample, there were 12 males (67%) and 6 females (33%) with a 
mean age of 66 years (range: 52 to 76 years). Mean duration of PD was 5 years 
(range: 8 months to 20 years). Average severity of PD was Hoehn and Yahr Stage II 
Eighty eight percent (N = 16) of participants were currently taking antiparkinsonian 
medications. There were no significant differences between demographic 
characteristics of participants in the Intervention and Waitlist conditions. Other 
demographic characteristics of the ITT sample appear in Table 13. 
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Table 13  
Demographic Characteristics of the Intent-to-Treat Sample  
 ITT 
N = 18 
Intervention 
N = 11 
Waitlist 
N = 7  
Sex, N (%) 
    Male 
    Female 
 
12 (67%) 
6 (33%) 
 
9 (82%) 
2 (18%) 
 
3 (43%) 
4 (57%) 
Demographic Characteristics 
    Mean age (SD) 
    Employed, N (%) 
 
66 (8.26) 
2 (11.1%) 
 
68 (7.72) 
1 (9%) 
 
62 (8.34) 
1 (14%) 
    Number of children, N 1.70 2 1.20 
 PD Characteristics 
    Age of onset, M (SD) 
    PD duration, M years 
    Currently taking PD medications, N (%) 
 
61 (8.29) 
5 years 
16 (88%) 
 
63 
5 years 
10 (91%) 
 
58 
4 years 
6 (86%) 
 
 
5.2.3 Procedure 
5.2.3.1 Ethical and registration procedures. Ethical approval from Curtin 
University’s Human Research Ethics Committee was sought and granted prior to any 
contact with participants (Approval number: HR 142/2009). The study was also 
registered with the Australian New Zealand Clinical Trials Registry (ACTR number: 
ACTRN12610000455066). 
 
5.2.3.2 Recruitment. Several recruitment strategies were used. Print 
advertisements for the study were run in several editions of the Parkinson’s 
Association of Western Australia’s (PWA) member newsletter and three community 
newspapers (Have-A-Go, The Post Newspaper, and the Canning Times). A media 
release calling for participants was published by Curtin University and targeted an 
extensive network of online, radio, print and television agencies. PWA specialist 
nurses were asked to distribute information packs about the study to their patients. 
Information packs were also distributed at a state-wide Parkinson’s Clinic based at 
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Fremantle Hospital. In addition, the trial was registered on the Michael J Fox 
Foundation’s Fox Trial Finders website, an international registry of clinical trials 
being conducted in the PD area with over 10 000 members. Interested individuals 
self-referred and were sent an information pack and consent form. Those who 
returned consent were then assessed for eligibility. 
 
5.2.3.3 Assessment. Eligibility for treatment was determined in a two-stage 
process, first involving a telephone screening followed by a clinical assessment for 
individuals identified as tentatively suitable. All assessments were conducted by 
Curtin University clinical psychologist trainees (either clinical psychology Masters 
or Doctoral candidates) at the Curtin University Psychology Clinic, under the 
supervision of experienced clinical psychologists. The primary researcher did not 
conduct any of the clinical assessments to reduce selection bias.  
 
All self-referred individuals were telephone screened using a semi-structured 
interview comprised of four components; (i) a cognitive status assessment using the 
Telephone Interview for Cognitive Status-30 (Brandt, Spencer & Folstein, 1988), (ii) 
a screen for initial signs of psychopathology using the Mini International 
Neuropsychiatric Interview-Screen (Sheehan, Janavas, & Baker, 2006), (iii) a screen 
for psychosis, and (iv) a screen for any suicidal risks both using the relevant modules 
of the Mini International Neuropsychiatric Interview 6.0 (Sheehan & Lecrubier, 
2009). Suitable individuals were defined as those showing initial signs of any 
depressive and/or anxiety disorder, while exhibiting no cognitive impairment, no 
current psychosis, and no suicidality. Individuals identified as tentatively suitable 
candidates were then invited to attend a clinical assessment at the Curtin Psychology 
Clinic while those found ineligible were referred to other appropriate sources of help 
if requested. Clinical assessments involved a structured diagnostic interview using 
the Structured Clinical Interview for DSM-IV (First et al., 1996) to determine any 
psychiatric diagnoses. All individuals identified as meeting DSM-IV-TR criteria for 
at least one anxiety or depressive disorder were offered a place in the study. All 
eligible participants accepted and at this stage were asked to complete pre-treatment 
questionnaires as baseline data. 
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5.2.3.4 Randomisation. A block randomisation procedure stratified by 
timing was implemented to allocate participants to conditions. Randomisation was 
performed following recruitment of sufficient participants for an Intervention and 
Waitlist group (approximately 10 to 14 participants). For Wave I, a 1:1 ratio was 
used to allocate participants to conditions. A randomisation list was computer 
generated by a person external to the study to limit any potential selection bias. 
Participants were then informed of their group allocation and associated treatment 
start dates. Participants in the Waitlist condition were advised of a period of 
symptom monitoring preceding treatment, while those assigned to the Intervention 
condition commenced treatment within a week of the clinical assessments. Due to 
significant recruitment difficulties, all eligible participants were assigned to the 
Intervention group in Wave II. 
 
5.2.3.5 Treatment and therapists. Participants in both Intervention and 
Waitlist conditions received the same treatment. Treatment consisted of eight 
sessions run over eight consecutive weeks with each session lasting two hours. Each 
group was facilitated by two therapists. There were four therapists in total; one 
clinical psychologist and three clinical psychologist trainees. All therapists received 
weekly supervision and training with a clinical psychologist who reviewed video 
recordings of each session to ensure treatment fidelity and adherence to protocol. 
 
5.2.3.6 Data collection. Table 14 displays the measurement points for the 
Intervention and Waitlist groups. For the Intervention groups, measurements were 
taken at four time points, whereas measurements were taken at five time points for 
the Waitlist participants. Completion of all outcome measures was voluntary. 
 
5.2.4 Treatment Protocol 
 The treatment used in the study was an adaptation of the Mood Management 
Course developed by the Centre for Clinical Interventions in Western Australia 
(MMC; Nathan et al., 2001). The MMC is a structured, time-limited, evidence-based 
CBT group programme targeting comorbid depression and anxiety, and has been 
found to be effective in primary psychiatric outpatient populations (Nathan, McEvoy, 
& Rees, 2004). The original MMC programme is delivered over 10  
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Table 14  
Measurement Time Points for the CBT and Waitlist Groups 
   CBT     Waitlist 
 Measurement Week Measurement Week 
Time 1 Pretreatment 0 Pretreatment 0 
Time 2 Posttreatment 8 Post-Waitlist 8 
Time 3 1-month F-Up 12 Posttreatment 16 
Time 4 6-month F-Up 32 1-month F-Up 20 
Time 5   6-month F-Up 40 
 
 
consecutive weekly sessions with a one month follow-up session. However, the 
MMC has been successfully delivered in eight sessions with clients with PD (e.g., 
Feeney et al., 2005) and this format was adopted for the present study. 
 
5.2.4.1 Treatment structure. The study treatment was an 8-week 
programme with each session of 2-hour duration. Each session involved a number of 
activities and discussions with main treatment components including 
psychoeducation, relaxation training, cognitive modification, problem solving and 
behavioural activation. Participants were assigned between-session tasks (or 
homework) every week and were also provided with a handout booklet at every 
session with more comprehensive information about that session’s activities.  
 
 5.2.4.2 Protocol adaptations.  A number of procedural and content 
adaptations were made to the original MMC protocol to accommodate participants’ 
PD symptoms as well as to address disease-specific issues and concerns, 
respectively. Procedural modifications included a significant reduction of in-session 
writing to accommodate difficulties with fine motor skills as well as the inclusion of 
regular breaks throughout each session. Participants were also free to take 
medications in-session when needed and encouraged to move around the room as 
they desired to relieve restless limbs while clinicians still engaged them in session. 
Content modifications were made to examples given in the original MMC in order to 
make them more age and disease appropriate. Specific PD sections were also 
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incorporated into the protocol. These included; the role of PD, loss and stress in 
depression and anxiety, PD symptoms as a trigger for panic and anxiety, the fear of 
falling, and preparing for disease progression. In addition, the graded exposure 
component of the original MMC protocol was removed from the study protocol as 
the focus was primarily on a cognitive approach to treatment. Table 15 outlines the 
content for each session used in the study treatment as well as shows the main 
adaptations made to the original MMC protocol. 
 
Table 15  
Outline of Treatment Protocol Session Content 
Session Content 
1 
Introductions. Programme overview. 
Psychoeducation: Focus on the role of PD, loss and stress 
in depression and anxiety. Goal setting. 
2 
Change process and decisional balance 
Behavioural activation 
Pacing: Scheduling around the on-off effect in PD 
3 
Calming technique 
The ABC connection 
Thought diaries 
Automatic thoughts 
Unhelpful thinking styles with specific PD examples 
4 
Calming technique 
Disputation 
Balanced thinking 
5 
Calming technique 
More disputation 
6 
Calming technique 
Physical sensations as triggers 
PD symptoms as triggers for anxiety 
The fear of falling 
Active coping 
7 
Calming techniques 
Flashcards 
Preparing for the future/disease progression 
8 
Calming technique 
Progress review 
Self-management plan 
Maintaining goals and staying well 
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5.2.5 Screening Measures 
 Measures used during telephone screening of participants were the Telephone 
Interview for Cognitive Status-30 (Brandt, Spencer, & Folstein, 1988), Mini 
International Neuropsychiatric Interview-Screen (Sheehan, Janavas, & Baker, 2006), 
and the Mini International Neuropsychiatric Interview (Sheehan & Lecrubier, 2009), 
while the Structured Clinical Interview for DSM-IV (First et al., 1996) was used in 
the clinical interviews. 
 
5.2.5.1 Telephone Interview for Cognitive Status-30 (TICS-30).  The 
Telephone Interview for Cognitive Status and its abbreviated forms (i.e., TICS-
Modified, TICS-40 and TICS-30) are a range of measures designed specifically to 
assess cognitive functioning over the phone and were developed based on the ‘gold 
standard’ measure of cognitive functioning, the Mini Mental State Examination 
(MMSE; Folstein, Folstein, & McHugh, 1975). 
 
The TICS-30 is the briefest form of the range of TICS interviews and was 
used in the present study to screen participants for cognitive impairment. The TICS-
30 was selected primarily due to the availability of clinical severity cut-offs for the 
measure that have not been developed for the original TICS. The measure contains 
eight items assessing various cognitive abilities including orientation, concentration, 
short-term memory, language, praxis and mathematical skills. Examples of items 
include “What year is this?”, “Count backwards from 20 to 1”, “Please spell the 
word ‘world’ backwards’ and a 10-word recall task. Items 1 (state full name), 10 
(finger tapping) and 11 (word opposites) from the original TICS are omitted in the 
TICS-30. There is no time limit to complete questions although the TICS-30 can 
generally be administered and completed in 5 to 10 minutes. 
 
Total TICS-30 scores can range from 0 to 30 with lower scores indicating 
more severe cognitive impairment. Severity ratings for the TICS-30 have been 
developed to match ratings established for the MMSE (i.e., Fong et al., 2009), and 
are as follows: 0-12 (severe cognitive impairment), 13-17 (mild impairment), and 18-
30 (unimpaired cognitive ability). Participants were required to score 18 or higher 
(i.e., exhibit no cognitive impairment) in order to be eligible for the study.  
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There is limited information about the psychometric properties of the TICS-
30. However, Fong and colleagues (2009) demonstrated that scores on the TICS-30 
correlated highly with those on the MMSE, (intraclass correlation coefficient = .80) 
and suggested that it is a useful alternative to the MMSE. The TICS-30 has also been 
used successfully as a screen for cognitive impairment in a clinical study with 
dementia patients (i.e., Breitner & Welsh, 1995) as well as an epidemiology study 
investigating cognitive impairment in 856 adults aged 70 and over (i.e., Langa et al., 
2005). More broadly, the original TICS has been shown to strongly correlate with the 
MMSE (r = .94) (de Jager, Budge, & Clarke, 2003; Desmond, Tatemichi, & 
Hanzawa, 1994; Grodstein et al., 2000; Plassman, Newman, Welsh, Helms, & 
Breitner, 1994), as well as show high sensitivity and specificity in detecting 
cognitive impairment in patients with Alzheimer’s disease (Brandt et al., 1988), post-
stroke patients (Barber & Stott, 2004), and community dwelling seniors aged 70-85 
years (Espeland et al., 2011). 
 
5.2.5.2 Mini International Neuropsychiatric Interview-Screen (MINI-
Screen). The MINI-Screen is a brief 21-item screening tool which detects initial 
signs of psychopathology. Each MINI-Screen item is a basic identifier of a 
psychological condition and corresponds to a specific Mini International 
Neuropsychiatric Interview (MINI) diagnostic category. For example, Item 1 (‘Have 
you been consistently depressed or down, most of the day, nearly every day, for the 
past two weeks?’) corresponds to MINI Module A which examines Major 
Depressive Episodes. Each MINI-Screen item is scored on a ‘YES/NO’ basis. For 
each item answered yes, the corresponding MINI module is administered to further 
investigate symptoms, although relevant sections of other DSM-based diagnostic 
interviews can also be used.  
 
The MINI-Screen was used in the present study to identify individuals 
presenting with initial signs of depression and/or anxiety during telephone screening. 
Participants were required to answer ‘yes’ to at least one screening question 
indicative of a potential anxiety (Items 7-14 and 17) or depressive disorder (Items 1-
3) in order to be eligible for a clinical interview.  
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5.2.5.3 Mini International Neuropsychiatric Interview (MINI). The third 
measure used in the telephone screens was the MINI, which is a brief structured 
diagnostic interview investigating 16 Axis-I psychological disorders in accordance 
with the DSM-IV-TR. In this study, only MINI Modules B (Suicidality) and K 
(Psychotic disorders) were administered. Both modules were administered to every 
participant to exclude those with a high suicide risk and/or psychosis. Participants 
were ineligible if they were identified as having high current suicidality (score > 17) 
or any current psychotic disorder. The MINI has demonstrated high interrater 
reliability with correlations between the number and type of diagnoses as rated by 
two independent interviewers ranging from .75 to 1 with a mean of .93 (Sheehan et 
al., 1998). Test-retest reliability of MINI diagnoses are also sound with a mean of .76 
over a 2 day period (Sheehan et al.).  
 
5.2.5.4 Structured Clinical Interview for DSM-IV – Patient Edition 
(SCID-I/P). All clinical assessments were conducted using relevant sections of the 
SCID-I/P by Curtin University Clinical Psychology Masters/Doctoral candidates. 
The primary researcher did not conduct any of the clinical assessments to reduce 
selection bias. 
 
The SCID-I/P is a comprehensive structured diagnostic interview which 
assesses the range of Axis-I psychological disorders as outlined in the DSM-IV-TR. 
Only relevant sections of the SCID-I/P were administered according to each 
participant’s MINI-Screen symptom profile in order to lessen any burden on 
participants. However, clinicians were also able to administer other sections if their 
clinical judgment suggested a presenting condition that was not detected on the 
MINI-Screen. The SCID is considered the ‘gold standard’ instrument for determining 
a primary psychiatric diagnosis in both research and clinical settings (First et al., 
1996). SCID diagnoses have been shown to be moderately to highly agreeable with 
diagnoses made using comparable structured interviews such as the MINI with 
correlation coefficients ranging between .43 to .90 (First et al.). In addition, excellent 
interrater reliability for the SCID-I/P has been demonstrated with Ventura, Liberman, 
Green, Shaner and Mintz (1998) reporting a mean Cohen’s kappa of .85 for 30 
independent raters (range = .71 - .91). 
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5.2.6 Primary Outcome Measures 
The primary outcomes measured in the study were depression, anxiety, stress, 
quality of life and negative cognitions. Depression, anxiety and stress were measured 
using the respective scales of the Depression, Anxiety and Stress Scale-21 (Lovibond 
& Lovibond, 1995), PD-related quality of life was assessed using the Parkinson’s 
Disease Questionnaire-39 (Jenkinson, Peto, Fitzpatrick, & Greenhall, 1995) and 
negative cognitions were measured using the Cognitions Checklist (Beck, Brown, 
Eidelson, & Riskind, 1987). 
 
5.2.6.1 Depression, Anxiety and Stress Scale-21 (DASS-21). The DASS-21 
is a 21-item short form of the 42-item DASS, and measures three negative affective 
states: Depression, Anxiety and Stress. Participants were asked to indicate the extent 
to which they experienced 21 negative psychological and/or physiological symptoms 
over the past week on a 4-point Likert scale ranging from 0 (did not apply to me at 
all) to 3 (applied to me very much). Examples of items for each dimension include “I 
felt downhearted and blue” (Depression), “I was worried about situations in which I 
might panic and make a fool of myself” (Anxiety) and “I tended to over-react to 
situations” (Stress). Possible scores for each dimension ranged from 0 to 21 with 
higher scores reflecting greater experience of symptoms on the respective scale. 
Severity ratings for each DASS-21 factor were assessed based on the corresponding 
percentile rank of each subscale score as established by Henry and Crawford (2005). 
Chapter 4 provided a preliminary investigation or the psychometric and clinimetric 
properties of the DASS-21 as a measure for depression and anxiety in PD and 
showed strong support for the validity and reliability of the DASS-21 in PD. 
 
5.2.6.2 Parkinson’s Disease Questionnaire-39 (PDQ-39). The PDQ-39 is a 
PD-specific scale designed to assess the impact of PD on patient perceived quality of 
life. The scale comprises 39 items assessing subjective quality of life over eight 
domains: Mobility, Daily Living, Emotional Well-being, Stigma, Social Support, 
Cognitions, Communication and Bodily Discomfort. Participants were asked to rate 
the extent to which they experienced various PD-related impediments to living over 
the past month on a 5-point Likert scale ranging from 0 (never) to 4 (always or 
cannot do at all). Examples of items include “Felt frightened or worried about falling 
over in public?” and “Felt embarrassed in public due to having Parkinson’s 
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disease?”. A domain score ranging from 0 (no problem at all) to 100 (maximum level 
of problem) is calculated for each factor as well as a total PDQ index score, also 
ranging from 0 (no problem at all) to 100 (maximum level of problem).  
 
 Excellent internal consistency for the PDQ-39 has been reported with alpha 
values ranging from .72 to .95 for the eight factors with a mean of .83 (Hagell & 
Nygren, 2007). Test-retest reliability of the  eight subscales over two weeks has also 
been established as high with correlation coefficients ranging from .76 to .93 for the 
eight factors with a mean of .86 (Hagell & Nygren). In addition, the PDQ-39 has also 
shown evidence of high convergent validity with various other measures of health-
related quality of life including the PD Quality of Life Questionnaire (r = -.91), 
Unified PD Rating Scale - Activities of Daily Living (r = .69) and the Schwab and 
England Scale (r = .60) (Martinez-Martin et al., 2007). 
 
5.2.6.3 Cognitions Checklist (CCL). The CCL is a measure of the frequency 
of depressive and anxious cognitions and was used in the study to assess any changes 
in participants’ negative thinking patterns across the study period. The scale 
comprises 26 items, 14 reflecting depressive cognitions and 12 reflecting anxious 
cognitions. Examples of items include “No one cares whether I live or die” 
(Depression) and “Something will happen to someone I care about” (Anxiety). 
Participants were required to rate the frequency in which they currently experience 
each thought in the CCL on a 5-point Likert scale ranging from 0 (never) to 4 
(always). Total scores can range from 0-56 for depression and 0-48 for anxiety, with 
higher scores indicating a greater presence of depressive and anxious cognitions, 
respectively. In this study, CCL scores were expressed as a percentage ranging from 
0 to 100% to reflect the frequency of depressive and anxious cognitions. Percentages 
for each individual were calculated by dividing individual scores by the maximum 
possible subscale score. Internal consistency of the CCL has been reported as high 
with α = .90 for the Anxiety subscale and α = .92 for Depression (Beck et al., 1987). 
Test-retest reliability of the scale has also been established as good with r = .79 over 
a six week period (Beck et al.). Evidence of convergent validity has also been shown 
with moderate to strong correlations between the Anxiety scale and the Ham-A (r = 
.54) and the CCL Depression scale and the Ham-D (r = .62; Beck et al.). 
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5.2.7 Credibility/Expectancy Questionnaire (CEQ) 
An additional questionnaire was used to examine participants’ expectations of 
treatments. The CEQ is a brief 6-item measure of treatment credibility and was 
administered to participants as part of the pre-treatment battery of questionnaires. 
The scale consisted of two subscales; Credibility and Expectancy. The Credibility 
factor reflects a cognitive-based process and assessed the extent to which participants 
thought the Group CBT treatment was believable, convincing and logical. The 
Expectancy factor reflects an affective-based process and measured the degree to 
which participants felt the study treatment would result in any improvement. The 
CEQ employs two Likert rating scales, a 9-point scale ranging from 1 (not at all) to 9 
(very much) for Items 1-3 and 5 and an 11-point scale ranging from 0% (not at all) to 
100% (very much) for Items 4 and 6. Separate factor scores for Credibility and 
Expectancy are derived by summing the corresponding individual item scores. Each 
factor score can range from 3 to 27, with higher scores indicating greater credibility 
or expectancy. Internal consistency for both CEQ factors has been shown to be high, 
with alpha values ranging from .79 and .86 for credibility and .81 to .90 for 
expectancy (Devilly & Borkovec, 2000). The CEQ also has good test-retest 
reliability with r = .82 (expectancy) and r = .75 (credibility) over a one-week period 
(Devilly & Borkovec). 
 
 
5.3 Hypotheses 
 
5.3.1 Effects of Group CBT versus Waitlist on Symptomatology 
 
H1: The Intervention group will show statistically significant improvement in 
depression (DASS-D) between pretreatment (Time 1) and posttreatment 
(Time 2), whereas the Waitlist group will show no significant changes 
between pretreatment (Time 1) and post-waitlist (Time 2). 
 
H2:  The Intervention group will show statistically significant improvement in 
anxiety (DASS-A) between pretreatment (Time 1) and posttreatment (Time 
2), whereas the Waitlist group will show no significant changes between 
pretreatment (Time 1) and post-waitlist (Time 2). 
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H3: The Intervention group will show statistically significant improvement in 
stress (DASS-S) between pretreatment (Time 1) and posttreatment (Time 2), 
whereas the Waitlist group will show no significant changes between 
pretreatment (Time 1) and post-waitlist (Time 2). 
 
H4: The Intervention group will show statistically significant changes in quality 
of life (PDQ-39) between pretreatment (Time 1) and posttreatment (Time 2), 
whereas the Waitlist group will show no significant changes between 
pretreatment (Time 1) and post-waitlist (Time 2). 
 
H5:  The Intervention group will show statistically significant reduction in the 
frequency of depressive cognitions (CCL-D) between pretreatment (Time 1) 
and posttreatment (Time 2), whereas the Waitlist group will show no 
significant changes between pretreatment (Time 1) and post-waitlist (Time 
2). 
 
H6: The Intervention group will show statistically significant reduction in the 
frequency of anxious cognitions (CCL-A) between pretreatment (Time 1) and 
posttreatment (Time 2), whereas the Waitlist group will show no significant 
changes between pretreatment (Time 1) and post-waitlist (Time 2). 
 
 
5.3.2 Effects of Group CBT on Symptomatology 
 
H7: The Intervention group will show statistically significant changes in all 
outcomes (DASS-D, DASS-A, DASS-S, PDQ-39, CCL-D, CCL-A) from 
baseline (Time 1) to posttreatment (Time 2). 
 
H8: The Intervention group will show statistically significant changes in all 
outcome (DASS-D, DASS-A, DASS-S, PDQ-39, CCL-D, CCL-A) from 
baseline (Time 1) to one-month follow-up (Time 3). 
 
H9: The Intervention group will show statistically significant changes in all 
outcome (DASS-D, DASS-A, DASS-S, PDQ-39, CCL-D, CCL-A) from 
baseline (Time 1) to six-month follow-up (Time 4). 
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H10: Group CBT will be equally effective in reducing outcomes (DASS-D, DASS-
A, DASS-S, PDQ-39, CCL-D, CCL-A) for participants who commenced 
treatment immediately (i.e., Intervention group) and participants who 
commenced treatment after the waiting period (i.e., Waitlist group).  
 
 
 
5.4 Data Analysis 
 
5.4.1 Statistical Hypothesis Testing 
Multilevel linear mixed-effects modelling (MLM; Bryk & Raudenbush, 1987; 
Holden, Kelley, & Argarwal, 2008) was used to test statistical hypotheses 
(Hypotheses 1 to 10). All MLM analyses were performed using the ‘MIXED’ 
procedure in SPSS 19.0.  
 
MLM is a regression based approach which can model average trajectory of 
change over time and provides a more powerful means of analysing nested and 
clustered data when compared with more conventional procedures for the 
comparison of group means (e.g., the ANOVA family of analyses; Van Der Leeden, 
1998). For data collected in groups or clusters, MLM recognises that change in 
outcome over time is affected by both a fixed effect (e.g., treatment) as well as 
random effects at both individual as well as group levels, and is able to explicitly 
account for this multilevel random variation (Bryk & Raudenbush, 1992). Moreover, 
MLM recognises that data collected in hierarchical structures are likely to be 
correlated and therefore does not require independence of observations (Bryk & 
Raudenbush). Other benefits include that MLM is less sensitive to participant 
attrition and missing data, robust to unequal group sizes and can account for 
unequally spaced data collection points (Holden et al., 2008). Ultimately, MLM is 
provides a more accurate estimation of group means when sample sizes are small 
(Verbeke & Molenbergs, 2000) which is particularly important for preliminary trials.  
 
In its simplest form, MLM models trajectory of change over time based on 
the following formula: 
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   Y = β0 + β1X + ε 
 
     where:  Y = outcome 
       X = time 
       β0 = intercept 
       β1 = slope (rate of change) 
       ε = random error 
 
Thus, change over time is represented as a linear function of baseline scores 
(intercept), fixed effects (rate of change) and random effects (error). In the mixed-
effects MLM model, additional error terms are also included to reflect random 
effects at each level of the hierarchical model. The fixed effect is the primary interest 
in clinical trials. Random effects are considered covariates and are adjusted for 
accordingly when determining the effect of the fixed effect on outcome, in much the 
same way as covariates are controlled for in ANCOVA (Bryk & Raudenbush, 1992).  
 
5.4.1.1 Assumption testing. There are three assumptions underpinning 
MLM, all which pertain to residuals rather than cases; (1) normality of residuals, (2) 
equal and constant variances of residuals, and (3) independence of residuals 
(Pinheiro & Bates, 2000). Each of the assumptions must be tested at each level of the 
MLM model as well as across levels prior to analysis (Snijders & Bosker, 1999). 
Normality of residuals was tested using the Shapiro-Wilk statistic (suitable for when 
group sizes are less than 50; Tabachnick & Fidell, 2007), along with visual 
inspection of histograms and Quantile-Quantile plots. Equality of variances of 
residuals was tested via inspection of scatterplots of standardised residuals versus 
predicted values. Independence of residuals was testing using bivariate correlations 
within levels as well as across levels. 
 
5.4.1.2 Model 1: Intervention versus Waitlist from Time 1 to Time 2. 
Hypotheses 1 to 6 were tested using a series of two-level MLM analyses 
(Participants nested within Treatment Condition). Six separate analyses were 
conducted, one for each outcome variable (DASS-D, DASS-A, DASS-S, PDQ-39, 
CCL-D, CCL-A). The data used for Model 1 was from the entire sample (N = 18). 
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All analyses were tested against an alpha level of .05 for statistical significance. No 
explicit adjustments were made for multiple comparisons as MLM implicitly adjusts 
for multiple comparisons within the analysis (Gelman, Hill, & Yajima, 2012). 
 
Each MLM analysis included four predictors; Time (fixed), Time (random), 
Condition (fixed) and the fixed interaction between Time and Condition (Time x 
Condition). The fixed effect of Time provides a mean estimate of the rate of change 
(slope) in outcomes from Time 1 and Time 2 for all participants. The random effect 
of Time provides an indication of any individual variation around the mean slope for 
the sample (i.e., whether participants significantly differed from the average rate of 
change in the sample). The Condition (fixed) effect provides a comparison of any 
differences in baseline levels of outcomes between the Intervention and Waitlist 
groups. The Time x Condition interaction was the primary variable of interest in each 
analysis. A significant Time x Condition interaction effect indicates a differential 
rate of change in outcomes between the Intervention and Waitlist conditions from 
Time 1 to Time 2. Thus, it was predicted that there would be a significant Time x 
Condition interaction effect for all outcomes, with the Intervention group 
experiencing statistically significant improvement between Time 1 and Time 2 while 
the Waitlist group did not. 
 
5.4.1.3 Model 2: Overall Effects of Group CBT on Symptoms from 
Pretreatment to Six-Month Follow-Up. Hypotheses 7 to 9 were tested using a 
series of two-level MLM analyses (Measurement Occasion nested within 
Participants) to examine average trajectory of change from pretreatment to 6-month 
follow-up for the Intervention group. Data from Waves I and II were collapsed to 
assess the efficacy of the CBT programme for both Intervention groups (N = 11). All 
analyses were tested against an alpha level of .05 for statistical significance. 
 
Each MLM analysis included two predictors; Time (continuous, random) and 
Measurement Occasion (categorical, fixed). Of interest in this analysis was the fixed 
effect of Measurement Occasion (pretreatment, posttreatment, 1-month follow-up 
and 6-month follow-up). A statistically significant slope at any measurement point 
for an outcome indicated that there was a statistically significant rate of change 
between pretreatment and the respective time point. Post-hoc pairwise comparisons 
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were also conducted to examine any significant rate of change between subsequent 
measurement points (e.g., between posttreatment and 1-month follow-up, and 1-
month follow-up and 6-month follow-up). It was predicted that there would be a 
significant slope at every time point for every outcome demonstrating acute and 
sustained treatment gains for the CBT programme. 
 
5.4.1.4 Model 3: Effect of Group CBT on Symptoms – Immediate versus 
Delayed Treatment Commencement. Hypothesis 10 was tested using a series of 
two-level MLM analyses (Participants nested within Condition) examining any 
significant differences between the rates of change in outcomes for participants who 
commenced treatment immediately (i.e., the Intervention group) and participants 
who had a delayed treatment start (i.e., Waitlist group). Model 3 used data from all 
participants in the ITT sample (N = 18). All analyses were tested against an alpha 
level of .05 for statistical significance. 
 
Average trajectory of change was modelled between Time 1 (pretreatment) 
and Time 4 (6-month follow-up). For participants in the Waitlist group, post-waitlist 
scores were used as Time 1 scores as they provided a more recent assessment of 
participants’ symptoms prior to treatment commencement as well as allowed direct 
comparison of the rate of change in outcomes over a 32-week period from the start of 
treatment to 6-month follow-up for all participants. 
  
Each MLM analysis included four predictors; Time (fixed), Time (random), 
Group (fixed) and the fixed interaction between Time and Group (Time x Group). It 
was predicted that there would be a significant fixed effect of Time for all outcomes 
whereas there would be non-significant Time (random) and Time x Condition (fixed) 
effects indicating that all participants experienced a significant rate of change in 
symptoms over the study period and that this rate of improvement was equivalent for 
all participants whether they commenced treatment immediately or after an eight 
week waiting period. 
 
5.4.1.5 Statistical power. To determine whether the MLM analyses were 
sufficiently powered, an a priori power analysis was computed to calculate the 
required sample size to establish a power level of .80. The current study sample size 
 150
was then compared to the a priori sample size to determine whether power at a .80 
level had been achieved. There were two steps involved in estimating the a priori 
sample size required for the study. First, an a priori power analysis for an analysis of 
covariance (ANCOVA) was computed using G*Power 3.1.3 (Franz, Erdfelder, 
Buchner, & Lang, 2009) as there are currently no tests and/or statistical programmes 
available to directly estimate a priori sample size for MLM analyses. This sample 
size was then multiplied by the design effect formula (Kish, 1965) which is an 
adjustment that is made for MLM analyses (i.e., analysis using clustered data).  
 
The power analysis was computed based on MLM Model 1 as it is the 
primary model of interest in the study, and for DASS-D as the outcome as it is the 
primary outcome variable. The following parameters were used in the estimation of 
the a priori sample size required for an ANCOVA; α = .05, power = .80, number of 
groups = 2 (Intervention and Waitlist), number of covariates = 1 (Time), and effect 
size = 1.12 as reported in a meta-analysis of CBT for depression in older adults by 
Pinquart and colleagues (2007) at posttreatment compared with a waitlist control. 
The required sample size was N = 21.  
 
The design effect (Deff) was then computed using the following formula: 
 
Deff = 1 + p(n – 1) 
 
   where:  n = participants per group 
     p = intracluster correlation  
        =  
 variancetotal
 variancesindividual-between
 
 
To calculate the intracluster correlation (ICC) for DASS-D, an unconditional 
means MLM model was run. The unconditional means model includes no fixed 
predictors and provides an estimate of the within-individuals and between-
individuals variance which can then be used to calculate the ICC. For DASS-D, the 
between-individuals variance was estimated at 10.39 and the within-individuals 
variance was 8.70 (see Appendix A). The ICC for DASS-D was therefore .54, 
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indicating a high degree of dependency within the data (ICC = 0 indicates 
independent data) as well as justified the use of MLM. Substituting the ICC into the 
design effect formula, the design effect was equal to 4.24. This was multiplied by the 
a priori sample size for an ANCOVA (N = 21) resulting in a total required sample 
size of 89 participants to sufficiently power a MLM analysis at a .80 level. 
 
5.4.2 Effect Size Calculations 
 Effect sizes (Cohen’s d) were calculated using the change scores method 
which was described earlier in Chapter 2.6.1. 
 
5.4.3 Clinically Significant and Reliable Change  
 Clinically significant and reliable change calculations were computed to 
assess the clinical relevance of any change that occurred over the course of 
treatment. The methodology outlined by Jacobson and Truax (1991) was used. 
According to the authors, treatment efficacy can be indexed by the degree to which 
participants return to normal functioning subsequent to treatment. Four possible 
outcomes are proposed; Recovered, Improved but not recovered, Unchanged and 
Deteriorated. Treatment efficacy is assessed by the proportion of individuals in each 
group following treatment, with effective treatments deemed those which result in a 
large proportion of ‘recovered’ patients. Determining which group an individual 
belongs depends on two factors; (i) the clinical significance of change and, (ii) the 
magnitude and reliability of any change as assessed by the Reliable Change Index. 
 
5.4.3.1 Clinically significant change. Clinically significant change is 
proposed to occur when participants belonging to a clinical population at the 
beginning of treatment are no longer part of that population at posttreatment and 
follow-up(s). Jacobson and Truax (1991) specify three methods in which this may be 
assessed depending on the availability of data such as clinical and general population 
norms (see original article for details). Following the authors’ recommendations, 
Method C was used to assess clinically significant change in the study as it is the 
least arbitrary and all the required norms are available for the DASS-21. 
 
 Method C posits that in order for clinically significant change to have 
occurred, participants’ level of functioning subsequent to therapy must place them 
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closer to the mean of the general population than the mean of clinical population. 
The midpoint between the general population mean and clinical population mean is 
calculated for each outcome and used as a cut-off against which participants’ 
posttreatment and follow-up scores are compared. Participants whose scores exceed 
this cut-off are considered to have changed to a clinically significant degree. 
 
The following formula was used to calculate the cut-off for clinically significant 
change: 
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where:  M1 = mean (clinical population) 
 M0 = mean (non-clinical population) 
 S1 = SD (clinical population) 
 S0 = SD (non-clinical population) 
 
5.4.3.2 Reliable change index. The Reliable Change Index (RCI) assesses 
the magnitude of any change that has occurred during the course of therapy. 
Jacobson and Truax (1991) assert that when the RCI is greater than 1.96, it is 
unlikely that real change has not occurred. RCIs for each participant were calculated 
using the following formula: 
2
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    where:  x1 = participant pretreatment score 
      x2 = score at comparison point 
      SE = standard error of measurement 
           = s1 xxr−1  
 
Table 16 displays the relevant data used to calculate clinically significant and 
reliable change statistics for each of the DASS factors. Non-clinical normative data 
was taken from Crawford, Caylely, Lovibond, Wilson and Hartley (2011) and based 
on 497 adults with a mean age of 42.14 (SD = 17.93, range 18 to 86). Clinical 
normative data for the DASS were taken from Antony, Bieling, Cox, Enns and 
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Swinson (1998) as these were the only normative data available for clinical 
populations. These norms were developed based on a sample of 258 ouptatients with 
MDD and/or anxiety (panic disorder, OCD, social anxiety) with a mean age of 44.9 
years. Reliability coefficients for each of the DASS-21 factors were taken from 
Henry and Crawford (2005). 
 
Table 16  
Data Used to Compute Clinically Significant Change for the DASS-21 
 DASS-D DASS-A DASS-S 
Non-clinical mean, M0 2.21 1.48 3.79 
Clinical mean, M1 14.98 9.36 12.15 
Non-clinical SD, S0 3.60 2.60 4.10 
Clinical SD, S1 4.59 5.39 4.92 
Reliability, rxx .88 .82 .90 
Standard error of measurement, SE 1.87 2.09 1.45 
Cut-off for clinically significant change, c 7.82 4.04 7.59 
 
 
5.4.3.3 Determination of outcome group. Participants’ clinically significant 
change results and RCIs for each of the DASS factors were combined to determine 
their treatment outcome at posttreatment and follow-ups. Table 17 displays Jacobson 
and Truax’s (1991) criteria for each outcome. Clinically significant change 
calculations were not computed for PDQ-39 and CCL scores as these are not clinical 
measures and there are no available clinical and/or population normative data. 
 
Table 17  
Criteria for Determination of Clinically Significant Change Treatment Outcomes 
Outcome Clinically significant 
change (exceed cut-off?) 
RCI 
Recovered Yes >  1.96 
Improved but not recovered No >  1.96 
Unchanged No - 1.96 < 0 > 1.96 
Deteriorated No <  - 1.96 
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5.5 Results 
 
5.5.1 Preliminary Analyses 
5.5.1.1 Missing data. Sixteen of 18 participants assigned to a treatment 
condition completed treatment (attrition rate = 11%). All treatment completers 
completed the relevant measurements at posttreatment and follow-ups. There were 
no missing data among responses for treatment completers. For the two individuals 
who withdrew from treatment, the Last Observation Carried Forward (LOCF) 
method was used to estimate posttreatment and follow-up data. That is, participants’ 
pretreatment scores were carried forward to posttreatment and follow-ups and thus 
no change was assumed over the study period for treatment dropouts. The LOCF 
method was selected as it is the most conservative approach for estimating missing 
data in clinical trials and protects against overestimation of treatment effects (Mohr 
et al., 2001). 
 
5.5.1.2 Statistical power. The required sample size to adequately power 
MLM Model 1 at a .80 level was 89 participants (see Section 4.4.1.5 for calculation 
details). This is equivalent to 44 participants per condition. The total sample size for 
Model 1 was 18 therefore the current study was underpowered and reported 
statistical results should be interpreted as tentative findings at present. 
 
5.5.2 Diagnostic and Baseline Characteristics 
5.5.2.1 Diagnostic information. Table 18 provides a summary of the 
diagnostic information for participants. There was a higher rate of anxiety than 
depression among the ITT sample. Seventeen of the 18 participants met DSM-IV-TR 
criteria for at least one anxiety disorder (94%) while seven participants had at least 
one depressive disorder (39%). Eleven participants had only anxiety diagnoses 
(61%), one had only a diagnosis of depression (5%), while six participants had 
comorbid diagnoses of depression and anxiety (33%). The most common diagnosis 
was GAD, followed by panic attacks and/or disorder, then major depressive disorder. 
The average number of diagnoses per participant was 1.78 (range: 1 to 4).  
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Table 18  
Diagnostic Information for the ITT sample, Intervention and Waitlist groups 
 ITT 
(N = 18) 
Intervention 
(N = 11) 
Waitlist 
(N = 7) 
Generalised anxiety 12 (66%) 8 (73%) 4 (57%) 
Panic attacks and/or panic disorder 7 (39%) 4 (35%) 3 (43%) 
Major depressive disorder 6 (33%) 2 (18%) 4 (57%) 
Dysthymia 6 (33%) 3 (27%) 3 (43%) 
Social anxiety disorder 4 (22%) 1 (9%) 3 (43%) 
Posttraumatic stress disorder 1 (5%) 0 1 (14%) 
 
5.5.2.2 Current medications. Table 19 displays the current antiparkinsonian, 
psychiatric and other medications taken by participants. Eighty-nine percent of 
participants were currently on antiparkinsonian medications. Half of the participants 
were currently on psychiatric medications and 50% were also on additional 
medications for other comorbid health conditions. On average, each participant in the 
study was taking 3 to 4 different medications daily during the study period. 
 
Table 19  
Current Medications utilised by Participants 
 ITT 
(N = 18) 
Intervention 
(N = 11) 
Waitlist 
(N = 7) 
Antiparkinsonian    
 Dopamine agonists, N (%) 8 (44%) 6 (55%) 2 (29%) 
 Levodopa, N (%) 15 (83%) 10 (91%) 5 (71%) 
 Neuroprotective, N (%) 2 (11%) 2 (18%) 0 
Psychiatric    
 SSRIs 9 (50%) 4 (36%) 5 (71%) 
 Benzodiazepines 1 (5%) 1 (9%) 0 
 Other 1 (%) 1 (9%) 0 
Other health conditions, N (%) 9 (50%) 6 (55%) 3 (43%) 
Total medications per person, M 
 
3.67 
 
3.85 
 
3.46 
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5.5.1.3 Pretreatment outcomes. Table 20 displays the pretreatment data for 
the ITT sample, as well as Intervention and Waitlist groups. For the entire sample, 
average pretreatment severity of depression was Moderate, anxiety was Severe, and 
stress was Moderate, as rated by the DASS-21. PD was perceived to have a low to 
moderate negative impact on quality of life (35%). On average, participants 
experienced depressive thoughts 23% of the time, and anxious thoughts 21% of the 
time. Clinically, the Intervention group had more severe anxiety symptoms at 
pretreatment while the Waitlist group had more severe depression. The Intervention 
group also experienced more frequent depressive and anxious thoughts than Waitlist 
participants. There were no statistically significant differences between the 
Intervention and Waitlist groups on all pretreatment outcomes, however. There were 
also no statistically significant correlations between demographic and PD variables 
(age, gender, PD severity, current antidepressant treatment) and any of the outcomes. 
Therefore, demographic and PD variables were not controlled for as covariates in the 
subsequent MLM analyses. 
 
Table 20  
Pretreatment Scores for ITT sample, Intervention and Waitlist groups 
 ITT Intervention Waitlist 
 M Severity M Severity M Severity 
Primary Outcomes      
DASS-D 10.44 Moderate 10.09 Moderate 10.71 Severe 
DASS-A 9.06 Severe 9.64 Extremely 
Severe 
8.57 Severe 
DASS-S 9.78 Moderate 10.64 Moderate 10.00 Moderate 
Secondary Outcomes       
PDQ-39 35% 
 
30% 
32% 
Low to 
Moderate 
36% 
 
31% 
32% 
Low to 
Moderate 
28% 
 
25% 
29% 
 
Low to 
Moderate 
 
 
 
CCL-D 
CCL-A 
CEQ-C 17.5 Moderate 17.55 Moderate 17.43 Moderate 
CEQ-E 16.33 Moderate 16.64 Moderate 15.86 Moderate 
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 5.5.1.4 Treatment credibility and expectancy. Mean perceived credibility 
of the group CBT treatment and expectancy of improvement following treatment 
were both in the Moderate range. There were no significant differences between the 
credibility and expectancy ratings for the Intervention and Waitlist groups. There 
were statistically significant correlations between PD severity and both CEQ-C  
(r = -.61, p = .008) and CEQ-E factors (r = -.50, p = .033), with participants with 
greater severity of PD reporting lower treatment credibility and expectancy ratings. 
There were no other significant correlations between CEQ factors and other 
demographic and PD or outcome variables. 
 
5.5.3 MLM Model 1: Intervention versus Waitlist from Time 1 to Time 2 
Model 1 examined the average trajectory of change in outcomes from Time 1 
(pretreatment) to Time 2 (posttreatment and post-waitlist) and assessed any 
differences in the rate of change between the Intervention and Waitlist participants. 
 
5.5.3.1 Assumption testing. Residuals for all outcomes were normally 
distributed according to the Shapiro-Wilk statistic (p > .05), except for the Level-1 
CCL-A residuals (p = .045). Inspection of the normality histogram and skewness and 
kurtosis statistics for Level-1 CCL-A residuals showed that residuals were near-
normally distributed, however, with only a minimal negative skew (-.023) and slight 
platykurtic distribution (i.e., negative kurtosis), suggesting no advantage to 
transformation (Tabachnick & Fidell, 2007). Residual plots for each outcome 
showed equal scatter above and below the standardised mean indicating constant 
variances. There were no significant correlations between Level-1 residuals, between 
Level-2 residuals or between Level-1 and 2 residuals indicating independence of 
residuals within as well as across levels. Outputs for all assumption tests appear in 
Appendix B. 
 
 5.5.3.2 Change in outcomes. Table 21 provides an overview of the results 
and effect sizes for changes in outcomes from Time 1 (pretreatment) to Time 2 
(posttreatment/post-waitlist).  
 
  5.5.3.2.1 Hypothesis 1. H1 predicted that participants in the Intervention 
group would experience significant improvement in depression between Time 1 and 
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Time 2 whereas participants in the Waitlist would show no significant change. This 
hypothesis was supported. A significant Time x Condition interaction effect was 
observed for DASS-D indicating a differential rate of change in depressive 
symptoms between the Intervention and Waitlist groups, F (1, 16) = 8.31, p = .011,  
d = 1.12. On average, participants who received CBT experienced a significant large 
reduction in symptoms at a rate of .49 points per week between pretreatment and 
posttreatment, t (16) = -4.31, p = .000, whereas the Waitlist group experienced no 
significant change in depressive symptoms from pretreatment to post-waitlist,  
t (16) = .04, p = .81. 
 
Table 21  
Model 1: Results of the MLM analyses and Effect Sizes for Average Rate of Change 
in Primary Outcomes from Time 1 to Time 2 
  Intervention (n = 11) Waitlist (n = 7)   
Outcome Time Mean (SD) Mean (SD) p-value* d* 
DASS-D 
1 10.09 (3.73) 10.71 (5.41) 
.011 1.12 
2 7.64 (2.77) 11.00 (5.20) 
DASS-A 
1 9.64 (2.01) 8.57 (4.61) 
.025 .89 
2 6.73 (2.90) 8.14 (4.85) 
DASS-S 
1 10.64 (3.26) 10.00 (4.28) 
.828 .08 
2 8.82 (1.83) 8.43 (4.50) 
PDQ-39 
1 36.03 (12.62) 28.48 (16.15) 
.095 .56 
2 32.82 (12.95) 32.88 (14.50) 
CCL-D 
1 31.22 (15.50) 24.49 (14.12) 
.009 1.26 
2 18.02 (15.94) 28.83 (9.86) 
CCL-A 
1 32.01 (10.51) 29.46 (14.00) 
.009 .92 
2 23.67 (11.27) 33.04 (15.38) 
*p-value for Time x Condition interaction effect 
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 5.5.3.2.2 Hypothesis 2. H2 predicted that participants who received CBT 
would experience a significant improvement in anxiety at posttreatment whereas 
those in Waitlist would show no significant change at post-waitlist. This hypothesis 
was also supported with a significant Time x Condition interaction effect also 
observed for DASS-A scores, F (1, 16) = 6.06, p = .025. On average, participants 
who received CBT experienced a significant reduction in anxiety symptoms at a rate 
of .42 points per week between pretreatment and posttreatment,  
t (16) = -5.30, p = .000, d = .99, while participants in the Waitlist group experienced 
no significant change from pretreatment to post-waitlist, t (18) = -1.08, p = .30. 
 
 5.5.3.2.3 Hypothesis 3. H3 predicted that participants in the Intervention 
group would experience a significant reduction in stress between pretreatment and 
posttreatment while those in the Waitlist group would show no significant change. 
H3 was partially supported.  A significant main effect for Time (fixed),  
F (1, 31) = 9.04, p = .005, and a non-significant Time x Condition interaction effect, 
F (1, 31) = .05, p = .83, was observed for DASS-S scores indicating that on average 
all participants experienced a significant and equivalent reduction in stress between 
Time 1 and 2. Thus, while participants who received CBT did experience a 
significant reduction in stress between pretreatment and posttreatment as predicted,  
t (31) = -2.59, p = .015, participants in the Waitlist group also experienced an 
equivalent reduction in stress over the waiting period, t (31) = -1.78, p = .05. The 
differential rate of change in depressive and anxiety symptoms between the 
Intervention and Waitlist groups is clearly visible in Figure 8. For Stress, both 
Intervention and Waitlist groups experienced a significant reduction in symptoms 
between Time 1 and Time 2 which is reflected in the relatively parallel slopes. 
 
 5.5.3.2.4 Hypothesis 4. H4 predicted that participants who received CBT 
would show a significant improvement in quality of life between pretreatment and 
posttreatment while those in the Waitlist group would show no significant change. 
H4 was not supported as there were no significant Time, F (1, 13) = .01, p = .923, or 
Time x Condition effects, F (1, 13) = 3.24, p = .095, for PDQ-39 scores indicating no 
significant change in quality of life for both Intervention and Waitlist groups.  
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Figure 8. Average trajectory of Change in Primary Outcomes for CBT and Waitlist 
Participants Between Time 1 (pretreatment) and Time 2 (posttreatment/post-waitlist) 
 
 
 5.5.3.2.5 Hypothesis 5. It was predicted in H5 that participants in the 
Intervention group would show a significant reduction in the frequency of depressive 
thoughts (CCL-D) between Time 1 and 2 while those in the Waitlist group would 
not. H5 was supported. A significant Time x Condition interaction effect was found 
for CCL-D scores, F (1, 17) = 8.86, p = .009, d = 1.26, indicating a differential rate 
of change in depressive thoughts between the Intervention and Waitlist groups. 
Participants who received CBT experienced a mean 13.2% reduction in the 
frequency of depressive thoughts following treatment, t (17) = -3.59, p = .002. 
Participants in the Waitlist group experienced a mean 4.4% increase in the frequency 
of depressive thoughts over the waiting period however this change was not 
significant, t (17) = .94, p = .36. 
 
 5.5.3.2.6 Hypothesis 6. H6 predicted that participants who received CBT 
would show a significant reduction in the frequency of anxious thoughts (CCL-A) 
between Time 1 and 2 while those in the Waitlist group would not. H6 was supported 
with a significant Time x Condition interaction effect observed,  
F (1, 16) = 8.75, p = .009. Participants who received CBT experienced a mean 8.45% 
reduction in the frequency of anxious thoughts, t (16) = -3.32, p = .004, while those 
in the Waitlist group experienced a mean 3.58% increase in anxious thoughts over 
the waiting period, t (16) = 1.14, p = .273, however again this change was not 
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statistically significant. Figure 9 provides a visual representation of the differences in 
the rate of change in PDQ-39, CCL-D and CCL-A between Time 1 and Time 2. 
 
     
Figure 9. Average Trajectory of Change in Secondary Outcomes for Intervention and 
Waitlist Groups between Time 1 and Time 2 
 
5.5.4 Model 2: Overall Effects of Group CBT on Symptoms from Pretreatment 
to Six-Month Follow-Up 
 Model 2 examined the average trajectory of change in outcomes over the 
entire study period for the participants in the Intervention groups (N = 11).  
 
5.5.4.1 Assumption testing. Residuals for all outcomes were normally 
distributed according to the Shapiro-Wilk statistic (p > .05). Residual plots for each 
outcome showed constant variances of residuals. There were no significant 
correlations within or across Level-1 and 2 residuals. Outputs for all assumption tests 
appear in Appendix C. 
 
5.5.4.2 Change in outcomes. Table 22 displays the results and effect sizes 
for changes in primary and secondary outcomes in Model 2. There was a significant 
main effect of Time for DASS-D, F (3, 24) = 10.32, p = .000, DASS-A, F (3, 24) = 
13.83, p = .000, DASS-S, F (3, 22) = 9.40, p = .000, CCL-D,  F (2, 23) = 6.91, p = 
.002 and CCL-A, F (3, 27) = 11.59, I = .000, indicating a statistically significant rate 
of change in depression, anxiety, stress and depressive and anxious thoughts between 
pretreatment and six-month follow-up. There was no significant change in quality of 
life over the study period, F (3, 20) = 2.05, p = .14. 
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Table 22  
Model 2: Results of the MLM analyses for Average Rate of Change in Primary 
Outcomes for the Intervention Group from Pretreatment to Six-Month Follow-Up 
Outcome Time Mean (SD) p-value d 
DASS-D 
Pretreatment 10.09 (3.73)   
Posttreatment 7.64 (2.77) .001 .75 
 1-month f-up 5.91 (3.27) .000 1.19 
 6-month f-up 3.82 (2.12) .000 2.07 
DASS-A 
Pretreatment 9.64 (2.01)   
Posttreatment 6.73 (2.90) .000 1.17 
 1-month f-up 5.82 (3.16) .000 1.44 
 6-month f-up 3.82 (3.03) .000 2.26 
DASS-S 
Pretreatment 10.64 (3.26)   
Posttreatment 8.82 (1.83) .031 .69 
 1-month f-up 6.91 (2.51) .000 1.28 
 6-month f-up 5.45 (2.98) .001 1.66 
PDQ-39 
Pretreatment 36.03 (12.62)   
Posttreatment 32.82 (12.95) .096 .25 
 1-month f-up 30.54 (11.99) .024 .45 
 6-month f-up 32.05 (16.26) .259 .27 
CCL-D 
Pretreatment 31.22 (15.50)   
Posttreatment 18.02 (15.94) .016 .84 
 1-month f-up 16.78 (11.80) .000 1.05 
 6-month f-up 18.83 (10.45) .002 .94 
CCL-A 
Pretreatment 32.01 (10.51)   
Posttreatment 23.67 (11.27) .003 .77 
 1-month f-up 20.08 (14.68) .000 .94 
 6-month f-up 16.31 (11.08) .000 1.45 
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5.5.4.2.1 Hypothesis 7. It was predicted in H7 that the Intervention group 
would show statistically significant changes in all outcomes at posttreatment. H7 was 
supported for all outcomes except for the PDQ-39. Significant large reductions in 
depression (d = .75), anxiety (d = 1.17) and depressive thoughts (d = .84) and 
significant moderate reductions in stress (d = .69) and anxious thoughts (d = .77) 
were observed at posttreatment. 
 
5.5.4.2.2 Hypothesis 8. H8 predicted that participants in the Intervention 
group would show statistically significant improvement and/or maintain acute 
treatment gains on all outcomes at one-month follow-up. H8 was supported for all 
outcomes. Significant large effects were observed for all DASS (depression;  
d = 1.19, anxiety; d = 1.44, stress; d = 1.28) and CCL factors (depressive thoughts;  
d = 1.05; anxious thoughts; d = .94). A significant moderate improvement in quality 
of life was also observed at 1-month follow-up (d = .45). 
 
5.5.4.2.2 Hypothesis 9. It was predicted in H9 that participants in the 
Intervention group would show statistically significant improvement and/or maintain 
acute treatment gains on all outcomes at six-month follow-up. H9 was supported for 
all outcomes except for PDQ-39. There was no significant change in quality of life 
from pretreatment to six-month follow-up. All posttreatment gains for DASS and 
CCL factors were maintained at six-month follow-up with significant large effects 
observed for all measures (DASS-D; d = 2.07, DASS-A; d = 2.26, DASS-S;  
d = 1.66, CCL-D; d = .94, CCL-A; d = 1.45). 
 
Moreover, post-hoc pairwise comparisons also showed significant mean 
differences between posttreatment and 1-month follow-up for DASS-D and DASS-S, 
and significant mean differences between 1-month follow-up and 6-month follow 
-up for all three factors (see Appendix D). Therefore, treatment benefits were not 
only observed at posttreatment and maintained at subsequent follow-ups, but 
continued to improve at a statistically significant rate in the period following therapy, 
with the greatest improvement observed at 6-month follow-up. 
 
Figure 10 displays the average rate of change in outcomes from pretreatment 
to six-month follow-up for participants in the Intervention group. A significant linear 
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decline in DASS and CCL scores is clearly visible although it must be noted that the 
slopes for CCL-D and CCL-A are not as steep as those observed for the DASS 
indicating less improvement in secondary outcomes.  
 
 
  Figure 10. Average Trajectory of Change in Primary and Secondary Outcomes 
from Pretreatment to Six-month Follow-up for the Intervention Group 
 
5.5.5 Model 3: Effect of Group CBT on Symptoms – Immediate versus Delayed 
Treatment Commencement 
Model 3 examined the trajectory of change in outcomes from pretreatment to 
6-month follow-up for the entire ITT sample and examined any differential rates of 
change in outcomes between participants who commenced treatment immediately 
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(i.e., Intervention group) and participants who had a delayed  treatment start (i.e., 
Waitlist group). Table 23 displays the results of the MLM analyses for Model 3.  
 
Table 23 
Model 3: Results of the MLM analyses for Average Rate of Change in All Outcomes 
from Time 1 to Time 4 
 DASS-D  DASS-A 
 β SE sig  β SE sig 
Intercept 10.58 1.68 .000  8.28 1.36 .000 
Time (fixed) -.21 .03 .000  -.15 .02 .000 
Time (random) .008 .005 n.s.  .002 .002 n.s. 
Condition x Time (fixed) - - n.s.  - - n.s. 
 Intervention x Time -.18 .04 .000  -.17 .03 .000 
 Waitlist x Time -.26 .05 .000  -.13 .03 .001 
  DASS-S  PDQ-39 
  β SE sig  β SE sig 
Intercept 8.53 1.30 .000  31.11 5.10 .000 
Time (fixed) -.16 .02 .000  -.15 .09 n.s. 
Time (random) .005 .003 n.s.  .07 .05 n.s. 
Condition x Time (fixed) - - n.s.  - - n.s. 
 Intervention x Time -.15 .03 .000  -.10 .11 n.s. 
 Waitlist x Time -.17 .04 .001  -.24 .14 n.s. 
  CCL-D  CCL-A 
 β SE sig  β SE sig 
Intercept 24.53 5.25 .000  27.49 5.01 .000 
Time (fixed) -.35 .09 .000  -.38 .09 .000 
Time (random) .01 .00 n.s.  .02 .00 n.s. 
Condition x Time (fixed) - - n.s.  - - n.s. 
 Intervention x Time -.32 .11 .007  -.44 .12 .000 
 Waitlist x Time -.41 .14 .006  -.29 .14 .046 
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5.5.5.1 Assumption testing. MLM assumptions of normality of residuals, 
constant variance and independence of residuals within and across levels were all 
met. Outputs for all assumption tests appear in Appendix E. 
 
5.5.5.2 Hypothesis 10. It was predicted in H10 that the group CBT treatment 
would be equally effective in reducing outcomes for participants who commenced 
treatment immediately and participants who commenced treatment after the waiting 
period. H10 was supported for all outcomes as on the DASS and CCL factors, a 
significant main effect of Time (fixed) was observed for all variables while there was 
a non-significant Time x Condition interaction effect for all factors. This result 
indicates that there was a statistically significant rate of change in depression, 
anxiety, stress, depressive thoughts and anxious thoughts between pretreatment and 
six-month for the entire sample, and this rate of change did not differ significantly 
between groups. For the PDQ-39, there was no significant main effect for Time 
(fixed) and no significant Time x Condition interaction effect indicating that all 
participants did not experience significant improvement in quality of life. Thus, the 
group CBT intervention had a consistent effect on outcomes regardless of treatment 
start time.  
 
Figure 11 displays the rates of change in all outcomes for the Intervention and 
Waitlist groups. As it can be seen, the slopes for DASS-D, DASS-S, PDQ-39 and 
CCL-D are relatively parallel while the slopes for DASS-A and CCL-A are 
essentially identical between the Intervention and Waitlist groups. Thus, overall, all 
participants experienced equivalent and significant reductions in depression, anxiety 
and stress regardless of whether they commenced treatment immediately or after an 
eight-week waiting period. 
 
 
5.5.6 Clinically Significant and Reliable Change 
Table 24 displays the results of the clinically significant change analyses for 
each of the DASS factors at posttreatment, 1-month and 6-month follow-ups based 
on the Jacobson and Truax (1991) method. There was a clear trend for all three 
factors where higher rates of clinically significant change (i.e., Improved or 
Recovered) were observed over each progressive measurement point. This is 
consistent with the results of the Model 2 MLM analyses which showed that 
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Figure 11. Average Trajectory of Change in Outcomes for Intervention and Waitlist 
Participants between Pretreatment and Six-Month Follow-Up 
 
 
symptoms continued to improve during the period following therapy and the greatest 
improvement for all primary outcomes was observed at 6-month follow-up. At 6-
month follow-up, 89% of participants showed clinically significant improvement in 
depression, 83% showed clinically significant improvement in stress, and 56% 
showed clinically significant improvement in anxiety. The lowest rate of clinically 
significant improvement was for anxiety, although more than half of participants 
evidenced clinically significant improvement at 6-month follow-up. One participant 
showed a clinically significant increase in stress between pretreatment and 
posttreatment however by 6-month follow-up, the participants’ severity of stress was 
within the normal range. No other participants experienced any deterioration in 
depression, anxiety or stress at any time point. 
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Table 24  
Results of Clinically Significant and Reliable Change Analyses 
 DASS-D  DASS-A  DASS-S 
 Post 1m 6m  Post 1m 6m  Post 1m 6m 
Recovered 0 28% 67%  6% 17% 39%  11% 28% 39% 
Improved 11% 11% 22%  0 6% 17%  11% 22% 44% 
Unchanged 89% 61% 11%  94% 78% 44%  72% 50% 17% 
Deteriorated 0 0 0  0 0 0  6% 0 0 
Total CSC* 11% 39% 89%  6% 23% 56%  22% 50% 83% 
*Post= posttreatment, 1m = 1-month follow-up, 6m = 6-month follow-up, CSC = clinically 
significant change (i.e., total percentage of participants who showed clinically significant 
positive change) 
 
 
5.6 Discussion 
 
This study was the first randomised controlled trial of group CBT for 
depression and anxiety in PD. In support of the growing body of evidence for the 
efficacy of CBT in treating depression and anxiety in PD, statistically and clinically 
significant improvements in depression, anxiety, and stress over the treatment period 
and all treatment gains were maintained at six month follow-up.  
 
5.6.1 Main Findings and Implications 
 5.6.1.1 Feasibility.  Overall, group CBT appeared to be a feasible treatment 
approach for depression and anxiety for participants in the study, with an 89% 
treatment completion rate (11% attrition rate) and participants attending a mean 7 out 
of 8 sessions (88%). This attrition rate is comparable with that recently reported in 
the first RCT of individual CBT for depression in PD (10%; Dobkin et al., 2011) and 
significantly lower than the 41% mean dropout rate reported across the four RCTs of 
antidepressants for the treatment of depression in PD to date (range: 14% to 73%; 
Anderson et al., 1980; Menza et al., 2009; Rabey et al., 1996; Wermuth et al., 1998). 
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Moreover, this finding is consistent with previous research showing that 
antidepressant treatment is associated with a 75% relative risk of discontinuation 
compared with CBT in primary populations (NICE, 2010) and supports the 
feasibility of CBT in treating depression and anxiety in PD.  
 
However, while the completion rates for study participants are positive, it 
must be noted that the small sample size and recruitment difficulties encountered in 
the study may suggest that the group treatment modality is not as feasible as and/or 
less preferred than individual therapy by those with PD. Prior research has found that 
often times, individuals with PD are reluctant to be around others with more 
advanced stage disease or to learn about additional complications of the illness that 
they are not yet experiencing, and many refuse to attend support groups for the same 
reason (Chaudhuri et al., 2007). Thus, the feasibility of group CBT in PD requires 
further exploration. 
 
5.6.1.2 Acute treatment gains. This study was the first to provide a 
controlled examination of the efficacy of CBT for depression and anxiety over the 
acute treatment period. At the end of the eight-week acute phase of treatment, 
participants who received CBT experienced significant improvements in depression, 
anxiety and stress and a significant reduction in the frequency of both depressive and 
anxious thoughts. In contrast, participants in the waitlist control showed no 
significant change in depression, anxiety or depressive and anxious thoughts, 
although a significant improvement in stress was observed. There was no significant 
change in quality of life for either group. 
 
The significant improvement in depression and anxiety observed over the 
acute phase of treatment adds significant support to the growing body of evidence for 
the efficacy of CBT for treating depression and anxiety in PD. Effect sizes were large 
for both depression (d =1.12) and anxiety (d = .89) relative to control and consistent 
with posttreatment effect size estimates recently reported by Dobkin and colleagues 
(2011) for individual CBT for depression in PD (depression; Ham-D,  
d = 1.57; BDI, d = 1.1; anxiety; Ham-A, d = .98), and warrant further investigation of 
this presently understudied treatment modality. 
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Significant improvement in stress over the acute treatment period was also 
observed for participants who received CBT (d = .57), however, participants in the 
Waitlist condition also experienced a significant reduction in stress over the 
corresponding period (d = .37). A possible explanation may be related to the well 
documented waitlist effect (Hesser, Weise, Rief, & Andersson, 2011). It has been 
demonstrated that participants assigned to waitlist controls in clinical trials often 
show a significant decrease in symptoms over the waiting period. In a study 
comparing change in psychological symptoms in 67 psychiatric outpatients and 231 
psychiatric inpatients over a 3-month waiting period prior to receiving treatment, 
Arrindell (2001) reported that significant small to moderate reductions (d = .07 to 
.29) were observed on a range of popular psychological rating scales including the 
Symptom Checklist-90-Revised, BDI and STAI.  
 
Several factors have been suggested to potentially underlie the waitlist effect 
including; retest effects, reduced test-anxiety, social desirablity and natural resolution 
of symptoms (Jorm et al., 1989). Two explanations of the waitlist effect are 
particularly relevant to this study. As suggested by Devilly and McFarlane (2009), 
the process of psychological assessment in the initial stages of clinical trials to 
determine participant eligibility may be therapeutic in itself and can result in a small 
reduction in symptoms. This is because through the assessment process, participants 
are provided an opportunity to speak with a professional regarding concerns that they 
may have not spoken about to anybody prior and this disclosure along with 
professional attention alone can effect symptom change (Henderson et al., 1981). 
Relatedly, confirmation of a psychological disorder may also relieve stress in that 
participants are provided with a logical explanation for any mood or behavioural 
changes that were previously unexplained (Devilly & McFarlane). This 
understanding of one’s own symptoms along with knowledge that one will be 
receiving professional help (expectancy effects) has also been shown to result in 
small to moderate reductions in symptoms (Hesser et al., 2011).  
 
In regards to secondary outcomes, a significant and large reduction in 
negative thinking was observed for participants who received CBT (CCL-D;  
d = 1.26, CCL-A; d = .92) over the acute treatment period while there was no change 
in the frequency of depressive and anxious thoughts for the control group. This 
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simultaneous reduction in DASS-D and DASS-A and CCL-D and CCL-A scores in 
participants who received CBT while no such change was observed in control 
participants is encouraging in that reduction in symptoms was associated with a 
reduction in negative thinking, which is consistent with the cognitive mediation 
hypothesis. 
 
Finally, no significant improvement in quality of life was observed for 
participants who received CBT or those in the waitlist condition. This finding is 
consistent with previous CBT in PD studies also employing the PDQ-39 as an 
outcome measure, where no significant improvement on PDQ-39 scores were also 
reported following treatment (e.g., A’Campo et al., 2010; Macht et al., 2007; Simons 
et al., 2006; Veazey et al., 2009). There are two possible explanations for this 
finding. First, it must be noted that pretreatment PDQ-39 levels were within the low 
range (M = 32.46, SD = 14.84). Therefore, it may be the case that a lack of 
significant change in quality of life may reflect a floor effect (i.e., change to a 
significant degree cannot occur as baseline levels are already within a normal range). 
Second, another possible explanation may be directly related to the broad nature of 
the PDQ-39 measure. The PDQ-39 is a general measure of PD-related quality of life 
and features a significant number of  questions measuring physical and/or somatic 
difficulties associated with living with PD (e.g., ‘How often have you had difficulty 
walking 100 metres?’, ‘Had difficulty dressing yourself?’, ‘Had difficulty cutting up 
your food?’). Reductions in depression and anxiety are not likely to affect these 
physical aspects of life with PD and may explain the lack of significant change in 
quality of life ratings in the present study as well as previous studies in the literature. 
 
5.6.1.3 Long-term treatment benefits. This study was also the first to 
examine the long-term effects of group CBT on psychological symptomatology in 
PD. To date the maximum length of follow-up for any CBT intervention in PD has 
only been one month. Follow-up analyses showed significant reductions in 
depression, anxiety and stress symptoms as well as significant declines in the 
frequency of depressive and anxious thoughts at both 1-month and 6-month follow-
ups. At 6-month follow-up, statistically significant and large effect sizes were 
observed for each of the DASS factors; Depression (d = 2.07), Anxiety (d = 2.26) 
and Stress (d = 1.66), as well as both of the CCL factors; Depressive cognitions (d = 
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.94) and Anxious cognitions (d = 1.45). Moreover, statistically significant reductions 
in symptoms were also observed between each time point indicating that symptoms 
continued to improve following therapy. Again, there was no significant change in 
quality over life from pretreatment to 6-month follow-up however. It must be noted 
that follow-up analyses were based on uncontrolled data, however. Due to ethical 
requirements as well as the timeframe of the study, the waiting period for the control 
participants was limited to only eight weeks, with Waitlist participants receiving 
CBT following the completion of post-waitlist measures. Thus, reported effect sizes 
for follow-up measurements may be overstated and must be interpreted with caution. 
 
Nevertheless, these results provide strong preliminary support for the long-
term efficacy of CBT in treating depression and anxiety in PD.  Significant long-term 
effects are arguably more important than acute treatment effects as long-term effects 
attest to the durability of a treatment as well as strongly indicate that a treatment 
effect is real (Durham et al., 2005). This study showed that six-months following 
completion of treatment, effect sizes for depression and anxiety were larger than all 
posttreatment effect sizes for both pharmacological and non-pharmacological 
treatments reported in the meta-analysis in Chapter 2. However, as noted earlier, this 
comparison must be made with caution due to the uncontrolled nature of follow-up 
effect sizes in the current study.  
 
Nevertheless, the follow-up results in this study are especially encouraging 
given that one of the most pertinent criticisms of existing pharmacological regimes 
for depression and anxiety in PD relates to the questionable long-term utility of such 
treatments. It is widely acknowledged that pharmacological treatments of depression 
and anxiety are associated with high rates of relapse and significant ongoing 
treatment is required to maintain any acute treatment gains. As noted in Chapters 1 
and 3, the National Institute of Health and Clinical Excellence (2010) currently 
recommend between 2 to 4 years of continuation therapy (same medication and 
dosage) in order to maintain acute treatment gains and prevent relapse for the 
treatment of major depression in older adults. In contrast, CBT has demonstrated 
long-term efficacy in the treatment of both depression and anxiety in primary 
populations following standard 12-week interventions (NICE) and the results of this 
trial provide preliminary support for the long-term utility of CBT with clients with 
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PD. The long-term utility of CBT has been attributed to the focus on self-
management and problem solving in CBT as well as the development of skills and 
techniques that enable clients to address any problems that may arise following 
cessation of therapy. Overall, this study supports the assertion that while there is a 
broad equivalence in the efficacy of CBT and pharmacotherapy in the acute phase of 
treatment, the long-term utility of CBT may indicate that it is a more beneficial 
treatment for depression and anxiety on the whole.  
 
Finally, the finding that DASS and CCL scores were both reduced at a 
comparable rate over each measurement point indicates that change in depressive and 
anxious symptoms was associated with a reduction in depressive and anxious 
thoughts. This finding adds to a growing number of studies also demonstrating 
simultaneous reductions in depression and negative thoughts following CBT in 
participants with PD (e.g., Dobkin et al., 2007; Dobkin et al., 2011; Farabaugh et al., 
2010) and may suggest that symptomatic improvement may be directly related to the 
active cognitive modification component of CBT, ultimately showing support for the 
cognitive mediation hypothesis.  
 
5.6.1.4 Clinical Significance. Clinical significance analysis showed a clear 
trend with higher rates of clinically significant change observed over each 
progressive measurement point. Interestingly, while statistical testing showed 
significant reductions in primary outcomes across each time-point, clinically 
significant analyses revealed that the majority of participants did not evidence 
clinically significant change in depression, anxiety or stress at posttreatment. By 6-
month follow-up, however, the vast majority of participants showed clinically 
significant improvement in Depression (89%) and Stress (83%) and just over half 
showed clinically significant improvement in Anxiety (56%). Thus, CBT appeared to 
have a delayed effect with the full benefits of therapy manifesting in the period 
following treatment completion. 
 
Delayed treatment effects have been previously observed in other trials of 
CBT for various psychological conditions (Booth & Rachman, 1992; O’Malley et al., 
1996; Petry, Weinstock, Ledgerwood, & Morasco, 2008; Sarin, Wallin, & Widerlov, 
2011; Sensky et al., 2000) as well as has long been documented in the process of 
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psychotherapy in general (Elkin, Pilkonis, Docherty, & Sotsky, 1988). In terms of the 
mechanisms underlying delayed treatment effects in psychotherapy, Kubie (1972) 
speculated that because psychotherapy is an ongoing process, observable change and 
maturation is likely to manifest only after all formal therapy has been terminated. 
Likewise, Rachman (1992) posits that CBT likely sets in motion a process of change 
that only manifests into observable change over time. Moreover, Rachman asserts 
that therapeutic changes in CBT frequently occur after, rather than during, treatment 
sessions, through the consolidation of skills, techniques and knowledge gained 
through therapy. This early work is also consistent with more recent research 
suggesting that the true benefits of CBT are commonly not observed until after the 
acute treatment period when clients have completed therapy, acquired the full set of 
skills necessary to elicit change, and become more proficient in applying those skills 
into their everyday lives (Westbrook et al., 2011). It has also been suggested that 
delayed treatment effects in CBT may reflect the time it takes to modify long-
standing schemas (Sarin et al.).  
 
Overall, the rates of clinically significant improvement, particularly for 
depression and stress, at 6-month follow-up are very promising and further attest to 
the durability of the study treatment. It must be noted that the rate of clinically 
significant improvement for anxiety was observably lower than that for depression 
and stress and may be directly related with the characteristics of the study sample 
and treatment protocol. First, the predominant diagnoses in the sample were anxiety 
(94%) rather than depressive disorders (39%) and pretreatment severity of anxiety 
was Severe compared with Moderate pretreatment levels of depression. Thus, there 
was a higher and more severe rate of anxiety than depression in the sample. This 
pattern of diagnoses is not typical of the presentation of depression and anxiety in 
PD, where a higher occurrence of depression has been widely demonstrated 
(Reijinders et al., 2008).  The study intervention featured more depression-based 
activities and specific anxiety modules (e.g., graded exposure) were also removed 
from the original protocol which may have contributed to the lower rate of clinical 
improvement in anxiety among participants. Therefore, the inclusion of more 
anxiety-specific treatment components may have resulted in a higher rate of 
improvement in anxiety. Nevertheless, the majority of participants evidenced 
clinically significant improvement in all primary outcomes across the study period, 
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thus supporting the clinical utility of the study intervention. It must be acknowledged 
however that as normative data used to calculate clinically significant change results 
(i.e., Antony et al., 1988; Crawford et al., 2011) were based on a younger sample 
than study participants (mean age 44.9 years in norms vs. 62 for the study), clinically 
significant change analyses are not as accurate as it would be had there been data 
available to directly compare the study sample with clinical and non-clinical data for 
older adults.This is a limitation of the study. 
 
 5.6.1.5 Immediate vs. delayed treatment start. The final key finding in this 
study relates to the effect of immediate and delayed treatment start. No significant 
differences were found between the trajectory of change for participants who 
commenced CBT immediately following assessments and participants who 
commenced treatment after the waitlist period. This finding is especially encouraging 
as it supports the consistency and real-world applicability of the study intervention in 
that results were equivalent across the three treatment groups, four therapists and 
over the three different treatment time periods. 
 
5.6.2 Limitations 
 While the results of this study support the efficacy of group CBT for the 
treatment of depression and anxiety in PD, there are several limitations which restrict 
the validity of reported results – the most pertinent limitation being the small sample 
size and associated issue of insufficient statistical power. In Chapter 3, the existing 
research base evaluating the utility of CBT for depression and anxiety in PD was 
criticised due to small sample sizes and related methodological limitations regarding 
reliability, validity and generalisability. This study was designed specifically to 
rectify sample size issues and aimed to provide the first methodologically sound 
evaluation of group CBT in PD. Although the current sample is the largest for a 
group CBT intervention in PD at present, it is acknowledged that a total sample of 18 
participants is not sufficient to adequately power an RCT and ultimately restricts the 
confidence with which results can be meaningfully interpreted. Although it is 
encouraging that significant large effect sizes were detected given the small sample 
size, the degree to which these findings can be generalised beyond the current sample 
is restricted. 
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It must be noted that the small sample size in the current study is directly 
linked with significant and unexpected recruitment difficulties. Despite widespread 
recruitment efforts including online, print and radio adverts along with referrals from 
various health professionals over a 28-month period from June 2010 to October 2012 
(see Section 4.2.3.2 for an outline of recruitment strategies), the response rate for the 
study was less than 1%. While reported findings in this study are based on two waves 
of treatment, recruitment was conducted for four planned treatment waves. The 
response to the initial call for participants for Treatment Wave 1 was promising and 
14 participants were randomised to either Intervention or Control. Based on this 
response, it was envisaged that four treatment waves would be sufficient to recruit 
the number of participants required to adequately power the study. However, there 
were no expressions of interest for Treatment Waves 2 and 4. Response to Treatment 
Wave 3 was also poor, with an insufficient amount of participants to conduct an 
Intervention and Waitlist group. Due to time limitations associated with the 
completion of the PhD programme, it was decided in October 2012 that further 
recruitment was not feasible and the available data was analysed. 
 
Similar recruitment difficulties have also been encountered by other 
researchers examining the utility of CBT in PD. Veazey and colleagues (2009) 
reported that of an initial pool of 54 adults with PD who screened positive for anxiety 
and/or depression attending an outpatient specialty neurology clinic in the US, only 
14 participants volunteered to take part in the their CBT trial. Four participants did 
not meet inclusion criteria resulting in an overall sample of 10. The authors stated 
that the difficulty in recruiting and retaining participants for their trial was highly 
unforeseen. Moreover, examination of the literature suggests that low sample sizes 
are common in studies examining the use of CBT in PD.  Across the 16 existing 
studies evaluating specific CBT interventions in PD, sample sizes have ranged from 
only 1 (i.e., Gupta, 2000; Heinrichs et al., 2001; Laidlaw et al., 2003; Mohlman et al., 
2010) to 80 (i.e., Dobkin et al., 2011), with a mean size of only 12 and median of 5.  
 
More broadly, it would appear that this low response rate is also evident in 
clinical trials of other treatments for anxiety and/or depressive disorders in PD. 
Although higher than those reported for trials of CBT, sample sizes across the eight 
RCTs of various pharmacological treatments for anxiety and/or depression in PD 
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patients have ranged from only 12 (Leentjens et al., 2003) to 115 (Richard et al., 
2012., 2009), with a mean of 31. Moreover, recruitment difficulties have also been 
reported in antidepressant trials in PD. Leentjens and colleagues examined the effect 
of the SSRI sertraline for depression in PD and had to terminate their trial due to a 
lack of interest from the public. The authors reported that in spite of intensive 
recruitment efforts over a 30-month period, only 12 people expressed interest in 
participating. 
 
This low response rate for clinical trials of anxiety and depression in PD may 
indicate that there are barriers to seeking psychological treatment among individuals 
with PD. There have been no previous studies examining barriers to psychological 
treatment in PD however the underutilisation of mental health services in older adult 
populations is widely acknowledged (Gurland et al., 1996; Hatfield, 1999; Mickus, 
Colenda, & Hogan, 2000; Robertson & Mosher-Ashley, 2003; Speer & Schneider, 
2003). Several salient barriers to initiating psychological care have been reported 
among older adults including stigma, negative attitudes regarding mental illness, 
financial issues, deteriorating health as well as issues regarding accessibility 
(Woodward & Pachana, 2009), and may have underlay recruitment difficulties 
experienced in the study.  
 
Other limitations in the study must also be noted. First, the absence of an 
active control condition (e.g., attention-matched or alternative psychological 
intervention) inhibits an examination of the effect of non-specific factors on 
participant change across the study period. While it is encouraging that reductions in 
depressive and anxious symptomatology over the study were associated with 
comparable reductions in depressive and anxious thoughts, observed improvements 
cannot be solely attributed to the study intervention at this stage. It may be possible 
that non-specific treatment factors such as social support and therapeutic alliance 
may have also contributed. However, as discussed in Chapter 3, Mohr and colleagues 
(2009) assert that in early efficacy studies, it is sufficient to demonstrate efficacy a 
non-active control to show that an intervention is more advantageous than doing 
nothing. Efficacy against active control conditions must be demonstrated in further 
stages of evaluation.  
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Second, due to ethical and time limitations, the control period for participants 
in the waitlist condition was only eight weeks. Thus, follow-up analyses reported in 
this study are based on uncontrolled data and must be interpreted with caution. Large 
effect sizes were reported at 6-month follow-up for all outcomes except for PDQ-39 
however these effects may be overstated (Butler et al., 2005). Finally, the sample 
predominantly comprised participants in the early stages of PD, with relatively 
unaffected mobility, no treatment-related dyskinesia, no cognitive impairment, high 
quality of life and who were relatively independent. Thus, the degree to which CBT 
may be effective with individuals with PD in the latter stages of disease and more 
pronounced motor and cognitive difficulties is not known. 
 
5.6.3 Directions for Future Research 
Overall, this study adds strong support to the growing body of evidence for 
the efficacy of CBT in treating depression and anxiety in PD. However, there are still 
several phases of research and evaluation to be conducted before CBT can be 
established as an effective treatment approach for depression and anxiety in PD. 
Chapter 3 outlined the phases involved in the experimental investigation of 
psychological therapies (see Mohr et al., 2009). Existing research for group CBT in 
PD was best classified as Phase I efficacy evidence (manual writing and pilot trial). 
This study can best be classified as Phase II evidence for the efficacy of CBT for 
depression and anxiety in PD (preliminary trials).  However, due to the limitations of 
this study, it is recommended that future researchers continue with conducting 
preliminary trials to provide a more methodologically sound estimate of the effect of 
group CBT in PD. Larger sample sizes would provide a more valid estimate of effect 
size, although the detection of significant and large effect sizes in this study is 
promising in light of the small number of participants. Future trials should also 
consider implementing a longer control period in order to provide a more reliable 
assessment of the long-term utility of group CBT for depression and anxiety in PD.   
 
Following this, the next step in establishing the efficacy of group CBT for 
depression and anxiety in PD would be to conduct Phase III research. Phase III 
research involves large efficacy trials across multiple sites with active control 
conditions. There are several important research questions that need to be addressed 
through Phase III trials. First, the effect of non-specific treatment factors on 
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participant change must be examined. Trials directly comparing group CBT with an 
alternate psychological intervention are needed to provide insight into whether the 
active components of CBT (i.e., cognitive mediation) or non-specific factors (e.g., 
attention, support, therapeutic alliance etc.) are responsible for change in outcomes.  
 
Second, trials directly comparing CBT and pharmacotherapy for depression 
and anxiety in PD are needed. Given that pharmacotherapy currently represents the 
first-line treatment for depression and anxiety in PD, it is important to directly 
examine if CBT is more beneficial than current treatment mainstays. At present, it 
would appear that CBT may be more effective than current first-line SSRI treatments 
for the acute treatment of depression and anxiety in PD based on the findings of the 
meta-analysis in Chapter 2, however, a direct comparison will allow a more 
meaningful conclusion to be drawn. Further, it has been argued that the major benefit 
of CBT over pharmacotherapy relates to its long-term utility however empirical 
evidence of this is lacking in PD populations at present. 
 
 Third, trials directly comparing group CBT with individual CBT will be 
useful to examine whether there are any differences in efficacy between the two 
treatment modalities. Thus far, individual CBT has been the treatment modality of 
choice for researchers evaluating CBT for depression and/or anxiety in PD with 80% 
of studies of CBT in PD focusing on Individual interventions while group CBT 
remains understudied. Comparison of effect size estimates between the current study 
and Dobkin and colleagues’ (2011) study suggests that group CBT may be equally 
efficacious as individual CBT for depression and anxiety in PD and warrants further 
investigation of this treatment modality, especially given the clear practical and 
therapeutic benefits of group therapy for older adults as well as individuals with 
chronic illness. 
 
Last, there is also a pressing need for studies specifically investigating the 
treatment of anxiety disorders in PD. As noted in discussion of the meta-analysis in 
Chapter 2, there currently are no RCTs of any treatment interventions specifically for 
anxiety in PD at the present time. Existing randomised controlled trials of 
psychological and pharmacological interventions for anxiety in PD have all focused 
on depression as the primary outcome with the alleviation of anxiety considered a 
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secondary benefit. This study highlights the prevalence and severity of anxiety 
disorders in PD and calls out for appropriate research and clinical attention. While 
depression has been the main focus of psychological researchers in PD, previous 
research has shown that there are additional and unique concerns and problems 
associated with anxiety in PD, that are unrelated to depression, and that have a 
significant impact on quality of life and well-being (Rahman et al., 2008). Thus, 
research solely focusing on the treatment of anxiety in PD is required.   
 
Finally, in addition to continuing empirical investigations of CBT for 
depression and anxiety in PD, there is a pressing need for research investigating 
mental health service utilisation in PD populations. While ongoing development and 
evaluation of optimal treatment options for depression and anxiety is essential to 
ensure that depressive and anxiety disorders are most effectively managed in PD, 
such treatments are only valuable to the extent that they are utilised by the 
individuals they are designed to help. Significant recruitment difficulties encountered 
in this and several previous studies, coupled with the low participation rate in 
treatment trials for depression and anxiety in PD in general, suggest that there may 
be pertinent barriers to seeking psychological care within PD populations. Current 
research has identified several salient barriers to seeking psychological care among 
older adults however there has been no specific study of mental health service 
utilisation among PD populations. Therefore, there is a pressing need for research in 
this area to provide a clearer insight into any factors that may be acting as obstacles 
to quality psychological care in PD. 
 
 
5.7 Chapter Summary 
 
This chapter presented the findings of the first randomised controlled trial of 
group CBT for the treatment of depression and anxiety in PD. Results supported the 
growing body of evidence for the efficacy of CBT in PD and especially highlighted 
the potential of the group therapy treatment modality for individuals with PD. 
 
The current interest in CBT treatments within PD stems from widespread 
criticisms of existing pharmacological regimes for depression and anxiety in PD. 
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This study adds growing support for CBT as a potentially more effective and well-
tolerated treatment approach than first-line SSRI interventions for depression in PD 
over both the acute and follow-up period. Ongoing development and evaluation of 
group CBT is needed in light of the limitations of the study, nonetheless the results 
of this preliminary trial show high promise for the utility of group CBT in treating 
depression and anxiety in PD. 
 
Ultimately, however, effective treatments are only valuable to the extent that 
they are utilised by their target population. Significant recruitment difficulties 
experienced in the study along with a low participation rate in other treatment trials 
for depression and anxiety in PD suggest that there may be pertinent barriers to 
seeking psychological treatment among PD populations. This area of research is yet 
to be explored and would be an instrumental first step in improving the provision of 
quality psychological care for individuals with PD. The next chapter explores 
barriers to seeking psychological treatment in PD in greater depth.  
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CHAPTER 6  |                            
 
Study IV.        An Exploratory Study of Barriers  
                         to Seeking Mental Health Treatment in  
                         Parkinson’s Disease 
 
 
 
6.1 Introduction 
 
Significant recruitment difficulties encountered in Study 3 led to the 
hypothesis that pertinent barriers to mental health treatment may be in place in 
Parkinson’s populations. This chapter presents the findings of a cross-sectional study 
exploring barriers to seeking mental health treatment among a sample of 327 
Australian adults with Parkinson’s disease (PD).  The overarching objective of this 
study was to examine patterns of mental health service utilisation among participants 
and to identify any barriers to seeking that exist in the population of people with PD. 
 
6.2 Overview of Barriers to Seeking Psychological Treatment 
 
It has long been recognised that mental health services are largely 
underutilised (Kessler et al., 2005). Comparisons between the rates of psychological 
disorders and mental health service utilisation show a clear discrepancy between 
clinical prevalence and service usage statistics. According to the Australian Bureau 
of Statistics (ABS; 2007), approximately 7.3 million Australian adults, or 45% of the 
Australian adult population, will be affected by a psychological disorder in their 
lifetime, with approximately 3.2 million (20%) affected by a psychological condition 
in any given 12-month period. The vast majority of Australian adults will not receive 
any form of professional psychological help, however, with research suggesting that 
between 65 and 80% of people who would benefit from psychological help are not 
seeking it (Mackenzie, Knox, Gekoski, & Macaulay, 2004). Between 2006 and 2007, 
the ABS (2007) reported that approximately 2.1 million Australian adults with a 
psychological illness did not seek any mental health treatment despite 
acknowledging a perceived need for professional help.  
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Many factors have been proposed to contribute to the underutilisaiton of 
mental health services and individual pathways leading to the decision to seek or not 
seek treatment are highly idiosyncratic. Broadly, the Theory of Planned Behaviour 
(Azjen, 1991) suggests that help-seeking behaviour can be conceptualised as a 
complex process shaped by the interaction between four factors; (1) intentions to 
seek treatment, (2) personal attitudes regarding mental illness and treatment, (3) 
perception of others’ view of mental illness and treatment (subjective norm), and (4) 
perception of the ease or difficulty of accessing treatment (perceived behavioural 
control; see Figure 12).  
 
 
Figure 12. Psychological Help-Seeking Process as Explained by the Theory of 
Planned Behaviour (Azjen, 1991) 
 
When dealing with voluntary behaviours, intention to perform a given 
behaviour is the strongest predictor of actual behaviour (Azjen, 1991). Thus, help-
seeking behaviour is most accurately predicted from an individual’s intentions to 
seek psychological treatment. Intentions to seek psychological treatment are in turn 
shaped by the individual’s attitudes toward treatment, the subjective norm, and their 
perceived ability to access treatment, with positive attitudes regarding mental health 
and treatment, positive societal views toward psychological treatment and adequate 
resources and opportunities associated with a higher likelihood of seeking 
psychological treatment (Mackenzie, et al., 2004). 
Attitudes toward 
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Consistent with this formulation, studies exploring the underutilisation of 
mental health services have reported that the majority of barriers to seeking 
psychological treatment fall into two broad categories; practical barriers, which are 
obstacles relating to the accessibility and availability of resources, and attitudinal 
barriers, which are cognitive factors such as beliefs and attitudes which hinder help-
seeking (Aupperle, Lifchus, & Coyne, 1998; Nada-Raja, Morrison, & Skegg, 2003). 
 
6.2.1 Practical Barriers to Mental Health Treatment 
Practical barriers to seeking mental health treatment are environmental 
factors affecting the feasibility and accessibility of treatment, and include 
organisational and systemic factors as well as personal variables (Pepin, Segal & 
Coolidge, 2009). Factors at the organisational and systemic level that influence 
mental health treatment utilisation include the availability and provision of services, 
training, availability and funding of qualified clinicians, treatment cost, health 
insurance reimbursement policies, and waiting list times (Parslow & Jorm, 2000). 
Personal factors contributing to the feasibility of seeking treatment include 
socioeconomic status, income, current financial situation, personal health insurance 
coverage, overall health condition, and time and transport availability (Barney, 
Griffiths, Jorm, & Christensen, 2006). 
 
According to Azjen (1991), having adequate access to resources and 
opportunities to perform an intended behaviour strongly enhances the likelihood of 
executing that behaviour. On a psychological level, having adequate access to 
resources and opportunities is proposed to enhance an individual’s confidence about 
their ability to successfully complete the intended behaviour and in turn facilitates 
actual behaviour (Bandura, 1991). According to Pepin and colleagues (2009), 
practical barriers to seeking psychological treatment operate predominantly on the 
personal rather than systemic level in the majority of developed countries where 
adequate mental health facilities and professionals are widely available to the general 
public. Consistent with this, Robb, Chen, and Haley (2002) reported that personal 
financial issues are the most commonly reported practical barrier to initiating 
psychological treatment for adults in developed countries, with a significant 
association between socioeconomic status and help-seeking for psychological 
problems clearly established (Komiya et al., 2000; Parslow & Jorm, 2000). Related 
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to personal financial situation, McAlpine and Mechanic (2000) found that among 
235 adults with schizophrenia or bipolar disorder, health insurance coverage was the 
strongest predictor of mental health service usage. Participants with health insurance 
were found to be between 2.5 and 7 times more likely to access specialty mental 
health services compared with those without coverage. Ultimately, these findings 
have important implications for policymakers to ensure that mental health services 
are accessible and affordable by the general public. 
 
6.2.2 Attitudinal Barriers to Treatment 
While practical concerns relating to cost and health insurance can limit access 
to psychological care for some individuals, it has been suggested that the 
predominant barriers to seeking psychological care within developed countries are 
largely attitudinal rather than practical in nature (Sareen et al., 2007). Attitudinal 
barriers are intrinsic cognitive factors which prevent people from seeking 
psychological treatment, and include personal beliefs, attitudes, values and 
knowledge (Cepeda-Benito & Short, 1998; Pepin et al., 2009). Common attitudinal 
barriers to mental health treatment include a lack of knowledge and/or awareness 
regarding mental illness, negative perceptions of psychological treatment and their 
utility and/or effectiveness, mental illness-related stigma, self-concealment and 
negative help-seeking attitudes (Barney et al., 2006; Komiya et al., 2000).  
 
Large-scale cross-sectional studies have demonstrated that knowledge of and 
attitudes toward mental illness and professional psychological treatment are 
generally poor and/or negative among the wider public. In a cross-sectional study 
examining awareness of and attitudes to depression among 900 Australian adults, 
Highet, Hickie and Davenport (2002) highlighted a significant lack of awareness and 
knowledge deficit regarding depression and other mental health problems in the 
general population. Only half of participants surveyed were able to correctly identify 
the symptoms of depression, almost two-thirds (64%) underestimated the lifetime 
prevalence of depression in Australia, and only 2% of participants identified 
depression and psychological disorders to be a major health concern in Australia. 
Attitudes towards seeking professional psychological help were also generally poor 
with the majority of participants (60%) indicating a preference to turn to families or 
friends rather than mental health professionals as a first-line source of help. 
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Studies investigating attitudinal barriers to seeking psychological help have 
identified two predominant attitudinal barriers to seeking psychological treatment in 
particular; mental illness-related stigma and negative help-seeking attitudes. 
 
6.2.2.1 Stigma. Mental illness-related stigma refers to negative beliefs and 
attitudes regarding psychological illness and individuals with such illnesses (Conner 
et al., 2010). Two forms of mental illness-related stigma have been defined; public 
stigma and self-stigma (Corrigan, 2004). Public stigma is synonymous with the lay 
definition of stigma which is the negative perception of mental illness and people 
with mental illnesses by others in a community (Conner et al.), while self-stigma 
describes the negative perception of oneself by individuals with mental illnesses as 
they internalise negative public stereotypes (Corrigan, 1998).  
 
Studies investigating public beliefs about mental illness have found that an 
unfavourable stigma is generally attached to individuals with psychological 
disorders. In a previous study, mental health stigma was found to be greater than the 
stigma associated with having a medical condition and of comparable stigma as 
criminal activity (Roeloffs et al., 2003). Similarly, in a review of 62 studies 
investigating lay beliefs about mental illness, Angermeyer and Dietrich (2006) found 
that the majority of the general public viewed people with psychological disorders to 
be weak, in need of help and dependent on others (Angermeyer, Beck, & 
Matschinger, 2003), unpredictable and unstable (Crisp, Gelder, Rix, Meltzer, & 
Rowlands, 2000), and to a lesser extent, violent and dangerous (Borinstein, 1992; 
Gaebel & Baumann, 2003; Stuart & Arboleda-Florez, 2001). Members of the general 
public also reported feelings of unease, uncertainty and fear towards individuals with 
mental illnesses as well as a tendency to distance themselves from such individuals 
in social contexts (Jorm, Angermeyer, & Katschnig, 2000). Public stigma typically 
results in negative actions against individuals with mental illnesses including 
stereotyping, prejudice, exclusion, and discrimination (Corrigan, 2004). 
 
Negative public perceptions of mental illness can in turn result in the 
development of self-stigmatising attitudes in individuals with mental illness. 
Corrigan, Watson and Barr (2006) assert that individuals with mental illness can 
often internalise negative societal views and subsequently develop unfavourable 
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views of themselves. Most commonly, self-stigmatising individuals with mental 
illness can often view themselves as weak, inadequate and socially inferior as a result 
of prevailing negative attitudes (Vogel, Wade, & Haake, 2006). Self-stigma has also 
been associated with a significant decrease in self-esteem, self-efficacy, self-worth 
and general psychological well-being (Link, Struening, Neese-Todd, Asmussen, & 
Phelan, 2001; Markowitz, 1998; Ritsher, Otilingam, & Grajales, 2003). In addition, 
self-stigma also manifests as feelings of shame, embarrassment, secrecy and the need 
for self-concealment (Corrigan, 2004). 
 
Research exploring the link between mental illness-related stigma and mental 
health service utilisation has shown that both perceived public stigma and self-stigma 
are significant barriers to seeking psychological care (Conner et al., 2010). In terms 
of public stigma, it has been suggested that individuals with mental illness who 
believe that others will view and/or respond to them negatively because of their 
psychological status (i.e., perceived public stigma) may avoid seeking treatment in 
order to evade negative judgement from others (Komiya et al., 2000; Vogel et al., 
2006; Vogel, Wester, Wei, & Boysen, 2005). Cooper, Corrigan and Watson (2003) 
refer to this phenomenon as ‘label avoidance’ which is the tendency to deny 
psychological problems and avoid treatment in order to avoid being labelled with the 
negative characteristics associated with having a mental illness. Consistent with this, 
a number of empirical studies have reported that the views and reactions of other 
people is a significant contributory factor in the decision to seek psychological 
treatment (Chadda, Agarwal, Singh, & Raheja, 2001) and can often act as a deterrent 
to seeking psychological care for a significant number of people with mental illness. 
 
Self-stigma has been found to act as a significant barrier to seeking 
psychological care for a similar reason to perceived public stigma however rather 
than attempting to avoid negative reactions from others, it has been hypothesised that 
self-stigmatising individuals may avoid seeking treatment in order to preserve or 
maintain a positive self-image (Vogel et al, 2006). Seeking professional help for 
mental health issues may be seen by self-stigmatising individuals as a threat to one’s 
self-esteem in that requiring help from another person is internalised as a sign of 
weakness, inferiority or failure (Fisher et al., 1982). These individuals may thus 
avoid or delay seeking treatment to prove to themselves that they are not weak, with 
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Vogel and colleagues suggesting that the admission of needing help may be 
perceived as more detrimental than the experience of psychological symptoms in 
itself for self-stigmatising individuals. Consistent with this, several empirical studies 
examining self-stigma and help-seeking behaviour have reported that people were 
less likely to seek help when they anticipated that help-seeking would make them 
feel inferior or incompetent (Karabenick & Knapp, 1991).  
 
While both perceived public stigma and self-stigma have been associated 
with treatment non-utilisation, self-stigma is generally considered to be a stronger 
barrier to seeking psychological treatment (Schomerus, Matschinger, & Angermeyer, 
2009). For example, Bayer and Peay (1997) examined factors contributing to the 
likelihood of seeking professional mental health treatment in a community sample of 
142 adults and found that personal attitudes towards seeking treatment were a 
stronger predictor of treatment use than subjective norms. Similarly, in a more recent 
large-scale internet-based study of 10,962 participants, Van Voorhees and colleagues 
(2006) reported personal attitudes towards mental health treatment were stronger 
predictors of perceived need for treatment than the opinion of others. Likewise, 
Barney and colleagues (2006) found that self-stigma was the strongest predictor of 
reduced likelihood of seeking help from a wide range of mental health professionals 
including general practitioners, counsellors, psychologists, psychiatrists and 
complementary practitioners. Thus, individual beliefs regarding psychological 
treatment and its perceived consequences appear to play a more pivotal role in the 
help-seeking decision-making process than approval or disapproval from others. 
 
6.2.2 Help-seeking attitudes. Studies exploring treatment underutilisation 
have focused particularly on the role of help-seeking attitudes in predicting mental 
health service use. Help-seeking attitudes can be described as a multidimensional set 
of personal beliefs reflecting an individual’s overall disposition towards seeking 
professional psychological care (Currin, Hayslip, Schneider, & Kooken, 1998). 
According to Mackenzie and colleagues (2004), an individual’s overall attitude 
towards seeking psychological help is represented by three factors; their 
psychological openness, help-seeking propensity and indifference to stigma. 
Psychological openness refers to the degree to which an individual is receptive to 
psychological experiences, whether positive or negative. Help-seeking propensity 
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describes the individual’s overall willingness and ability to seek professional help, 
and indifference to stigma refers to the extent to which the individual is not affected 
by others’ views regarding seeking psychological treatment. A person with positive 
psychological help-seeking attitudes is described as one who exhibits high levels of 
psychological openness and help-seeking propensity while showing low concern 
over others’ reactions to their help-seeking behaviour (Mackenzie et al.).  
 
A growing body of research has found that help-seeking attitudes are the 
strongest and most consistent predictor of treatment utilisation or non-utilisation, 
with a strong positive correlation reported between help-seeking attitudes and mental 
health service utilisation (e.g., Deane & Todd, 1996; Diala et al., 2000; Komiya et 
al., 2000; Rickwood & Braithwaite, 1994; Vogel et al., 2005). For example, in a 
study exploring the influence of help-seeking attitudes on the underutilisation of 
mental health services among 206 community-dwelling adults, Mackenzie, Gekoski 
and Knox (2006) found that help-seeking propensity (i.e., an individual’s willingness 
to seek professional psychological help) was the strongest unique predictor of 
intentions to visit a mental health professional over other factors including past use 
of services and psychiatric symptomatology. Similarly, in a recent large-scale 
epidemiological survey of 21 000 adults living in six European countries, Ten Have 
and colleagues (2010) found that individuals who were open about their emotional 
and psychological problems (i.e., ‘would feel comfortable talking about personal 
problems’) were 1.8 times more likely to have used mental health services. Most 
significantly, it was found that individuals who displayed a propensity to seek 
psychological help (i.e., ‘would go for professional help in case of a serious 
emotional problem’) were 3 times more likely to have utilised professional 
psychological services than those with more negative help-seeking attitudes.  
 
6.3 Barriers to Seeking Mental Health Treatment among Older Adults 
 
Of particular relevance to barriers to psychological treatment in PD is the 
literature on mental health service utilisation in older adults. While the 
underutilisation of mental health services in the general population is concerning, 
statistics show that older adults with psychological disorders are even less likely to 
receive specialty mental health care (Gurland et al., 1996; Hatfield, 1999; Robertson 
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& Mosher-Ashley, 2003; Schneider, 1997). Early studies based on data from the 
United States estimated that between only 3 and 8% of adults aged 65 and over 
reported visits to mental health professionals in the preceding year (Lasoski, 1986; 
Lebowitz et al., 1997). More recent studies have reported an increase in the rate of 
mental health service utilisation among contemporary older adults; however, younger 
adults are still more than twice as likely to seek professional psychological help 
(Robb et al., 2003). Moreover, among older adults who do utilise mental health 
services, there is a general tendency to exclusively consult general medical 
practitioners and concentrate solely on the treatment of physical and somatic aspects 
of mental illness (Mickus, Colenda, & Hogan, 2000; Woodward & Pachana, 2009).  
 
As with barriers to psychological care in the general population, both 
practical and attitudinal barriers to seeking psychological help have been described in 
older adult populations. However, attidunal factors have been identified as the most 
salient barriers to psychological care among older adults and include significant 
knowledge deficits and negative mental illness-related attitudes (Hayslip, Maiden, 
Thomison, & Temple, 2010; Robertson & Mosher-Ashley, 2003). 
 
6.3.1 Attitudinal Barriers to Seeking Treatment among Older Adults 
 Negative attitudes towards mental illness and psychological treatment have 
long been recognised among older adults. Early studies found that older adults 
exhibited less psychological openness than younger adults. For example, Hayslip, 
Ritter, Oltman and McConnel (1980) reported that the majority of older adults did 
not view mental health as an important need while Waxman and colleagues (1984) 
found that older adults generally held lower opinions of the effectiveness of 
psychological interventions. Early studies also identified a significant lack of 
knowledge regarding psychological treatment among older adults. For example, a 
substantial proportion of surveyed older adults indicated that all mental health 
treatment is conducted in ‘insane asylums’ (e.g., Woodruff et al., 1988) or custodial 
institutions (e.g., Lasoski, 1986). A lower help-seeking propensity for psychological 
problems has also been reported among older adults. Ray, Raciti and MacLean 
(1992) explored help-seeking decisions among a sample of 110 adults aged over 65 
and found that only 15% of participants indicated they would go directly to a mental 
health professional for help with psychological problems, with the majority opting to 
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seek support within their social network or to work through their difficulties on their 
own. The authors also found that older adults tended to blame themselves for their 
psychological problems and thus believed it was their responsibility to deal with their 
troubles on their own.  
 
In addition, mental illness-related stigma has been found to be a particularly 
pertinent barrier to seeking psychological treatment among older adults (Hayslip et 
al., 2010; Sirey, Bruce, Alexopoulos, Perlik, Friedman, & Meyers, 2001). The World 
Health Organisation and World Psychiatric Association have both acknowledged that 
stigma and discrimination against older adults with psychological illnesses is 
widespread and has significant negative consequences for older adults’ self-esteem, 
quality of life as well as help-seeking behaviours (Depla et al., 2005; Link et al., 
2001). Similarly, the United States Surgeon General report identified mental illness-
related stigma as a ‘powerful obstacle’ to seeking psychological care among older 
adults (US Department of Health and Human Services, 1999).  
 
Both perceived public stigma and self-stigma have been reported in older 
adult populations. In a comparison of mental illness beliefs between a group of 
undergraduate students and community dwelling adults aged 60 years and over, 
Segal, Coolidge, Mincic and O’Riley (2005) found that older adults perceived 
individuals with psychological disorders to be significantly more embarrassing, 
socially undesirable and socially unskilled than the younger group. In particular, self-
stigmatising attitudes regarding mental illness are suggested to be widespread among 
older adults (Depla et al., 2005). Early studies found that older adults tended to 
regard seeking treatment for psychological problems as a sign of personal failure, 
weakness and/or spiritual inadequacy (Currin et al., 1998; Woodruff et al., 1988) and 
that engagement in psychological treatment is seen as a ‘disgrace’ (Kahn, 1975). 
Studies have also found that older adults indicated they would feel shameful, fearful 
and embarrassed if they were to have a mental illness (Hatfield, 1999).  
 
It has been suggested that widespread negative societal views prevalent prior 
to the deinstitutionalisation of mental illness may underlie these stigmatising and 
negative help-seeking attitudes among older adults (Morris, 2001). In support, more 
recent studies have found that both knowledge of mental illness and help-seeking 
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attitudes in contemporary older adult samples are significantly more positive than 
those reported 14 years prior (e.g., Currin et al., 1998). There is also evidence of a 
decline in mental illness-related stigma among contemporary older adults (e.g., Sirey 
et al., 2001). Moreover, recent studies have also found that there are no longer 
significant differences between the help-seeking attitudes of younger and older adults 
(e.g., Segal et al., 2005) or even, that older adults report more positive help-seeking 
attitudes than younger adults (e.g., Mackenzie et al., 2006). In a study of 
psychological help-seeking attitudes and treatment beliefs among 1341 community 
dwelling adults aged 55 and older, Mackenzie, Scott, Mather and Sareen (2008) 
reported that more than 80% of participants had positive attitudes towards seeking 
professional psychological help and more than 70% had positive treatment beliefs. 
Similarly, Sirey and colleagues compared perceived public stigma of mental illness 
between older and younger outpatients with major depressive disorder and reported 
lower levels of perceived public stigma among participants aged 65 and over. 
However, perceived public stigma was a significant predictor of treatment 
discontinuation among older participants while it was not significantly associated 
with treatment use in younger participants. Thus, while a decrease in mental illness-
related stigma has been observed among older adults in recent times, stigma remains 
a significant barrier to psychological care for older individuals.  
 
6.3.2 Practical Barriers to Seeking Psychological Treatment for Older Adults 
In addition to attitudinal barriers, several practical obstacles also affect the 
accessibility of psychological treatment for older adults. The most significant of 
these barriers has been suggested to be comorbid chronic illnesses (Choi & 
Gonzalez, 2001; Mohr et al., 2006), which is particularly relevant to PD populations. 
 
6.3.2.1 Chronic illness. Chronic illnesses are markedly prevalent among 
older adults. According to Chodosh and colleagues (2005), approximately 79% of 
community dwelling older adults over the age of 70 report having at least one 
chronic illness. There are several elements of having a chronic illness that can act as 
potential barriers to seeking psychological help for older adults, including both 
practical (e.g., increased functional impairment, transportation issues, costs of 
additional treatment) and attitudinal factors (e.g., an overshadowing concern for 
physical symptoms; Greenberg, 2004; Mohr et al., 2006).  
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In terms of the practicality of accessing treatment for psychological problems, 
increased functional impairment can make it difficult to travel to treatment facilities. 
Lasoski (1986) asserts that due to increased physical limitations, older adults often 
require the assistance of others for transportation and difficulties with arranging 
transport can hinder treatment imitation and/or lead to discontinuation. The cost of 
additional treatment may also be a significant obstacle to seeking psychological care 
for many older adults with comorbid chronic and psychological illness (Katon, 
2000). A multitude of studies have shown that older adults with depression have 
significantly higher medical costs than older adults without a psychological diagnosis 
(e.g., Callahan et al., 1994; Ciechanowski, Katon, & Russo, 2000; Katon et al., 1990; 
Simon, Von Korff, & Barlow, 1995). These costs are even higher for older adults 
with comorbid chronic and psychological conditions with Sullivan, Simon, Spertus 
and Russo (2002) showing that older adults with congestive heart failure and 
depression incurred between 26 to 29% higher medical costs than older adults with 
congestive heart failure alone over a 3-year period.  
 
Attitudinal variables associated with having a chronic illness may also hinder 
initiation of psychological treatment among older adults. It has been shown that the 
majority of the general public regard physical illnesses a higher priority than 
psychological disorders. For example, in an Australian survey of 900 adults, Highet 
and colleagues (2002) found that when questioned over the “major health problem(s) 
in Australia at present”, 98% of respondents indicated a physical illness. Thus 
concerns for physical illness often overshadow treatment-seeking for any 
psychological complications in individuals with comorbid medical and psychological 
diagnoses. This overshadowing concern for physical symptoms has also been 
observed on behalf of treating medical physicians with Himelohoch, Weller, Wu, 
Anderson and Cooper (2004) observing that the majority of physicians prioritised 
medical problems during time-limited encounters. Similarly, an early study by 
Maguire (1985) found that general physicians working with cancer patients admitted 
that they would not generally discuss psychological or emotional difficulties and 
assumed that a patient requiring psychological help would consult them. When 
patients did raise emotional concerns, Maguire noted that physicians often employed 
‘distancing strategies’ including switching the topic of conversation, prematurely 
reassuring or ignoring cues. Maguire also suggested that a fear of stigmatisation from 
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medical professionals can as a potential barrier to seeking psychological treatment 
among individuals with chronic illness, with cancer patients reluctant to disclose any 
psychological problems to their primary physician as they believed it would make 
them appear ‘weak willed’, ‘crazy’ or ‘not strong enough’ to cope with their cancer. 
Thus, attitudinal variables on behalf of both patients and doctors can often serve as 
significant barriers to psychological treatment for individuals with comorbid physical 
and psychological illnesses. 
 
6.3.2.2 Organisational barriers. In addition to chronic illness-related 
barriers, there are also several structural and organisational obstacles to accessing 
psychological care for older adults. These include; a shortage of geriatric mental 
health services, lack of qualified mental health professionals trained to work with 
older adults and a lack of referrals by medical physicians to existing mental health 
facilities (Crabb & Hunsley, 2006; Qualls et al., 2002). 
 
 According to Woodward and Pachana (2009), there is a severe shortage of 
specialist geriatric mental health services in Australia. This shortage is also mirrored 
globally, with Lima, Levav, Jacobsson and Rutz (2003) stating that geriatric mental 
health services across Europe are lacking and/or underdeveloped with only 65% of 
European nations offering specialist mental health services for older adults. In 
contrast, all European countries have specialist psychological services for children 
despite older adults comprising a larger proportion of the population. Corrigan, 
Watson, Warpinski and Gracia (2004) suggest that the lack of specialist mental 
health services for older adults is directly related to a lack of funding for such 
services and reflects unequal resource allocation and systemic discrimination against 
mental health care for older adults by policymakers and government bodies.  
 
Discrimination has also been suggested to be evident in the structure of 
training programmes for psychological and psychiatric professionals (Woodward & 
Pachana, 2009). In a review of Australian postgraduate clinical psychology 
programmes, Kneebone (1996) reported that only 3% of a standard two-year Masters 
programme was dedicated to mental health problems in older adults. Similarly, Lima 
and colleagues (2003) found that only 10% of the psychiatry residency programme in 
Europe involved training in older adult psychopathology. The shortage of qualified 
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professionals may also in part be related to negative attitudes regarding geriatric 
mental health among health professionals themselves (Snowdon, Ames, Chiu, & 
Wattis, 1995). Studies have shown that trainee professionals including medical, 
psychology, and nursing graduates generally indicate that working with older people 
is their least preferred area of specialty (Lee, Volans, & Gregory, 2003). Finally, 
ageist attitudes regarding psychological illness in older adults among medical 
physicians and mental health professionals can also act as a barrier to psychological 
care for older adults. According to Ferguson and Koder (1998), only 8% of all 
general practitioner (GP) referrals to psychologists in Australia comprise adults over 
the age of 50, with GPs generally preferring to treat older people with psychological 
difficulties in primary care using pharmacotherapy due to belief that cognitive, 
personality and behaviour change through psychological intervention is less likely to 
be successful in older people who are more ‘set in their ways’ and have stronger and 
more established personalities than younger adults (Steuer et al., 1984).  
 
 
6.4 The Present Study: An Exploration of Barriers to Seeking  
Mental Health Treatment in PD 
 
The research presented in the preceding section provides a broad 
understanding of the factors that may be preventing people with PD experiencing 
psychological difficulties from seeking professional help. Specifically, limited 
knowledge regarding mental illness and contemporary treatment options, negative 
help-seeking attitudes, mental illness-related stigma as well as various factors 
associated with chronic illness and concerns for physical health have all been 
identified as significant obstacles to seeking psychological care among older adults. 
However, specific investigations into mental health service utilisation among 
individuals with PD are lacking in the literature at the present moment and are duly 
needed to provide a clearer insight into any factors that may be contributing to 
mental health service underutilisation in this population.  
 
There are several unique aspects of clinical management in PD that may be 
contributing to the undertreatment of psychological complications. First, due to the 
traditional conceptualisation of PD as a motor disorder, an overshadowing concern 
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for physical sympoms has been previously observed on behalf of both treating 
medical physicians and individuals with PD themselves (Frisina et al., 2008). 
Relatedly, there is also a general lack of awareness that an extensive range of non-
motor symptoms also comprise part of the clinical picture of PD, with Chaudhuri and 
Schapira (2009) stating that up to 62% of non-motor complications are not declared 
to PD physicians as patients are unaware that such symptoms are linked to PD. 
Underrecognition and underreporting of psychological symptoms thus place a greater 
onus on medical physicians to detect any comorbid psychological complications. 
However, unlike other medical conditions that can be primarily managed by a 
general practioner, the primary health providers for people with PD are neurologists, 
whose expertise lie in treatment of the motor manifestations of PD. Thus, again, 
there is an overshadowing emphasis on the treatment of physical symptoms during 
medical consultations in PD with Shulman and colleagues (2002) reporting that over 
half of a sample of 101 PD neurologists in their study had never discussed 
psychological complications in PD with their patients. Finally, as the primary 
symptoms of PD are related to motor dysfunction, individuals with PD often 
experience greater functional and/or physical impairment compared with people with 
other chronic illnesses and this may impact on their ability to physically access 
mental health services. 
 
There have only been two studies investigating mental health service 
utilisation in PD. Qureshi, Amspoker, Calleo, Kunik and Marsh (2012) examined 
general health care utilisation among a sample of 273 male veterans with PD and 
reported that only 12.8% of the sample had reported any visits to a mental health 
outpatient facility during the study period. The rate of mental health service 
utilisation was higher among a subsample of participants who currently met ICD-9 
diagnostic criteria for a depressive disorder at 32.3% however it would still remain 
that over two-thirds of participants with a depressive disorder were not currently 
engaged in any form of professional treatment, thus confirming the underutilisation 
of mental health services in PD. This study was primarily aimed at investigating 
general health care utilisation in PD, however, as well as used a highly selective and 
unrepresentative sample (i.e., veteran males with PD) which ultimately restricts the 
generalisability of findings beyond the study sample.  
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Most recently, Dobkin and colleagues (2013) published a large-scale study 
examining several purported barriers to mental health care utilisation among a 
sample of 883 individuals with PD in the United States. In regards to future 
treatment, the three most frequently perceived barriers were concerns in relation to 
high out of pocket costs, sensitivity issues, and a lack of local services. The most 
common reasons for not seeking treatment in the past were low mental health 
literacy/problem recognition, and again cost, and sensitivity concerns. This study was 
the first to examine barriers to mental health service utilisation in a PD sample and 
provided valuable insight into factors that may be preventing treatment usage. 
However, the authors’ analysis was limited to describing the frequency with which 
each purported barrier was endorsed in the sample and examining predictors of each 
barrier, rather than examining the predictive relationship between each barrier and 
service utilisation or non-utilisation. Moreover, important attitudinal barriers to 
seeking mental health care among older adults such as stigma and negative help-
seeking attitudes were not assessed. 
 
The present study is the first to examine mental health service utilisation 
among an Australian PD sample. The aim of the study was to explore factors 
contributing to willingness to seek professional psychological treatment and to 
identify any significant barriers to treatment that may have underlay recruitment 
difficulties experienced in Study 3. 
 
 
6.5 Methodology 
 
6.5.1 Research Design  
 This study was a cross-sectional survey exploring patterns of mental health 
utilisation and barriers to treatment of depression and anxiety among a PD sample.  
 
6.5.2 Participants and Procedure 
 A non-probability convenience sample was used. A questionnaire package 
was assembled and mailed out to all members of Parkinson’s Western Australia 
(PWA) following ethical approval from both the Curtin University HREC and PWA 
research committee. In total, 950 questionnaire packages were sent out. The 
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questionnaire package consisted of a cover letter, participant information sheet, 
questionnaire and reply-paid envelope. The information sheet outlined the nature of 
the research and invited PWA members to participate by completing and returning 
the enclosed questionnaire. A link to a web-based version of the questionnaire was 
provided for participants who preferred to submit their responses online. A gourmet 
teabag was included with each package to thank participants for their time. In 
addition, Parkinson’s Associations across Australia were contacted and asked to post 
a link to the online questionnaire on their websites. The questionnaire was 
anonymous and no personally identifying details were collected. The information 
sheet clearly outlined that (i) submission of responses was deemed consent to use the 
individual’s data in the study, and (ii) due to the anonymous nature of the survey, 
participants will not be able to request their responses be excluded from the research 
at a later date. Questionnaire packages were disseminated to PWA members in 
October 2012. Participants were given three months to return questionnaires. Data 
collection was completed in December 2012. 
 
 
6.5.3 Measures 
 The questionnaire package used in the study consisted of seven components: 
1. A demographic and medical history questionnaire 
2. DASS-21 (Lovibond & Lovibond, 1995) 
3. PDQ-39 (Jenkinson et al., 1995) 
4. Inventory of Attitudes towards Seeking Mental Health Services 
(Mackenzie, Knox, Gekoski, & Macaulay, 2004) 
5. Needs Survey (Weinberger, Nelson, & Roth, 2011) 
6. Depression Stigma Scale (Griffiths, Christensen, Jorm, Evans, & 
Groves, 2004) 
7. Self-Stigma of Depression Scale (Barney, Griffiths, Christensen, & 
Jorm, 2010) 
 
The demographic and medical history questionnaire and adaptation of the 
Needs Survey used in the study appear in Appendix F. All other scales are available 
in the public domain.  
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 6.5.3.1 Demographic and medical history questionnaire. The demographic 
and medical history questionnaire consisted of four sections. Section A asked about 
demographic information (e.g., age, gender, relationship status, employment and 
children). Section B contained questions relating to participants’ PD history 
including age of diagnosis, relatives with PD, current symptoms and current PD 
medication. Section C examined general medical history and Section D asked about 
participants’ psychiatric history and treatment preferences including past/current 
diagnoses, current psychiatric medications, usage of mental health services and 
preferred treatment modality (i.e., pharmacotherapy or psychotherapy). Willingness 
to seek mental health treatment was also assessed by the question ‘Would you be 
willing to see a mental health professional (e.g., psychiatrist, psychologist, 
counsellor) for help with psychological problems?’. 
 
6.5.3.2 DASS-21 and PDQ-39. Chapter 4 provides a detailed description of 
the DASS-21 and its validity and reliability in PD. The PDQ-39 was described in 
detail in Chapter 5.2.6.2. 
 
6.5.3.3 Inventory of Attitudes towards Seeking Mental Health Services 
(IASMHS). The IASMHS is a 24-item scale measuring attitudes towards seeking 
professional psychological help and was developed based on Azjen’s (1991) Theory 
of Planned Behaviour (TPB) specifically for the prediction of mental health service 
utilisation. The scale comprises three subscales measuring the three components of 
TPB, namely, Psychological Openness (attitudes), Indifference to Stigma (social 
norms) and Help-Seeking Propensity (perceived behavioural control). 
 
Two subscales of the IASMHS were used to assess help-seeking attitudes in 
the present study; Psychological Openness and Help-Seeking Propensity. The 
Indifference to Stigma subscale was not used as two other more comprehensive 
stigma measures were also included in the study. The Psychological Openness factor 
comprises eight items measuring an individual’s openness to acknowledging and 
experiencing psychological problems e.g., “There are certain problems which should 
not be discussed outside of one’s immediately family”. The Help-Seeking Propensity 
factor comprises eight factors measuring the degree to which an individual is willing 
and able to seek help for psychological problems from a mental health professional 
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e.g., “I would have a very good idea of what to do and who to talk to if I decided to 
seek professional help”. Items are rated on a 5-point Likert scale ranging from 0 
(disagree) to 4 (agree). Possible scores for each factor range from 0 to 32, with 
higher scores indicating more positive help-seeking attitudes. Both subscales of the 
IASMHS demonstrated excellent internal consistency within the present sample with 
α = .77 (Help-Seeking Propensity) and α = .83 (Psychological Openness). 
 
6.5.3.4 Needs Survey. The Needs Survey by Weinberger and colleagues 
(2011) was originally developed to examine perceived barriers to treatment of 
psychological distress in prostate cancer patients and was adapted for PD in the 
present study. The measure comprises 35 items examining attitudes to the treatment 
of mental health problems in addition to a primary medical condition and was used to 
provide insight into whether chronic illness-related barriers may be contributing to 
low mental health service usage rates in PD populations. The Needs Survey assesses 
nine categories of barriers: Weakness (e.g., “It is a sign of weakness to talk with a 
mental health professional about emotional distress”), Health/Life Benefits (e.g., “I 
can afford to pay for treatment for mental health problems”), Efficacy (e.g., “I 
believe that treatment for emotional problems will help me”), Dependency (e.g., “I 
don’t want to become dependent on psychiatric medication”), Doctor’s Reaction 
(e.g., “Most doctors want to hear about any problems a patient is having in addition 
to those related to Parkinson’s”), Stigma (e.g., “I don’t want to get treatment for 
mental health problems because my family and friends will think I am crazy”), 
Access/Logistics (e.g., “I would rather not seek help for emotional problems because 
it is too difficult getting around to see yet another doctor”), Side Effects (e.g., “I 
worry about becoming too sedated from psychiatric medications”) and 
Miscellaneous/Concern for physical illness (e.g., “Getting help for emotional 
problems will take away time and energy that I need to spend coping with PD”).  
 
The Needs Survey was selected for the present study as it was the only 
measure available in the literature which examined treatment of mental health 
problems in addition to a primary medical condition. Therefore, in addition to 
general practical (e.g., access, logistics, health benefits) and attitudinal barriers (e.g., 
stigma, weakness, efficacy), the survey also examined chronic/medical illness-related 
barriers such as the perception that patients’ primary physical illness may be more 
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important than their psychological distress, concerns about the medical physician’s 
reactions, and concerns regarding drug/treatment interactions.  
 
In this study, the Needs Survey was administered using a 5-point Likert scale 
ranging from 0 (strongly disagree) to 4 (strongly agree) rather than the dichotomous 
‘Yes/No’ nature in the original questionnaire. Total scores for each factor were 
computed by summing the relevant items, dividing summed scores by the maximum 
score for each factor and multiplying by 10 to produce a rating ranging between 0 
and 10, with higher scores indicating greater concern for the respective factor.  
 
6.5.3.5 Depression Stigma Scale (DSS). The DSS is an 18-item scale 
measuring stigma toward depression and comprises two subscales; Personal Stigma 
and Perceived Stigma. The Perceived Stigma subscale was used to measure 
participants’ perceived public stigma towards depression and anxiety in the present 
study. The scale consists of nine items assessing beliefs about the way depression 
and mental illness is perceived by others. Examples of items include “Most people 
believe that people with depression are dangerous” and “Most people believe that 
depression is a sign of personal weakness”. Items were rated on a 5-point Likert scale 
ranging from 1 (strongly disagree) to 5 (strongly agree). Total subscale scores ranged 
from 5 to 45 with higher scores indicating a higher level of perceived public stigma. 
The Perceived Stigma subscale of the DSS has shown evidence of sound 
psychometric properties with reports of excellent internal consistency (α = .82; 
Griffiths et al., 2004) and good test-retest reliability over a 5-week period in both 
community (r = .67) and clinical samples (r = .73; Griffiths et al.). The DSS-
Perceived Stigma subscale also demonstrated good internal consistency within the 
present sample (α = .76). 
 
6.5.3.6 Self-Stigma of Depression Scale (SSDS). The SSDS is a 16-item 
scale measuring the extent to which an individual internalises negative stereotypes 
about depression/mental illness across four factors; Shame, Self-Blame, Social 
Inadequacy, and Help-Seeking Inhibition.  Three subscales of the SSDS (Shame, 
Self-Blame and Social Inadequacy) were used to assess how participants would feel 
about themselves if they had depression or anxiety. The Help-Seeking Inhibition 
subscale was excluded as the IASMHS provided a more comprehensive assessment 
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of help-seeking attitudes. Each subscale of SSDS consisted of four items. Examples 
of items include “If I had depression or anxiety, I would feel ashamed” (Shame), “If I 
had depression or anxiety, I think I would only have myself to blame” (Self-blame), 
and “If I had depression or anxiety, I would feel inadequate around other people” 
(Social inadequacy). Items were rated on a 5-point Likert scale ranging from 1 
(strongly disagree) to 5 (strongly agree). Total subscale scores ranged from 4 to 20 
with higher scores indicative of a higher degree of self-stigma. Within the present 
sample, the three SSDS subscales showed strong evidence of internal consistency 
with α = .87 (Shame), α = .84 (Self-Blame), and α = .72 (Social Inadequacy). 
 
 
6.6 Data Analysis  
 
6.6.1 Confirmatory Factor Analysis 
 As all scales used in this study apart from the PDQ-39 have not previously 
been validated in PD samples, confirmatory factor analyses (CFA) were conducted to 
verify the factor structure of each scale within the sample. CFA was conducted using 
structural equation modelling (SEM) using EQS 6.1.. Principal Components Analysis 
(PCA) was used to examine the structure of the Needs Survey and DSS as these 
scales do not measure an underlying latent variable. PCA was conducted using SPSS 
19.0. 
 
 6.6.1.1 Structural equation modelling. SEM was used to verify the factor 
structure of the IASMHS and SSDS in the current sample. Maximum Likelihood was 
the estimation method employed. The Yuan-Bentler correction (Yuan & Bentler, 
1998) was applied to Maximum Likelihood estimates where the assumption of 
multivariate normality was not met. Model fit was assessed via three indices; the χ² 
statistic, CFI and RMSEA (see Chapter 4.4.4.3).  
 
 6.6.1.2 Principal components analysis.  To test the structure of the Needs 
Survey and DSS within the current sample, two separate PCAs were run using the 
Principal Components method of extraction with Varimax rotation with Kaizer 
normalisation. In each PCA, the number of components to be extracted was specified 
beforehand in accordance with the a priori structure posited by each scale’s 
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developers. Adequacy of fit was assessed by inspection of component loadings to 
determine whether each item loaded onto the hypothesised component. 
 
6.6.2 Predictors of Willingness to Seek Future Psychological Treatment in PD 
Predictors of willingness to use mental health services were examined using a 
sequential logistic regression analysis. Logistic regression provides an examination 
of the impact of a set of independent variables on a dichotomous outcome 
(Tabachnick & Fidell, 2011). Sequential logistic regression is analogous to 
hierarchical multiple regression whereby order of entry of predictors is selected 
based on theoretical grounding. 
 
6.6.2.1 Assumption testing. Logistic regression is more flexible than 
standard regression analyses and requires fewer assumptions. Specifically, normality, 
linearity and homoscedasticity of predictors are not required, however, independence 
of observations, absence of outliers and multicollinearity and an adequate cases to 
predictors ratio are still required (Tabachnick & Fidell, 2011). In addition, logistic 
regression also requires the assumption of linearity in the logit which refers to a 
linear relationship between continuous predictors and the logarithmic transformation 
of the dependent variable (Tabachnick & Fidell).  
 
The ratio of cases to predictors was computed by dividing the sample size by 
the number of predictors in the final regression model. Coakes and Steed (2003) 
suggest a 1:20 ratio to ensure cross-validity of results. Independence of observations 
was not formally assessed but assumed as part of the design of the study whereby 
respondents completed the questionnaire at home and thus responses were not likely 
to be influenced by other participants. Univariate outliers were examined via 
inspection of standardised residuals for cases greater than 3.29 standard deviations 
above or below the mean. Multivariate outliers were assessed through inspection of 
the Mahalanobis Distance statistic and Cook’s distance value for each case. As the 
logistic regression procedure in SPSS does not automatically compute Mahalanobis 
distance values, Mahalanobis distance scores were computed using leverage values 
using the following formula: 
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(Tabachnick & Fidell, 2011). 
 
Multicollinearity was assessed via examination of the zero-order correlation 
matrix among continuous predictors for any correlations > .90. Further, a multiway 
frequency analysis was conducted to examine any significant sources of 
multicollinearity among discrete predictors as recommended by Tabachnick and 
Fidell (2011). Linearity in the logit was tested using the Box-Tidwell approach 
(Hosmer & Lemeshow, 2000). 
 
6.6.2.2 Model testing. Willingness to seek professional mental health 
treatment (Yes/No) served as the dependent variable. Predictor and control variables 
and order of entry of independent variables appear in Table 25. An initial logistic 
regression was run including all predictor and control variables. Variables that did 
not contribute significantly to the prediction of Willingess to seek professional 
mental health treatment were then removed from the model and a second logistic 
regression was rerun with only significant predictors. By removing redundant 
predictors, both model fit and statistical power are improved (Burns & Burns, 2008). 
No specific hypotheses regarding the contribution of individual predictors were made 
as this was an exploratory study. 
 
 
6.7 Results 
 
6.7.1 Preliminary Analyses  
 6.7.1.1 Response rate. A total of 327 questionnaire responses were received 
between October and December 2012. The majority of responses were received from 
the PWA questionnaire mail-out (N = 302, response rate = 32%). An additional 25 
responses were received through the online questionnaire however it is not possible 
to determine the source or response rate of online responses (i.e., PWA members 
submitting their responses online or members from other Parkinson’s associations 
around Australia). 
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Table 25  
Predictors and Control Variables for Sequential Logistic Regression Analysis 
Predicting Willingness to use Psychological Services 
Step 1: Control Variables Age (categorical) 
Gender 
Background 
Relationship status 
Employment status 
PD duration 
PDQ-39  
DASS-D 
DASS-A 
DASS-S 
Step 2: Predictor Variables Past use of psychological services 
Previous psychological diagnosis 
Current antidepressant treatment 
Psych talk 
DSS-Perceived public stigma 
SSDS-Shame 
SSDS-Self-blame 
SSDS-Social Inadequacy 
IASMHS-Psychological Openness 
IASMHS-Help-Seeking Propensity 
NS-Concerns for PD 
NS-Cost 
NS-Doctor’s reaction 
NS-Access/logistics 
NS-Side Effects 
NS-Weakness 
NS-Dependency 
NS-Efficacy 
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6.7.1.2 Statistical power. A post-hoc power analysis was conducted to 
determine the statistical power of the study. According to Peduzzi and colleagues 
(1996), the minimum number of cases required for a logistic regression analysis at a 
.80 power level can be computed using the formula:  
 
p
10k
  =N  
  where:  k = number of predictors 
p = the smallest of the proportions of negative or    
       positive cases in the population 
 
The final number of predictors (k) = 8 and p = .294 (i.e., 29% of participants 
indicated they would not be willing to use psychological services in the future). 
Therefore the required sample size was 10(8) / 0.294 = 272.  The study sample size 
exceeds this value thus it can be concluded that this study was sufficiently powered 
at a .80 level. 
 
6.7.1.3 Missing data. Of the 327 questionnaire responses received, Missing 
Values Analysis revealed minimal missing data with no variables or cases missing 
more than 2.3% of data. Little’s MCAR test indicated that the data were missing 
completely at random, χ² (4079) = 4444.11, p > .05. Expectation Maximisation (EM) 
was employed to estimate missing data.  
 
6.7.1.4 Scale structure. Confirmatory factor analysis showed that the 
IASMHS, SSDS, DSS and Needs Survey were all valid measures within the sample 
(see Table 26). The Yuan-Bentler corrected Maximum Likelihood estimation method 
was used in the SEM analyses for the IASMHS and SSDS as the assumption of 
multivariate normality was violated for both scales.  
 
The IASMHS is originally a three-factor scale measuring attitudes towards 
seeking professional psychological help across three dimensions; Psychological 
Openness, Help-Seeking Propensity and Indifference to Stigma. However, only two 
subscales of the IASMHS were used in this study (Help-Seeking Propensity and 
Psychological Openness). Thus, while Mackenzie and colleagues (2004) proposed a 
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three-factor correlated structure, a two-factor correlated structured was specified in 
the SEM analysis. Results showed that the two-factor correlated structure was a good 
fit for the sample (corrected CFI = .90, RMSEA = .053).  
 
Table 26  
Results of Confirmatory Factor Analyses for DASS-21, IASMHS, SSDS and DSS  
 Maximum Likelihood 
Maximum Likelihood 
with Yuan-Bentler 
correction 
 χ² p Relative χ² CFI RMSEA  χ² p CFI RMSEA 
IASMHS 
Two-factor 
correlated 
 
232.25 
 
.000 
 
2.26 
 
.90 
 
.06 
 
 
 
152.64 
 
.001 
 
.90 
 
.053 
SSDS 
Three-factor 
correlated 
 
217.31 
 
.000 
 
4.26 
 
.92 
 
.10 
 
 
 
133.26 
 
.000 
 
.93 
 
.080 
*IASMHS = Inventory of Attitudes towards Seeking Mental Health Services, SSDS = Self-
Stigma of Depression Scale 
 
Similarly, the SSDS is originally a four-factor scale measuring the self-stigma 
of depression across four dimensions; Shame, Self-Blame, Social Inadequacy and 
Help-Seeking Inhibition. Three scales of the SSDS were used in the present study 
(Shame, Self-Blame and Social Inadequacy) thus a three- rather than four-factor 
correlated structure was specified. The CFA results indicated that the three-factor 
model was an acceptable fit for the data (corrected CFI = .93, RMSEA = .08). 
 
The scale structures of the DSS and Needs Survey were examined through 
PCA. Multivariate normality was violated for both scales with all items in each scale 
violating the assumption of univariate normality (p < .05), however, assumptions 
regarding the distribution of variables are not strictly enforced in PCA (Tabachnick 
& Fidell, 2011). Both scales were deemed appropriate for factoring with Bartlett’s χ² 
(1, 630) = 3769.91, p = .000 and KMO = .84 for the Needs Survey and Bartlett’s χ² 
(1, 36) = 1096.63, p = .000 with KMO = .84 for the DSS. 
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The DSS was developed as an 18-item two-component scale measuring 
Personal Stigma of depression and Perceived Public Stigma of depression (Griffiths 
et al., 2008). Only the Perceived Public Stigma scale of the DSS was used in the 
current study thus a one-component solution was specified for extraction in the PCA. 
Results showed that a one-component solution was an acceptable model for the data 
accounting for 44.53% of variance and with all items loading strongly on to the one 
component with a mean item-factor loading of .65. The Cronbach’s alpha value for 
the total scale was good with α = .76. 
 
The Needs Survey was written as a 36-item questionnaire measuring barriers 
to mental health treatment among men with prostate cancer across nine categories 
(Weinberger et al., 2011). The original Needs Survey consisted of 36 dichotomous 
‘agree/disagree’ items and the authors primarily used descriptive statistics to describe 
the frequency of responses to each item among the sample. In this study, responses 
were assessed on a 5-point Likert scale and item scores for each category were 
summed to create nine general and medical barriers to seeking mental health 
treatment. To assess the validity of using the Needs Survey in this manner, a PCA 
specifying nine components for extraction was run.  
 
Results indicated that a nine-component model fit the data with nine 
components with Eigenvalues > 1 extracted and collectively accounting for 57.50% 
of variance in the data. The majority of items were grouped together as expected 
although there was a moderate degree of cross-loadings evident. Eight items loaded 
poorly onto the hypothesised component (loadings < .30). Cronbach’s alpha values 
for the Access/Logistics and Concern for PD components were unacceptable  
(α < .50), however this may likely be related to the very small number of items (i.e., 
2) within each of these components. Nunnally (1978) states that Cronbach’s values 
are dependent on the number of items within a scale and that scales with a small 
number of items often result in very low Cronbach’s values. Cronbach’s alpha values 
for the remaining six components ranged from low reliability (α = .54; Stigma) to 
acceptable (α = .73; Doctor’s Reaction). Appendix G displays the component-item 
loadings and Cronbach’s alpha values for the Needs Survey. Overall, the Needs 
Survey appears to be an acceptable measure of general and medical barriers to 
seeking psychological help in PD although further item refinement is necessary. 
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Overall, all scales appeared to be acceptable measures of their purported 
constructs within the present sample. As only partial subscales of the IASMSHS, 
SSDS and DSS were used in this study, future research will need to investigate the 
structure and psychometric properties of each scale in its entirety. However, the 
current results provide strong support for the use of these scales in the study. 
 
6.7.2 Participant Characteristics 
The sample consisted of 205 males (62.7%) and 122 females (37.3%) with a 
mean age of 69.9 years. The majority of participants were of an Australian 
background (87.5%), currently married (70.6%) and no longer engaging in paid 
employment (84.1%). Average age of PD diagnosis was 62 years, average duration 
of PD was 8.14 years, and the vast majority of participants were currently on 
antiparkinsonian medications (93.3%). Other demographic characteristics of the 
sample appear in Table 11 in Chapter 4.2.2.2. 
 
6.7.3 Psychological Symptoms 
Consistent with previous research in PD, there was a higher severity of both 
depressive and anxiety symptoms within the sample relative to the general 
population. Based on normative data for the DASS-21 published by Henry and 
Crawford (2005), mean levels of depression (M = 5.26, SD = 5.08) corresponded to a 
‘Mild’ clinical severity (81
st
 percentile) while mean levels of anxiety (M = 5.28, SD 
= 3.99) corresponded to a ‘Moderate’ clinical severity (89
th
 percentile). Average 
levels of stress (M = 5.65, SD = 4.69) were within the normal range (69
th
 percentile). 
 
To assess the frequency of clinically relevant symptoms of depressive and 
anxiety symptoms within the sample, DASS-D and DASS-A scores were 
dichotomised into two groups based on severity ratings provided by Lovibond and 
Lovibond (1995). DASS-D scores ≤ 4.5 and DASS-A scores ≤ 3.5 corresponded to 
‘Normal’ levels of depression and anxiety, while DASS-D scores > 4.5 and DASS-A  
scores > 3.5 corresponded to ‘Clinically relevant’ levels of symptoms. Based on this 
classification, 43.1% (N = 141) of the sample displayed clinically relevant symptoms 
of depression while 58.7% (N = 192) had clinically relevant symptoms of anxiety. 
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6.7.4 Rates of Psychological Disorders  
The prevalence of psychological disorders (past or current) within the sample 
was lower than the commonly cited statistic of between 30 to 50% in PD (Burn, 
2002).  Twenty-one per cent of participants (N = 68) reported having a current or 
previous psychological disorder, of which major depressive disorder was the most 
common diagnosis (N = 49, 15%) followed by panic disorder (N = 15, 4.59%).   
 
6.7.5 Quality of Life 
 On average, participants perceived PD to have a low to moderate negative 
impact on quality of life (M = 31.08, SD = 18.43). To investigate the determinants of 
poor quality of life in PD, a standard multiple regression analysis (MRA) was 
conducted including 17 common motor, autonomic, cognitive and psychological 
symptoms of PD as predictors of quality of life.  
 
 6.7.5.1 Assumption testing.  Preliminary tests for normality, linearity and 
homoscedasticity were conducted via inspection of the standardised residual plot for 
the MRA model. The shape and distribution of residuals in the plot showed relatively 
equal scatter about zero indicating that the assumptions of normality, linearity and 
homoscedasticity were met. Standardised residuals for all cases were within ± 3.29 
standard deviations of the mean indicating no univariate outliers. One multivariate 
outlier was identified where the Mahalanobis distance value (43.76) exceeded the 
Chi Square critical value of χ²(17) = 40.79, p = .001, however the Cook’s distance 
value for this case was less than 1 indicating that the case was not influential within 
the data set and was thus retained. All other Cook’s distance values were also less 
than 1 further indicating no influential cases within the data. All zero-order 
correlations between predictors were less than .90 indicating no multicollinearity or 
singuarlity amongst variables. Further inspection of tolerance and Variable Inflation 
Factor (VIF) values confirmed the absence of multicollinearity with tolerance values 
> .2 and VIF values > 1 for all variables.  
 
 6.7.5.2 Model results. Collectively, all 17 symptoms accounted for 58.3% of 
variance in quality of life, F (17, 325) = 25.37, p = .000. Consistent with existing 
studies in the literature (i.e., Behair et al., 2005; Carod-Artal et al., 2008; Rahman et 
al., 2008), all unique significant predictors of poor quality of life within the sample 
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were non-motor symptoms namely; Confusion, Anxiety, Stress, Depression and 
Incontinence. All four cardinal symptoms did not significantly contribute to poor 
quality of life (see Table 27). 
 
Table 27 
Predictors of Quality of Life in Parkinson's Disease (N = 327) 
Predictor β r sr p 
Bradykinesia .03 .13 .03 n.s. 
Rigidity .08 .18. .07 n.s. 
Tremor .01 .08 .01 n.s. 
Postural instability .05 .23 .05 n.s. 
Dizziness .08 .31 .07 n.s. 
Sweating .06 .28 .05 n.s. 
Bladder frequency .04 .11 .03 n.s. 
Bladder urgency .01 .16 .01 n.s. 
Headaches .02 .26 .02 n.s. 
Incontinence .12 .31 .10 .009 
Pain .04 .28 .04 n.s. 
Memory problems .02 .25 .02 n.s. 
Confusion .17 .38 .15 .000 
Fatigue .02 .21 .01 n.s. 
Depression .15 .60 .09 .024 
Anxiety .22 .63 .12 .002 
Stress .24 .64 .12 .001 
n.s. = non-significant a the .05 level 
 
6.7.6 Mental Health Service Utilisation 
Just under half of participants reported that that their primary PD specialist 
physician (neurologist or GP) had spoken to them regarding depression, anxiety and 
other psychological conditions that can occur in PD (N = 159, 48.6%). The majority 
of participants (51.4%) had never had a discussion regarding psychological 
symptoms in PD with their primary PD physician. 
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Over a quarter of the sample were currently taking antidepressant 
medications (N = 85, 26%). SSRIs were the most frequently administered class of 
antidepressants (54.1%) with Zoloft (sertraline, N = 25, 29.4%) and Avanza 
(mirtazapine, N = 21, 24.7%) the most commonly reported medications among the 
sample. Forty-percent (N = 34) of those currently on antidepressants reported taking 
a TCA despite the known high side effect profile of this class of medications in PD. 
Most interestingly, of those who listed an antidepressant among their current 
medications, 74% (N = 63) answered ‘no’ to the question ‘Are you currently taking 
any psychiatric medications? 
 
Table 28 displays the patterns of mental health service utilisation for the 
sample over the past month, year and five years as well as lifetime usage. Only 8% 
of participants were currently engaged in mental health treatment. The lifetime usage 
of mental health services was 24%. Psychologists were reported as the most 
commonly utilised mental health professional across each surveyed time period, 
followed by psychiatrists, counsellors then general practitioners.  
 
6.7.7 Willingness to Seek Future Mental Health Treatment  
The majority of participants indicated that they would be willing to seek 
mental health treatment in the future if needed (N = 231, 70.6%). Again, there was a 
significant difference between age groups in willingness to seek future mental health 
treatment. Participants under 65 years were the most receptive towards seeking 
future treatment with 87.2% (N = 75) indicating that they would be willing to seek 
professional help if required. Just under three-quarters of participants aged between 
65 and 74 (72.5%, N = 103) showed positive intentions towards seeking future 
mental health treatment while just over half of participants aged over 75 years 
indicated that they would be willing to seek help from a mental health professional in 
the future (53.5%, N = 53). 
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Table 28  
Patterns of Mental Health Service Utilisation among the Sample (N = 327) 
 N % 
Mental health treatment in past month 28 8.00% 
 GP 3 .90% 
 Psychiatrist 7 2.10% 
 Psychologist 13 4.00% 
 Counsellor 4 1.20% 
Mental health treatment in past year 53 16.00% 
 GP 5 1.53% 
 Psychiatrist 14 4.28% 
 Psychologist 25 7.65% 
 Counsellor 5 1.53% 
Mental health treatment in past five years 59 18.00% 
 GP 5 1.53% 
 Psychiatrist 17 5.20% 
 Psychologist 30 9.17% 
 Counsellor 7 2.10% 
Mental health treatment in lifetime 80 24.00% 
 GP 6 1.83% 
 Psychiatrist 21 6.42% 
 Psychologist 40 12.23% 
 Counsellor 8 2.44% 
 
 
6.7.8 Help-Seeking Attitudes and Stigma 
 Scores on the Help-Seeking Propensity factor of the IASMHS were also high 
indicating a positive attitude towards seeking professional help for psychological 
problems among the sample (M = 24.10, SD = 6.69). Mean scores were even more 
positive than the means reported by Mackenzie and colleagues (2004) in their 
validation sample of 297 undergraduate students (M = 20.61, SD = 5.07). However, 
scores on the Psychological Openness factor of the IASMHS were considerably 
lower (M = 15.61, SD = 8.82) indicating that participants were less open to 
acknowledging and experiencing psychological problems. Consistent with recent 
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research showing a decrease in mental-illness related stigma among the 
contemporary cohort of older adults, Perceived Public Stigma (M = 25.92, SD = 
6.00) as well as scores for the three self-stigma of depression factors (Shame, M = 
9.51, SD = 3.60; Self-Blame, M = 10.98, SD = 3.48; Social Inadequacy, M = 12.38, 
SD = 2.92) were all lower than the respective means reported in validation samples 
for each scale (see Barney et al., 2010; Griffiths et al., 2004). 
 
6.7.9 Practical, Medical, PD-related and other General Barriers to Treatment 
 Table 29 displays the means and standard deviations for each of the Needs 
Survey categories.  The three most pertinent concerns for participants were related to 
Dependency (e.g., ‘I do not want to become dependent on a therapist or 
antidepressant medication’), Side Effects (e.g., ‘I worry about becoming too sedated 
from psychiatric medication’) and Efficacy (e.g., ‘I believe that treatment for 
emotional problems will help me; reverse coded). Stigma and concern regarding 
Doctor’s Reaction were of lowest concern among the sample. 
 
Table 29  
Means and Standard Deviations for Needs Survey Subscales 
 M SD 
Weakness 4.03 1.70 
Cost 3.97 1.44 
Efficacy 4.91 1.75 
Stigma 2.12 1.08 
Access 3.86 2.15 
Side Effects 5.19 1.87 
Doctor’s Reaction 2.49 1.34 
Dependency 6.88 2.10 
Concern for PD 3.38 1.91 
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6.7.10 Predictors of Willingness to Use Mental Health Services 
 A logistic regression analysis was used to examine predictors of willingness 
to use psychological services among the sample. Willingness to seek professional 
mental health treatment served as the binary categorical dependent variable. 
 
 6.7.10.1 Assumption testing. There are five assumptions underlying logistic 
regression; ratio of cases to predictors, independence of observations, absence of 
outliers, absence of multicollinearity and linearity in the logit. 
 
 The final logistic regression model had 8 predictors and a sample of 327 
equalling a case to predictor ratio of 1:41. This ratio exceeds the minimal ratio of 
1:20 specified by Coakes and Steed (2003) to ensure cross-validity of results. 
Twenty-one univariate outliers (4.62%) were identified where cases exceeded 3.29 
standard deviations above or below the mean. To reduce the influence of extreme 
scores on the data while maintaining an adequate sample size, extreme scores were 
changed to one value above the next highest score in the distribution for that variable 
as recommended by Schinka and Velicer (2003). Multivariate outliers were assessed 
through inspection of Cook’s and Mahalanobis distance statistics for each case. The 
highest Cook’s distance value (.28) was less than 1 and all Mahalanobis distance 
values were less than the Chi Square critical value of χ
2
(8) = 26.125 indicating no 
multivariate outliers (see Appendix H). 
 
 Examination of the zero-order correlation matrix between predictors in the 
final model revealed no correlations greater than .90 indicating no multicollinearity 
amongst variables. A multiway frequency analysis was conducted to examine any 
significant sources of multicollinearity among discrete predictors. All parameter 
estimates between discrete predictors were also less than .90 indicating absence of 
multicollinearity among discrete variables. Outputs for tests for multicollinearity 
appear in Appendix I.  Linearity in the logit was assessed using the Box-Tidwell 
approach. Interaction terms between each continuous variable in the final logistic 
regression model and their natural logarithm were computed in SPSS then added to 
the logistic regression alongside the original continuous variables. All interaction 
terms were non-significant thus satisfying the assumption of linearity in the logit. 
Outputs for the regression model testing linearity in the logit appear in Appendix J. 
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6.7.10.2 Initial logistic regression model. An initial logistic regression 
analysis was run including 20 predictors as outlined in Table 24 to identify 
significant predictors for inclusion in the final analysis. The Chi-square omnibus test 
showed that the 20 predictors in combination reliably distinguished between 
individuals who were willing and unwilling to seek professional psychological help 
in the future, χ²(20) = 96.69, p = .000. The accuracy of prediction rate for the model 
was 78%. Eight predictors were identified as significant predictors of willingness to 
use psychological services in the future; Age(categorical), Current antidepressant 
usage, Discussion with primary PD physician regarding psychological symptoms in 
PD, Lifetime treatment, IASMHS-Help Seeking Propensity, SSDS-Social 
Inadequacy, NS-Weakness and NS-Efficacy.  
 
 6.7.10.3 Final logistic regression model. A final logistic regression analysis 
was then run including only the eight significant predictors identified in the initial 
analysis. By removing redundant predictors, both model fit and statistical power are 
improved (Burns & Burns, 2008). The Chi-square omnibus test of the final model 
was statistically significant, χ²(8) = 78.33, p = .000, indicating that the predictors in 
combination reliably distinguished between individuals who were willing and 
unwilling to use psychological services in the future. The model was able to correctly 
predict participants’ willingness to use psychological services 77% of the time. Thus, 
eliminating 11 predictors from the initial model only reduced the predictive power of 
the model by 1%. Table 30 displays the results of the final logistic regression model.  
 
6.7.10.3.1 Barriers to seeking mental health treatment. Two significant 
barriers to seeking psychological treatment were identified (i.e., predictors associated 
with a reduction in the likelihood of being willing to seek psychological treatment; 
odds ratio < 1); increasing age and higher scores on the NS-Weakness factor. 
Participants aged between 65 and 74 years were 58% less likely than participants 
aged < 65 years to be willing to seek future psychological treatment. Similarly, 
participants aged over 75 years were 76% less likely to be willing to utilise 
psychological services in the future than participants aged < 65 years. Finally, as 
participants increasingly endorsed beliefs that seeking treatment represented personal 
weakness (i.e., an increase on the NS-Weakness factor by 1), the odds of being 
willing to seek future psychological treatment were reduced by 12.4%.  
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6.7.10.3.2 Facilitators of willingness to seek mental health treatment.  
Six significant facilitators of psychological treatment-seeking were identified (odds 
ratio > 1); previous treatment, current antidepressant use, help-seeking propensity, 
social inadequacy, beliefs regarding the efficacy of treatment, and having had a 
discussion regarding psychological symptoms in PD with a PD physician. 
 
The most substantial predictors of positive willingness to seek future 
treatment were all practical factors. Participants who were currently taking 
antidepressant medication and who had received some form of mental health 
treatment in the past had a 3.3 and 3.1 times increase in the odds of being willing to 
seek future treatment respectively. The odds of being willing to seek future treatment 
were also increased 2.2 times for participants whose primary PD physician had 
spoken to them about psychological complications that can manifest in PD relative to 
those whose PD doctors had not. 
 
Table 30  
Regression Coefficients, Standard Errors, Wald Statistics, Odds Ratios and 
Significance Levels for the Final Logistic Regression Model (N = 327) 
 B S.E. Wald 
χ
2
 
Odds 
Ratio 
p 
Age(categorical) - - 11.15 - .004 
    65 to 75 years* -.864 .41 4.49 .42 .034 
    Over 75 years* -1.41 .43 10.96 .24 .001 
Currently taking antidepressants 1.16 .38 9.24 3.19 .002 
Previous treatment (lifetime) 1.19 .41 8.23 3.28 .004 
Spoken to primary PD physician 
regarding psychological symptoms in PD 
.20 .10 .45 2.22 .50 
IASMHS-Help-seeking propensity .05 .02 6.45 1.06 .011 
SSDS-Social inadequacy .14 .05 658 1.15 .010 
NS-Weakness -.13 .05 7.72 .88 .005 
NS-Efficacy .122 .05 7.07 1.13 .008 
*reference category = participants aged under 64 years 
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In terms of attitudinal factors, higher help-seeking propensity, more positive 
beliefs regarding the efficacy of mental health treatment and higher scores on the 
SSDS-Social inadequacy subscale were all also associated with an increased 
likelihood of being willing to seek future treatment. As participants held increasingly 
positive beliefs regarding the efficacy of psychological treatment (i.e., a 1-point 
increase on the NS-Efficacy subscale), the odds of being willing to seek future 
treatment were increased by 13%. Similarly, as scores on the SSDS-Social 
Inadequacy factor increased by 1, the odds of being willing to seek future treatment 
were also increased by 15%. Thus, based on the maximum possible score of 20 for 
the SSDS Social Inadequacy factor, those who completely equated depression and 
anxiety with social inadequacy had a 300% increase in the odds of being willing to 
seek future psychological care (i.e., 20 x 15%). Finally, as scores on the IASMHS-
Help Seeking Propensity factor increased by 1, the odds of an individual being 
willing to seek future mental health treatment were increased by 5%. Thus, based on 
the maximum possible score of 32 for the Help-Seeking Propensity subscale, 
participants who showed complete propensity towards seeking help had a 160% 
increase in the odds of being willing to seek future psychological treatment.  
 
 
 
6.8 Discussion 
 
 Significant recruitment difficulties encountered in Study 3 led to the 
hypothesis that pertinent barriers to psychological treatment may be in place in PD 
populations. This study was conceptualised specifically to address this research 
question and was the first to specifically explore mental health service usage in PD. 
In support of the original hypothesis, only 8% of a sample of 327 adults with PD 
were currently engaged in some form of professional mental health treatment despite 
elevated levels of depressive and anxious symptoms, thus confirming the 
underutilisation of mental health services in PD. Several salient barriers, and more 
positively, facilitators to seeking mental health care were identified among the 
sample and have important implications for researchers, doctors and policymakers 
alike. This section provides a discussion of the study’s key findings and implications, 
limitations and direction for future research. 
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6.8.1 Psychological Symptoms in PD 
 The interest in depression and anxiety in PD stems from the marked 
prevalence of both conditions in PD relative to the general population as well as 
other medical populations. The prevalence of psychological disorders (past or 
current) within the present sample at 21% was lower than the commonly cited 
statistic of between 40 to 50% in the literature (Burn, 2002), however it must be 
noted that prevalence in this study was based on existing clinical diagnoses whereas 
epidemiological studies explicitly assess psychological symptoms within large PD 
samples to determine prevalence estimates. The underdiagnosis of psychological 
conditions in PD is widely acknowledged (Okun & Watts, 2002) and therefore it is 
likely that the true prevalence of depression and/or anxiety within the sample is 
higher than reported. Inspection of the mean levels and frequency of clinically 
significant depressive and anxiety symptoms within the sample supports this 
hypothesis. Forty-three percent of participants had clinically relevant symptoms of 
depression while 59% displayed clinically relevant anxiety symptoms. Moreover, the 
mean level of depressive symptoms within the sample corresponded to an 81
st
 
percentile in terms of severity while mean levels of anxious symptoms corresponded 
to an 89
th
 percentile of severity. Thus, there was an elevated level of both depressive 
and anxious symptoms within the sample relative to the general population and it is 
likely that a high number of participants meet the clinical criteria for either a 
depressive and/or anxiety disorder but have not been formally diagnosed.  
 
Nevertheless, the conservative estimate at 21% is still two to seven times 
greater than the 10% prevalence rate of depression (Blazer, 2002; Hunkeler et al., 
2006) and 3.5 to 9% rate of anxiety (Walsh & Bennett, 2001) in general older adult 
populations which ultimately only serves to reinforce the significance of 
psychological disorders in PD and the need for appropriate clinical attention, 
especially given the negative impact of both conditions on quality of life as 
demonstrated in this as well as previous studies in the literature (e.g., Behair et al., 
2005; Carod-Artal et al., 2008; Gulati et al., 2004; Hely et al., 2005; Kupio et al., 
2000; Rahman et al., 2008). 
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6.8.2 Patterns of Mental Health Service Utilisation 
 In regards to mental health service usage, only 8% of participants were 
currently engaged in some form of professional psychological treatment, which is 
consistent with Qureshi and colleagues’ (2012) recent finding of a 12% rate of 
current mental health service utilisation among 273 male veterans with PD. Thus, in 
spite of elevated levels of depressive and anxious symptoms among the sample, 
treatment usage was disproportionately lower. The lifetime treatment usage rate was 
24% which is also consistent with a previous estimate of 20% for lifetime mental 
health treatment in PD by Frisina and colleagues (2008).  However, it may be 
possible that the rate of mental health service utilisation obtained in this study 
represents an underestimate of actual service utilisation. Over a quarter of the sample 
listed an antidepressant in their current medications (26%), yet only 8% of the 
sample explicitly reported current mental health treatment. This finding suggests that 
participants may not perceive consultations with their GP/neurologist as a form of 
mental health treatment.  
 
Two demographic variables were significantly associated with lifetime 
mental health service usage; younger age and female gender. Mental health service 
usage significantly declined across each progressively increasing age group, with just 
under half (48.8%) of participants under the age of 65 having consulted a mental 
health professional at some point compared with only 10% of the over 75s. This 
finding is consistent with a significant body of research showing that while older 
adults tend to underutilise mental health services in general, ‘older-older’ adults are 
even significantly less likely to receive any form of professional mental health 
treatment (Mackenzie et al., 2006). For example, in a study of 12 810 individuals 
who had begun treatment through the Texas pubic mental health system in 1999, 
Karlin and Norris (2006) noted that adults over the age 60 comprised only 5% of all 
treatment initiators, and that within this subsample, 82% were adults aged between 
60 and 75. It has been suggested that heavily salient and negative societal views 
regarding psychological treatment prior to the deinstitutionalisation of mental illness 
are responsible for fostering negative attitudes toward mental health treatment among 
older generations, and ultimately reflected in the very low rates of service use among 
this subsample (Morris, 2001). 
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The finding that females are more receptive to seeking mental health 
treatment is also consistent with a large body of previous research (e.g., Crabb & 
Hunsley, 2006; Klap et al., 2003; Olfson & Pincus, 1996; Schonert-Reichl & Muller, 
1996). In this study, just under half of all female participants reported having had 
engaged in some form of professional mental health treatment compared with less 
than a quarter of male participants. Gender differences in attitudes and willingness to 
utilise mental health services have been observed as early as the beginning of 
adolescence and linked with stigma, gender roles and social norms (Chandra & 
Minkovitz, 2006).  
 
Clinical variables significantly associated with lifetime treatment usage 
included previous psychological diagnosis, current antidepressant usage, higher 
severity of depressive, anxious and stress symptoms and lower PD-related quality of 
life, all which make intuitive sense. Higher levels of subjective distress and higher 
perceived need are widely acknowledged as the strongest predictors of actual service 
use (Currin et al., 1998) while it would appear pragmatic that previous psychological 
diagnosis and current antidepressant use would be associated with previous 
professional treatment as professional consultation would be required in order to 
ascertain both a diagnosis as well as a prescription for antidepressants. 
 
 Most interestingly, contrary to the literature asserting that older adults are 
significantly less likely to consult with specialty mental health professionals 
(Unutzer, 2002), participants who had received treatment reported clinical 
psychologists as the most frequent treatment providers across every surveyed time 
period (currently, past year, five years and lifetime). However, it is not clear whether 
psychologists were directly consulted by participants or whether treatment was 
facilitated via referral from initially-consulted general medical physicians. Studies 
examining the use of different mental health providers among older adults have 
mostly been based on initial consultations, where general medical physicians are 
largely favoured as a first point of contact for older adults (Holvast et al., 2012). 
Thus, it is a possibility that participants initially approached general physicians with 
mental health concerns who then facilitated treatment through a psychologist.  
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Nevertheless, the finding that psychologists were the most frequent treatment 
providers among participants who had received treatment is certainly not a unique or 
novel discovery. Several studies examining mental health treatment preferences 
among older adult samples have reported a preference for psychotherapy over 
pharmacological treatments for mental health problems. For example, in a cross-
sectional survey of 1602 older adults aged 65 and over across 18 US primary care 
clinics, Gum and colleagues (2006) reported that the majority of participants showed 
a preference for counselling (57%) over medication therapy (43%) for the treatment 
of emotional problems. Similarly, in a PD-specific qualitative study examining 
attitudes toward different treatments for depression among 33 participants, Oehlberg 
and colleagues (2008) reported a more favourable impression of the efficacy of 
psychotherapy for depression in PD relative to antidepressants as well as potent 
concerns regarding side-effects. These results were mirrored among the present 
sample, with 64% of participants disagreeing with the statement ‘I prefer medication 
to psychotherapy for emotional problems’. Moreover, 73% of participants agreed 
with the statement ‘I worry about interactions between psychiatric medication and 
my Parkinson’s medication’. Thus, given a choice of services, it is not surprising that 
psychologists were the most frequent treatment providers among the sample. 
 
6.8.3 Predictors of Willingness to Seek Future Mental Health Treatment 
 The Theory of Planned Behaviour (Azjen, 1991) proposes that actual 
behaviour can be most accurately predicted from an individual’s intentions to 
perform the given behaviour, with a strong positive association observed between the 
two. Thus, one may have expected that willingness to seek mental health treatment 
among the sample would be low in light of the low rates of actual service usage. On 
the contrary, however, it was very encouraging to note that over 70% of participants 
indicated that they would be willing to seek future professional mental health 
treatment if needed.  
 
This finding is consistent with an emerging trend in the gerontology literature 
showing a significant positive shift in attitudes towards mental health treatment 
among contemporary older adults (e.g., Mackenzie et al., 2006; Robb et al., 2003; 
Segal et al., 2001). In an early study of attitudes toward professional mental health 
treatment among 110 older adults aged 65 years and over, Ray and colleagues (1992) 
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reported that only 15% of participants indicated that they would go directly to a 
mental health professional for help with psychological problems. However, 
Mackenzie and colleagues (2008) more recently assessed willingness to seek 
professional treatment for mental health problems among a sample of 1341 older 
adults aged 55 years and over and reported that 83.7% of participants indicated that 
they would be willing to ‘seek professional help if they had serious emotional 
problems’. Thus, the proportion of older adults willing to seek professional mental 
health treatment had increased five-fold over the 16 years between the two studies. 
 
Currin and colleagues (1998) propose that the positive shift in attitudes 
towards mental health treatment among contemporary older adults can be directly 
attributed to generational and societal differences between progressive cohorts of 
older adults. Negative societal views regarding psychological treatment prevalent 
prior to the deinstitutionalisation of mental illness are posited to underlie negative 
attitudes toward mental health treatment among ‘older-older’ adults (Morris, 2001), 
while the subsequent deinstitutionalisation of mental illness in later years coupled 
with advances in education, science and technology have promoted more acceptance 
and positive attitudes towards seeking psychological treatment among ‘younger-
older’ adults (Currin et al.). In support, several studies have reported a significant 
discrepancy in attitudes towards mental health treatment between older adults aged 
between 60 and 79 and ‘older-older’ adults over 80 years (Crabb & Hunsley, 2006). 
This same pattern of results was also found in the current study with a significant 
difference in willingness to utilise mental health services identified between 
‘younger-older adults’ (< 65 years), ‘older adults’ (65 to 74), and ‘older-older adults’ 
(> 75 years), with a significant decline in willingness to seek psychological treatment 
observed over each increasing age group. 
 
In summary, this study supports the trend of a positive shift in attitudes 
regarding mental health treatment among older adults although it must be noted that 
the proportion of participants with PD receptive to seeking future psychological 
treatment in this study (71%) was somewhat lower than has been reported for general 
older adult samples (84%; Mackenzie et al., 2008). Thus, while attitudes towards 
seeking treatment among the sample were generally positive, it would appear that 
there was less willingness to seek psychological treatment among the PD sample, 
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consistent with previous research asserting that older adults with chronic illnesses are 
less likely to seek treatment for mental health problems (Choi & Gonzalez, 2001; 
Lazarus et al., 1991; Mohr et al., 2006). Several factors have been implicated in this 
phenomenon including increased functional impairment, increased costs for 
additional treatment and an overshadowing concern for physical illness. Interestingly 
however, the logistic regression analysis revealed that none of the PD-specific 
variables (e.g., PD duration, PD-related quality of life, NS-Concerns for PD, NS-
Doctor’s Reaction, NS-Cost) served as significant barriers to willingness to seek 
professional psychological treatment among the sample. Only two predictors were 
significantly negative associated with willingness to seek future psychological care 
within the sample; increasing age and higher perceptions that professional help 
reflected personal weakness. 
 
6.8.3.1 Barriers to seeking mental health treatment. Increasing age was 
the most significant barrier to seeking mental health treatment in this study. Both 
‘older adults (65 to 74 years)’ and ‘older-older adults (75+ years)’ were significantly 
less likely than participants aged under 65 years to be willing to seek professional 
psychological treatment. Being over 75 years of age was an especially pertinent 
barrier to seeking mental health treatment and associated with a 76% reduction in the 
odds of being willing to seek future treatment. This finding suggests that while 
attitudes towards seeking mental health treatment have significantly improved among 
older adults, age still remains an important barrier to seeking mental health care 
particularly for ‘older-older’ adults (Currin et al., 1998). In support, in a large-scale 
Canadian study of 59 302 older adults, Crabb and Hunsley (2006) found that adults 
aged between 45 and 64 years were four times more likely than participants aged 
over 75 to have had consulted a mental health professional. Similarly, participants 
aged between 65 and 74 were also 1.7 times more likely than participants aged over 
75 to have had previously consulted a mental health professional at some point. 
 
It may be argued that a range of factors commonly associated with advancing 
age including longer duration and higher severity of PD as well as increasing 
comorbid health complications and functional disability may potentially underlie the 
relationship between increasing age and decreased willingness to seek psychological 
treatment, however, PD duration, PD severity and presence of other health conditions 
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did not significantly predict willingness to seek treatment in the logistic regression 
analysis. Moreover, age remained a significant negative predictor of willingness to 
seek mental health treatment after controlling for all other predictors in the model, 
thus suggesting a robust relationship between increasing age and willingness to seek 
psychological treatment that is likely a function of generational differences in 
perceptions of mental illness and help-seeking (Currin et al., 1998). This finding has 
important practical implications. Given that unhelpful views of mental illness are 
proposed to underlie negative attitudes towards mental health treatment among older 
generations, educational campaigns targeting this population may prove useful in 
dispelling inaccurate assumptions. 
 
The other significant barrier to seeking psychological treatment among the 
sample was the NS-Weakness factor. As participants increasingly endorsed beliefs 
that engaging in treatment for mental health problems reflected personal weakness, 
the odds of being willing to seek future mental health treatment were reduced by 
12.4%. A reluctance to seek formal mental health treatment in order to maintain a 
self-image of strength has been previously described in a number of studies with 
Vogel and colleagues (2006) explaining that for certain individuals, the admission of 
being in need of professional help may be perceived to be more detrimental than the 
experience of psychological distress in itself. Older-older adults in particular have 
been found to display the highest levels of self-reliance over all other age groups in 
spite of increased rates of disability, chronic illness and bereavement (Nygren et al., 
2005). Again, generational differences in perceptions of seeking and receiving 
assistance have been suggested to play a significant role (Currin et al., 1998). Thus, 
self-reliance among older-older adults can somewhat constitute a double-edged 
sword with Crabb and Hunsley (2006) questioning whether such attributes are 
positive protective factors equipping older adults with the strength to cope with 
emotional distress on their own, or significant impediments preventing older-older 
adults from seeking and receiving the appropriate mental health care. 
 
6.8.3.2 Facilitators of willingness to seek mental health treatment.  
It is encouraging to note that the logistic regression analysis identified more 
significant facilitators of willingness to seek mental treatment rather than barriers. 
Facilitators of treatment-seeking were predictors that increased the likelihood of a 
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participant being willing to seek future treatment. Low or negligible levels of a 
facilitator variable did not reduce the likelihood of treatment-seeking intentions so 
much as had no significant effect on the odds. 
 
6.8.3.2.1 Treatment experience. Consistent with a multitude of previous 
studies, the strongest facilitators of willingness to seek professional mental health 
treatment in this study were related to treatment experience (Lasoski & Thelen, 1987; 
Speer, Williams, West, & Dupree, 1991). Current antidepressant usage  and lifetime 
mental health treatment were both associated with a three-fold increase in the 
likelihood of a participant being willing to seek professional treatment in the future. 
In relation to why this relationship exists, it has been suggested that actual treatment 
experience offers older adults a chance to directly dispel any misconceptions 
regarding what mental health treatment involves, hence fostering positive attitudes 
about treatment and enhancing confidence and familiarity with such services, which 
all in turn enhances willingness to utilise such services again if needed at some point 
in the future (Currin et al., 1998).  In support, in a study with 248 older adults, 
Connor and colleagues (2010) found a significant relationship between no treatment 
history and negative attitudes regarding mental health treatment. Similarly, Deane 
and Todd (1996) found that participants who had prior experience with a 
professional had significantly more positive intentions to seek professional help in 
the future as well as less treatment fearfulness compared to those with no treatment 
history.  
 
Ultimately, while an individual’s treatment history is not a factor that can be 
altered by researchers or physicians, this finding has important implications for 
future treatment use. Given the strong relationship between treatment experience and 
willingness to seek future treatment, doctors should encourage their patients to make 
use of and become familiar with such services to ultimately enhance the likelihood of 
an individual being willing to seek treatment again in the future should they have any 
further complications. 
 
6.8.3.2.2 Discussion with primary PD physician. This study also highlighted 
another important role of the primary PD physician in facilitating mental health 
treatment usage. Second to treatment experience, having had a discussion about 
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psychological symptoms in PD with a primary PD physician was the next most 
substantial predictor of positive willingness to seek future psychological treatment. 
For participants who had had such a discussion with their PD doctors, the odds of 
being willing to seek future psychological care were increased 2.2 times relative to 
those who had not. Unfortunately, however, the majority of participants (51.4%) 
reported that their primary PD physician had never discussed with them the range of 
psychological complications that can often present in PD. This statistic is consistent 
with the findings of an earlier study by Shulman, Taback, Rabinstein and Weiner 
(2002) who surveyed 101 individuals with PD and reported that over half stated that 
they had never discussed nor received any information about non-motor symptoms 
from their primary PD physician. Given that significant awareness of the importance 
of psychological and other non-motor symptoms of PD has emerged over the past 
decade, this finding is somewhat disappointing and suggests that increased awareness 
of non-motor symptoms among researchers and physicians has not translated into 
increased clinical attention over the past 10 years. 
 
 It is also interesting to note that while having had a discussion with a PD 
physician regarding psychological symptoms increased the odds of being willing to 
seek future treatment, concern over the primary PD physician’s reaction towards 
disclosure of mental health problems (NS-Doctor’s Reaction factor) was among one 
of the lowest concerns for participants. This likely suggests that a discussion with the 
PD physician serves to facilitate awareness of psychological symptoms in PD for 
participants and that it is not necessarily the doctor’s approval that participants are 
seeking. Indeed, a significant lack of awareness in regards to non-motor symptoms in 
PD has been previously described among individuals with PD and directly related to 
failure on behalf of PD doctors to inform patients of such symptoms (Chaudhuri, 
2003). In summary, in light of the myriad of negative outcomes associated with 
untreated non-motor symptoms in PD, it is imperative that PD physicians take the 
time to address the full spectrum of motor and non-motor symptoms with patients. 
 
6.8.3.2.3 Stigma. In terms of attitudinal variables, self-stigma in relation to 
social inadequacy was the strongest attitudinal facilitator of treatment-seeking 
willingness in this sample. That is, the more a participant believed that having 
depression and/or anxiety reflected social inadequacy on their behalf, the greater the 
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odds were of being willing to seek future treatment. While this finding is in direct 
contrast with the literature positing that self-stigma often serves as a powerful 
barrier to initiating psychological treatment in the general population (Barney et al., 
2006), it is consistent with the results of a recent investigation by Conner and 
colleagues (2010), also investigating intentions to seek mental health treatment 
among  a sample of older adults aged over 60 years, and also reporting that 
participants with higher levels of internalised stigma were significantly more likely 
to show positive intentions to seek mental health treatment. Thus, there may be a 
differential effect of self-stigma on treatment-seeking intentions between the general 
population and older adults including people with PD. Connor and colleagues 
speculated that it may be a greater perceived need among self-stigmatising older 
adults which leads them to seek treatment. Indeed, it would seem plausible that older 
adults who internalise the negative stereotypes of depression and/or anxiety are likely 
to experience higher levels of distress, lower self-esteem and self-efficacy (Corrigan 
et al., 2006) and thus show a greater perceived need for treatment.  
 
It must be noted however that the two other subscales of the SSDS (Self –
Blame and Shame), although not significantly predictive of willingness to seek 
psychological treatment, were negatively associated with treatment-seeking 
intention. Thus participants who blamed themselves for, and who were ashamed 
about having depression and/or anxiety were less likely to be willing to seek 
treatment, while it was only participants who believed that having depression and/or 
anxiety affected their social ability were at a higher likelihood of being willing to 
seek treatment. It is well documented that the majority of people – both younger and 
older adults – show a preference to seek help for emotional problems initially from 
within their social network (Ray et al., 1992). At the same time, it is also well 
documented that older adults tend to experience less social contact than younger 
adults as well as are more likely to have diminished social networks (Thompson, 
2000). Thus, limited social opportunities coupled with feelings of social inadequacy 
are likely to make it difficult for some older adults to confide in family or friends, 
thus increasing the likelihood of seeking help from a professional. Moreover, in line 
with Connor and colleagues’ (2010) greater perceived need explanation, social 
isolation and inadequate social support have been identified as significant risk as 
well as maintenance factors for depression among older adults (Glass et al., 2006). 
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Thus, it may be the case that feelings of social inadequacy lead to increasing social 
isolation and more severe depression, ultimately leading to a greater perceived need 
for professional help.  
 
Perceived public stigma was not significantly predictive of willingness to 
seek future psychological treatment, consistent with several previous studies (e.g., 
Barney et al., 2006; Bayer & Peay, 1997; Van Voorhees et al., 2006), and ultimately 
supports the notion that it is individual beliefs regarding psychological treatment and 
its perceived consequences that play a more pivotal role in the help-seeking decision-
making process rather than approval or disapproval from others. 
 
6.8.3.2.4 Efficacy and help-seeking propensity. Finally, higher beliefs 
regarding the efficacy of mental health treatment and higher help-seeking propensity 
were the other two significant attitudinal facilitators of willingness to seek 
professional treatment. Both findings make intuitive sense. Participants who believed 
that mental health treatment would be beneficial for them were more likely to be 
willing to seek such services if needed. Similarly, participants who indicated that 
they had the capacity, were able, and were receptive to seeking treatment were more 
likely to be willing to seek actual treatment in the future if needed. In particular, the 
finding that help-seeking propensity was associated with an increase in the likelihood 
of being willing to seek future psychological treatment is consistent with a growing 
body of research reporting a significant association between help-seeking attitudes 
and treatment utilisation (e.g., Deane & Todd, 1996; Diala et al., 2000; Komiya, 
Good, & Sherrod, 2000; Morgan et al., 2003; Rickwood & Braithwaite, 1994; Ten 
Have et al., 2010; Tijhuis, Vogel et al., 2005). On the whole, this finding is very 
positive given that both beliefs regarding the efficacy of treatment and help-seeking 
propensity can be improved through educational campaigns, although it is very 
encouraging to note that levels of help-seeking propensity among the sample were 
already within a high range. 
 
6.8.4 The Underutilisation of Mental Health Services in PD: Is a Lack of 
Awareness the Underlying Explanation? 
The results of this study showed that contrary to expectations, contributory 
factors in the help-seeking decision process for older adults with PD do not 
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significantly differ from general older adult populations. The two significant barriers 
to seeking mental health treatment in this sample were increasing age and 
perceptions that treatment was associated with weakness, both of which have been 
well-documented barriers to initiating mental health care among general older adults. 
Treatment experience, higher help-seeking propensity and beliefs about the efficacy 
of treatment and higher self-stigma related to social inadequacy were all identified as 
facilitators of willingness to seek treatment and have all also been previous 
documented in older adult samples. 
 
In contrast to the literature asserting that individuals with chronic physical 
illnesses are less likely to seek help for psychological complications due to factors 
such as increased functional impairment, an overshadowing concern for physical 
illness, increased medical costs, less time availability and concern over the reaction 
of the medical physician, this study found that the majority of PD-related factors did 
not significantly affect participants’ willingness to seek mental health treatment. The 
only PD-specific variable to significantly predict willingness to use mental health 
services was having had a PD physician-initiated discussion regarding psychological 
symptoms in PD. Second to treatment experience, having had a discussion with a PD 
physician was the most important facilitator of mental health service usage among 
the sample, over help-seeking propensity, beliefs regarding efficacy and self-stigma. 
 
It was suggested earlier that such a discussion likely facilitates awareness 
regarding psychological complications in PD for participants which then facilitates 
treatment-seeking. Studies have demonstrated a significant lack of awareness 
regarding psychological and other non-motor symptoms among people with PD.  
Chaudhuri and Schapira (2009) state that up to 62% of non-motor complications are 
not declared to PD physicians as patients and carers alike are unaware that such 
symptoms are linked to PD. Thus, psychological and non-motor symptoms are 
largely underrecognised and underreported by patients and consequently 
underdiagnosed and undertreated, which only reemphasises the integral role of the 
PD physician in informing patients of the full spectrum of symptoms in PD. 
Moreover, the discrepancy between rates of diagnosed psychological disorders and 
severity of depressive and anxious symptoms within the current sample is also 
indicative of underreporting and underdiagnosis of psychological conditions in PD.  
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It has been suggested that there exists a general assumption among PD 
neurologists that non-motor symptoms will be managed in the community by a GP or 
family physician and thus time-limited consultations are reserved for the assessment 
and discussion of motor symptoms (Chaudhuri et al., 2005). Even if this is case and 
should primary PD physicians not be actively involved in the treatment of non-motor 
symptoms, physicians still have a responsibility to discuss the full range of potential 
motor and non-motor symptoms in PD with patients. Moreover, Chaudhuri and 
colleagues (2006) assert that even if not actively involved in their treatment, PD 
physicians are generally the most suitably qualified to identify psychological 
complications in PD as they would be more skilled in distinguishing between PD 
motor symptoms and symptoms of depression and anxiety than a non-specialist, 
especially given the high overlap between the three conditions. 
 
Ultimately, given that the current study as well as previous studies in the 
literature have shown that psychological and other non-motor symptoms are 
consistently rated by people with PD to be more distressing and debilitating than 
motor symptoms (e.g., Behair et al., 2005; Carod-Artal et al., 2008; Rahman et al., 
2008), it would be useful for PD physicians to adopt a more holistic treatment 
approach with patients. 
 
6.8.5 Direction for Future Research: Examining the Gap between Willingness 
and Actual Service Use 
This study originally set out to identify barriers that may be preventing 
individuals with PD with psychological complications from seeking professional 
help. Although no formal hypotheses were postulated as this was an exploratory 
study, several barriers were anticipated based on the relevant literature on older 
adults, particularly that negative attitudes towards seeking mental health treatment 
may be underlying low service usage. It was therefore welcoming to note that the 
majority of participants displayed positive help-seeking attitudes and were willing to 
seek psychological treatment in the future if deemed necessary. However, it would 
appear that a positive shift in attitudes towards mental health treatment among 
contemporary older adults has not translated into increased service usage. Despite 
generally positive attitudes and willingness to seek professional mental health 
treatment among the sample, rates of actual service usage were disproportionately 
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lower in the presence of elevated depressive and anxious symptoms. Thus, there 
appears to be a significant gap between intentions and actual behaviour. This area of 
research has not as yet been explored in PD and would be a highly worthwhile 
avenue of work for future researchers. 
 
 6.8.5.1 The role of perceived need? Existing studies examining the gap 
between intentions to utilise and actual usage of mental health services in general 
adult populations have highlighted the role of an important mediating factor; 
perceived need (Katz, Kessler, Frank, Leaf, & Lie, 1997). Perceived need refers to an 
individual’s subjective assessment as to whether professional treatment is required 
for a given problem (Mojtabai, Olfson, & Mechanic, 2002) and has been found to be 
the most significant and strongest predictor of actual treatment usage (Currin et al., 
1998; Mackenzie et al., 2010). Thus, an individual may hold very positive attitudes 
toward mental health treatment and may have similar positive intentions regarding 
seeking treatment, such as within the current sample, but if the individual does not 
consider themselves as in need of professional treatment, actual treatment initiation 
is highly unlikely.  
 
 Older adults with depression especially have been found to be less likely to 
perceive a need for treatment even when experiencing significant depressive 
symptoms, or even when diagnosed with a clinical disorder compared with younger 
adults (Black, Rabins, German, McGuire, & Roca, 1997). For example, using data 
from the 1997 US HealthCare for Communities Telephone Survey conducted with 9 
585 respondents, Klap, Unroe and Unutzer (2003) reported that only 4% of older 
adults aged over the age of 65 perceived a need for mental health care. Among older 
adults who met criteria for a probable psychological disorder and thus whom had an 
objective need for treatment (as assessed using the Composite International 
Diagnostic Interview), only 28% perceived a need for professional treatment. Thus, 
there is a generally low perception of need for mental health treatment among older 
adults both with and without an objective need for treatment.  
 
 Again, stigma and negative attitudes regarding psychological treatment have 
been implicated in the low perceived need for mental health services among older 
adults (Garrido, Kane, Kaas, & Kane, 2009). However, a decrease in mental illness-
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related stigma and positive shift in attitudes towards psychological treatment 
observed among contemporary older adults has not translated into significantly 
increased perceived need for treatment (Mackenzie et al., 2010).  Klap and 
colleagues (2003) and Katz and colleagues (1998) identified low problem-
recognition among older adults as a significant underlying factor, which again only 
serves to highlight the integral role of medical physicians in detecting signs and 
symptoms of psychological disturbance and actively encouraging older adults to seek 
formal treatment. 
 
A longitudinal study specifying and testing a path model capturing the 
complex relationship between demographic and clinical variables, help-seeking 
attitudes, stigma, resources, intentions, perceived need and actual service usage 
would be instrumental in improving current understanding of the decision process 
underlying mental health service usage. 
 
6.8.6 Limitations 
 Finally, there are several limitations in this study that must be noted. First, 
due to the cross-sectional nature of the study, causal inferences cannot be made. 
Second, the convenience method of sampling employed restricts the generalisability 
of reported findings to all individuals with PD. Third, due to the self-report nature of 
the study, response bias cannot be ruled out. It is a possibility that individuals who 
chose not to complete and return the questionnaire were not interested in the research 
topic (i.e., psychological treatment in PD) and thus the positive attitudes towards 
mental health treatment observed among the study sample may be overstated. Fourth, 
although it was deduced that a lack of awareness regarding psychological symptoms 
in PD may significantly underlie low treatment rates, awareness of psychological 
symptoms in PD was not directly assessed. Future research should consider directly 
assessing awareness by listing a range of motor and non-motor symptoms and asking 
participants to select all symptoms which they believe to be a part of PD.  
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6.9 Chapter Summary 
 
The underutilisation of mental health services among the general population 
as well as older adult populations is well documented. This study was the first to 
examine mental health service utilisation among a sample of 327 Australian adults 
with PD and was conceptualised specifically to provide insight into recruitment 
difficulties encountered in Study 2. Consistent with speculation that the 
underutilisation of mental health services by people with PD was likely responsible 
for recruitment difficulties in Study 2, it was found that only 8% of participants were 
currently engaged in some form of professional mental health treatment despite 
elevated levels of both depressive and anxious symptoms.   
 
While service usage statistics were very low, it was encouraging to note that 
the majority of the sample showed positive help-seeking attitudes and were receptive 
to seeking future mental health treatment if deemed necessary. The logistic 
regression analysis revealed that factors involved in the help-seeking decision-
process for participants with PD did not differ significantly from what has been 
described for older adults in general, with age, perceptions of weakness, help-seeking 
propensity, beliefs about efficacy and self-stigma all important factors in the help-
seeking process.  
 
Most importantly, this study highlighted the integral role of the PD physician 
in facilitating mental health treatment for individuals with PD. Given traditional 
classifications of PD as a motor disorder, a significant proportion of individuals with 
PD are unaware of the myriad of non-motor complications that can also manifest in 
PD. Lack of awareness consequently leads to underrecognition and underreporting of 
such symptoms, which results in underdiagnosis and undertreatment. Given recent 
widespread recognition of the prevalence and negative impact of psychological and 
other non-motor symptoms in PD among researchers and doctors, it would be useful 
for this knowledge to translate into a more holistic treatment approach for patients 
that takes into account treatment of psychological symptoms. 
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 CHAPTER 7  |              General Discussion  
 
 
 
 
7.1 Introduction 
 
The overarching aim of this research was to make a significant contribution 
to the existing knowledge base in relation to the treatment of depressive and anxiety 
disorders in Parkinson’s disease. Four studies were conducted, each offering a unique 
scientific contribution to this field of knowledge. A comprehensive discussion of 
each study’s findings, implications, limitations and direction for future research is 
presented within the respective study chapters. This final chapter provides a general 
discussion of the unique contributions of the present work to the current state of 
knowledge in relation to depression and anxiety in PD, along with an outline of 
clinical and future research recommendations, beginning with a restatement of the 
main findings of this research.  
 
 
7.2 Summary of Research Findings 
 
7.2.1 Study 1: A Meta-Analysis of Randomised Placebo-Controlled Treatment 
Trials for Depression and/or Anxiety in PD 
Study 1 was the first broad meta-analysis of randomised placebo-controlled 
treatment trials for depression and/or anxiety in PD. This study systematically 
integrated the existing empirical treatment literature on depression and anxiety in PD 
and aimed to identify the most viable treatment modality for depression and anxiety 
in PD at the present time. This meta-analysis was distinguished from existing meta-
analyses for depression in PD in that it was the first to review both pharmacological 
and non-pharmacological treatment interventions, as well as the first meta-analysis of 
any kind for treatments for anxiety in PD. 
 
There were three key findings in this study. First, Study 1 supported previous 
research asserting that on the whole, there is a lack of empirical evidence to support 
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the widespread use of antidepressants in PD at the present time (i.e., Antonini et al., 
2000; Chung et al., 2003, Klaasen et al., 1995).  The pooled effect of antidepressant 
therapies in general (d = .71, 95% CI = -1.33 to 3.08) and the pooled effect for the 
current first-line SSRI treatments for depression in PD (d = .57, 95% CI = -1.33 to 
2.47) were both non-significant. However, it must be noted that the moderate 
magnitude of these pooled effects suggests that antidepressant therapies do have a 
positive effect on depression in PD relative to placebo, even if not at a statistically 
significant level. Because of the very limited number of available placebo-controlled 
RCTs in the literature at present (N = 5), it is likely that the non-significance of the 
pooled effect for antidepressants in PD reflects a Type II error. Ultimately, there is a 
need for more controlled research to resolve the amibiguity surrounding the efficacy 
of antidepressant therapies in PD at present. 
 
The second main finding of Study 1 was related to the potential of 
psychotherapy, specifically, Cognitive Behavioural Therapy (CBT) in treating 
depression and anxiety in PD. A recent randomised controlled trial of individual 
CBT in PD (i.e., Dobkin et al., 2011) resulted in the largest effect on depression in 
PD over all other interventions in the meta-analysis (d = 1.57, 95% CI = 1.06 to 2.07) 
and also resulted in a large secondary effect on anxiety symptoms (d = 1.03, 95% CI 
= .57 to 1.50). Further exploration of CBT as a treatment for depression and anxiety 
in PD is thus strongly warranted.  
 
The final finding from Study 1 concerned the limited state of the current 
empirical treatment literature on depression and anxiety in PD. Despite increasing 
awareness of the negative impact of psychological complications in PD over the past 
decade and a half, there remains a dearth of empirical research in the area of 
depression and anxiety treatment in PD, with only eight randomised placebo-
controlled trials of interventions for depression in PD available for analysis. There 
were no RCTs of any treatments for anxiety in PD. This lack of research ultimately 
restricted the drawing of any definitive conclusions regarding the efficacy of 
different treatment modalities for depression and anxiety in PD and highlighted 
further empirical studies in this area as an important direction for future research. 
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7.2.2 Study 2: A Preliminary Examination of the Validity and Reliability of the 
Depression Anxiety and Stress Scale-21 in Parkinson’s Disease 
 Study 2 examined the scale structure and psychometric properties of the 
DASS-21 in a PD sample to support its use as a primary outcome measure in Studies 
3 and 4, as well as to provide information about the utility of the scale as a clinical 
assessment tool for use in PD in general. A convenience sample of 327 Australian 
adults with PD completed the DASS-21 as part of a wider battery of questionnaires 
for Study 4. DASS-21 responses from this sample were used as data for Study 2.  
 
Overall, Study 2 provided preliminary evidence for the validity and reliability 
of the DASS-21 in PD. Factorial validity was demonstrated through replication of 
Lovibond and Lovibond’s (1995) three-factor correlated structure within the study 
sample. Cronbach’s alpha values of internal consistency for each factor were good to 
excellent with α = .92 (Depression), α = .77 (Anxiety) and α = .88 (Stress). The 
distribution of scores was good for all three factors with no significant floor or 
ceiling effects observed. There were no significant problems with symptom overlap 
between depression, anxiety and PD, with only one item (Item 6: trembling) 
presenting a possible confound in the assessment of depression and anxiety among 
individuals with PD. Criterion and discriminant validity were both demonstrated. 
Participants who reported an existing psychiatric diagnosis had significantly higher 
scores on all three DASS-21 subscales compared to those without, and all three 
scales showed a fair degree of accuracy in differentiating between the two groups 
(area under the curve = .70). Overall, Study 2 provided strong support for the use of 
the DASS-21 as an outcome measure in the present work as well as in research and 
clinical settings involving individuals with PD in general, although a more 
comprehensive examination of psychometric and clinimetric properties is needed.  
 
7.2.3 Study 3: A Randomised Controlled Trial of Group Cognitive Behavioural 
Therapy for Depression and Anxiety in Parkinson’s Disease 
 Study 3 was the first randomised waitlist-controlled trial of group CBT for 
depression and anxiety in PD. This study aimed to make a direct contribution to the 
empirical treatment literature on depression and anxiety in PD by evaluating the 
efficacy of an 8-week PD-specific group CBT intervention. The results of this trial 
were positive and provided preliminary support for the efficacy of CBT in treating 
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depression and anxiety in PD. At the end of the eight-week treatment, participants 
who received CBT experienced significant improvements in depression, anxiety and 
stress, while the only significant change observed for participants in the waitlist 
control was a small improvement in stress. Posttreatment effect sizes for depression 
(d = 1.12) and anxiety (d = .89) were both large and consistent with effect size 
estimates reported by Dobkin and colleagues (2011) for individual CBT in PD. 
Follow-up analyses showed significant reductions in depression, anxiety and stress 
symptoms as well as significant declines in the frequency of depressive and anxious 
thoughts at both 1-month and 6-month follow-ups. At 6-month follow-up, 
statistically significant and large effect sizes were observed for each of the DASS 
factors; Depression (d = 2.07), Anxiety (d = 2.26) and Stress (d = 1.66), as well as 
both of the CCL factors; Depressive cognitions (d = .94) and Anxious cognitions (d 
= 1.45). Overall, Study 3 provided support for the efficacy of group CBT for 
depression and anxiety in PD.  
 
Despite these positive results, significant recruitment difficulties encountered 
during Study 3 ultimately reduced the validity and generalisability of the study’s 
findings. Despite widespread recruitment efforts over a 28-month period, only 18 
individuals with PD took part in the trial. Examination of the literature revealed that 
similar recruitment difficulties had been encountered by previous researchers 
evaluating both pharmacological and non-pharmacological treatments for depression 
in PD. This observation led to the speculation that individuals with PD experiencing 
psychological difficulties may not be seeking professional treatment, ultimately 
resulting in the conceptualisation of Study 4. 
 
7.2.4 Study 4: An Exploratory Study of Barriers to Seeking Psychological 
Treatment in People with PD 
 Study 4 was the first to explore mental health service utilisation and barriers 
to psychological treatment in an Australian PD population. A cross-sectional survey 
methodology was employed and responses were received from 327 adults with PD. 
This study confirmed the underutilisation of mental health services among the PD 
population. Despite clinically significant symptoms of depression and/or anxiety in 
up to 59% of the sample, only 8% of participants were currently engaged in some 
form of professional treatment. As a positive however, attitudes towards and 
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intentions regarding seeking future psychological treatment were generally positive 
among the sample, with 70% of participants indicating that they would be willing to 
seek professional treatment. Significant predictors of willingness to seek mental 
health treatment among the sample were largely the same as those previously 
reported for older adults in general.  Treatment experience, higher help-seeking 
propensity and beliefs about the efficacy of treatment and higher self-stigma in 
relation to social inadequacy were all associated with an increase in the likelihood of 
a participant being willing to seek treatment, while increasing age and perceptions 
that treatment-seeking is associated with personal weakness were associated with a 
reduction in the likelihood of being willing to seek treatment. The most significant 
and unique finding of Study 4 was that participants whose PD physicians had 
discussed with them the range of psychological symptoms that can present in PD 
were 2.2 times more likely to be willing to seek future psychological treatment, 
ultimately highlighting the integral role of primary PD physicians in facilitating 
mental health treatment.  
 
The next part of this chapter integrates the findings presented in this thesis 
and presents a general discussion of key results, fundamental issues, and implications 
for researchers, practitioners and individuals with PD alike. 
 
 
7.3 Depression and Anxiety in PD:  
Contribution of Research Findings to the Current State of Knowledge  
 
 Over the past 25 years, scientific interest into psychological and other non-
motor complications in PD has significantly increased, with a five-fold increase in 
the number of scientific articles on depression and anxiety in PD published between 
1986 and 2011 (Weintraub & Burn, 2011). Although initially considered secondary 
aspects of PD, the clinical significance of depression, anxiety and other psychiatric 
disturbances in PD is now widely acknowledged, with the recent emergence of a 
movement towards the reconceptualisation of the classic definition of PD to 
incorporate cognitive and psychiatric symptoms as core elements of the disease (i.e., 
Stern, Lang, & Poewe, 2012) perhaps the most significant acknowledgement of the 
importance of psychological complications in PD.   
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 In a recent review of the current state of knowledge regarding depression and 
anxiety in PD, Weintraub and Burn (2011) outlined five key areas of research in the 
field of psychological disturbances in PD. The following is a review of each of these 
areas along with an outline of the contribution of the current research to scientific 
knowledge in each area. 
 
7.2.1 The Clinical Significance of Depression and Anxiety in PD 
There has been much work into the epidemiology and clinical significance of 
depression and anxiety in PD. While the marked prevalence of depression and 
anxiety in PD has long been recognised, recent longitudinal studies have shown that 
the clinical significance of psychological and cognitive disorders in PD is even 
greater than initially thought, with most psychiatric disturbances in PD having a 
prevalence of well over 50% (Weintraub & Burn, 2011). The current research adds 
further support to the vast literature attesting to the clinical significance of depression 
and anxiety in PD. Among a non-clinical sample of 327 Australian adults with PD in 
Study 4, 43% of participants had clinically relevant symptoms of depression, 59% 
displayed clinically relevant anxiety symptoms, and mean levels of depressive and 
anxiety symptoms within the sample corresponded to 81st and 89
th
 percentile 
rankings in terms of severity, respectively. Rates of existing (past or current) 
psychiatric diagnoses among the sample were lower at 21%  however this figure is 
likely lower than the true prevalence of psychological conditions among the sample 
given that the underdiagnosis of psychological conditions is widely acknowledged 
(Okun & Watts, 2002). 
 
In particular, this research adds to an emerging number of studies 
highlighting the significance of anxiety disorders in PD (e.g., Dissanayaka et al., 
2010; Leentjens et al., 2012). To the author’s knowledge, this is the largest 
assessment of the prevalence of anxiety symptoms within an Australian PD sample 
to date. Across both clinical (Study 3) and non-clinical samples (Study 4), there was 
a greater frequency as well as higher severity of anxiety among participants. Within 
the clinical sample, 17 of 18 participants (94%) met DSM-IV-TR criteria for at least 
one anxiety disorder and pretreatment severity of anxiety was ‘Severe’ 
corresponding to a >99
th
 percentile ranking. Depressive disorders were significantly 
lower within the sample (39%) and pretreatment severity of depressive symptoms 
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was Moderate. Among the non-clinical sample, 59% of the sample of 327 
participants displayed clinically relevant symptoms of anxiety compared with 43% 
for depression. This result is consistent with the findings of a recent and the largest 
study of anxiety symptoms in PD to date by Negre-Pages and colleagues (2010) who 
also reported a higher prevalence of clinically relevant anxiety symptoms (51%; 
HADS-A > 7) among a sample of 450 of French adults with PD than depressive 
symptoms (40%; HADS-D > 7). Thus, while much of the literature on psychiatric 
disturbances in PD has primarily focused on depression in PD, the current findings 
add to an emerging body of research strongly highlighting the study of anxiety 
disorders as an important and independent area of research in PD.  
 
7.2.2 The Clinical Impact of Depression and Anxiety in PD 
A second key area of research in the psychological PD literature has been 
focused on investigating the correlates of depression, anxiety and other non-motor 
symptoms in PD to provide insight into the clinical impact of these conditions in PD. 
A multitude of studies have shown that depression and anxiety are strongly 
associated with a number of negative outcomes including excess disability, lower 
health status, poorer PD outcomes, higher caregiver burden, and risk of 
institutionalisation (i.e., Behair et al., 2005; Carod-Artal et al., 2008; Chaudhuri & 
Martinez-Martinez, 2008; Den Oudsten et al., 2007; Hagell et al., 2002; Hinnell et 
al., 2011; Rahman et al., 2008; Schrag et al., 2000). In particular, a  body of research 
has demonstrated that non-motor and psychological symptoms are consistently rated 
as more detrimental to quality of life and well-being than motor symptoms (Rahman 
et al., 2008; Soh et al., 2011), even in the most advanced stages of disease where 
motor symptoms have fully progressed (i.e., Hely et al., 2005). 
 
The current research adds further empirical support to this knowledge base. 
Study 4 replicated the findings of existing studies showing that it is non-motor, and 
particularly, psychological symptoms, that are the strongest determinants of poor 
quality of life in PD. Across 17 common motor, autonomic, gastrointestinal, 
cognitive and psychological symptoms of PD, the only significant predictors of poor 
quality of life among participants were all non-motor symptoms namely; Confusion, 
Anxiety, Stress, Depression and Incontinence. The four cardinal motor symptoms of 
PD (rigidity, tremor, postural instability and bradykinesia) had no significant impact 
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on quality of life. While this is certainly not a novel finding, it is an important one. 
There have been many empirical investigations into the determinants of quality of 
life in PD conducted in locations across the world including Australia (Hely et al., 
2005), India (Behair et al., 2005), the United Kingdom (Hinnell et al., 2011; Rahman 
et al., 2008; Schrag et al., 2000), Norway (Karlsen, 1999; 2000), and Finland (Kupio, 
2000). All of these studies have reported the same finding – that depression is the 
most significant contributory factor to poor quality of life in PD. The consistency of 
this finding across different measures of quality of life and depression and different 
study designs and participants is remarkable and only further highlights the 
importance of depression in PD and the need for appropriate clinical and research 
attention. 
 
In addition, Study 4 again highlighted the clinical significance and impact of 
anxiety in PD and the need for appropriate clinical and research attention. In the 
multiple regression analysis, anxiety symptoms (DASS-A) were found to be a 
stronger unique predictor of poor quality of life among participants (sr = .12) than 
depressive symptoms (sr = .09). In a previous investigation of quality of life in PD, 
Rahman and colleagues (2008) demonstrated that anxiety symptoms significantly 
accounted for a further 17% of unique variance in quality of life in addition to the 
variance already explained by depressive symptoms. This was the first study to 
recognise the additional contribution of anxiety to health-related quality of life in PD. 
To the author’s knowledge, the present study was the first to show that anxiety 
symptoms may have a more detrimental effect on subjective well-being than 
depressive symptoms in PD, which serves to reinforce the need for more research 
into anxiety disorders in PD.  
 
7.2.3 Aetiology of Depression and Anxiety in PD 
 Continuing investigations into the aetiology of depression and anxiety in PD 
are of utmost importance for the development of optimal treatment interventions. 
Currently, there is a general consensus among researchers that depressive and 
anxiety disorders likely manifest in PD as a result of a complex interaction between 
neurochemical changes inherent within the PD degenerative process and 
environmental stressors associated with living and coping with a chronic and 
progressively disabling illness (Poewe & Seppi, 2001; Serra-Mestres & Ring, 2002), 
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however, no model accounting for this process has been proposed.  Previous broad 
psychological explanations for the aetiology of psychological disorders in PD have 
suggested that depression and anxiety in PD are likely to develop as a reactive 
consequence to the many life changes, lossess and stressors associated with living 
and coping with a chronic illness, however this explanation lacks an account of the 
role of the PD neurochemical changes in the development of psychopathology. Other 
previous research has proposed that neurochemical changes inherent within PD are 
likely to place individuals with PD at greater vulnerability for developing depression 
and anxiety however it has not been suggested as to how this vulnerability operates.  
 
In Chapter 3.2.1, the Cognitive Model was outlined as a potential explanation 
for the occurrence of psychological disturbances in PD. It was proposed that 
neurochemical changes in PD are likely to lower the activation thresholds of latent, 
dysfunctional schemas thereby making it easier for individuals with PD to develop 
depression and/or anxiety in response to the many stresses, changes and challenges 
associated with living and coping with PD. The cognitive model appears to be a 
promising explanation that is able to account for both the elevated levels of 
depression and anxiety in PD relative to other medical populations (i.e., lowered 
schema-activation threshold due to PD-related neurochemical changes) as well as 
why not all individuals with PD develop depression and/or anxiety (i.e., dependent 
on individual core beliefs shaped by early developmental experiences and reaction to 
stressful experiences in later life). Empirical tests are needed to test the validity of 
this aetiological model, however, it is acknowledged that this may be difficult to 
accomplish as there is no clear method of directly and objectively measuring schema 
activation thresholds.  
 
7.2.4 Validation of Screening Instruments for Depression and Anxiety in PD 
 The fourth key area of psychological research in PD identified by Weintraub 
and Burn (2011) was in relation to screening instruments for depression and anxiety 
in PD. The authors stated that research into the evaluation and validation of 
screening instruments for depression and anxiety in PD is important for enhancing 
both clinical management and the quality of scientific research. Over the past five 
years particularly, there have been significant advances in the number of validated 
rating scales for depression and anxiety in PD. Scales that have now been validated 
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in PD populations include the Ham-D, BDI-II, GDS and HADs for depression, and 
the Ham-A, BAI, HADs and GAI for anxiety.  
 
The current research contributed to this area of knowledge by providing 
evidence of the validity and reliability of the DASS-21 as a screening tool for 
depression, anxiety and stress in a PD population. Currently, expert taskforces in PD 
recommend the use of the BDI and BAI as clinical screening tools for depression and 
anxiety in PD due to their self-report nature and thus ability to enhance time-
effectiveness (i.e., Leentjens et al., 2012; Schrag et al., 2007). Study 4 showed that 
the DASS-21 may be a suitable alternative to the BDI and BAI in PD. The DASS-21 
showed strong evidence of factorial validity, internal consistency, criterion validity, 
and diagnostic accuracy, comparable to the psychometric properties reported for both 
the BDI and BAI in PD populations. A particular strength of the DASS-21 appears to 
be its ability to provide an assessment of anxiety and depressive symptoms in PD 
that is not confounded or inflated by an overlap with PD symptoms, with only one 
item (Item 6: ‘trembling in the hands’) on the DASS-21 representing a symptom 
overlap between the three conditions. This is in direct contrast with the BAI which 
contains nine items (43%) that may present a potential confound in the assessment of 
anxiety among individuals with PD as items overlap with PD symptoms (i.e., 
numbness or tingling, feeling hot, wobbliness in legs, dizzy, unsteady, hands 
trembling, shaky, indigestion, hot/cold sweats). Moreover, the DASS-21 has the 
additional benefits of being more time- and cost-effective than the BDI and BAI as it 
assesses both depression and anxiety within the same scale and is available in the 
public domain, and thus may be particularly suitable for use in large-scale, 
epidemiological or longitudinal research. Further research is required to provide a 
more comprehensive examination of the psychometric and clinimetric properties of 
the DASS-21 in PD but at this stage it would appear that the DASS-21 is a reliable 
and valid measure of depression and anxiety in PD. 
 
7.2.5 Treatment of Depression and Anxiety in PD 
 Given the significance and impact of depression and anxiety in PD, research 
into the treatment of these conditions in PD is arguably the most important area of 
work. However, Weintraub and Burn (2011) state that scientific knowledge in this 
area remains the most limited and described the paucity of controlled research in this 
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area a significant ‘source of frustration’. The current research added two unique 
contributions to the existing knowledge regarding the treatment of depression and 
anxiety in PD.  
 
Study 1 provided the first meta-analysis of both pharmacological and non-
pharmacological treatments for depression in PD, as well as the first meta-analysis of 
any kind for anxiety in PD. This study offered three unique contributions to the 
literature. First, this study was the first meta-analysis to provide a controlled pooled 
effect size estimate for antidepressant therapies for depression in PD. While there 
have been four prior meta-analyses assessing the efficacy of antidepressant therapies 
for depression in PD to date (Klaassen et al., 1995; Rocha et al., 2013; Skapinakis et 
al., 2010; Weintraub et al., 2005), none of these reviews calculated a pooled effect 
size of antidepressant therapies in PD.  There was insufficient empirical data to do so 
at the time of the two earlier reviews (i.e., Klaassen et al.; Weintraub et al.), while 
the two most recent meta-analyses of antidepressants (Rocha et al., 2013; Skapinakis 
et al., 2010) calculated and reported risk ratios for antidepressant response in PD 
rather than standardised treatment effects. Study 1 reported a moderate but non-
significant pooled effect for both antidepressant therapies in general in PD (d = .71, 
95% CI = -1.33 to 3.08) and current first-line SSRI treatments (d = .57, 95% CI = -
1.33 to 2.47).  
 
The finding that both antidepressants in general and SSRI therapies have a 
non-significant pooled effect on depression in PD relative to placebo is consistent 
with all three prior meta-analyses as well as previous systematic reviews in PD (i.e., 
Chung et al., 2007). However, while earlier reviews suggested that this result 
indicates that the widespread use of antidepressants in PD is largely unjustified, the 
magnitude of the pooled effect obtained in this study suggests that antidepressant 
therapies show promise in the treatment of the depression in PD. A pooled effect size 
of .71 is of moderate to large magnitude and indicates that individuals with PD 
treated with antidepressants do experience a reduction in depressive symptoms 
compared with placebo, even if this effect is statistically non-significant. At this 
stage, it is likely that the non-significance of the pooled effect for antidepressants in 
PD reflects a Type II error due to the very limited number of available placebo-
controlled RCTs in the literature at present. Consequently, there is a need for more 
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controlled research to resolve the amibiguity surrounding the efficacy of 
antidepressant therapies in PD at present. 
 
However, although antidepressant therapies do show promise in terms of 
symptom reduction, there still remains potent concerns regarding polypharmacy, 
adverse drug interactions and harmful side effects. Thus, Study 1 also systematically 
evaluated the efficacy of non-pharmacological treatment interventions for depression 
in PD as these offer a safer alternative, and was the first meta-analysis to include 
both pharmacological and non-pharmacological treatment interventions for 
depression in PD. The comparison of pharmacological and non-pharmacological 
interventions highlighted the potential of non-pharmacological treatments as viable 
alternatives to current mainstay antidepressant therapies. Two trials of non-
pharmacological interventions for depression in PD resulted in large and statistically 
significant effects on depressive symptoms relative to placebo; Omega-3 
supplementation (d = .92, 95% CI = .15 to 1.69; Da Silva et al., 2008) and individual 
CBT (d = 1.57, 95% CI = 1.06 to 2.07). The trial of individual CBT in particular 
resulted in the largest effect on depression in PD over all other interventions in the 
analysis and highlighted the potential of this treatment modality for use with 
individuals with PD.  
 
Finally, Study 1 was also the first meta-analysis of any kind for the treatment 
of anxiety in PD. The dearth of empirical research on the treatment of anxiety 
disorders in PD was again highlighted in this study, with no RCTs of any treatment 
intervention for anxiety in PD identified. Data from four depression trials reporting 
the secondary effect of treatment on anxiety were used to examine the efficacy of 
pharmacological and non-pharmacological treatments for anxiety in PD at present. 
The results for this analysis mirrored those reported for depression. Antidepressant 
therapies in general (d = 1.13, 95% CI = -.67 to 2.94) and SSRI treatments (d = .85, 
95% CI = -.40 to 2.09) both had large but statistically non-significant effects on 
anxiety. Again, rather than indicate that antidepressants are not effective for anxiety 
in PD, this result shows that pharmacological treatments are promising in the 
treatment of anxiety in PD but there is a need for more research to establish a more 
valid assessment of treatment effect.  Again, the potential of CBT was highlighted in 
this second analysis. The individual CBT trial by Dobkin and colleagues (2011) also 
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resulted in a significant and large secondary effect on anxiety in PD (d = 1.03; 95% 
CI = .57 to 1.50). CBT was the only intervention to result in large and statistically 
signficant reductions in both depresion and anxiety in PD. Thus, while the main 
focus of the empirical literature on the treatment of depression and anxiety in PD has 
been on pharmacological treatments, the results of this meta-analysis strongly 
suggest that future research needs to also be directed at the development and 
evaluation of CBT interventions in PD. 
 
Following from the findings of the meta-analysis and particularly the 
potential of CBT in the treatment of depression and anxiety in PD, the second 
contribution of the present research to current knowledge regarding the treatment of 
depression and anxiety in PD was Study 3. This study was the first controlled 
examination of a group CBT intervention for depression and anxiety in a PD sample. 
While increasing evidence of the efficacy of individual CBT for depression and/or 
anxiety in PD has emerged in recent times, group CBT treatments remain 
understudied despite clear practical and therapeutic advantages that are particularly 
suited for older adults and individuals with chronic illnesses. Study 3 thus aimed to 
make a direct contribution to the empirical treatment literature on depression and 
anxiety in PD by evaluating the efficacy of an 8-week PD-specific group CBT 
intervention. The results of this trial provided preliminary support for the efficacy of 
CBT in treating depression and anxiety in PD and showed significant and large 
reductions in both depression (d = 1.12) and anxiety (d = .89) at postreatment relative 
to waitlist control, comparable with the results repored by Dobkin and colleagues 
(2011) for individual CBT for depression in PD (depression; Ham-D, d = 1.57; BDI, 
d = 1.1; anxiety; Ham-A, d = .98).  
 
In particular, this study highlighted the potential long-term efficacy of CBT 
in the treatment of depression and anxiety in PD. To date in the literature, the 
maximum length of follow-up for a CBT study has only been one month. Study 3 
showed that all acute treatment gains for the Intervention group were maintained and 
continued to improve at 6-month follow-up (ds = .94 to 2.26). This result is 
especially encouraging given that one of the most pertinent criticisms of existing 
pharmacological regimens for depression and anxiety in PD relates to the 
questionable long-term utility of such treatments and high relapse rates. The long-
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term utility of CBT has been attributed to the focus on self-management and problem 
solving as well as the development of skills that enable clients to address any 
problems that may arise following cessation of therapy. Overall, this research 
supports the assertion that while there is a broad equivalence in the efficacy of CBT 
and pharmacotherapy in the acute phase of treatment, the long-term utility of CBT 
may indicate that it is a more beneficial treatment for depression and anxiety in PD 
on the whole. It is hoped that this research will inspire future researchers to continue 
with empirical investigations into the utility of CBT in PD. 
 
7.2.6 A Sixth Area for Psychological Research in PD: Understanding the 
Underutilisation of Mental Health Services 
Finally, in addition to the contribution of the current research to the five 
existing key areas in relation to depression and anxiety in PD, this research identified 
a novel area of research that has yet to be extensively explored in PD; understanding 
the underutilisation of mental health services among individuals with PD. Much of 
the present research and clinical work into depression and anxiety in PD has been 
focused on understanding underlying causes to ultimately develop effective 
treatments. While ongoing development and evaluation of optimal treatment options 
for depression and anxiety is essential to ensure that depressive and anxiety disorders 
are most effectively managed in PD, it must be reiterated that such treatments are 
only valuable to the extent that they are utilised by the individuals they are designed 
to help. Study 3 raised speculation regarding the underutilisation of mental health 
services among individuals with PD; despite widespread recruitment efforts over a 
28-month period, only 18 eligible individuals with PD volunteered to take part in the 
clinical trial. Study 4 then confirmed the underutilisation of mental health services 
among individuals with PD. Despite elevated symptoms of depression and anxiety, 
only 8% of a sample of 327 Australian adults with PD were currently engaged in 
some form of professional treatment. 
 
While previous research has suggested that stigma, negative help-seeking 
attitudes, increased functional disability, financial concerns and overshading concern 
for physical illness can often act as significant barriers to seeking psychological 
treatment for older adults, Study 4 showed that this was not the case within the 
present sample. It was a welcoming finding to note that attitudes and intentions 
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towards seeking professional psychological treatment were generally very positive 
among participants with 70% of participants indicating that they would be willing to 
seek mental health treatment in the future. Similarly, help-seeking attitudes were 
high among the sample while mental illness-related stigma was low and concerns 
regarding additional costs or PD-related factors were not a significant issue for the 
majority of participants. Thus, there appeared to be another factor underlying the 
underutilisation of mental health services among the sample. It was hypothesised that 
the underutilisation of mental health services in PD may stem from a lack of 
awareness on behalf of individuals with PD. Previous studies have demonstrated a 
significant lack of awareness regarding psychological symptoms among people with 
PD that is directly linked with failure on the part of PD physicians to discuss non-
motor symptoms (Chaudhuri & Schapira, 2009; Shulman et al., 2002). Indeed, it was 
found that the majority of participants’ primary PD physician had never discussed 
with them the range of psychological and other non-motor symptoms that can present 
in PD. However, the logistic regression analysis showed that when PD physicians 
had initiated a discussion regarding psychological symptoms with patients, 
participants were 2.2 times more likely to be willing to seek future psychological 
treatment, ultimately highlighting the integral role of PD physicians in raising 
awareness and facilitating mental health treatment for patients. Further research is 
required to directly assess awareness of psychological symptoms in PD and its 
influence on mental health treatment utilisation however it is hoped that this seminal 
study will pave the way for future researchers in this area.  
 
 Overall, although significant advances in both research and clinical efforts 
into addressing depression and anxiety in PD have been observed over the past 25 
years, there is still significant room for improvement in optimising the clinical 
management of depression and anxiety in PD. The next section outlines several 
clinical recommendations based on the findings of this research that may be helpful 
in improving the provision of psychological treatment to individuals with PD. 
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7.3 Clinical Recommendations 
 
 Currently, there are no best practice guidelines or procedures in place to aid 
PD physicians in diagnosing and treating depression and anxiety in PD. The 
following are stepped recommendations based on the findings of this research. 
 
7.3.1 Step 1: Facilitating Awareness of Depression and Anxiety in PD 
 PD physicians need to take an active role in raising patient awareness in 
regards to depression, anxiety and other non-motor symptoms in PD. Ideally, this 
should be done as close to initial diagnosis as possible to promote understanding that 
PD is more than just a motor disorder from the outset. Previous research has shown 
that one of the primary reasons individuals with PD fail to disclose non-motor 
symptoms to PD neurologists is because they are not aware that such symptoms are 
linked with PD (Chaudhuri, 2003). Facilitating awareness would be best achieved 
through a discussion with patients and their caregivers. Along with outlining the 
range of non-motor symptoms, physicians should also encourage patients to report 
non-motor symptoms as they experience them. Study 4 showed that participants 
whose primary PD physician had initiated a conversion regarding the range of 
psychological complications that can manifest in PD were 2.2 times more likely to be 
willing to seek mental health treatment.  
 
Given that the time-limited nature of neurological consultations in PD has 
been previously described (Weller et al., 2004), it would also be acceptable to 
provide patients with educational materials outlining the range of psychological and 
other non-motor symptoms of PD, how to recognise them, and emphasising that 
reporting of non-motor symptoms is as important as reporting motor symptoms in 
PD. It may also be useful to include materials emphasising the importance of treating 
psychological symptoms and how their treatment can improve other aspects of PD 
including cognition, independence, motor functioning and quality of life in light of 
Study 3 findings that beliefs regarding efficacy of treatment also significantly 
increase the likelihood of treatment-seeking. Materials promoting the utility and 
benefits of treatment may also serve to dispel any misconceptions and/or negative 
beliefs regarding mental health treatment among older-older adults. 
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7.3.2 Step 2: Screening for Depression and Anxiety in PD 
 Screening for depression and anxiety in PD should be conducted with all 
individuals with PD, and not just with patients who report psychological symptoms. 
Study 4 showed a discrepancy between level of severity of depressive and anxiety 
symptoms among the sample and rates of clinical diagnoses supporting the assertion 
that the majority of cases of depression and anxiety in PD are undetected (McDonald 
et al., 2003). Screening for depression and anxiety in PD can be easily accomplished. 
Okun and Watts (2002) suggested that PD physicians ask patients to complete self-
rating scales in the waiting room before an appointment. Screening using rating 
scales is quick, convenient and can be highly effective in detecting signs of 
psychological disturbance in PD (Okun & Watts). Scores on these scales can then be 
used to determine whether patients require a more comprehensive clinical 
assessment.  Selection of appropriate scales for use with persons with PD is essential, 
however. A recent Movement Disorder Society task review identified the BDI as the 
most appropriate clinical screening tool for depression in PD due to its self-report 
nature and previous validation in a PD sample. Study 2 showed that the DASS-21 is 
also a valid measure in PD. Moreover, the DASS-21 assesses both depression and 
anxiety as well as stress symptoms and is available in the public domain thus 
enhancing both time- and cost-effectiveness. 
 
7.3.3 Step 3: Clinical Assessment of Depression and Anxiety in PD 
 PD physicians should be involved in the assessment process for depression 
and anxiety in PD. A comprehensive assessment process is crucial for detecting 
depression and anxiety in PD especially given the symptom overlap between the 
three conditions. While this assessment will most likely be conducted by a mental 
health professional or general practitioner rather than the PD neurologist, PD 
specialists still should play an active role in this process. The DSM-IV-TR operates 
on an exclusive diagnostic approach and advises that symptoms than can be clearly 
and fully accounted for by a general medication be excluded from any psychological 
diagnosis and it has been suggested that PD neurologists are the most suitably 
qualified professionals to make this distinction (Chaudhuri et al., 2006). Thus, even 
if not primarily responsible for conducting assessment or treatment, PD neurologists 
need to work closely with the assessing professional in order to enhance the accuracy 
of diagnosis.  
 252
7.3.4 Step 4: Treatment of Depression and Anxiety in PD 
 SSRI treatments should not automatically be considered the treatment of 
choice for depression and anxiety in PD and individuals with PD should be 
giventreatment options. The preference for administering pharmacological treatments 
for depression and anxiety among PD physicians is widely documented (Palanci et 
al., 2011). However, Study 1 showed that there is currently no empirical evidence to 
suggest that SSRIs are more beneficial than placebo for the treatment of depression 
or anxiety in PD. Moreover, Study 4 showed that in contrary to physician 
preferences, 64% of participants with PD indicated a preference of psychotherapy 
over pharmacological treatments for psychological complications. This finding is 
particularly important given that matching treatment to patient preference has been 
shown to enhance treatment outcome (Oehlberg et al., 2008; Sotsky et al., 1991), 
service utilisation (Dwight-Johnson, Unutzer, Sherbourne, Tang, & Wells, 2001), 
and patient satisfaction (Bedi et al., 2000). Thus where possible, physicians should 
offer patients a choice of pharmacological and non-pharmacological treatments. 
 
 Physicians should consider the potential of CBT as alternative to 
pharmacological interventions for depression and anxiety in PD. Study 1 highlighted 
CBT as a potential treatment of choice for depression in PD, with a recent RCT of 
individual CBT resulting in the largest effect size for depression over all other 
interventions. Study 3 provided further empirical support for this finding. After eight 
weeks of treatment, participants who received CBT treatment showed significant 
large improvements in both depression and anxiety while participants in the waitlist 
condition showed no significant change. Effect size estimates were larger than has 
been reported for pharmacotherapy for depression and anxiety in older adult 
populations (Pinquart & Duberstein, 2007) and may indicate that CBT is more 
efficacious than pharmacotherapy for depression and anxiety in PD. Moreover, Study 
3 showed that Group CBT was a feasible and accepted treatment approach with only 
an 11% attrition rate compared to rates of 14 to 73% in antidepressant trials in PD. 
When considering that the major criticisms of current mainstay antidepressant 
treatments in PD are related to a lack of efficacy, aversive side effects and high 
relapse rates, it would appear that CBT has the potential to constitute a more 
beneficial treatment option on the whole if similar rates of efficacy to those reviewed 
in this research can be found in future trials.  
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7.4 Recommendations for Future Research 
  
Comprehensive recommendations and directions for future research for each 
study were presented in the respective chapters. These recommendations are 
summarised in the following section.  
 
7.4.1 Treatments for Depression and Anxiety in PD 
 Continuing research and development into optimal treatments, both 
pharmacological and non-pharmacological, for depression and anxiety is duly 
needed. From this research are four specific recommendations for future researchers. 
 
1. Resolve the ambiguity surrounding the efficacy of SSRIs in PD. There is a 
pressing need for more controlled trials of SSRIs for depression and anxiety 
in PD. Given that SSRIs currently constitute the first-line and most widely 
used treatments for depression and anxiety in PD, it is important to resolve 
the present ambiguity regarding the efficacy of this class of medications to 
ensure that individuals with PD are being offered the most optimal first-line 
treatment. 
 
2. Conduct specific research into the treatment of anxiety in PD. Treatment 
trials specifically for anxiety in PD are duly needed. While the empirical 
literature for depression treatments in PD is steadily increasing, there remains 
no RCTs of any pharmacological or non-pharmacological treatments for 
anxiety in PD. There are core components of anxiety disorders that are 
distinct from depression and that require specific clinical attention.  
 
3. Continue with preliminary trials of CBT for depression and anxiety in 
PD. Preliminary data indicates that CBT is an efficacious treatment approach 
for depression and anxiety and in PD however in light of the limitations of 
Study 3, it is recommended that future researchers continue with conducting 
preliminary trials with a larger sample to provide a more reliable estimate of 
the effect of group CBT in PD. Future preliminary trials should also 
implement a longer control period to provide a more reliable assessment of 
long-term utility. 
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4. Conduct active comparison trials of CBT for depression and anxiety in 
PD. Following preliminary trials, the next step in establishing the efficacy of 
group CBT for depression and anxiety in PD would be to conduct large 
efficacy trials across multiple sites with active control conditions. Active 
control conditions should include: (1) alternate psychological interventions 
(to examine the effect of non-specific treatment factors on change), (2) SSRIs 
(to allow a direct comparison of the efficacy of group CBT relative to current 
first-line treatments) and (3) individual CBT (to examine any significant 
differences in efficacy between the two modalities). 
 
7.4.2 Barriers to Seeking Psychological Treatment in PD 
 While ongoing development and evaluation of optimal treatment options for 
depression and anxiety is essential to ensure that depressive and anxiety disorders are 
most effectively managed in PD, such treatments are ultimately only valuable to the 
extent that they are utilised by the targeted population. Therefore ongoing research 
into the underutilisation of mental health services in PD is also crucial. Future 
researchers in this area should: 
  
1. Replicate Study 4 in a random sample of PD participants. While Study 4 
had an adequate sample size, the convenience sampling method restricts the 
representatitveness and generalisability of findings. Replication of the study 
in a larger and more representatitve sample of individuals with PD will 
provide a more valid assessment of any barriers to seeking psychological 
treatment among individuals with PD. 
 
2. Directly assess the influence of lack of awareness of psychological 
symptoms in PD on willingness to seek mental health treatment. This 
research found that it is a lack of awareness regarding psychological 
symptoms in PD that contributes to lessened willingness to seek treatment. A 
direct assessment is needed to draw more valid conclusions. Future research 
should directly assess awareness by listing a range of motor and non-motor 
symptoms and asking participants to select all symptoms which they believe 
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to be a part of PD, then examining the impact of levels of awareness on 
willingness to seek treatment. 
 
3. Investigate the gap between attitudes and willingness to use mental 
health services, and actual service utilisation. This research showed that 
despite positive intentions to use mental health services, actual service usage 
statistics are disproportionately lower suggesting the presence of a mediating 
factor that was not included in the present analysis. Perceived need was 
identified as the potential mediating factor. A longitudinal study specifying 
and testing a path model capturing the complex relationship between 
demographic and clinical variables, help-seeking attitudes, stigma, resources, 
intentions, perceived need and actual service usage would be instrumental in 
furthering current understanding of the decision process underlying mental 
health service usage. 
 
7.4.3 Validation of Psychometric Scales in PD 
 Finally, there is also some work to be done in the area of validation of 
psychometric scales in PD. Specifically, future researchers should: 
 
1. Replicate the factor structure of the DASS-21 in a larger PD sample. 
While the sample size in Study 2 exceeded the minimum required for factor 
analysis, Tabachnick and Fidell (2011) recommend larger sample (N = 500 to 
1000) to allow for more reliable estimation of correlation coefficients. 
 
2. Conduct a more comprehensive examination of the psychometric and 
clinimetric properties of the DASS-21 (e.g., sensitivity, specificity, 
convergent validity, test-retest reliability etc.). As the data for Study 2 was 
not collected specifically for the purpose of scale evaluation, full evaluation 
of the psychometric and clinimetric properties of the DASS-21 was not 
possible. In particular, a study directly comparing the DASS-21, BDI and 
BAI among a single sample would provide useful insight into the 
comparative utility of the DASS-21 against the currently recommended scales 
for use in PD. 
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3. Investigate the scale structure and psychometric properties of the full 
IASMHS, SSDS and DSS scales. Preliminary evidence for the reliability and 
validity of the IASMHS, SSDS and DSS was presented in Study 4. However, 
as only partial subscales of these measures were used in this research, 
investigation of the structure and properties of each scale in its entirety was 
not possible. Future researchers will need to administer and evaluate the 
structure of the full IASMHS, SSDS and DSS in PD. 
 
4. Consider item and scale refinement of the Needs Survey to improve 
internal consistency.  Finally, there is a need for some work to be done in 
relation to scale and item refinement in the Needs Survey if future researchers 
would like to continue using the measure in inferential analyses. Using 
Principal Components Analysis, Study 4 showed that, overall, the NS items 
are relatively reliable indicators of the components that Weinberger and 
colleagues (2011) suggested especially considering that items were not 
generated based on a rigorous theoretical grounding, however there is room 
for improvement. A number of items loaded poorly onto the specified 
component and a degree of cross-loadings was present, which ultimately 
contributed to the low-to-moderate Cronbach’s alpha values for each 
component. Item refinement will thus be useful in minimising cross-loadings 
and improving internal consistency. 
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7.6 Closing Words 
 
When one thinks of Parkinson’s disease, the image that is conjured is 
typically dominated by physical and motor ailments depicting a loss of control of 
one’s own body – trembling limbs, a stooped posture, shuffling gait and involuntary, 
jerky movements. As described by Michael J. Fox, ‘Every unwanted movement in my 
hand or arm, every twitch that I cannot anticipate or arrest, is a reminder that even 
in the domain of my own being, I am not calling the shots.’ 
 
Throughout this thesis, cognitive and psychological symptoms of PD have 
been directly compared with motor symptoms and at times it would seem that the 
argument is made that there is an overemphasis on motor symptoms in PD. But this 
is not at all the message of this research. Rather, this research is about helping people 
with PD to enhance control over their bodies and lives and to be better equipped to 
cope with motor restrictions.  
 
There is currently no cure for Parkinson’s, meaning that progressive motor 
disability is an inescapable truth of this disease. But there are effective treatments for 
depression and anxiety. It is sincerely hoped that the research presented in this thesis 
will provide some inspiration for researchers continuing to advance knowledge in 
relation to the treatment of depression, anxiety and other psychological disturbances 
in PD.   
 
To close this thesis are two further quotes from Michael J. Fox, both 
ultimately highlighting the importance of cognitive and emotional control in PD: 
 
‘I have no choice about whether or not I have Parkinson's.. [but] I have nothing but 
choices about how I react to it’ 
 
‘If I let it affect everything, it’s gonna [sic] own everything. I don’t deny it or pretend 
it’s not there, but if I don’t allow it to be bigger than it is, then I can do anything 
else.’ 
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Appendix A  
SPSS output of DASS-D unconditional means model for calculation of intracluster 
correlation to estimate design effect 
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Appendix B  
MLM Model 1: Assumption Testing 
 
Normality of Residuals 
 
Tests of Normality 
 Kolmogorov-Smirnov
a
 Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
DepL1 Residuals .075 35 .200
*
 .989 35 .972 
ANXL1Residuals .139 35 .087 .962 35 .266 
StressL1Residuals .162 35 .021 .943 35 .067 
PDQL1Residuals .091 35 .200
*
 .990 35 .980 
CCLDL1Residuals .066 35 .200
*
 .983 35 .838 
CCLAL1Residuals .108 35 .200
*
 .981 35 .783 
DEPL2Residuals .160 35 .224 .885 35 .202 
ANXL2Residuals .106 35 .200
*
 .976 35 .627 
STRESSL2Residuals .161 35 .023 .942 35 .065 
PDQL2Residuals .107 35 .200
*
 .977 35 .673 
CCLDL2Residuals .118 35 .200
*
 .968 35 .396 
CCLAL2Residuals .094 35 .200
*
 .972 35 .509 
a. Lilliefors Significance Correction 
*. This is a lower bound of the true significance. 
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Constant variances of Residuals 
Level 1 
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Constant variances of Residuals 
Level 2 
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Independence of Residuals 
 
 
Level 1 Residuals and Units                                    Level 2 Residuals and Units 
 
Time 
    
L1_DASSD Correlation Coefficient .011 
Sig. (2-tailed) .951 
L1_DASSS Correlation Coefficient .091 
Sig. (2-tailed) .598 
L1_DASSA Correlation Coefficient -.043 
Sig. (2-tailed) .804 
L1_PDQ Correlation Coefficient -.075 
Sig. (2-tailed) .664 
L1_CCLD Correlation Coefficient -.011 
Sig. (2-tailed) .951 
L1_CCLA Correlation Coefficient .011 
Sig. (2-tailed) .951 
 
 
Across Levels (Level 1 Residuals and Level 2 Residuals) 
 
 
L2_DASSD L2_DASSA L2_DASSS L2_PDQ L2_CCLD L2_CCLA 
L1_DASSD Pearson Correlation -.009      
Sig. (2-tailed) .960      
L1_DASSA Pearson Correlation  -.214     
Sig. (2-tailed)  .211     
L1_DASSS Pearson Correlation   -.001    
Sig. (2-tailed)   .996    
L1_PDQ Pearson Correlation    -.009   
Sig. (2-tailed)    .958   
L1_CCLD Pearson Correlation     .003  
Sig. (2-tailed)     .985  
L1_CCLA Pearson Correlation      .000 
Sig. (2-tailed)      1.000 
 
Number 
 
L2_DASSD Correlation Coefficient -.276 
Sig. (2-tailed) .104 
L2_DASSA Correlation Coefficient -.054 
Sig. (2-tailed) .756 
L2_DASSS Correlation Coefficient .231 
Sig. (2-tailed) .176 
L2_PDQ Correlation Coefficient .231 
Sig. (2-tailed) .176 
L2_CCLD Correlation Coefficient .184 
Sig. (2-tailed) .283 
L2_CCLA Correlation Coefficient -.231 
Sig. (2-tailed) .176 
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Appendix C 
MLM Model 2: Assumption Testing 
 
Normality of Residuals: Intervention Group 
 
Tests of Normality
b
 
 Kolmogorov-Smirnov
a
 Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
DepL1 Residuals .085 44 .200
*
 .963 44 .168 
AnxL1Residuals .065 44 .200
*
 .990 44 .963 
SL1Residuals .070 44 .200
*
 .989 44 .954 
PDQL1Residuals .060 44 .200
*
 .988 44 .924 
CCLDL1Residuals .098 44 .200
*
 .980 44 .650 
CCLAL1Residuals .075 44 .200
*
 .979 44 .596 
DepL2Residuals .082 44 .200
*
 .960 44 .130 
AnxL2Residuals .053 44 .200
*
 .990 44 .956 
StresL2Residuals .076 44 .200
*
 .988 44 .929 
PDQL2Residuals .057 44 .200
*
 .990 44 .966 
CCLDL2Residuals .103 44 .200
*
 .975 44 .435 
CCLAL2Residuals .084 44 .200
*
 .978 44 .555 
a. Lilliefors Significance Correction 
*. This is a lower bound of the true significance. 
b. Group = Intervention 
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Constant variances of Residuals 
Level 1: Intervention Group 
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Constant variances of Residuals 
Level 2: Intervention Group 
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Independence of Residuals: Intervention Group 
 
 
       Level 1 Residuals and Units                                   Level 2 Residuals and Units 
 
Time 
    
L1_DASSD Correlation Coefficient .063 
Sig. (2-tailed) .749 
L1_DASSS Correlation Coefficient .170 
Sig. (2-tailed) .387 
L1_DASSA Correlation Coefficient -.115 
Sig. (2-tailed) .561 
L1_PDQ Correlation Coefficient -.051 
Sig. (2-tailed) .795 
L1_CCLD Correlation Coefficient -.308 
Sig. (2-tailed) .110 
L1_CCLA Correlation Coefficient -.095 
Sig. (2-tailed) .631 
 
 
 
Across Levels (Level 1 Residuals and Level 2 Residuals) 
 
 
L2_DASSD L2_DASSA L2_DASSS L2_PDQ L2_CCLD L2_CCLA 
L1_DASSD Pearson Correlation -.009      
Sig. (2-tailed) .960      
L1_DASSA Pearson Correlation  -.214     
Sig. (2-tailed)  .211     
L1_DASSS Pearson Correlation   -.001    
Sig. (2-tailed)   .996    
L1_PDQ Pearson Correlation    -.009   
Sig. (2-tailed)    .958   
L1_CCLD Pearson Correlation     .003  
Sig. (2-tailed)     .985  
L1_CCLA Pearson Correlation      .000 
Sig. (2-tailed)      1.000 
 
Number 
 
L2_DASSD Correlation Coefficient -.115 
Sig. (2-tailed) .561 
L2_DASSA Correlation Coefficient .008 
Sig. (2-tailed) .968 
L2_DASSS Correlation Coefficient -.210 
Sig. (2-tailed) .284 
L2_PDQ Correlation Coefficient -.008 
Sig. (2-tailed) .968 
L2_CCLD Correlation Coefficient .024 
Sig. (2-tailed) .905 
L2_CCLA Correlation Coefficient -.047 
Sig. (2-tailed) .810 
 316
Appendix D 
Post-hoc comparisons for MLM Model 2 
 
DASS-D 
(I) Time2 (J) Time2 
Mean 
Difference 
(I-J) 
Std. 
Error df Sig.
a
 
95% Confidence Interval 
for Difference
a
 
Lower 
Bound 
Upper 
Bound 
Pretreatment Posttreatment -2.091
*
 .798 18.512 .017 -3.763 -.419 
1m F-up -3.818
*
 .887 14.513 .001 -5.715 -1.922 
6m F-up -6.273
*
 1.082 10.407 .000 -8.671 -3.874 
Posttreatment Pretreatment 2.091
*
 .798 18.512 .017 .419 3.763 
1m F-up -1.727
*
 .554 22.385 .005 -2.875 -.579 
6m F-up -4.182
*
 .646 29.613 .000 -5.501 -2.863 
1m F-up Pretreatment 3.818
*
 .887 14.513 .001 1.922 5.715 
Posttreatment 1.727
*
 .554 22.385 .005 .579 2.875 
6m F-up -2.455
*
 .590 27.959 .000 -3.663 -1.246 
6m F-up Pretreatment 6.273
*
 1.082 10.407 .000 3.874 8.671 
Posttreatment 4.182
*
 .646 29.613 .000 2.863 5.501 
1m F-up 2.455
*
 .590 27.959 .000 1.246 3.663 
 
 
DASS-A 
(I) Time2 (J) Time2 
Mean 
Difference 
(I-J) 
Std. 
Error df Sig.
a
 
95% Confidence Interval 
for Difference
a
 
Lower 
Bound 
Upper 
Bound 
Pretreatment Posttreatment -2.000
*
 .757 26.301 .014 -3.556 -.444 
1m F-up -2.909
*
 .795 20.036 .002 -4.568 -1.250 
6m F-up -5.818
*
 .885 10.937 .000 -7.768 -3.868 
Posttreatment Pretreatment 2.000
*
 .757 26.301 .014 .444 3.556 
1m F-up -.909 .666 21.066 .187 -2.295 .477 
6m F-up -3.818
*
 .698 28.254 .000 -5.248 -2.389 
1m F-up Pretreatment 2.909
*
 .795 20.036 .002 1.250 4.568 
Posttreatment .909 .666 21.066 .187 -.477 2.295 
6m F-up -2.909
*
 .678 24.165 .000 -4.309 -1.509 
6m F-up Pretreatment 5.818
*
 .885 10.937 .000 3.868 7.768 
Posttreatment 3.818
*
 .698 28.254 .000 2.389 5.248 
1m F-up 2.909
*
 .678 24.165 .000 1.509 4.309 
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PDQ-39 
(I) Time2 (J) Time2 
Mean 
Difference 
(I-J) 
Std. 
Error df Sig.
a
 
95% Confidence Interval 
for Difference
a
 
Lower 
Bound 
Upper 
Bound 
Pretreatment Posttreatment 1.515 2.807 22.223 .595 -4.303 7.334 
1m F-up -.291 3.041 16.798 .925 -6.713 6.131 
6m F-up -4.253 3.568 10.616 .259 -12.140 3.635 
Posttreatment Pretreatment -1.515 2.807 22.223 .595 -7.334 4.303 
1m F-up -1.806 2.213 21.602 .423 -6.401 2.788 
6m F-up -5.768
*
 2.427 29.801 .024 -10.727 -.809 
1m F-up Pretreatment .291 3.041 16.798 .925 -6.131 6.713 
Posttreatment 1.806 2.213 21.602 .423 -2.788 6.401 
6m F-up -3.962 2.296 25.926 .096 -8.681 .758 
6m F-up Pretreatment 4.253 3.568 10.616 .259 -3.635 12.140 
Posttreatment 5.768
*
 2.427 29.801 .024 .809 10.727 
1m F-up 3.962 2.296 25.926 .096 -.758 8.681 
 
 
DASS-S 
(I) Time2 (J) Time2 
Mean 
Difference 
(I-J) 
Std. 
Error df Sig.
a
 
95% Confidence Interval 
for Difference
a
 
Lower 
Bound 
Upper 
Bound 
Pretreatment Posttreatment -1.455 .910 25.117 .123 -3.329 .420 
1m F-up -3.364
*
 .965 18.966 .002 -5.385 -1.343 
6m F-up -5.182
*
 1.093 10.826 .001 -7.593 -2.771 
Posttreatment Pretreatment 1.455 .910 25.117 .123 -.420 3.329 
1m F-up -1.909
*
 .777 21.205 .023 -3.523 -.295 
6m F-up -3.727
*
 .824 28.821 .000 -5.412 -2.042 
1m F-up Pretreatment 3.364
*
 .965 18.966 .002 1.343 5.385 
Posttreatment 1.909
*
 .777 21.205 .023 .295 3.523 
6m F-up -1.818
*
 .795 24.647 .031 -3.456 -.180 
6m F-up Pretreatment 5.182
*
 1.093 10.826 .001 2.771 7.593 
Posttreatment 3.727
*
 .824 28.821 .000 2.042 5.412 
1m F-up 1.818
*
 .795 24.647 .031 .180 3.456 
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CCL-D 
(I) Time2 (J) Time2 
Mean 
Difference 
(I-J) 
Std. 
Error df Sig.
a
 
95% Confidence Interval 
for Difference
a
 
Lower 
Bound 
Upper 
Bound 
Pretreatment Posttreatment 2.055 3.416 23.266 .553 -5.008 9.119 
1m F-up -3.626 3.455 24.328 .304 -10.752 3.499 
6m F-up -12.392
*
 3.551 27.137 .002 -19.675 -5.108 
Posttreatment Pretreatment -2.055 3.416 23.266 .553 -9.119 5.008 
1m F-up -5.682 3.331 21.031 .103 -12.609 1.245 
6m F-up -14.447
*
 3.360 21.764 .000 -21.420 -7.475 
1m F-up Pretreatment 3.626 3.455 24.328 .304 -3.499 10.752 
Posttreatment 5.682 3.331 21.031 .103 -1.245 12.609 
6m F-up -8.765
*
 3.342 21.305 .016 -15.710 -1.821 
6m F-up Pretreatment 12.392
*
 3.551 27.137 .002 5.108 19.675 
Posttreatment 14.447
*
 3.360 21.764 .000 7.475 21.420 
1m F-up 8.765
*
 3.342 21.305 .016 1.821 15.710 
 
 
 
CCL-A 
(I) Time2 (J) Time2 
Mean 
Difference 
(I-J) 
Std. 
Error df Sig.
a
 
95% Confidence Interval 
for Difference
a
 
Lower 
Bound 
Upper 
Bound 
Pretreatment Posttreatment -3.762 2.638 28.345 .165 -9.163 1.639 
1m F-up -7.360
*
 2.699 31.050 .010 -12.864 -1.856 
6m F-up -15.694
*
 2.848 38.490 .000 -21.456 -9.931 
Posttreatment Pretreatment 3.762 2.638 28.345 .165 -1.639 9.163 
1m F-up -3.598 2.500 22.872 .164 -8.772 1.576 
6m F-up -11.932
*
 2.547 24.631 .000 -17.182 -6.682 
1m F-up Pretreatment 7.360
*
 2.699 31.050 .010 1.856 12.864 
Posttreatment 3.598 2.500 22.872 .164 -1.576 8.772 
6m F-up -8.334
*
 2.518 23.524 .003 -13.536 -3.131 
6m F-up Pretreatment 15.694
*
 2.848 38.490 .000 9.931 21.456 
Posttreatment 11.932
*
 2.547 24.631 .000 6.682 17.182 
1m F-up 8.334
*
 2.518 23.524 .003 3.131 13.536 
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Appendix E 
MLM Model 3: Assumption Testing  
 
Normality of Residuals 
 
 
Tests of Normality 
 Kolmogorov-Smirnov
a
 Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
DepL1 Residuals .084 72 .200
*
 .951 72 .070 
AnxL1Residuals .070 72 .200
*
 .985 72 .525 
SL1Residuals .109 72 .033 .984 72 .506 
PDQL1Residuals .057 72 .200
*
 .992 72 .917 
CCLDL1Residuals .076 72 .200
*
 .985 72 .572 
CCLAL1Residuals .068 72 .200
*
 .984 72 .479 
DepL2Residuals .089 72 .200
*
 .952 72 .080 
AnxL2Residuals .072 72 .200
*
 .982 72 .396 
StresL2Residuals .105 72 .049 .984 72 .513 
PDQL2Residuals .049 72 .200
*
 .993 72 .951 
CCLDL2Residuals .082 72 .200
*
 .982 72 .394 
CCLAL2Residuals .064 72 .200
*
 .985 72 .551 
a. Lilliefors Significance Correction 
*. This is a lower bound of the true significance. 
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Constant variances of Residuals 
Level 1 
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Constant variances of Residuals 
Level 2 
  
 
 
 
 
 
322 
 
Independence of Residuals 
 
Level 1 Residuals and Units                                            Level 2 Residuals and Units 
 
 
Time 
    
L1_DASSD Correlation Coefficient -.041 
Sig. (2-tailed) .735 
L1_DASSS Correlation Coefficient -.005 
Sig. (2-tailed) .968 
L1_DASSA Correlation Coefficient -.128 
Sig. (2-tailed) .284 
L1_PDQ Correlation Coefficient -.003 
Sig. (2-tailed) .980 
L1_CCLD Correlation Coefficient -.108 
Sig. (2-tailed) .366 
L1_CCLA Correlation Coefficient -.161 
Sig. (2-tailed) .177 
 
 
 
Across Levels (Level 1 Residuals and Level 2 Residuals) 
 
 
Number 
 
L2_DASSD Correlation Coefficient -.170 
Sig. (2-tailed) .530 
L2_DASSA Correlation Coefficient -.424 
Sig. (2-tailed) .101 
L2_DASSS Correlation Coefficient -.097 
Sig. (2-tailed) .721 
L2_PDQ Correlation Coefficient .243 
Sig. (2-tailed) .365 
L2_CCLD Correlation Coefficient -.182 
Sig. (2-tailed) .500 
L2_CCLA Correlation Coefficient -.582 
Sig. (2-tailed) .118 
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L2_DASSD L2_DASSA L2_DASSS L2_PDQ L2_CCLD L2_CCLA 
L1_DASSD Pearson Correlation .039      
Sig. (2-tailed) .743      
L1_DASSA Pearson Correlation  -.006     
Sig. (2-tailed)  .959     
L1_DASSS Pearson Correlation   -.018    
Sig. (2-tailed)   .880    
L1_PDQ Pearson Correlation    -.029   
Sig. (2-tailed)    .807   
L1_CCLD Pearson Correlation     .000  
Sig. (2-tailed)     .999  
L1_CCLA Pearson Correlation      .021 
Sig. (2-tailed)      .859 
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Appendix F – Study III questionnaire package 
Demographic and Medical History Questionnaire 
 
 
A.  Demographic Information 
Age:    ___  years     Gender:    M    |    F      (please circle) 
Nationality:   __________________ 
Relationship status:   (please circle) 
Single  In a relationship        De facto     Engaged  
Married  Separated         Divorced     Widowed            Other: _________
Do you have any children?       Y    |     N             If yes, how many?   ______ 
Are you currently employed?    Y    |     N           If yes, on what time basis?  _____________ 
                                                                                                   (e.g., full-time, part-time, casual, contract
B.  Parkinson’s Disease History 
How old were you when you: 
First noticed signs of PD?     ____  years 
Were formally diagnosed with PD?     ____  years             By who?     ________________    
                                                                                            (e.g., GP, neurologist etc.) 
 
Do or have any of your relatives have or had PD?    Y    |     N      
 
  If yes, what relation are/were they to you?        1. _____________  2. _____________ 
        3. _____________  4. _____________ 
Please place a tick next to the symptoms that you have experienced. 
 
Slowness of movement   Vomiting   Headache/migraine 
Stiffness   Dizziness or fainting   Urinary incontinence 
Tremor   Excessive sweating   Pain 
Falls   Stooped posture   Memory problems 
Loss of balance   Bladder frequency   Confusion 
Difficulty in dressing   Bladder urgency   Fatigue 
Difficulty in walking   Constipation   Nausea 
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Please provide a list of the medication you are currently taking for your Parkinson’s. 
 
1. 2. 3. 
4. 5. 6. 
 
 
C.  General Medical History 
Do you have any medical condition(s) other than Parkinson’s?    Y    |    N    
 
 If yes, what condition(s)?     ________________________________________________________
            _______________________________________________________________________________
 
Are you currently taking any medication for these conditions?    Y    |    N    
 
If yes, please specify the type of medication and which condition it is used for. 
            _______________________________________________________________________________
 
D.  Psychiatric History 
Has your GP/neurologist ever spoken to you about anxiety, depression or other psychological conditions 
           that can occur in PD?     Y   |    N 
 
Would you see a mental health professional (eg psychiatrist, psychologist, counsellor) for help with 
psychological 
problems ?                   Y   |    N 
 
Have you ever been diagnosed with a psychological disorder?    Y    |    N       
If yes, please specify which disorder(s) and what year(s) you were diagnosed.  
_______________________________________________________________________________       
Are you currently taking any medication for a psychological condition?    Y    |    N       
 If yes, please list these medications.      ________________________________________________
 
Have you seen a mental health professional N.  
 In the past month?    Y   |    N      Type of professional: (eg, psychiatrist, psychologist, counsellor)  _______________ 
In the past 6 months?    Y   |    N      Type of professional:  _______________ 
In the past year?    Y   |    N      Type of professional:  _______________ 
In the past 5 years?    Y   |    N      Type of professional: _______________ 
Ever?                             Y   |    N      Type of professional: _______________ 
 
Have you seen the advertisement for the “Anxiety and Depression in Parkinson’s Disease Treatment 
Trial” at Curtin University in the PWA newsletter from 2010-2011?            Y      |       N 
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Please read the following statements and indicate whether you 
Agree, Disagree or Neither Agree or Disagree with each (Neutral).  
 
 
   Strongly  
Disagree 
Disagree 
 
Neutral 
 
Agree Strongly  
Agree 
1 It is a sign of weakness to talk 
with a mental health 
professional about emotional 
distress 
      
2 I do not like taking any 
medication for emotional 
difficulties 
      
3 It is a sign of weakness to take 
medication for emotional 
difficulties 
      
4 I feel like I should be able to 
take care of my problems by 
myself 
      
5 If a person always takes 
medication whenever upset or 
feeling down then the 
medication might not work as 
well when it is really needed 
      
6 If I sought help for my 
emotional problems then I 
might lose my health benefits 
      
7 I can afford to pay for 
treatment for mental health 
problems 
      
8 I would rather not seek help 
for mental health problems 
because I might lose my 
health benefits 
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   Strongly  
Disagree 
Disagree 
 
Neutral 
 
Agree Strongly 
Agree
9 The cost of mental health 
treatment is well covered by 
my health insurance 
      
10 Getting help for my mental 
health problems may 
jeopardise getting life 
insurance 
      
11 I believe that treatment for 
emotional problems will help 
me 
      
12 I would be less depressed if I 
talked about my problems 
 
 
 
     
13 I would cope better with my 
Parkinson's if I got help for 
my emotional problems 
 
 
 
 
     
14 I prefer to use prayer to treat 
emotional problems rather 
than going for therapy or 
taking pills 
      
15 Talking about my emotional 
problems may help my 
Parkinson's to get better 
      
16 I don't want to become 
dependent on a therapist 
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17 I don't want to become 
dependent on psychiatric 
medication 
      
18 Good patients do not talk 
about their emotional 
problems with their doctors 
      
19 Most doctors want to hear 
about any problems a patient 
is having in addition to those 
related to Parkinson's 
      
20 My doctor may not want me 
to be his/her patient anymore 
if I talk too much about my 
emotional problems 
      
21 I don't want to reveal that I 
have emotional problems 
because I am afraid of what 
my doctor would think of me 
      
22 I don't want to see a mental 
health professional because 
my doctor will think I am 
weak 
      
23 Most doctors are more than 
willing to listen to patients 
talk about their emotional 
distress 
      
24 I don't want to get treatment 
for mental health problems 
because my family and friends 
will think I am crazy 
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25 It is normal for anyone with 
Parkinson's to be distressed 
therefore help for emotional 
problems is not needed 
      
26 I would rather not seek 
emotional help because I am 
afraid my employer would 
find out (if employed) 
      
27 I know where to go to find a 
therapist if I need one 
      
28 I would rather not seek help 
for emotional problems 
because it is too difficult 
getting around to see yet 
another doctor 
      
29 I worry that taking 
psychiatric medication may 
cause distressing side effects 
(e.g., nausea, constipation and 
sexual problems) 
      
30 I think that it is easier to put 
up with emotional distress 
than with the side effects that 
may come from psychiatric 
medications 
      
31 I don't want to take 
psychiatric medications in a 
bad way 
      
32 I fear that using relaxation 
techniques might make me do 
things without being able to 
control them 
      
   Strongly  
Disagree 
Disagree 
 
Neutral 
 
Agree Strongly 
Agree
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33 I worry about becoming too 
sedated from psychiatric 
medications 
      
34 Getting help for my emotional 
problems will take away time and 
energy that I need to spend 
coping with Parkinson's 
      
35 It is as important for my doctor 
to listen to me about  my 
emotional problems as it is for 
him/her to help me with my PD 
      
36 I feel like I should be able to take 
care of my problems by myself 
      
37 Taking psychiatric medication 
would dull my emotions 
      
38 Medication is more effective than 
psychotherapy for emotional 
problems 
      
39 Psychotherapy is more effective 
than medication for emotional 
problems 
      
40 Medication and psychotherapy 
are equally effective for 
emotional problems 
      
41 I worry about interactions 
between psychiatric medication 
and my Parkinson's medication 
      
42 I prefer medication for emotional 
problems rather than 
psychotherapy 
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Appendix G 
Item-Component Loadings and Cronbach's Alpha Values of Internal Consistency for 
the Needs Survey 
 Loading α 
Weakness   
1 It is a sign of weakness to talk with a mental health professional about emotional distress .10 
.69 
2 I do not like taking any medication for emotional difficulties .50 
3 It is a sign of weakness to take medication for emotional difficulties .35 
4 I feel like I should be able to take care of my problems by myself .59 
5 If a person always takes medication whenever upset or feeling down then the medication 
might not work as well when it is really needed 
.50 
Cost/Health Benefits   
6 If I sought help for my emotional problems then I might lose my health benefits .67 
.61 
7 I can afford to pay for treatment for mental health problems .10 
8 I would rather not seek help for mental health problems because I might lose my health 
benefits 
.66 
9 The cost of mental health treatment is well covered by my health insurance .19 
10 Getting help for my mental health problems may jeopardise getting life insurance .57 
Efficacy   
11 I believe that treatment for emotional problems will help me .78 
.57 
12 I would be less depressed if I talked about my problems .82 
13 I would cope better with my Parkinson's if I got help for my emotional problems .81 
14 I prefer to use prayer to treat emotional problems rather than going for therapy or taking pills .14 
15 Talking about my emotional problems may help my Parkinson's to get better .52 
Dependency   
16 I don't want to become dependent on a therapist .70 
.55 17 I don't want to become dependent on psychiatric medication .66 
Doctor’s Reaction   
18 Good patients do not talk about their emotional problems with their doctors .66 
.73 
19 Most doctors want to hear about any problems a patient is having in addition to those related 
to Parkinson's 
.10 
20 My doctor may not want me to be his/her patient anymore if I talk too much about my 
emotional problems 
.73 
21 I don't want to reveal that I have emotional problems because I am afraid of what my doctor 
would think of me 
.79 
22 I don't want to see a mental health professional because my doctor will think I am weak .73 
23 Most doctors are more than willing to listen to patients talk about their emotional distress .14 
Stigma   
24 I don't want to get treatment for mental health problems because my family and friends will 
think I am crazy 
.33 
.54 
25 It is normal for anyone with Parkinson's to be distressed therefore help for emotional 
problems is not needed 
.14 
26 I would rather not seek emotional help because I am afraid my employer would find out .61 
Access/Logistics   
27 I know where to go to find a therapist if I need one .38 
.37 
28 I would rather not seek help for emotional problems because it is too difficult getting around 
to see yet another doctor 
.65 
Side Effects   
29 I worry that taking psychiatric medication may cause distressing side effects .73 
.60 
30 I think that it is easier to put up with emotional distress than with the side effects that may 
come from psychiatric medications 
.47 
31 I don't want to take psychiatric medications in a bad way .09 
32 I fear that using relaxation techniques might make me do things without being able to control 
them 
.33 
33 I worry about becoming too sedated from psychiatric medications .74 
34 Taking psychiatric medication would dull my emotions .64 
Concern for PD   
35 Getting help for my emotional problems will take away time and energy that I need to spend 
coping with Parkinson's 
.57 
.37 36 It is as important for my doctor to listen to me about my emotional problems as it is for him/her to help me with my PD 
.42 
332 
 
Appendix H – Study IV Outlier Tests 
 
Univariate outliers 
 
Extreme Values 
 Case Number Value 
Zscore(DASSDEP) Highest 1 206 3.29196 
2 269 3.09526 
3 49 2.89856 
4 312 2.89856 
5 104 2.70186
a
 
Lowest 1 327 -1.03544 
2 325 -1.03544 
3 321 -1.03544 
4 315 -1.03544 
5 313 -1.03544
b
 
Zscore(DASSANX) Highest 1 104 3.19013 
2 206 3.19013 
3 267 3.19013 
4 297 3.19013 
5 35 2.68867
c
 
Lowest 1 327 -1.32303 
2 315 -1.32303 
3 313 -1.32303 
4 299 -1.32303 
5 294 -1.32303
d
 
Zscore(DASSSTRESS) Highest 1 128 3.27098 
2 76 3.05788 
3 267 3.05788 
4 297 3.05788 
5 45 2.84479 
Lowest 1 327 -1.20405 
2 322 -1.20405 
3 320 -1.20405 
4 315 -1.20405 
5 314 -1.20405
e
 
Zscore(PDQtotal) Highest 1 128 3.57251 
2 267 2.84732 
3 1 2.50200 
4 49 2.43293 
5 70 2.39840 
Lowest 1 20 -1.60739 
2 313 -1.53832 
3 299 -1.53832 
4 265 -1.53832 
5 125 -1.53832 
Zscore(PsychOpenness) Highest 1 12 2.76671 
2 24 2.76671 
3 42 2.76671 
4 44 2.76671 
5 1 2.65329
f
 
Lowest 1 299 -1.77030 
2 269 -1.77030 
3 111 -1.77030 
4 72 -1.77030 
5 25 -1.77030 
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Zscore(HelpSeekPropensity) Highest 1 3 1.31650 
2 4 1.16890 
3 11 1.16890 
4 111 1.16890 
5 119 1.16890
g
 
Lowest 1 127 -3.55437 
2 92 -3.55437 
3 70 -3.55437 
4 25 -3.55437 
5 5 -3.25917 
Zscore(PerceivedPubStigma) Highest 1 322 7.39858 
2 267 2.77373 
3 110 1.69460 
4 131 1.69460 
5 132 1.69460
h
 
Lowest 1 313 -2.62193 
2 264 -2.62193 
3 187 -2.62193 
4 291 -2.46776 
5 257 -2.31360
i
 
Zscore(Shame_SSDS) Highest 1 58 2.35958 
2 128 2.35958 
3 120 2.08176 
4 4 1.80395 
5 7 1.80395
j
 
Lowest 1 32 -1.58264 
2 326 -1.52985 
3 320 -1.52985 
4 316 -1.52985 
5 313 -1.52985
k
 
Zscore(SelfBlame_SSDS) Highest 1 120 2.59475 
2 131 2.01932 
3 132 2.01932 
4 18 1.73161 
5 3 1.44390
l
 
Lowest 1 313 -2.00866 
2 306 -2.00866 
3 304 -2.00866 
4 299 -2.00866 
5 291 -2.00866
m
 
Zscore(SocInadequacy_SSDS) Highest 1 267 2.61391 
2 38 2.27098 
3 18 1.92804 
4 49 1.92804 
5 131 1.92804
n
 
Lowest 1 205 -2.53010 
2 313 -2.18716 
3 291 -2.18716 
4 270 -2.18716 
5 253 -2.18716 
Zscore(NSWeakness) Highest 1 4 2.91649 
2 58 2.62319 
3 181 2.62319 
4 91 2.03658 
5 150 2.03658
o
 
Lowest 1 318 -2.36300 
2 206 -2.36300 
3 123 -2.36300 
4 13 -2.36300 
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5 253 -2.13422 
Zscore(NSCost) Highest 1 155 5.06305 
2 18 2.70577 
3 166 2.70577 
4 167 2.70577 
5 32 2.36902 
Lowest 1 326 -2.34554 
2 189 -2.34554 
3 280 -2.00878 
4 275 -2.00878 
5 268 -2.00878
p
 
Zscore(NSEfficacy) Highest 1 17 3.53536 
2 104 2.90928 
3 238 2.59624 
4 327 2.28321 
5 15 1.97017
q
 
Lowest 1 120 -3.03844 
2 296 -2.72540 
3 325 -2.41237 
4 278 -2.41237 
5 277 -2.41237
r
 
Zscore(NSDepenendecy) Highest 1 38 2.67348 
2 17 2.07883 
3 44 2.07883 
4 2 1.48418 
5 3 1.48418
s
 
Lowest 1 326 -3.27300 
2 325 -3.27300 
3 276 -3.27300 
4 252 -3.27300 
5 125 -3.27300
t
 
Zscore(NSStigma) Highest 1 4 4.16346 
2 283 3.14519 
3 67 2.63605 
4 3 2.12691 
5 15 2.12691
u
 
Lowest 1 327 -1.94618 
2 325 -1.94618 
3 322 -1.94618 
4 318 -1.94618 
5 310 -1.94618
v
 
Zscore(NSAccess) Highest 1 128 2.85421 
2 4 2.56353 
3 15 2.27285 
4 16 2.27285 
5 129 2.27285
w
 
Lowest 1 327 -1.79670 
2 326 -1.79670 
3 322 -1.79670 
4 321 -1.79670 
5 320 -1.79670
x
 
Zscore(NSMisc) Highest 1 1 3.80972 
2 2 2.98351 
3 3 2.98351 
4 4 2.15730 
5 5 2.15730
y
 
Lowest 1 327 -3.62618 
2 326 -3.62618 
3 325 -3.62618 
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4 324 -2.79997 
5 323 -2.79997 
 
 
Extreme Values 
 Case Number Value 
Zscore(NSWeakness) Highest 1 4 2.91649 
2 58 2.62319 
3 181 2.62319 
4 91 2.03658 
5 150 2.03658
a
 
Lowest 1 318 -2.36300 
2 206 -2.36300 
3 123 -2.36300 
4 13 -2.36300 
5 253 -2.13422 
Zscore(NSCost) Highest 1 155 5.06305 
2 18 2.70577 
3 166 2.70577 
4 167 2.70577 
5 32 2.36902 
Lowest 1 326 -2.34554 
2 189 -2.34554 
3 280 -2.00878 
4 275 -2.00878 
5 268 -2.00878
b
 
Zscore(NSEfficacy) Highest 1 17 3.53536 
2 104 2.90928 
3 238 2.59624 
4 327 2.28321 
5 15 1.97017
c
 
Lowest 1 120 -3.03844 
2 296 -2.72540 
3 325 -2.41237 
4 278 -2.41237 
5 277 -2.41237
d
 
Zscore(NSDepenendecy) Highest 1 38 2.67348 
2 17 2.07883 
3 44 2.07883 
4 2 1.48418 
5 3 1.48418
e
 
Lowest 1 326 -3.27300 
2 325 -3.27300 
3 276 -3.27300 
4 252 -3.27300 
5 125 -3.27300
f
 
Zscore(NSStigma) Highest 1 4 4.16346 
2 283 3.14519 
3 67 2.63605 
4 3 2.12691 
5 15 2.12691
g
 
Lowest 1 327 -1.94618 
2 325 -1.94618 
3 322 -1.94618 
4 318 -1.94618 
5 310 -1.94618
h
 
Zscore(NSAccess) Highest 1 128 2.85421 
2 4 2.56353 
3 15 2.27285 
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4 16 2.27285 
5 129 2.27285
i
 
Lowest 1 327 -1.79670 
2 326 -1.79670 
3 322 -1.79670 
4 321 -1.79670 
5 320 -1.79670
j
 
Zscore(NSMisc) Highest 1 1 3.80972 
2 2 2.98351 
3 3 2.98351 
4 4 2.15730 
5 5 2.15730
k
 
Lowest 1 327 -3.62618 
2 326 -3.62618 
3 325 -3.62618 
4 324 -2.79997 
5 323 -2.79997 
 
 
 
Multivariate Outliers 
 
Extreme Values 
 Case Number Value 
Analog of Cook's influence 
statistics 
Highest 1 300 .31007 
2 295 .24803 
3 311 .23582 
4 212 .22936 
5 78 .21936 
Lowest 1 254 .00003 
2 257 .00006 
3 37 .00006 
4 158 .00006 
5 267 .00006 
MahalonobisD Highest 1 53 -.86 
2 55 -.89 
3 253 -.89 
4 201 -.90 
5 239 -.92 
Lowest 1 254 -.99 
2 158 -.99 
3 267 -.99 
4 257 -.99 
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Extreme Values 
 Case Number Value 
Analog of Cook's influence 
statistics 
Highest 1 300 .31007 
2 295 .24803 
3 311 .23582 
4 212 .22936 
5 78 .21936 
Lowest 1 254 .00003 
2 257 .00006 
3 37 .00006 
4 158 .00006 
5 267 .00006 
MahalonobisD Highest 1 53 -.86 
2 55 -.89 
3 253 -.89 
4 201 -.90 
5 239 -.92 
Lowest 1 254 -.99 
2 158 -.99 
3 267 -.99 
4 257 -.99 
5 37 -.99 
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Appendix I 
Study II: Tests for multicollinearity 
 
Zero-order correlation matrix 
Correlations 
 
Age 
Would you 
see a mental 
health 
professional 
for help with 
psychological 
problems? 
Psych 
Talk 
Treat
ment 
lifetim
e 
HelpSeek 
Propensity 
SocInade
quacy 
SSDS 
NS 
Efficacy 
NS 
Weakness 
Age 1 -.311
**
 .179
**
 -.318
**
 -.123
*
 -.023 -.136
*
 .235
**
 
 .000 .001 .000 .026 .683 .014 .000 
Would you seee a 
mental health 
professional for help 
with psychological 
problems? 
-.311
**
 1 -.143
**
 .271
**
 .186
**
 .095 .229
**
 -.232
**
 
.000 
 
.009 .000 .001 .085 .000 .000 
Has your 
GP/neurologist ever 
spoken to you about 
psychological 
conditions that can 
occur in PD? 
.179
**
 -.143
**
 1 -.353
**
 -.047 -.051 -.065 .178
**
 
.001 .009 
 
.000 .393 .362 .244 .001 
Treatment_lifetime -.318
**
 .271
**
 -.353
**
 1 .027 .150
**
 .205
**
 -.267
**
 
.000 .000 .000  .627 .007 .000 .000 
HelpSeekPropensity -.123
*
 .186
**
 -.047 .027 1 -.162
**
 .034 -.229
**
 
.026 .001 .393 .627  .003 .535 .000 
SocInadequacy_SSDS -.023 .095 -.051 .150
**
 -.162
**
 1 .075 .142
**
 
.683 .085 .362 .007 .003  .178 .010 
NSEfficacy -.136
*
 .229
**
 -.065 .205
**
 .034 .075 1 -.103 
.014 .000 .244 .000 .535 .178  .062 
NSWeakness .235
**
 -.232
**
 .178
**
 -.267
**
 -.229
**
 .142
**
 -.103 1 
.000 .000 .001 .000 .000 .010 .062  
327 327 327 327 327 327 327 327 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Multiway Frequency Analysis for Multicollinearity between Discrete Predictors 
 
 
 
Parameter Estimates 
Effect Parameter Estimate 
Std. 
Error Z Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Treatment_lifetime*PsychMe
dication*PsychTalk  
1 -.180 .356 -.504 .614 -.878 .519 
Treatment_lifetime*PsychMe
dication  
1 .180 .356 .504 .614 -.519 .878 
Treatment_lifetime*PsychTal
k  
1 .034 .356 .096 .924 -.664 .732 
PsychMedication*PsychTalk  1 -.129 .356 -.361 .718 -.827 .569 
Treatment_lifetime  1 -.034 .356 -.096 .924 -.732 .664 
PsychMedication  1 .129 .356 .361 .718 -.569 .827 
PsychTalk  1 -.148 .356 -.030 .000 -.846 1.450 
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Appendix J 
Study III. Tests for Linearity in the Logit 
 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1
a
 Age -.071 .019 14.458 1 .000 .932 
PsychMedication(1) 1.241 .393 9.977 1 .002 3.457 
Treatment_lifetime 1.087 .423 6.593 1 .010 2.965 
PsychTalk(1) .243 .312 .607 1 .436 1.275 
HelpSeekPropensity .195 .097 4.019 1 .045 1.215 
SocInadequacy_SSDS .148 .359 .169 1 .681 1.159 
NSWeakness -.203 .131 2.394 1 .122 .816 
NSEfficacy .389 .211 3.391 1 .066 1.476 
HelpSeek_LN -6.119 4.152 2.172 1 .141 .002 
SocInad_LN -.370 9.474 .002 1 .969 .691 
Eff_LN -5.867 4.631 1.606 1 .205 .003 
Weakness_LN 1.317 1.923 .469 1 .493 3.734 
Constant 9.087 6.568 1.914 1 .167 8836.515 
a. Variable(s) entered on step 1: PsychMedication, Treatment_lifetime, PsychTalk, HelpSeekPropensity, 
SocInadequacy_SSDS, NSWeakness, NSEfficacy, HelpSeek_LN, SocInad_LN, Eff_LN, Weakness_LN. 
 
 
